<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19047609</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>179</Volume><Issue>12</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.</ArticleTitle><Pagination><StartPage>1279</StartPage><EndPage>1287</EndPage><MedlinePgn>1279-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.070804</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The management of severe Alzheimer disease often presents difficult choices for clinicians and families. The disease is characterized by a need for full-time care and assistance with basic activities of daily living. We outline an evidence-based approach for these choices based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed evidence-based guidelines using systematic literature searches, with specific criteria for the selection and quality assessment of articles, and a clear and transparent decision-making process. We selected articles published from January 1996 to December 2005 that dealt with the management of severe Alzheimer disease. Subsequent to the conference, we searched for additional articles published from January 2006 to March 2008 using the same search terms. We graded the strength of the evidence using the criteria of the Canadian Task Force on Preventive Health Care.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 940 articles, of which 838 were selected for further study. Thirty-four articles were judged to be of at least good or fair quality and were used to generate 17 recommendations. Assessment of severe Alzheimer disease should include the measurement of cognitive function and the assessment of behaviour, function, medical status, nutrition, safety and caregiver status. Management could include treatment with a cholinesterase inhibitor or memantine, or both. Treatment of neuropsychiatric symptoms begins with nonpharmacologic approaches to addressing behavioural problems. Severe agitation, aggression and psychosis, which are potentially dangerous to the patient, the caregiver and others in the environment, can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular events and death. All pharmacologic approaches require careful monitoring and periodic reassessment to determine whether continued treatment is necessary. Caregiver support and use of community resources are essential.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Severe Alzheimer disease requires frequent monitoring by health professionals. Simple nonpharmacologic approaches may address problems with mood and agitation. Antipsychotic drug therapy is occasionally necessary despite the inherent risks. Therapy with a cholinesterase inhibitor and memantine may be useful for selected patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre and University of Toronto, Ont., Canada. n.herrmann@utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19047609</ArticleId><ArticleId IdType="pmc">PMC2585109</ArticleId><ArticleId IdType="doi">10.1503/cmaj.070804</ArticleId><ArticleId IdType="pii">179/12/1279</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Canadian Study of Health and Aging. Study methods and prevalence of dementia. CMAJ 1994;150:899-913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1486712</ArticleId><ArticleId IdType="pubmed">8131123</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson CJ, Gauthier S, Bergman H, et al. Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. CMAJ 1999;160:1738-42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1230413</ArticleId><ArticleId IdType="pubmed">10410640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertkow H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ 2008;178:316-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211335</ArticleId><ArticleId IdType="pubmed">18227452</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114305</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007;19:421-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17480241</ArticleId></ArticleIdList></Reference><Reference><Citation>Boller F, Verny M, Hugonot-Diener L, et al. Clinical features and assessment of severe dementia. A review. Eur J Neurol 2002;9:125-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11882053</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherder E, Oosterman J, Swaab D, et al. Recent developments in pain in dementia. BMJ 2005;330:461-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549660</ArticleId><ArticleId IdType="pubmed">15731144</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NH, Burns A, Newton V, et al. The effects of improving hearing in dementia. Age Ageing 2003;32:189-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615563</ArticleId></ArticleIdList></Reference><Reference><Citation>Magri F, Borza A, del Vecchio S, et al. Nutritional assessment of demented patients: a descriptive study. Aging Clin Exp Res 2003;15:148-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandy s, Parsons S, Cryer C, et al. Development and preliminary examination of the predictive validity of the Falls Risk Assessment Tool (FRAT) for use in primary care. J Public Health 2004;26:138-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2004;18:S17-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettl P. Helping families with end-of-life care in Alzheimer's disease. J Clin Psychiatry 2007;68:445-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">17388717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelman MS, Roth DL, Coon DW, et al. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatry 2004;161:850-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15121650</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Berg JD, Thomas R, et al. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology 1999;52:714-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078715</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert R, Dubois MF, Wolfson C, et al. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2001;56:M693-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanctot KL, Bowles SK, Herrmann N, et al. Drugs mimicking dementia. Dementia symptoms associated with psychotropic drugs in institutionalised cognitively impaired patients. CNS Drugs 2000;14:381-90.</Citation></Reference><Reference><Citation>Feldman HH, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 2008;178:825-36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267847</ArticleId><ArticleId IdType="pubmed">18362376</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263837</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003;51:1305-17.</Citation><ArticleIdList><ArticleId IdType="pubmed">12919245</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005;20:301-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006;166:2182-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101935</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Edelstein BA. Behavioral interventions for agitation in older adults with dementia: an evaluative review. Int Psychogeriatr 2006;18:195-225.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472409</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 1997;52:159-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev 2006;(1)CD003477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15266489</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006;18:623-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805928</ArticleId></ArticleIdList></Reference><Reference><Citation>Svansdottir HB, Snaedal J. Music therapy in moderate and severe dementia of Alzheimer's type: a case&#x2013;control study. Int Psychogeriatr 2006;18:613-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16618375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134141</ArticleId><ArticleId IdType="pubmed">12451085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395813</ArticleId><ArticleId IdType="pubmed">15111472</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Canada endorsed important safety information on atypical antipsychotic drugs and dementia: increased mortality associated with the use of atypical antipsychotic drugs in elderly patients with dementia [Dear Health Care Professional letter]. Ottawa (ON): Canadian Adverse Drug Reaction Monitoring Program, Health Canada; 2005. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2005/atyp-antipsycho_hpc-cps-eng.php (accessed 2008 Sept 25).</Citation></Reference><Reference><Citation>Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15697324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549652</ArticleId><ArticleId IdType="pubmed">15668211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005;66:1090-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16187764</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004;12:437-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548409</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I, de Deyn PP, Mintzer J, et al. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007;22:475-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2002;14:197-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004;65:114-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744180</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanctot KL. Pharmacological management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007;52:630-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">18020111</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias, Second Edition. Am J Psychiatry 2007;164:1-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18340692</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin J, Schneider L, Katz I, et al. Provisional diagnostic criteria for depression of Alzheimer Disease. Am J Geriatr Psychiatry 2002;10:125-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11925273</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington (DC): American Psychiatric Press; 2000. p. 369-76.</Citation></Reference><Reference><Citation>Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 2007;52:248-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17500306</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559955</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11843990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16083542</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581404</ArticleId></ArticleIdList></Reference><Reference><Citation>Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17664405</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 Jan 25;(1):CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10885864</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RW, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:258-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243195</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24:20-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:138-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622761</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006;20:263-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132971</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19:919-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15449303</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005;65:481-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087923</ArticleId></ArticleIdList></Reference><Reference><Citation>Monastero R, Camarda C, Pipia C, et al. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007;78:546. Epub 2006 Oct 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117848</ArticleId><ArticleId IdType="pubmed">17030587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007;52:519-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">17955915</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255446</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18:282-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673601</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson S, Beavis D, Leddy A, et al. Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatr Bull 2005;29:410-2.</Citation></Reference><Reference><Citation>Herrmann N. Treatment of moderate to severe Alzheimer's disease: rationale and trial designs. Can J Neurol Sci 2007;34:S103-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006;367:1031-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581383</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned? Drug Saf 2006;29:833-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19010568</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Neuroglobin and Alzheimer's dementia: genetic association and gene expression changes.</ArticleTitle><Pagination><StartPage>1835</StartPage><EndPage>1842</EndPage><MedlinePgn>1835-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2008.10.003</ELocationID><Abstract><AbstractText>We previously reported strong genetic linkage on chromosome 14q to Alzheimer's disease (AD) using the presence of co-morbid hallucinations as a covariate. Those results suggested the presence of a gene increasing the risk for a genetically homogeneous form of AD characterized by the absence of comorbid hallucinations. Here we report our follow up of that study through the analysis of single nucleotide polymorphisms (SNPs) in five functional candidate genes. This work provides significant evidence of association for the gene coding for neuroglobin (NGB), a nervous system globin known to protect cells against amyloid toxicity and to attenuate the AD phenotype of transgenic mice. On further experiments we found that NGB expression is reduced with increasing age and lower in women consistent with their increased risk. NGB expression is up-regulated in the temporal lobe of AD patients consistent with a response to the disease process, as reported for NGB and hypoxia. We speculate that a compromised response due to DNA variation might increase the risk for AD. Our and others' data strongly support the involvement of NGB in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2008 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szymanski</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McKusick Nathans Institute of Genetic Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruihua</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Danielle</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Avramopoulos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG021804</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG022099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 RR020278-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021804</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 RR020278</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000078787">Neuroglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9004-22-2</RegistryNumber><NameOfSubstance UI="D005914">Globins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002883" MajorTopicYN="N">Chromosomes, Human, Pair 14</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005914" MajorTopicYN="N">Globins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078787" MajorTopicYN="N">Neuroglobin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of Interest:</b> The authors have no actual or potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19010568</ArticleId><ArticleId IdType="mid">NIHMS244879</ArticleId><ArticleId IdType="pmc">PMC2967779</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.10.003</ArticleId><ArticleId IdType="pii">S0197-4580(08)00367-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Avramopoulos D, Fallin MD, Bassett SS. Linkage to chromosome 14q in Alzheimer&#x2019;s disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet. 2005;132(1):9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Landreth GE. Inflammation, apoptosis, and Alzheimer&#x2019;s disease. Neuroscientist. 2002;8(3):276&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061507</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. The current status of Alzheimer&#x2019;s disease genetics: what do we tell the patients? Pharmacol Res. 2004;50(4):385&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304236</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE. Results of a high-resolution genome screen of 437 Alzheimer&#x2019;s disease families. Hum Mol Genet. 2003;12(1):23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AM, Gordon D, Lee H, Caudy M, Haroutunian V, Blass JP. Substantial linkage disequilibrium across the dihydrolipoyl succinyltransferase gene region without Alzheimer&#x2019;s disease association. Neurochem Res. 2004;29(3):629&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15038610</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunori M, Vallone B. Neuroglobin, seven years after. Cell Mol Life Sci. 2007;64(10):1259&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11135978</ArticleId><ArticleId IdType="pubmed">17385072</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmester T, Weich B, Reinhardt S, Hankeln T. A vertebrate globin expressed in the brain. Nature. 2000;407(6803):520&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11029004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer&#x2019;s patients. Free Radic Biol Med. 2002;33(10):1372&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta. 2002;1585(2&#x2013;3):153&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531549</ArticleId></ArticleIdList></Reference><Reference><Citation>Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000;66(1):196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="pubmed">10631151</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G, Ottman R, Tang MX, Marder K, Stern Y, Mayeux R. Familial aggregation of Alzheimer disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. Arch Neurol. 2000;57(1):72&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634451</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008;66(2):87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386559</ArticleId><ArticleId IdType="pubmed">18382088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat Rev Genet. 2006;7(8):632&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847463</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Shen Y, Sun W, Wang H, Wang Y, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe&#x2019;er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Altshuler D, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Tsunoda T, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Zeng C, Zhao H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Gibbs RA, Belmont JW, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Wheeler DA, Yakub I, Gabriel SB, Onofrio RC, Richter DJ, Ziaugra L, Birren BW, Daly MJ, Altshuler D, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L&#x2019;Archeveque P, Bellemare G, Saeki K, Wang H, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689609</ArticleId><ArticleId IdType="pubmed">17943122</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science. 2002;296(5576):2225&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55(9):809&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9736007</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GE, Huang HM. Oxidative stress in Alzheimer&#x2019;s disease. Neurobiol Aging. 2005;26(5):575&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708429</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349(6311):704&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg DA, Jin K, Khan AA. Neuroglobin: an endogenous neuroprotectant. Curr Opin Pharmacol. 2008;8(1):20&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2387246</ArticleId><ArticleId IdType="pubmed">17942367</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold S, Fago A, Weber RE, Dewilde S, Moens L. Reactivity studies of the Fe(III) and Fe(II)NO forms of human neuroglobin reveal a potential role against oxidative stress. J Biol Chem. 2004;279(22):22841&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15020597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvik G, Larson EB, Goddard K, Schellenberg GD, Wijsman EM. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet. 1996;58(1):191&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914964</ArticleId><ArticleId IdType="pubmed">8554056</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Mao XO, Xie L, Khan AA, Greenberg DA. Neuroglobin protects against nitric oxide toxicity. Neurosci Lett. 2008;430(2):135&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265792</ArticleId><ArticleId IdType="pubmed">18035490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ. A full genome scan for late onset Alzheimer&#x2019;s disease. Hum Mol Genet. 1999;8(2):237&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Mao XO, Banwait S, Jin K, Greenberg DA. Neuroglobin attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo. Proc Natl Acad Sci U S A. 2007a;104(48):19114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141917</ArticleId><ArticleId IdType="pubmed">18025470</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Ou Mao X, Banwait S, Dermardirossian CM, Bokoch GM, Jin K, Greenberg DA. Regulation of hypoxic neuronal death signaling by neuroglobin. Faseb J 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746758</ArticleId><ArticleId IdType="pubmed">18198211</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Sun Y, Jin K, Mao XO, Chen S, Ellerby LM, Greenberg DA. A neuroglobin-overexpressing transgenic mouse. Gene. 2007b;398(1&#x2013;2):172&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2098872</ArticleId><ArticleId IdType="pubmed">17537594</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Wang Y, Sun Y, Mao XO, Xie L, Miles E, Graboski J, Chen S, Ellerby LM, Jin K, Greenberg DA. Neuroglobin-overexpressing transgenic mice are resistant to cerebral and myocardial ischemia. Proc Natl Acad Sci U S A. 2006;103(47):17944&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693852</ArticleId><ArticleId IdType="pubmed">17098866</ArticleId></ArticleIdList></Reference><Reference><Citation>Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15806104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunugi H, Nanko S, Ueki A, Isse K, Hirasawa H. DLST gene and Alzheimer&#x2019;s disease. Lancet. 1998;351(9115):1584&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10326565</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer&#x2019;s disease locus on chromosome 1. Science. 1995;269(5226):970&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HS, Wang D, Shen Q, Schonemann MD, Gorski JA, Jones KR, Temple S, Jan LY, Jan YN. Inactivation of Numb and Numblike in embryonic dorsal forebrain impairs neurogenesis and disrupts cortical morphogenesis. Neuron. 2003;40(6):1105&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687546</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">18063223</ArticleId></ArticleIdList></Reference><Reference><Citation>Li RC, Pouranfar F, Lee SK, Morris MW, Wang Y, Gozal D. Neuroglobin protects PC12 cells against beta-amyloid-induced cell injury. Neurobiol Aging 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586918</ArticleId><ArticleId IdType="pubmed">17560688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Chan P, Yang J. [Association between DLST gene polymorphism and Alzheimer&#x2019;s disease] Zhonghua Yi Xue Za Zhi. 2001;81(20):1246&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825528</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita S, Arai H, Yuzuriha T, Kato M, Matsui T, Urakami K, Higuchi S. No association between DLST gene and Alzheimer&#x2019;s disease or Wernicke-Korsakoff syndrome. Neurobiol Aging. 2001;22(4):569&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445257</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006;9(3 Suppl):271&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914866</ArticleId></ArticleIdList></Reference><Reference><Citation>Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology. 2002;58(2):209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805246</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano K, Ohta S, Nishimaki K, Miki T, Matuda S. Alzheimer&#x2019;s disease and DLST genotype. Lancet. 1997;350(9088):1367&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9365459</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(7):631&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16825950</ArticleId></ArticleIdList></Reference><Reference><Citation>Peers C, Pearson HA, Boyle JP. Hypoxia and Alzheimer&#x2019;s disease. Essays Biochem. 2007;43:153&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17705799</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL. Identification of novel genes in late-onset Alzheimer&#x2019;s disease. Exp Gerontol. 2000;35(9&#x2013;10):1343&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PH, Zou K, Hwang JK, Jan YN, Zhong W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature. 2002;419(6910):929&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12410312</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, Nagga K, Bogdanovic N, Blennow K, Brookes AJ. Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer&#x2019;s disease. Eur J Hum Genet. 2001;9(6):437&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11436125</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007;35(Database issue):D61&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1716718</ArticleId><ArticleId IdType="pubmed">17130148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol. 2007;82:297&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678968</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D&#x2019;Agostino RB. Lifetime risk of dementia and Alzheimer&#x2019;s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6):1498&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375(6534):754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu KF, Brown AM, Kristal BS, Kalaria RN, Lilius L, Lannfelt L, Blass JP. A DLST genotype associated with reduced risk for Alzheimer&#x2019;s disease. Neurology. 1999;52(7):1505&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227647</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Gibson GE. Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(4):276&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109432</ArticleId><ArticleId IdType="pubmed">18090434</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S. Apoptosis in Alzheimer&#x2019;s disease--an update. Apoptosis. 2000;5(1):9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11227497</ArticleId></ArticleIdList></Reference><Reference><Citation>Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron. 2003;39(1):43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848931</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Jin K, Mao XO, Xie L, Peel A, Childs JT, Logvinova A, Wang X, Greenberg DA. Effect of aging on neuroglobin expression in rodent brain. Neurobiol Aging. 2005;26(2):275&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582755</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Jin K, Mao XO, Zhu Y, Greenberg DA. Neuroglobin is up-regulated by and protects neurons from hypoxic-ischemic injury. Proc Natl Acad Sci U S A. 2001;98(26):15306&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65025</ArticleId><ArticleId IdType="pubmed">11742077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Jin K, Peel A, Mao XO, Xie L, Greenberg DA. Neuroglobin protects the brain from experimental stroke in vivo. Proc Natl Acad Sci U S A. 2003;100(6):3497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152321</ArticleId><ArticleId IdType="pubmed">12621155</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer&#x2019;s disease. J Pharmacol Sci. 2005;97(3):312&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750290</ArticleId></ArticleIdList></Reference><Reference><Citation>The_International_HapMap_Consortium. The International HapMap Project. Nature. 2003;426(6968):789&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685227</ArticleId></ArticleIdList></Reference><Reference><Citation>Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol. 2008;65(3):329&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18332245</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer&#x2019;s disease. Vitam Horm. 2006;74:505&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12(9):1005&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PL, Siedlak SL, Perry G. Vascular oxidative stress in Alzheimer disease. J Neurol Sci. 2007;257(1&#x2013;2):240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952687</ArticleId><ArticleId IdType="pubmed">17337008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18982919</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1176-9092</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Clinical interventions in aging</Title><ISOAbbreviation>Clin Interv Aging</ISOAbbreviation></Journal><ArticleTitle>Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.</ArticleTitle><Pagination><StartPage>491</StartPage><EndPage>501</EndPage><MedlinePgn>491-501</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis of Alzheimer's disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in view of the modest efficacy and relative safety until FDA warnings were issued in 2005 and meta-analytic studies showed no significant difference to placebo. The FDA warnings on the cardiac, metabolic, cerebrovascular, and mortality risks have caused serious concerns for the use of atypical antipsychotic agents in elderly patients with dementia. Only a few studies have evaluated prospectively the effects of aripiprazole in psychosis associated with AD. These studies show improvement in the symptoms of psychosis associated with AD with aripiprazole. The safety and tolerability profile of aripiprazole suggests a low potential for negative impact on dementia and overall patient health. Further studies comparing the efficacy and tolerability of aripiprazole vs other atypical antipsychotics in dementia are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madhusoodanan</LastName><ForeName>Subramanian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St John's Episcopal Hospital Far Rockaway, NY 11691, USA. sdanan@ehs.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Payal</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Interv Aging</MedlineTA><NlmUniqueID>101273480</NlmUniqueID><ISSNLinking>1176-9092</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18982919</ArticleId><ArticleId IdType="pmc">PMC2682381</ArticleId><ArticleId IdType="doi">10.2147/cia.s3351</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AGS/AAGP. Consensus Statement on Improving the Quality of Mental Health Care in US Nursing Homes. Management of Depression and Behavioral Symptoms Associated with Dementia [online]  [Accessed Dec 2005].  URL:  http://www.psychiatrist.com.ezproxy.med.nyu.edu/privatepdf/2004/v65s02/v65s0203.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">12919243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, et al. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Streim J, Carpenter D, et al. The Expert Consensus Guideline Series: using antipsychotics in older patients. J Clin Psychiatry. 2004;65(Suppl 2):1&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">14994733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer&#x2019;s disease: prevalence and clinical correlates. Int J Geriatr Psychiatry. 2000;15:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679840</ArticleId></ArticleIdList></Reference><Reference><Citation>Breder C, Kostic D, Forbes A, et al. Overall safety of aripiprazole in trials of patients with psychosis of Alzheimer&#x2019;s dementia (poster). Presented at the 158th American Psychiatric Association Meeting; 2005 May 21&#x2013;26; Atlanta, Georgia. 2005.</Citation></Reference><Reference><Citation>Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065741</ArticleId></ArticleIdList></Reference><Reference><Citation>Byars A, Burris KD, Jordan S, et al. Aripiprazole, a dopamine-serotonin system stabilizer. Eur Neuropsychopharmacol. 2002;12:S290.</Citation></Reference><Reference><Citation>Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer&#x2019;s disease. Arch Neurol. 1994;51:676&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. J Geriatr Psychiatry Neurol. 1995;8:52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7710649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. A conceptual review. J Am Geriatr Soc. 1986;34:711&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol. 2002;5(suppl 1):S185.</Citation></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2004;19:115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer&#x2019;s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25:463&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160622</ArticleId></ArticleIdList></Reference><Reference><Citation>Defilippi JL, Crismon ML. Antipsychotic agents in patients with dementia. Pharmacotherapy. 2000;20:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10641973</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220010</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Brockington CD, Moody BJ, et al. Behavioral syndromes in Alzheimer&#x2019;s disease. Int Psychogeriatr. 1992;4(Suppl 2):161&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">1288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Eustace A, Coen R, Walsh C, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2002;17:968&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt DE, Fields DR, Soumerai SS, et al. Resident behavior and staff distress in the nursing home. J Am Geriatr Soc. 1991;39:792&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2071810</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17:617&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202186</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician&#x201d;. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976. Clinical Global Impressions (CGI) pp. 218&#x2013;22. US Department of Health, Education, and Welfare Publication (ADM) 76-338.</Citation></Reference><Reference><Citation>Health Canada. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Health Canada; 2005.</Citation></Reference><Reference><Citation>Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169702</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins MW, Libon DJ. Neuropsychological functioning of dementia patients with psychosis. Arch Clin Neuropsychol. 2005;20:771&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15936921</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Rockwell E, Harris MJ, et al. Conventional versus newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7:70&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9919323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Finkel SI. Psychosis of Alzheimer&#x2019;s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002;441:137&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12063084</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging. 2002;19:257&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12038878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostic D, Breder C, Marcus R, et al. Aripiprazole for treatment of agitation in inpatients with psychosis of Alzheimer&#x2019;s dementia (poster). Presented at the 158th American Psychiatric Association Meeting; May 21&#x2013;26 2005; Atlanta, Georgia. 2005.</Citation></Reference><Reference><Citation>Lieberman JA. Partial dopamine agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15015905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological treatment of the psychosis of Alzheimer&#x2019;s disease. What is the best approach? CNS Drugs. 2007;21:101&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17284093</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhusoodanan S, Brenner R, Gupta S, et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectrums. 2004;9:862&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15520608</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhusoodanan S, Sinha S, Brenner R, et al. Use of olanzapine for elderly patients with psychotic disorders: a review. Ann Clin Psychiatry. 2001;13:201&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958362</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729864</ArticleId></ArticleIdList></Reference><Reference><Citation>Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(Suppl 8):43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811243</ArticleId></ArticleIdList></Reference><Reference><Citation>MHRA. Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomised clinical trials of risperidone conducted in patients with dementia [online]  [Accessed December 2005].  URL:  http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafety-message/con019490.pdf.</Citation></Reference><Reference><Citation>Miller RJ, Snowdon J, Vaughan R. The use of the Cohen-Mansfield Agitation Inventory in the assessment of behavioral disorders in nursing homes. J Am Geriatr Soc. 1995;43:546&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7730539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15:918&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17974864</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799&#x2013;812.</Citation></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s dementia: a review of 55 studies published form 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajatovic M, Coconcea N, Ignacio R, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: A 12-week, open label trial. J Clin Psychiatry. 2008;69(1):41&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18312036</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L, Tariot P, Dagerman K, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2018;s disease. N Engl J Med. 2006;355:1525&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer&#x2019;s Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Streim JE, Breder C, Swanink R, et al. Flexible dose aripiprazole in psychosis of Alzheimer&#x2019;s dementia [poster]. Presented at the 157th American Psychiatric Association Meeting; May 1&#x2013;6 2004; New York, NY. 2004.</Citation></Reference><Reference><Citation>Tariot PN, Schneider L, Katz I, et al. Quetiapine in nursing home residents with Alzheimer&#x2019;s dementia and psychosis. Presented at the 15th annual meeting of the American Association for Geriatric Psychiatry; Feb 24&#x2013;27, 2002; Orlando, Fl. 2002.</Citation></Reference><Reference><Citation>US Food and Drug Administration. 2003 safety alert: risperidone (Risperdal) [Dear Healthcare Professional Letter] Rockville, MD: US Food and Drug Administration; 2003. April 16, 2003.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Rockville, MD: US FDA; 2005. FDA Public Health Advisory.</Citation></Reference><Reference><Citation>Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319382</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Tractenberg RE, Jin S, et al. Assessing Alzheimer&#x2019;s disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications. J Psychiatr Res. 2002;36:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood S, Cummings JL, Hsu MA, et al. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134141</ArticleId><ArticleId IdType="pubmed">12451085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395813</ArticleId><ArticleId IdType="pubmed">15111472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong K, Tariot P, Minkwitz M, et al. Quetipine for treatment of agitation in elderly institutionalized patients with dementia: a randomized double blind trial. American College of Neuropsychopharmacology annual meeting; Dec 2004; San Juan, Puerto Rico. 2004.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18975643</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1268-6034</ISSN><JournalIssue CitedMedium="Print"><Issue>73</Issue><PubDate><Year>2008</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Soins. Gerontologie</Title><ISOAbbreviation>Soins Gerontol</ISOAbbreviation></Journal><ArticleTitle>[Symptoms of psychiatric diseases in the aged].</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>34</EndPage><MedlinePgn>32-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Dastumer</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Groupe hospitalier Sainte-P&#xe9;rine-Chardon Lagache-Rossini (AP-HP), Paris. bruno.le-dastumer@spr.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>No&#xeb;l</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>S&#xe9;guy</LastName><ForeName>Carole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Thorez</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Les sympt&#xf4;mes psycho-comportementaux du sujet &#xe2;g&#xe9;.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Soins Gerontol</MedlineTA><NlmUniqueID>9616322</NlmUniqueID><ISSNLinking>1268-6034</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005851" MajorTopicYN="Y">Geriatric Nursing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005852" MajorTopicYN="N">Geriatric Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011568" MajorTopicYN="Y">Psychiatric Nursing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18975643</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18971872</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2008</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms and the progression of dementia of the Alzheimer type in nursing home residents.</ArticleTitle><Pagination><StartPage>CR559</StartPage><EndPage>CR567</EndPage><MedlinePgn>CR559-67</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behavioral and psychological symptoms are common in the course of dementia of the Alzheimer's type (DAT). Some behavioral and psychological symptoms may be predictors of the progression of dementia and cognitive impairment in DAT. However, studies on this topic face serious methodological problems. The aim of our study was to investigate how aggressive and impulsive behaviors correlate with the progression of dementia and related cognitive impairments in DAT patients.</AbstractText><AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">Using the Cohen-Mansfield Agitation Inventory (CMAI) and the ADAS-cog we examined 39 nursing home residents diagnosed with mild to moderate DAT. Of these participants, 26 were re-evaluated with the ADAS-cog two years after baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Aggressive and impulsive behaviors correlated with the degree of cognitive impairment. However, we also found that particular ADAS-cog items correlated differently with the CMAI score. Moreover, various CMAI categories were differently related to cognitive disorders. Impairments in cognitive functioning best explain the fluctuations of verbal aggression and physical agitation (non-aggressive). At baseline, the more demented subjects had a higher general score on the CMAI scale and showed greater rates of physical aggression, verbal aggression and non-aggressive physical agitation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Particular items of the CMAI scale significantly differentiated our subjects in terms of progression of cognitive impairment. Aggressive behaviors in patients with DAT are linked to both the severity of dementia and the rate of its progression. At the same time, significant differences were noted with respect to particular behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Leszek</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Developmental, Psychotic, and Geriatric Psychiatry, Medical University of Gdansk, Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachalska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grochmal-Bach</LastName><ForeName>Bozena</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Mariola</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jastrzebowska</LastName><ForeName>Grazyna</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="Y">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18971872</ArticleId><ArticleId IdType="pii">869443</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18929940</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0749-0704</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Critical care clinics</Title><ISOAbbreviation>Crit Care Clin</ISOAbbreviation></Journal><ArticleTitle>Detection and management of pre-existing cognitive impairment and associated behavioral symptoms in the Intensive Care Unit.</ArticleTitle><Pagination><StartPage>723</StartPage><EndPage>viii</EndPage><MedlinePgn>723-36, viii</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccc.2008.05.006</ELocationID><Abstract><AbstractText>Recent increase in both the elderly population and associated incidence of dementia are of critical importance to patient care in ICUs in the United States. Identification of pre-existing cognitive impairment, such as mild cognitive impairment and dementia, could prevent delirium and associated morbidity and mortality in the ICU. Additionally, noncognitive behavioral symptoms, such as depression, psychosis, agitation, and catastrophic reactions, are common in patients with pre-existing cognitive impairment. Detection and management of noncognitive behavioral symptoms associated with MRI and dementia in ICU leads to improved delivery of life-saving critical care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hochang B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287-5371, USA. Hochang@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeLoatch</LastName><ForeName>Candyce J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>SeongJin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mears</LastName><ForeName>Simon C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Sieber</LastName><ForeName>Frederick E</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH068793</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH068793-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Clin</MedlineTA><NlmUniqueID>8507720</NlmUniqueID><ISSNLinking>0749-0704</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005853" MajorTopicYN="N">Geriatrics</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18929940</ArticleId><ArticleId IdType="mid">NIHMS78119</ArticleId><ArticleId IdType="pmc">PMC2610456</ArticleId><ArticleId IdType="doi">10.1016/j.ccc.2008.05.006</ArticleId><ArticleId IdType="pii">S0749-0704(08)00031-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Census Bureau. Current Population Reports, Series P23-209. Sixty-Five Plus in US: 2005.  Retrieved March 6th 2008 from  www.census.gov.</Citation></Reference><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s Facts and Figures, 2007.  Retrieved March 6th, 2008 from  www.alz.org.</Citation></Reference><Reference><Citation>Chelluri L, Pinsky MR, Donahoe MP, et al. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA. 1993;269:3119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">8505814</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">1959406</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Kelley MA, Schmitz RJ, et al. Caring for the critically ill patient: current and projected workforce requirements for care of the critically ill and patients with pulmonary disease; can we meet the requirements of an aging population? JAMA. 2000;284:2762&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105183</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Wikstrom J, Palo J, et al. Dementia among medical inpatients: evaluation of 2000 consecutive admissions. Arch Intern Med. 1986;146:1923&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">3767536</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. 4. American Psychiatric Association; Washington, DC: 1994.</Citation></Reference><Reference><Citation>Rabins P, Lyketsos CG, Steele CD. Practical Dementia Care. Oxford University Press; New York: 1999.</Citation></Reference><Reference><Citation>Fox N, Warrington E, Seiffer A, Agnew S, Rossor M. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer&#x2019;s disease: a longitudinal prospective study. Brain. 1998;121:1631&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9269213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer&#x2019;s disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349:763&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9074575</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani MA, McNicoll L, et al. Cognitive Impairment in the Intensive Care Unit. Clinical Chest Medicine. 2003;24:727&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">14710700</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields SD, MacKenzie CR, Charlson ME, et al. Cognitive impairment: can it predict the course of hospitalized patients? J Am Geriatr Soc. 1986;34:579&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">3088089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) Crit Care Med. 2001;29(7):1370&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445689</ArticleId></ArticleIdList></Reference><Reference><Citation>McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc. 2003;51(5):591&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani MA, Murphy TE, Van Ness PH, Araujo KL, Inouye SK. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med. 2007;167(15):1629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698685</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006;354(11):1157&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16540616</ArticleId></ArticleIdList></Reference><Reference><Citation>Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001;27(12):1892&#x2013;00.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095464</ArticleId><ArticleId IdType="pubmed">11797025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15082703</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompei P, Foreman M, Rudberg MA, Inouye SK, Braund V, Cassel CK. Delirium in hospitalized older persons: outcomes and predictors. J Am Geriatr Soc. 1994;42(8):809&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8046190</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe ST, Lavan JN. Predicting delirium in elderly patients: development and validation of a risk-stratification model. Age Ageing. 1996;25(4):317&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831879</ArticleId></ArticleIdList></Reference><Reference><Citation>Litaker D, Locala J, Franco K, Bronson DL, Tannous Z. Preoperative risk factors for postoperative delirium. Gen Hosp Psychiatry. 2001;23(2):84&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry. 2003;25(5):345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972226</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild JM, Leape LL, Smith AH. The Nature and Extent of Medical Injury in Older Patients: Executive Summary. Washington, DC: AARP Public Policy Institute; 2000.</Citation></Reference><Reference><Citation>Roca RP, Klein LE, Kirby SM, et al. Recognition of dementia among medical patients. Arch Intern Med. 1984;144:73&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6691777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani MA, Redlich C, et al. Under-recognition of Pre-existing Cognitive Impairment by Physicians in Older ICU Patients. Chest. 2003;124:2267&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665510</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med. 1995;122:422&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">7856990</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160:2964&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardern M, Mayou R, Feldman E, et al. Cognitive impairment in the elderly medically ill: how often is it missed. Int J Geriatr Psychiatry. 1993;8:929&#x2013;37.</Citation></Reference><Reference><Citation>Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27:859&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430542</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Research. 1975;12(3):189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Scott R, Cullen JS, et al. Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia. Psychol Med. 1991;21:785&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">1946866</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani MA, Inouye SK, McNicoll L, Redlich CA. Screening for pre-existing cognitive impairment in older intensive care unit patients: use of proxy assessment. J Am Geriatr Soc. 2003;51(5):689&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, et al. Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment. Results from the cardiovascular health study. JAMA. 2002;288:1475&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg M, Sheppard JM, et al. The Incidence of Mental and Behavioral Disturbances in Dementia: the Cache County Study. J Neuropsychiatry Clin Neurosci. 2003;15:340&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928510</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg M, Tschanz JT, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2004;19:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan DC, Kasper JD, Black BS, Rabins PV. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry. 2003;18(2):174&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12571828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Olin J. Depression in Alzheimer&#x2019;s disease: overview and treatment. Biol Psychiatry. 2002;52(3):243&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182930</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002;10(2):129&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11925274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson&#x2019;s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137166</ArticleId><ArticleId IdType="pubmed">17898337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. Neuropsychopharmacology. 2007 Jul 18; Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553721</ArticleId><ArticleId IdType="pubmed">17637610</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LJ. The use of cognitive enhancers in behavioral disturbances of Alzheimer&#x2019;s disease. Consult Pharm. 2007;22:754&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198970</ArticleId></ArticleIdList></Reference><Reference><Citation>Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, Tariot PN. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2005;2(5):553&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16375658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. Alzheimer&#x2019;s Disease Cooperative Study, Valproate Nursing Home Study Group. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13(11):942&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9433339</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmalee PA. Pain in cognitively impaired older persons. Clin Geriatr Med. 1996;12(3):473&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">8853940</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18925489</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1369-1627</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International review of psychiatry (Abingdon, England)</Title><ISOAbbreviation>Int Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in dementia: importance and treatment considerations.</ArticleTitle><Pagination><StartPage>396</StartPage><EndPage>404</EndPage><MedlinePgn>396-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540260802099968</ELocationID><Abstract><AbstractText>Neuropsychiatric symptoms are frequent in people with dementia, result in distress for the people experiencing them and their caregivers, and are a common precipitant of institutional care. The safe and effective treatment of these symptoms is a key clinical priority, but is a long way from being achieved. Psychological interventions are recommended as the first line treatment strategy in most good practice guidelines, and there is emerging evidence of efficacy for agitation and depression. Neuroleptics remain the mainstay of pharmacological treatment, although meta-analyses indicate that they are mainly of benefit for the short-term (up to 12 weeks) treatment of aggression in people with Alzheimer's disease, and there have been increasing concerns about serious adverse effects including mortality. The evidence is limited for other pharmacological approaches for the treatment of agitation, and psychosis in people with Alzheimer's disease is limited, but post-hoc analyses do indicate that memantine may be a promising therapy and aromatherapy may be a useful alternative. Autopsy studies indicate that the adrenergic system may be an important therapeutic target. Clinical experience suggests that antidepressants are effective in people with severe depression in the context of dementia, but the evidence base regarding the broader value of antidepressants is far from clear. There are very few trials specifically focusing upon the treatment of neuropsychiatric symptoms in common non-Alzheimer dementias, which is a major limitation and urgently needs to be addressed to provide an evidence base to enable the safe and effective treatment of these individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wing</LastName><ForeName>Gayle</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Psychiatry</MedlineTA><NlmUniqueID>8918131</NlmUniqueID><ISSNLinking>0954-0261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>85</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18925489</ArticleId><ArticleId IdType="doi">10.1080/09540260802099968</ArticleId><ArticleId IdType="pii">904265078</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18923405</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Target identification for CNS diseases by transcriptional profiling.</ArticleTitle><Pagination><StartPage>18</StartPage><EndPage>54</EndPage><MedlinePgn>18-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/npp.2008.172</ELocationID><Abstract><AbstractText>Gene expression changes in neuropsychiatric and neurodegenerative disorders, and gene responses to therapeutic drugs, provide new ways to identify central nervous system (CNS) targets for drug discovery. This review summarizes gene and pathway targets replicated in expression profiling of human postmortem brain, animal models, and cell culture studies. Analysis of isolated human neurons implicates targets for Alzheimer's disease and the cognitive decline associated with normal aging and mild cognitive impairment. In addition to tau, amyloid-beta precursor protein, and amyloid-beta peptides (Abeta), these targets include all three high-affinity neurotrophin receptors and the fibroblast growth factor (FGF) system, synapse markers, glutamate receptors (GluRs) and transporters, and dopamine (DA) receptors, particularly the D2 subtype. Gene-based candidates for Parkinson's disease (PD) include the ubiquitin-proteosome system, scavengers of reactive oxygen species, brain-derived neurotrophic factor (BDNF), its receptor, TrkB, and downstream target early growth response 1, Nurr-1, and signaling through protein kinase C and RAS pathways. Increasing variability and decreases in brain mRNA production from middle age to old age suggest that cognitive impairments during normal aging may be addressed by drugs that restore antioxidant, DNA repair, and synaptic functions including those of DA to levels of younger adults. Studies in schizophrenia identify robust decreases in genes for GABA function, including glutamic acid decarboxylase, HINT1, glutamate transport and GluRs, BDNF and TrkB, numerous 14-3-3 protein family members, and decreases in genes for CNS synaptic and metabolic functions, particularly glycolysis and ATP generation. Many of these metabolic genes are increased by insulin and muscarinic agonism, both of which are therapeutic in psychosis. Differential genomic signals are relatively sparse in bipolar disorder, but include deficiencies in the expression of 14-3-3 protein members, implicating these chaperone proteins and the neurotransmitter pathways they support as possible drug targets. Brains from persons with major depressive disorder reveal decreased expression for genes in glutamate transport and metabolism, neurotrophic signaling (eg, FGF, BDNF and VGF), and MAP kinase pathways. Increases in these pathways in the brains of animals exposed to electroconvulsive shock and antidepressant treatments identify neurotrophic and angiogenic growth factors and second messenger stimulation as therapeutic approaches for the treatment of depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altar</LastName><ForeName>C Anthony</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>NeuroDrug Consulting, Garrett Park, MD 20896-0498, USA. tonyaltar@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vawter</LastName><ForeName>Marquis P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG014449-07</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-010003</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617-090008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH074307-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-11A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-020003</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447-050001</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-08</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617-070008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447-01A20001</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617-080008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-06</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH074307-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447-030001</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-09</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS48447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617-060008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH085801</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447-040001</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-10</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-03</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH074307</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447-020001</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005069" MajorTopicYN="N">Evaluation Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18923405</ArticleId><ArticleId IdType="mid">NIHMS76513</ArticleId><ArticleId IdType="pmc">PMC2675576</ArticleId><ArticleId IdType="doi">10.1038/npp.2008.172</ArticleId><ArticleId IdType="pii">npp2008172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer&#x2019;s disease. J Neurosci Res. 2002;70:447&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391605</ArticleId></ArticleIdList></Reference><Reference><Citation>ABI. Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR. Foster City, CA: Applied Biosystems Inc.; 2004. pp. 1&#x2013;60. Product Guide.</Citation></Reference><Reference><Citation>Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, et al. GAD1 (2q31.1) which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry. 2005;10:581&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505639</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han V, Lin R, et al. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem. 2003;278:12722&#x2013;12728.</Citation><ArticleIdList><ArticleId IdType="pubmed">12551948</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jr, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995;52:258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">7702443</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23:10800&#x2013;10808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374594</ArticleId><ArticleId IdType="pubmed">14645472</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA. Neurotrophins and depression. Trends Pharmacol Sci. 1999;20:59&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10101965</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Hunt RA, Jurata LW, Webster MJ, Derby E, Gallagher P, et al. Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry. 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">18973876</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry. 2005;58:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16038679</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci. 2004;24:2667&#x2013;2677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729526</ArticleId><ArticleId IdType="pubmed">15028759</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Marshall JF. Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors. Ann NY Acad Sci. 1988;515:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">3364894</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Martin A, Thurkauf A. Antipsychotic agents. In: Abraham DJ, editor. Burger&#x2019;s Medicinal Chemistry and Drug Discovery. Hoboken: Wiley &amp; Sons; 2003a. pp. 599&#x2013;672.</Citation></Reference><Reference><Citation>Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull. 1986;16:517&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">2872945</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry. 2003b;54:703&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512210</ArticleId></ArticleIdList></Reference><Reference><Citation>Amenta F, Mignini F, Ricci A, Sabbatini M, Tomassoni D, Tayebati SK. Age-related changes of dopamine receptors in the rat hippocampus: a light microscope autoradiography study. Mech Ageing Dev. 2001;122:2071&#x2013;2083.</Citation><ArticleIdList><ArticleId IdType="pubmed">11589924</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand R, Seiberling M, Kamtchoua T, Pokorny R. Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers. Clin Pharma-cokinet. 2007;46:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">17375985</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289330</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AA, Kendal CE, Garcia-Maya M, Kenny AV, Morris-Triggs SA, Wu T, et al. A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival. J Neurochem. 2005;95:570&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135080</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res. 2006;66:1949&#x2013;1955.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang ET, Gomez-Pinilla F. Potential therapeutic effects of exercise to the brain. Curr Med Chem. 2007;14:2564&#x2013;2571.</Citation><ArticleIdList><ArticleId IdType="pubmed">17979709</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyama S, Koga K, Mori A, Miyaji H, Sekine S, Kase H, et al. Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res. 2002;953:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384245</ArticleId></ArticleIdList></Reference><Reference><Citation>Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsycho-pharmacology. 2001;25:892&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750182</ArticleId></ArticleIdList></Reference><Reference><Citation>Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2007;62:711&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2080683</ArticleId><ArticleId IdType="pubmed">17568569</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res. 2004;77:858&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">15334603</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. 2005;10:309&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15303102</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience. 2002;114:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12220580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol. 2005;32:173&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">16215281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC. Gene expression profiling in the post-mortem human brain&#x2014;no cause for dismay. J Chem Neuroanat. 2001;22:79&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470556</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker C, Belbin O, Kalsheker N, Morgan K. SERPINA3 (aka alpha-1-antichymotrypsin) Front Biosci. 2007;12:2821&#x2013;2835.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485262</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A, et al. Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. Neuropsychopharmacology. 2007;32:1774&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203012</ArticleId></ArticleIdList></Reference><Reference><Citation>Barja G. Free radicals and aging. Trends Neurosci. 2004;27:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15374670</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton AJL, Pearson RCA, Najlerahim A, Harrison PJ. Pre- and postmortem influences on brain RNA. J Neurochem. 1993;61:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7685811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10833325</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley CL, Pennington K, Behan A, Wait R, Dunnx MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics. 2006;6:3414&#x2013;3425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16637010</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res. 1997;24:349&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">9134596</ArticleId></ArticleIdList></Reference><Reference><Citation>Behan A, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18268500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R, Munro J, Russ C, Powell JF, Bruinvels A, Kerwin RW, et al. Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case&#x2013;control analysis in schizophrenia. Am J Med Genet. 2000;96:736&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121172</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Berretta S. Amygdalo-entorhinal inputs to the hippocampal formation in relation to schizophrenia. Ann NY Acad Sci. 2000;911:293&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911881</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci USA. 2007;104:10164&#x2013;10169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888575</ArticleId><ArticleId IdType="pubmed">17553960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezin V, Bock E. NCAM mimetic peptides: pharmacological and therapeutic potential. J Mol Neurosci. 2004;22:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">14742908</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci. 2003;4:752&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951567</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger UV, Hediger MA. Distribution of the glutamate transporters GLT-1 (SLC1A2) and GLAST (SLC1A3) in peripheral organs. Anat Embryol (Berl) 2006;211:595&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">16868771</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsch B, Ogden CA, Sidhu K, Le-Niculescu H, Kuczenski R, Niculescu AB. Convergent functional genomics: a Bayesian candidate gene identification approach for complex disorders. Methods. 2005;37:274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">16308156</ArticleId></ArticleIdList></Reference><Reference><Citation>Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008;17:1156&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184693</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci. 2003;23:3807&#x2013;3819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742177</ArticleId><ArticleId IdType="pubmed">12736351</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer&#x2019;s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press; 1950.</Citation></Reference><Reference><Citation>Boissiere F, Faucheux B, Ruberg M, Agid Y, Hirsch EC. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer&#x2019;s disease. Exp Neurol. 1997;145:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997;278:1481&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">9411767</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscher C, Mege RM. Cadherin-11 interacts with the FGF receptor and induces neurite outgrowth through associated downstream signalling. Cell Signal. 2008;20:1061&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">18302981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res Bull. 2005;65:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811599</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry. 2002;41:9003&#x2013;9014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2571077</ArticleId><ArticleId IdType="pubmed">12119013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges D, Moorhead GB. 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE. 2005;2005:re10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16091624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RL, et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer&#x2019;s disease. Brain Res. 2007;1127:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">17109828</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9915498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res. 2005;75:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunney WE, Bunney BG, Vawter MP, Tomita H, Li J, Evans SJ, et al. Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. Am J Psychiatry. 2003;160:657&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668351</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbaeva GS, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:675&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustany P, Trenque T, Crambes O, Moulin M. Restoration of brain protein synthesis in mature and aged rats by a DA agonist, piribedil. Fundam Clin Pharmacol. 1995;9:458&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">8617410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol. 2002;29:23&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">12200227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002;1:163&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769625</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan LM, Vaules WA, Coleman PD. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:275&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197819</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson R, Craig D, McGuinness B, Johnston JA, O&#x2019;Neill FA, Passmore AP, et al. Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer&#x2019;s disease. J Med Genet. 2008;45:244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057084</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter TL, Rissman RA, Mishizen-Eberz AJ, Wolfe BB, Hamilton RL, Gandy S, et al. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer&#x2019;s disease patients according to Braak stage. Exp Neurol. 2004;187:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15144856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecconi D, Mion S, Astner H, Domenici E, Righetti PG, Carboni L. Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res. 2007;1135:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196950</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AC, Shin KH, Duman RS, Sanacora G. ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT. 2001;17:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11281511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: causal or correlative? Nucleic Acids Res. 2007;35:7417&#x2013;7428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190714</ArticleId><ArticleId IdType="pubmed">17913751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, Chen CH. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol. 2008;11:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868501</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Black IB, DiCicco-Bloom E. Hippocampal granule neuron production and population size are regulated by levels of bFGF. Eur J Neurosci. 2002;15:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin MH, Qian WJ, Wang H, Petyuk VA, Bloom JS, Sforza DM, et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson&#x2019;s disease. J Proteome Res. 2008;4:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319057</ArticleId><ArticleId IdType="pubmed">18173235</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson&#x2019;s and Alzheimer&#x2019;s diseases. J Biol Chem. 2004;279:13256&#x2013;13264.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722078</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res. 2008;100:270&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746974</ArticleId><ArticleId IdType="pubmed">18243664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou TF, Wagner CR. Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins. J Biol Chem. 2007;282:4719&#x2013;4727.</Citation><ArticleIdList><ArticleId IdType="pubmed">17158446</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005;102:15653&#x2013;15658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257393</ArticleId><ArticleId IdType="pubmed">16230605</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen C, Lauridsen JB, Berezin V, Bock E, Kiselyov VV. The neural cell adhesion molecule binds to fibroblast growth factor receptor 2. FEBS Lett. 2006;580:3386&#x2013;3390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709412</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson&#x2019;s disease and related disorders. J Comp Neurol. 2006;494:495&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564615</ArticleId><ArticleId IdType="pubmed">16320253</ArticleId></ArticleIdList></Reference><Reference><Citation>Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002;70:462&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391607</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, He B, Che S, Ikonomovic MD, Dekosky ST, Ginsberg SD, et al. {alpha}7 Nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol. 2007;64:1771&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071042</ArticleId></ArticleIdList></Reference><Reference><Citation>Couve A, Kittler JT, Uren JM, Calver AR, Pangalos MN, Walsh FS, et al. Association of GABA(B) receptors and members of the 14-3-3 family of signaling proteins. Mol Cell Neurosci. 2001;17:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11178869</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft LL, Freund KM, Culpepper L, Perna FM. Intervention study of exercise for depressive symptoms in women. J Womens Health. 2007;16:1499&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">18062765</ArticleId></ArticleIdList></Reference><Reference><Citation>Crino PB, Khodakhah K, Becker K, Ginsberg SD, Hemby S, Eberwine JH. Presence and phosphorylation of transcription factors in dendrites. Proc Natl Acad Sci USA. 1998;95:2313&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19330</ArticleId><ArticleId IdType="pubmed">9482882</ArticleId></ArticleIdList></Reference><Reference><Citation>de Magalhaes JP. From cells to ageing: a review of models and mechanisms of cellular senescence and their impact on human ageing. Exp Cell Res. 2004;300:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383309</ArticleId></ArticleIdList></Reference><Reference><Citation>de Magalhaes JP, Costa J, Toussaint O. HAGR: the Human Ageing Genomic Resources. Nucleic Acids Res. 2005;33(Database issue):D537&#x2013;D543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539971</ArticleId><ArticleId IdType="pubmed">15608256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean B, Boer SA, Mackinnon A, Berk M. CNS 14-3-3zeta: changes with sex but not psychiatric diagnoses or psychotropic drug treatment. Schizophr Res. 2007;93:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17399951</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+presenilin&#x2212;1 transgenic mice. J Neurosci. 2003;23:5219&#x2013;5226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741153</ArticleId><ArticleId IdType="pubmed">12832546</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty P, Walsh FS. CAM-FGF receptor interactions: a model for axonal growth. Mol Cell Neurosci. 1996;8:99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">8954625</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan S, Gao R, Xing Q, Du J, Liu Z, Chen Q, et al. A family-based association study of schizophrenia with polymorphisms at three candidate genes. Neurosci Lett. 2005;379:32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15814194</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson&#x2019;s disease. Neurogenetics. 2006;7:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699787</ArticleId></ArticleIdList></Reference><Reference><Citation>Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236543</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi Y, Mondal AC, Rizavi HS, Conley RR. Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry. 2005;58:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">15939410</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60:804&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12912764</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberwine J, Kacharmina JE, Andrews C, Miyashiro K, McIntosh T, Becker K, et al. mRNA expression analysis of tissue sections and single cells. J Neurosci. 2001;21:8310&#x2013;8314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762801</ArticleId><ArticleId IdType="pubmed">11606616</ArticleId></ArticleIdList></Reference><Reference><Citation>Eells JB, Lipska BK, Yeung SK, Misler JA, Nikodem VM. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res. 2002;136:267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12385813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr. 2008;18:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">18089462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9:42&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">14581931</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Hariry I, Pignatelli M, Lemoine NR. FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. Br J Cancer. 2001a;84:1656&#x2013;1663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2363682</ArticleId><ArticleId IdType="pubmed">11401320</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Hariry I, Pignatelli M, Lemoine NR. FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer. 2001b;94:652&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">11745459</ArticleId></ArticleIdList></Reference><Reference><Citation>Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, et al. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci. 2007;31:221&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17726228</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996;274:998&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">8875945</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H, et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA. 2004;101:15506&#x2013;15511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC523463</ArticleId><ArticleId IdType="pubmed">15483108</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SJ, Choudary PV, Vawter MP, Li J, Meador-Woodruff JH, Lopez JF, et al. DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles. Neurobiol Dis. 2003;14:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098567</ArticleId><ArticleId IdType="pubmed">14572446</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyles D, Almeras L, Benech P, Patiatian A, Mackay-Sim A, McGrath J, et al. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol. 2007;103:538&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">17293106</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber R, Trimble MR. Electroconvulsive therapy in Parkinson&#x2019;s disease and other movement disorders. Mov Disord. 1991;6:293&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">1758447</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology. 2006;31:1888&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407901</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Ageing and Parkinson&#x2019;s disease: substantia nigra regional selectivity. Brain. 1991;114:2283&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, et al. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol. 1999;154:61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853427</ArticleId><ArticleId IdType="pubmed">9916919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 1997;321:143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9063681</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman WM, Hemby SE. Proteomics for protein expression profiling in neuroscience. Neurochem Res. 2004;29:1065&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843356</ArticleId><ArticleId IdType="pubmed">15176464</ArticleId></ArticleIdList></Reference><Reference><Citation>Frizzo ME, Dall&#x2019;Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15049516</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Ginsberg SD. Expression profiling in the aging brain: a perspective. Ageing Res Rev. 2005;4:529&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly S, Gastel JA, Weller JL, Schwartz C, Jaffe H, Namboodiri MA, et al. Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. Proc Natl Acad Sci USA. 2001;98:8083&#x2013;8088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC35471</ArticleId><ArticleId IdType="pubmed">11427721</ArticleId></ArticleIdList></Reference><Reference><Citation>Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology. 2003;28:1515&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12799618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull. 2006;70:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gems D, McElwee JJ. Ageing: microarraying mortality. Nature. 2003;424:259&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD. Expression profile analysis of brain aging. In: Riddle DR, editor. Brain Aging: Models, Methods and Mechanisms. New York: CRC Press; 2007. pp. 159&#x2013;185.</Citation></Reference><Reference><Citation>Ginsberg SD, Che S, Counts SE, Mufson EJ. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurochem. 2006a;96:1401&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">16478530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Counts SE, Mufson EJ. Single cell gene expression profiling in Alzheimer&#x2019;s disease. NeuroRx. 2006b;3:302&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593387</ArticleId><ArticleId IdType="pubmed">16815214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75 gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer&#x2019;s disease. J Neurochem. 2006c;97:475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VM-Y, Eberwine JH, et al. Predominance of neuronal mRNAs in individual Alzheimer&#x2019;s disease senile plaques. Ann Neurol. 1999a;45:174&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Crino PB, Lee VM-Y, Eberwine JH, Trojanowski JQ. Sequestration of RNA in Alzheimer&#x2019;s disease neurofibrillary tangles and senile plaques. Ann Neurol. 1997;41:200&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Elarova I, Ruben M, Tan F, Counts SE, Eberwine JH, et al. Single cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res. 2004;29:1054&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">15176463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Galvin JE, Chiu T-S, Lee VM-Y, Masliah E, Trojanowski JQ. RNA sequestration to pathological lesions of neurodegenerative disorders. Acta Neuropathol. 1998;96:487&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Hemby SE, Lee VM-Y, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in Alzheimer&#x2019;s disease tangle-bearing CA1 neurons. Ann Neurol. 2000;48:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ. Cell and tissue microdissection in combination with genomic and proteomic applications. In: Zaborszky L, Wouterlood FG, Lanciego JL, editors. Neuroanatomical Tract Tracing 3: Molecules, Neurons, and Systems. New York: Springer; 2006d. pp. 109&#x2013;141.</Citation></Reference><Reference><Citation>Ginsberg SD, Mirnics K. Functional genomic methodologies. Prog Brain Res. 2006;158:15&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Schmidt ML, Crino PB, Eberwine JH, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer&#x2019;s disease and related disorders. In: Peters A, Morrison JH, editors. Cerebral Cortex. Neurodegenerative and Age-Related Changes in Structure and Function of Cerebral Cortex. vol. 14. New York: Kluwer Academic/Plenum; 1999b. pp. 603&#x2013;653.</Citation></Reference><Reference><Citation>Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159:1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091195</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden TR, Melov S. Microarray analysis of gene expression with age in individual nematodes. Aging Cell. 2004;3:111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15153179</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsworthy SM, Stockton PS, Trempus CS, Foley JF, Maronpot RR. Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue. Mol Carcinog. 1999;25:86&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">10365909</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodnick PJ. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother. 2006;7:401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503812</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J. Tau and transgenic animal models. Brain Res Brain Res Rev. 2001;35:266&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423157</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry. 2004;9:734&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">15136794</ArticleId></ArticleIdList></Reference><Reference><Citation>Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. J Neural Transm. 1996;103:249&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8739837</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray L, Scarr E, Dean B. N-Ethylmaleimide sensitive factor in the cortex of subjects with schizophrenia and bipolar I disorder. Neurosci Lett. 2006;391:112&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16165270</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in Parkinsonism. Neurobiol Dis. 2005;18:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649693</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin&#x2013;proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111:1543&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15455214</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E, Mandel S, Maor G, Youdim MB. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson&#x2019;s disease using cDNA microarray: effect of R-apomorphine. J Neurochem. 2001;78:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432968</ArticleId></ArticleIdList></Reference><Reference><Citation>Guang W, Wang H, Su T, Weinstein IB, Wang JB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol. 2004;66:1285&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496510</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57:1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutala RV, Reddy PH. The use of real-time PCR analysis in a gene expression study of Alzheimer&#x2019;s disease post-mortem brains. J Neurosci Methods. 2004;132:101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687679</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">17388706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 2001;98:4746&#x2013;4751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31905</ArticleId><ArticleId IdType="pubmed">11296301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554096</ArticleId><ArticleId IdType="pubmed">15707482</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 2007;10:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">17291370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2008;13:147&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882638</ArticleId><ArticleId IdType="pubmed">17471287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 2005;25:372&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725470</ArticleId><ArticleId IdType="pubmed">15647480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23:6315&#x2013;6326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740534</ArticleId><ArticleId IdType="pubmed">12867516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hata R, Masumura M, Akatsu H, Li F, Fujita H, Nagai Y, et al. Up-regulation of calcineurin Abeta mRNA in the Alzheimer&#x2019;s disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun. 2001;284:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">11394878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser ER, Pericak-Vance MA. Genetic analysis for common complex disease. Am Heart J. 2000;140:S36&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11011322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with Parkinsonism. Arch Neurol. 2005;62:917&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa T, Ishiguro H, Toru M, Hamaguchi H, Arinami T. Systematic search for mutations in the 14-3-3 eta chain gene on chromosome 22 in schizophrenics. Psychiatr Genet. 1998;8:33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9564686</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci. 2003;28:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193979</ArticleId><ArticleId IdType="pubmed">14517576</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffernan JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ. Temporal cortex synaptophysin mRNA is reduced in Alzheimer&#x2019;s disease and is negatively correlated with the severity of dementia. Exp Neurol. 1998;150:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellsten J, Wennstrom M, Mohapel P, Ekdahl CT, Bengzon J, Tingstrom A. Electroconvulsive seizures increase hippocampal neurogenesis after chronic corticosterone treatment. Eur J Neurosci. 2002;16:283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry. 2002;59:631&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12090816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemby SE, Trojanowski JQ, Ginsberg SD. Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. J Comp Neurol. 2003;456:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4048549</ArticleId><ArticleId IdType="pubmed">12509874</ArticleId></ArticleIdList></Reference><Reference><Citation>Henshall DC, Araki T, Schindler CK, Lan JQ, Tiekoter KL, Taki W, et al. Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J Neurosci. 2002;22:8458&#x2013;8465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757765</ArticleId><ArticleId IdType="pubmed">12351720</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs BW, Elashoff M, Richman S, Barci B. An online database for brain disease research. BMC Genomics. 2006;7:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489945</ArticleId><ArticleId IdType="pubmed">16594998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer&#x2019;s disease assessed by DNA microarray technique. Neurosci Lett. 2001;298:191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11165439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC328459</ArticleId><ArticleId IdType="pubmed">14519205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR, et al. Antidepressant actions of the exercise-regulated gene VGF. Nat Med. 2007;13:1476&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt-Newbury R, Viveiros R, Johnsen R, Mah A, Anastas D, Fang L, et al. High-throughput in vivo analysis of gene expression in Caenorhabditis elegans. PLoS Biol. 2007;5:e237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1971126</ArticleId><ArticleId IdType="pubmed">17850180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd MR, Lewohl JM, Scott HL, Dodd PR. Biochemical and molecular studies using human autopsy brain tissue. J Neurochem. 2003;85:543&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">12694381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer&#x2019;s disease. Hippocampus. 1995;5:469&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773259</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai C, Sugai T, Iritani S, Niizato K, Nakamura R, Makifuchi T, et al. A quantitative study on the expression of synapsin II and N-ethylmaleimidesensitive fusion protein in schizophrenic patients. Neurosci Lett. 2001;305:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara A, Saito H, Nishiyama N. Basic fibroblast growth factor ameliorates learning deficits in basal forebrain-lesioned mice. Jpn J Pharmacol. 1992;59:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1507660</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563509</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K, Kato T. Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist. 2006;12:349&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16840711</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Nomoto M, Miyata A. Microarray analysis of laser capture microdissected substantia nigra pars compacta after a single administration of MPTP in common marmosets. Nihon Shinkei Seishin Yakurigaku Zasshi. 2007;27:161&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer&#x2019;s disease. J Alzheimers Dis. 2007;11:97&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P, et al. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA. 2007;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042206</ArticleId><ArticleId IdType="pubmed">17911251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeanclos EM, Lin L, Treuil MW, Rao J, DeCoster MA, Anand R. The chaperone protein 14-3-3eta interacts with the nicotinic acetylcholine receptor alpha 4 subunit. Evidence for a dynamic role in subunit stabilization. J Biol Chem. 2001;276:28281&#x2013;28290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352901</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Yu X, Zhang B, Yuan Y, Xu Q, Shen Y. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. Eur Psychiatry. 2004;19:377&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363479</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18072813</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods. 1997;77:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9402561</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce JN, Kaeger C, Ryoo H, Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer&#x2019;s disease. Neurosci Lett. 1993;154:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">8361636</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurata LW, Bukhman YV, Charles V, Capriglione F, Bullard J, Lemire AL, et al. Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods. 2004;138:173&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325126</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski N, Friedman N. Practical approaches to analyzing results of microarray experiments. Am J Respir Cell Mol Biol. 2002;27:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10:381&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851172</ArticleId></ArticleIdList></Reference><Reference><Citation>Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res. 2007;92:108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363222</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002;16:1328&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154010</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res. 2005a;77:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">15923110</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel PL, Davis KL, Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer&#x2019;s disease. Int Rev Neurobiol. 2005b;63:41&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797465</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer&#x2019;s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22:475&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics. 2007;8:413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211497</ArticleId><ArticleId IdType="pubmed">17997842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120:437&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734677</ArticleId></ArticleIdList></Reference><Reference><Citation>Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, et al. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25&#x2013;35. Neuroscience. 2007;145:209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17223274</ArticleId></ArticleIdList></Reference><Reference><Citation>Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, Ffrench-Mullen J, et al. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17938633</ArticleId></ArticleIdList></Reference><Reference><Citation>Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF. Molecular abnormalities in the major psychiatric illnesses: classification and regression tree (CRT) analysis of post-mortem prefrontal markers. Mol Psychiatry. 2002;7:392&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986983</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig R, Baldessari D, Pollet N, Niehrs C, Eils R. Reliability of gene expression ratios for cDNA microarrays in multiconditional experiments with a reference design. Nucleic Acids Res. 2004;32:e29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373422</ArticleId><ArticleId IdType="pubmed">14966261</ArticleId></ArticleIdList></Reference><Reference><Citation>Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kothapalli R, Yoder SJ, Mane S, Loughran TP., Jr Microarray results: how accurate are they? BMC Bioinformatics. 2002;3:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126254</ArticleId><ArticleId IdType="pubmed">12194703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozisek ME, Middlemas D, Bylund DB. The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment. Neuropharmacology. 2008;54:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraeplin E. Dementia Praecox and Paraphrenia. Huntington: RE Krieger Publishing; 1919.</Citation></Reference><Reference><Citation>Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics. 2002;18:405&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">11934739</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbe EE, Welsh MC, Delaney D. Effects of consistent aerobic exercise on the psychological functioning of women. Percept Mot Skills. 1988;67:919&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">3226848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, Haroutunian V. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience. 2006;137:843&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20:8&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774091</ArticleId><ArticleId IdType="pubmed">10627576</ArticleId></ArticleIdList></Reference><Reference><Citation>Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry. 2008;26:26.</Citation><ArticleIdList><ArticleId IdType="pubmed">18301394</ArticleId></ArticleIdList></Reference><Reference><Citation>Le-Niculescu H, McFarland MJ, Mamidipalli S, Ogden CA, Kuczenski R, Kurian SM, et al. Convergent functional genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers. Neurosci Biobehav Rev. 2007;31:897&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313450</ArticleId><ArticleId IdType="pubmed">17614132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet. 2000;25:294&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Song JY, Kim JW, Jin SY, Hong MS, Park JK, et al. Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia. Behav Brain Funct. 2005;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1215472</ArticleId><ArticleId IdType="pubmed">16131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Gomez-Ramirez J, Johnston TH, Visanji N, Brotchie JM. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated l-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson&#x2019;s disease. Synapse. 2008;62:310&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">18241048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrmann E, Hyde TM, Vawter MP, Becker KG, Kleinman JE, Freed WJ. The use of microarrays to characterize neuropsychiatric disorders: postmortem studies of substance abuse and schizophrenia. Curr Mol Med. 2003a;3:437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">12942997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrmann E, Oyler J, Vawter MP, Hyde TM, Kolachana B, Kleinman JE, et al. Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003b;3:27&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1907635</ArticleId><ArticleId IdType="pubmed">12629581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030651</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV, et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet. 2004;13:609&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734628</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Kolkova K, Rudenko O, Soroka V, Poulsen FM, Bock E, et al. Triple effect of mimetic peptides interfering with neural cell adhesion molecule homophilic cis interactions. Biochemistry. 2005;44:5034&#x2013;5040.</Citation><ArticleIdList><ArticleId IdType="pubmed">15794641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci. 2007;8:803&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17882256</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Puche AC, Wang JB. Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS) Neurochem Res. 2008;33:1263&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">18270824</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT., Jr The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson&#x2019;s disease susceptibility. Cell. 2002;111:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pubmed">9634850</ArticleId></ArticleIdList></Reference><Reference><Citation>Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer&#x2019;s disease. DNA Cell Biol. 2001;20:683&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe XR, Lu X, Marchetti F, Wyrobek AJ. The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. Brain Res. 2007;1174:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17850769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res. 2004;29:1287&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15176485</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med. 1999;5:117&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883850</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhav TR, Pei Q, Zetterstrom TS. Serotonergic cells of the rat raphe nuclei express mRNA of tyrosine kinase B (trkB), the high-affinity receptor for brain derived neurotrophic factor (BDNF) Brain Res Mol Brain Res. 2001;93:56&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">11532338</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingstrom A. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry. 2000;47:1043&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862803</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng S, Zarate CA, Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">17643398</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science. 1999;283:496&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamounas LA, Blue ME, Siuciak JA, Altar CA. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci. 1995;15:7929&#x2013;7939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577955</ArticleId><ArticleId IdType="pubmed">8613731</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer&#x2019;s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004;5:147&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15075441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel S, Weinreb O, Youdim M. Using cDNA microarray to assess Parkinson&#x2019;s disease models and the effects of neuroprotective drugs. Trends Pharmacol Sci. 2003;24:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, et al. Suicide prevention strategies: a systematic review. JAMA. 2005;294:2064&#x2013;2074.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249421</ArticleId></ArticleIdList></Reference><Reference><Citation>Martel RR, Botros IW, Rounseville MP, Hinton JP, Staples RR, Morales DA, et al. Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay Drug Dev Technol. 2002;1:61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090157</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin H, Rostas J, Patel Y, Aitken A. Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J Neurochem. 1994;63:2259&#x2013;2265.</Citation><ArticleIdList><ArticleId IdType="pubmed">7964746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33:2080&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">18172433</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka N, Nozaki K, Takagi Y, Nishimura M, Hayashi J, Miyatake S, et al. Adenovirus-mediated gene transfer of fibroblast growth factor-2 increases BrdU-positive cells after forebrain ischemia in gerbils. Stroke. 2003;34:1519&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730553</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzilevich DA, Rall JM, Moore AN, Grill RJ, Dash PK. High density microarray analysis of hippocampal gene expression following experimental brain injury. J Neurosci Res. 2002;67:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891777</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res. 2007;90:15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880890</ArticleId><ArticleId IdType="pubmed">17223013</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007;17:605&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Medhurst AD, Zeng BY, Charles KJ, Gray J, Reavill C, Hunter AJ, et al. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment. Neuroscience. 2001;105:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R, et al. Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res Mol Brain Res. 2005;139:317&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122832</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002;22:2718&#x2013;2729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758309</ArticleId><ArticleId IdType="pubmed">11923437</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton FA, Peng L, Lewis DA, Levitt P, Mirnics K. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology. 2005;30:974&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">15726117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikel UV, Becker RL., Jr A comparative study of quantitative stains for DNA in image cytometry. Analyt Quant Cytol Histol. 1991;13:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">1718295</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer&#x2019;s disease and normal aging. J Neurosci. 2008;28:1410&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="pubmed">18256261</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RM, Callahan LM, Casaceli C, Chen L, Kiser GL, Chui B, et al. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-lesioned mouse substantia nigra. J Neurosci. 2004;24:7445&#x2013;7454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729635</ArticleId><ArticleId IdType="pubmed">15329391</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson&#x2019;s disease. Neurobiol Dis. 2006;21:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Lewis DA. Genes and subtypes of schizophrenia. Trends Mol Med. 2001;7:281&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001;6:293&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11326297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics ZK, Mirnics K, Terrano D, Lewis DA, Sisodia SS, Schor NF. DNA microarray profiling of developing PS1-deficient mouse brain reveals complex and coregulated expression changes. Mol Psychiatry. 2003;8:863&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">14515137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni R, Ying Z, Gomez-Pinilla F. Differential effects of acute and chronic exercise on plasticity-related genes in the rat hippocampus revealed by microarray. Eur J Neurosci. 2002;16:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383240</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CM, Frazier JA, Glod CA, Breeze JL, Dieterich M, Finn CT, et al. Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulated cortex. J Am Acad Child Adolesc Psychiatry. 2007;46:524&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090056</ArticleId><ArticleId IdType="pubmed">17420688</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CM, Wardrop M, de BFB, Renshaw PF. Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study. Psychopharmacology (Berl) 2006;188:236&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">16944105</ArticleId></ArticleIdList></Reference><Reference><Citation>Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis. 1999;58:585&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752943</ArticleId><ArticleId IdType="pubmed">10460194</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse JK, Wiegand SJ, Anderson K, You Y, Cai N, Carnahan J, et al. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J Neurosci. 1993;13:4146&#x2013;4156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576390</ArticleId><ArticleId IdType="pubmed">8080477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimer&#x2019;s disease. In: Dawbarn D, Allen SJ, editors. Neurobiology of Alzheimer&#x2019;s Disease. 3rd edn. Oxford: Oxford University Press; 2007a. pp. 283&#x2013;321.</Citation></Reference><Reference><Citation>Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res. 2007b;4:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003;26:233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">14729126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullis KB. The unusual origin of the polymerase chain reaction. Sci Am. 1990;262:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">2315679</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M, Elfenbein A, Simons M. Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res. 2008;78:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056763</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwangi S, Anitha M, Fu H, Sitaraman SV, Srinivasan S. Glial cell line-derived neurotrophic factor-mediated enteric neuronal survival involves glycogen synthase kinase-3beta phosphorylation and coupling with 14-3-3. Neuroscience. 2006;143:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16996218</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeve GS, Ramakrishnan M, Kramer R, Hevroni D, Citri Y, Theill LE. Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis. Proc Natl Acad Sci USA. 1997;94:2648&#x2013;2653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20143</ArticleId><ArticleId IdType="pubmed">9122250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I, et al. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet. 2006;15:1949&#x2013;1962.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687443</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano M, Centonze D, Calce A, Picconi B, Spiezia S, Gulino A, et al. Experimental Parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis. 2002;10:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270699</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano M, Picconi B, Centonze D, Bernardi G, Calabresi P, Gulino A. l-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neurosci Lett. 2006;398:211&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16529858</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci. 2003;23:10841&#x2013;10851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740983</ArticleId><ArticleId IdType="pubmed">14645477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539&#x2013;7547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578063</ArticleId><ArticleId IdType="pubmed">7472505</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova SI, He F, Cutrufello NJ, Lidow MS. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiol Dis. 2006;23:61&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16549361</ArticleId></ArticleIdList></Reference><Reference><Citation>Obsil T, Ghirlando R, Klein DC, Ganguly S, Dyda F. Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase complex. A role for scaffolding in enzyme regulation. Cell. 2001;105:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11336675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, et al. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry. 2004;9:1007&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med. 2005;83:1014&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">16211407</ArticleId></ArticleIdList></Reference><Reference><Citation>Palfreyman MG, Hook DJ, Klimczak LJ, Brockman JA, Evans DM, Altar CA. Novel directions in antipsychotic target identification using gene arrays. Curr Drug Targets CNS Neurol Disord. 2002;1:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769629</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005;377:106&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">15740846</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Singh K, Singh S, Singh MP. Gene expression profiles of mouse striatum in control and maneb+paraquat-induced Parkinson&#x2019;s disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol Biotechnol. 2008;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">18386188</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007;13:1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">17767166</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, et al. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res. 2003;71:526&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17938637</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004;176:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15138753</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, et al. Identification of novel genes in late-onset Alzheimer&#x2019;s disease. Exp Gerontol. 2000;35:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J, Eberwine JH. Antisense RNA amplification: a linear amplification method for analyzing the mRNA population from single living cells. Methods Enzymol Suppl. 1996;10:283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">8954839</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletcher SD, Stumpf MP. Population genomics: ageing by association. Curr Biol. 2002;12:R328&#x2013;R330.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007435</ArticleId></ArticleIdList></Reference><Reference><Citation>Plomin R, McClearn GE. Nature, Nurture and Psychology. Washington, DC: American Psychological Association; 1993.</Citation></Reference><Reference><Citation>Pozuelo Rubio M, Geraghty KM, Wong BH, Woodx NT, Campbell DG, Morrice N, et al. 14-3-3-Affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J. 2004;379(Part 2):395&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224091</ArticleId><ArticleId IdType="pubmed">14744259</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684&#x2013;697. 643.</Citation><ArticleIdList><ArticleId IdType="pubmed">15098003</ArticleId></ArticleIdList></Reference><Reference><Citation>Prolla TA. DNA microarray analysis of the aging brain. Chem Senses. 2002;27:299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11923192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulver AE. Search for schizophrenia susceptibility genes. Biol Psychiatry. 2000;47:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10682219</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghothama C, Harsha HC, Prasad CK, Pandey A. Bioinformatics and proteomics approaches for aging research. Biogerontology. 2005;6:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16333756</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer&#x2019;s disease. Hum Mol Genet. 2004;13:1225&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115763</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19:368&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Lonnberg P, Marjamaki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res. 1990;508:349&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">2407314</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers A, Antoshechkin I, Bieri T, Blasiar D, Bastiani C, Canaran P, et al. WormBase 2007. Nucleic Acids Res. 2008;36:D612&#x2013;D617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238927</ArticleId><ArticleId IdType="pubmed">17991679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rome S, Clement K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, et al. Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem. 2003;278:18063&#x2013;18068.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621037</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3:353&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15060530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003;53:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology. 1999;21:679&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">10516964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry. 2006;11:965&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryoo HL, Joyce JN. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer&#x2019;s disease. J Comp Neurol. 1994;348:94&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">7814686</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarelainen T, Pussinen R, Koponen E, Alhonen L, Wong G, Sirvio J, et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long-term spatial memory but normal hippocampal LTP. Synapse. 2000;38:102&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">10941145</ArticleId></ArticleIdList></Reference><Reference><Citation>Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry. 2007;7:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2080573</ArticleId><ArticleId IdType="pubmed">17822540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61:822&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754299</ArticleId><ArticleId IdType="pubmed">17141740</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastry PS, Sita Ratnax W. Intrathecal therapy with trastuzumab may be beneficial in cases of refractory schizophrenia. Med Hypotheses. 2004;62:542&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Suzuki K, Nakanishi S. NMDA receptor stimulation and brain-derived neurotrophic factor upregulate homer 1a mRNA via the mitogen-activated protein kinase cascade in cultured cerebellar granule cells. J Neurosci. 2001;21:3797&#x2013;3805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762687</ArticleId><ArticleId IdType="pubmed">11356868</ArticleId></ArticleIdList></Reference><Reference><Citation>Saviouk V, Moreau MP, Tereshchenko IV, Brzustowicz LM. Association of synapsin 2 with schizophrenia in families of Northern European ancestry. Schizophr Res. 2007;96:100&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169360</ArticleId><ArticleId IdType="pubmed">17766091</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry. 2007;61:1161&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239354</ArticleId></ArticleIdList></Reference><Reference><Citation>Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569999</ArticleId></ArticleIdList></Reference><Reference><Citation>Secher T, Novitskaia V, Berezin V, Bock E, Glenthoj B, Klementiev B. A neural cell adhesion molecule-derived fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention. Neuroscience. 2006;141:1289&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16784819</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genotypes, phenotypes, and treatments. Science. 1997;275:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA, Jr, et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry. 2006;63:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16389195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequeira A, Klempan T, Canetti L, ffrench-Mullen J, Benkelfat C, Rouleau GA, et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry. 2007;12:640&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequeira A, Turecki G. Genome wide gene expression studies in mood disorders. Omics. 2006;10:444&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">17233556</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano F, Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev. 2004;3:431&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X, Tashiro H, Lin CL. The identification and characterization of oxidized RNAs in Alzheimer&#x2019;s disease. J Neurosci. 2003;23:4913&#x2013;4921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741200</ArticleId><ArticleId IdType="pubmed">12832513</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, et al. Mitochondrial involvement in psychiatric disorder. Ann Med. 2008;40:281&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098560</ArticleId><ArticleId IdType="pubmed">18428021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry. 2008;64:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098561</ArticleId><ArticleId IdType="pubmed">18191109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheedy D, Garrick T, Dedova I, Hunt C, Miller R, Sundqvist N, et al. An Australian brain bank: a critical investment with a high return! Cell Tissue Bank. 2008;10:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391553</ArticleId><ArticleId IdType="pubmed">18543078</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer&#x2019;s disease. Biochem Biophys Res Comm. 1997;236:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">9240416</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoda S, Schindler CK, Quan-Lan J, Saugstad JA, Taki W, Simon RP, et al. Interaction of 14-3-3 with Bid during seizure-induced neuronal death. J Neurochem. 2003;86:460&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibille E, Arango V, Galfalvy HC, Pavlidis P, Erraji-Benchekroun L, Ellis SP, et al. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology. 2004;29:351&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603265</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone NL, Remaley AT, Charboneau L, Petricoin EF, III, Glickman JW, Emmert-Buck MR, et al. Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am J Pathol. 2000;156:445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850045</ArticleId><ArticleId IdType="pubmed">10666374</ArticleId></ArticleIdList></Reference><Reference><Citation>Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF) Pharmacol Biochem Behav. 1997;56:131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981620</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets. 2008;7:46&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18289031</ArticleId></ArticleIdList></Reference><Reference><Citation>Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res. 2001;43:411&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">11394932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520933</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273:59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987625</ArticleId><ArticleId IdType="pubmed">8658196</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res. 2000;42:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742653</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, Mayhew MB, et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry. 2007;12:854&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">17767149</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenningsson P, Arts J, Gunne L, Andren PE. Acute and repeated treatment with l-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Res. 2002;955:8&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419516</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Is aging part of Alzheimer&#x2019;s disease, or is Alzheimer&#x2019;s disease part of aging? Neurobiol Aging. 2007;28:1465&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer&#x2019;s disease brains. J Neurol Sci. 2000;175:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10831767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:933&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258263</ArticleId></ArticleIdList></Reference><Reference><Citation>Taya S, Shinoda T, Tsuboi D, Asaki J, Nagai K, Hikita T, et al. DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. J Neurosci. 2007;27:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672274</ArticleId><ArticleId IdType="pubmed">17202468</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry. 2008;69:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">18363452</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, et al. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci. 2007;27:12156&#x2013;12167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363962</ArticleId><ArticleId IdType="pubmed">17989282</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res. 2008;60:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">18068248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry. 2004;55:346&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098566</ArticleId><ArticleId IdType="pubmed">14960286</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong G, Jahr CE. Block of glutamate transporters potentiates postsynaptic excitation. Neuron. 1994;13:1195&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Shen H, Perreau VM, Balazs R, Cotman CW. Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol Dis. 2001;8:1046&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741400</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry. 2005;57:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691526</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res. 2000;44:151&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10913747</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyooka K, Muratake T, Tanaka T, Igarashi S, Watanabe H, Takeuchi H, et al. 14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia. Am J Med Genet. 1999;88:164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206237</ArticleId></ArticleIdList></Reference><Reference><Citation>Traina G, Valleggi S, Bernardi R, Rizzo M, Calvani M, Nicolai R, et al. Identification of differentially expressed genes induced in the rat brain by acetyl-l-carnitine as evidenced by suppression subtractive hybridisation. Brain Res Mol Brain Res. 2004;132:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548429</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. The Alzheimer&#x2019;s brain: finding out what&#x2019;s broken tells us how to fix it. Am J Pathol. 2005;167:1183&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603781</ArticleId><ArticleId IdType="pubmed">16251403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007;566:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">17445798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang MT, Stone WS, Faraone SV. The genetics of schizophrenia. Curr Psychiatry Rep. 1999;1:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner CA, Akil H, Watson SJ, Evans SJ. The fibroblast growth factor system and mood disorders. Biol Psychiatry. 2006;59:1128&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631131</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H. Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res. 2008;1224:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2532793</ArticleId><ArticleId IdType="pubmed">18586016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545746</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VMD, Ginsberg SD, Lee VM-Y, Trojanowski JQ. The use of fixed human post mortem brain tissue to study mRNA expression in neurodegenerative diseases: applications of microdissection and mRNA amplification. In: Geschwind DH, Gregg JP, editors. Microarrays for the Neurosciences: AN Essential Guide. Boston: MIT Press; 2002. pp. 201&#x2013;235.</Citation></Reference><Reference><Citation>Vawter MP. Dysregulation of the neural cell adhesion molecule and neuropsychiatric disorders. Eur J Pharmacol. 2000;405:385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033343</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Atz ME, Rollins BL, Cooper-Casey KM, Shao L, Byerley WF. Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia. Hum Genet. 2006a;119:558&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077091</ArticleId><ArticleId IdType="pubmed">16604350</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, III, Donovan DM, et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull. 2001;55:641&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">11576761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophrenia Res. 2002a;58:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12363385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Evans S, Choudary P, Tomita H, Meador-Woodruff J, Molnar M, et al. Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology. 2004a;29:373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130534</ArticleId><ArticleId IdType="pubmed">14583743</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry. 2000;48:486&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11018222</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Shannon Weickert C, Ferran E, Matsumoto M, Overman K, Hyde TM, et al. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res. 2004b;29:1245&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15176481</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Thatcher L, Usen N, Hyde TM, Kleinman JE, Freed WJ. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry. 2002b;7:571&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12140780</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S, et al. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry. 2006b;11:615, 663&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098558</ArticleId><ArticleId IdType="pubmed">16636682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijg J, Suh Y. Genetics of longevity and aging. Annu Rev Med. 2005;56:193&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15660509</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent VA, DeVoss JJ, Ryan HS, Murphy GM., Jr Analysis of neuronal gene expression with laser capture microdissection. J Neurosci Res. 2002;69:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210823</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt IR, Lees AJ, Evert BO, Klockgether T, Bonin M, Wullner U. Transcriptional changes in multiple system atrophy and Parkinson&#x2019;s disease putamen. Exp Neurol. 2006;199:465&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626704</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37:554&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">8691238</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Amaya MD, Cortes EP, Mancevska K, Keller CE. Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. Cell Tissue Bank. 2008;26:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847415</ArticleId><ArticleId IdType="pubmed">18581261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Katz J, Dagostino P, Soghomonian JJ. Unilateral 6-hydroxydo-pamine lesion of dopamine neurons and subchronic l-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata. Neuroscience. 2007a;145:727&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1894759</ArticleId><ArticleId IdType="pubmed">17218060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HS, Duan SW, Xing QH, Du J, Li XW, Xu YF, et al. Association study between NPY and YWHAH gene polymorphisms and schizophrenia. Yi Chuan Xue Bao. 2005;32:1235&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">16459651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XT, Pei DS, Xu J, Guan QH, Sun YF, Liu XM, et al. Opposing effects of Bad phosphorylation at two distinct sites by Akt1 and JNK1/2 on ischemic brain injury. Cell Signal. 2007b;19:1844&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17555943</ArticleId></ArticleIdList></Reference><Reference><Citation>Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8:592&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">12851636</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphalen RI, Scott HL, Dodd PR. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease. J Neural Transm. 2003;110:1013&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">12938024</ArticleId></ArticleIdList></Reference><Reference><Citation>Whatley SA, Curti D, Marchbanks RM. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996;21:995&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">8897462</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Winblad B, J&#xf6;nsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer Dement. 2007;3:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595921</ArticleId></ArticleIdList></Reference><Reference><Citation>Winge I, McKinney JA, Ying M, D&#x2019;Santos CS, Kleppe R, Knappskog PM, et al. Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem J. 2008;410:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AH, Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, et al. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr Res. 2005;78:137&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AH, Macciardi F, Klempan T, Kawczynski W, Barr CL, Lakatoo S, et al. Identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and the 14-3-3eta gene. Mol Psychiatry. 2003;8:156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610648</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:457&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15784157</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC100354</ArticleId><ArticleId IdType="pubmed">11842121</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer&#x2019;s disease. Neurobiol Dis. 2003;12:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667465</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, Armstrong DM. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer&#x2019;s disease pathology: a biochemical study. Brain Res. 1995;678:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO, Jr, et al. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 2006;66:11179&#x2013;11186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17145862</ArticleId></ArticleIdList></Reference><Reference><Citation>Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci USA. 2002;99:10587&#x2013;10592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124982</ArticleId><ArticleId IdType="pubmed">12149437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA, Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894061</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng BY, Jolkkonen J, Jenner P, Marsden CD. Chronic l-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproen-kephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 1995;66:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">7637869</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstrom TS, Pei Q, Grahame-Smith DG. Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res. 1998;57:106&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res. 2006;84:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci. 2005;25:4493&#x2013;4502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725025</ArticleId><ArticleId IdType="pubmed">15872096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zink M, Schmitt A, May B, Muller B, Demirakca T, Braus DF, et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res. 2004;66:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">15061247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchero T, Ahmed S. Genetics of proliferative aging. Exp Gerontol. 2006;41:992&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">17049783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18845693</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>6</Issue><PubDate><MedlineDate>2008 Dec-2009 Jan</MedlineDate></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.</ArticleTitle><Pagination><StartPage>593</StartPage><EndPage>601</EndPage><MedlinePgn>593-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533317508320603</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study was to investigate an efficacy of galantamine in treatment of behavioral and psychological symptoms of dementia in Thai elderly who suffered from possible Alzheimer's disease (AD) with or without cerebrovascular disease and vascular dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 6-month, multicenter, open-label, uncontrolled trial was undertaken in 75 patients. Eligible patients received an initial galantamine dose of 8 mg/dayand escalated over 5 to 8 weeks to maintenance doses of 16 or 24 mg/day. The behavioral response was assessed as an intention-to-treat analysis using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Galantamine improved behavioral and psychological symptoms of dementia (P &lt; .05 vs baseline) over the 24 weeks of treatment. BEHAVE-AD score was significantly improved from baseline in paranoid and delusion ideation, diurnal rhythm disturbances, anxieties, and phobias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Galantamine may be a well-tolerated and effective treatment option for improving psychotic, behavioral, and psychological symptoms in Thai elderly with possible AD with or without cerebrovascular disease and vascular dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tangwongchai</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. sookjaroen@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thavichachart</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Senanarong</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Poungvarin</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Phanthumchinda</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Praditsuwan</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nidhinandana</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chankrachang</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N" Type="Geographic">Thailand</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18845693</ArticleId><ArticleId IdType="pmc">PMC10846018</ArticleId><ArticleId IdType="doi">10.1177/1533317508320603</ArticleId><ArticleId IdType="pii">1533317508320603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finkel SI Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001;62(suppl 21):3-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584987</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI, Costa e Silva J., Cohen G., Miller S., Sartorius, N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(suppl 3):497-500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Lyketsos CG, Steele C. Practical Dementia Care. New York, NY: Oxford University Press; 1999.</Citation></Reference><Reference><Citation>Lyketsos CG, Steele C., Steinberg M. Neuropsychiatric symptoms in dementia. In: Gallo JJ, Busby-Whitehead J, Rabins PV, eds. Care of the Elderly: Clinical Aspects of Aging. 5th ed. Baltimore, MD: Williams &amp; Wilkins; 1999. :214-228.</Citation></Reference><Reference><Citation>Rosenstein LD Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev. 1998. ;8:109-167.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834489</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL Treatment of Alzheimer's disease. Clin Cornerstone. 2001;3:27-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O., Jones B., Fitzpatrick AL, Breitner J., DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288: 1475-1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Ebbitt B., Jun SP, Finch MD Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42:1689-1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">1513455</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TP, Tinklenberg JR, Brooks JO 3rd, Fenn HH, Yesavage JA Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol . 1993;6:235-238.</Citation><ArticleIdList><ArticleId IdType="pubmed">8251053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F., DeKosky ST Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266-1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JS, Welch HG, Larson EB Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429-434.</Citation><ArticleIdList><ArticleId IdType="pubmed">2386336</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878-885.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurvich T., Cunningham JA Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician. 2000;61:1437-1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS , Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PS, Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005. ;353:2335-2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Valenstein M., Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medication. Am J Psychiatry. 2007;164:1568-1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibach B., Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des. 2004;10:231-251.</Citation><ArticleIdList><ArticleId IdType="pubmed">14754384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47:876-883.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857712</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ Treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 1991;5(suppl 1):S32-S36.</Citation><ArticleIdList><ArticleId IdType="pubmed">1685885</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C. Abnormalities of neural circuitry m Alzheimer's disease: hippocampus and cortical cholmergic innervation. Neurology. 1998;51(suppl 1):S18-S29.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. Brain. 1984;107:253-274.</Citation><ArticleIdList><ArticleId IdType="pubmed">6538106</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease . Gerontology. 1999;45(suppl 1):15-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9876214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, et al. for the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;359:1283-1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11965273</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh NH, Hoblyn J., Mohanty S., Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289: 210-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517232</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593. doi:10.1002/14651858.CD.005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavicachart N., Phanthumchinda K., Chankrachang S., et al. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in thai patients: a slow-titration regimen. J Clin Pract. 2006;60:533-540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473179</ArticleId><ArticleId IdType="pubmed">16700849</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D., Albert MS, Bassett SS Reliability and validity of NINDCS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Geriatrics Initiative. Arch Neurol. 1994;51:1198-1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">7986174</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TC, Erkinjuntti T. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Train the Brian Forum Committee (Thailand). Thai Mental State Examination. Siriraj Hosp Gazette. 1993; 45:359-374.</Citation></Reference><Reference><Citation>Thavichachart N., Worakul P., Karnjananakin P. Alzheimer's disease Assessment Scale ADAS): Thai version. J Gerontol Geriatr Med. 2002. ;3:21-32.</Citation></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatry . 1984;141: 1356-1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B. , Borenstein J., Salob SP Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:S9-S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LC Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2005;(1):CD001747. doi:10.1002/14651858.CD001747. Date of last substantive update Novermber 15, 2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961200</ArticleId><ArticleId IdType="pubmed">16437436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002;127:20-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn ZJ, Cummings JL Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:100-108.</Citation><ArticleIdList><ArticleId IdType="pubmed">14564129</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DB, Green CR, Schmeidler J., et al. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc. 1997;45:1331-1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361658</ArticleId></ArticleIdList></Reference><Reference><Citation>Eustace A., Coen R., Walsh C., et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry . 2002;17:968-973.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit M., Robert PH, Staccini P., et al. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J Nutr Health Aging. 2005;9:95-99.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu LW, Yik PY, Mok W., Chung CP A 2-year open-label study of galantamine therapy in Chinese Alzhiemer's disease patients in Hong Kong. Int J Clin Pract. 2007. ;61: 403-410.</Citation><ArticleIdList><ArticleId IdType="pubmed">17313606</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh GH, Yeon Jung H., Uk Lee C., et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzhiemer's disease in a Korean population. Clin Ther. 2004;26:1608-1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Brown CV, Mandelkern MA, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 2003. ;160:341-349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentis MJ, Weinstein EA, Horwitz B., et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer's disease. Biol Psychiatry. 1995;38:438-449.</Citation><ArticleIdList><ArticleId IdType="pubmed">8672604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano S., Yamashita F., Matsuda H., Kodama C., Yamada T. Relationship between delusions and regional cerebral blood flow in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;21:16-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lojkowska W., Ryglewicz D., Jedrzejczak T., Minc S., Jarosz H., Bochynska A. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci . 2003;216:119-126.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceravolo R., Volterrani D., Tognoni G., et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer's disease. Clin Neuropharmacol. 2004;27: 166-170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Schneider L., Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and care-giver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161: 532-538.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke JR, Loredo JS, Liu L., et al. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs Aging. 2006. ; 23:503-511.</Citation><ArticleIdList><ArticleId IdType="pubmed">16872233</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis B., Sadik K. Circadian cholinergic rhythms: implication for cholinergic inhibitor therapy . Dement Geriatr Cogn Disord. 2006;21:120-129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391473</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz JS , Gutterman EM, Lilienfeld S., Papadopoulos G. Sleep-related outcomes in persons with mild to moderate Alzheimer's disease in a placebo-controlled trial of galantamine . Sleep. 2003;26:602-606.</Citation><ArticleIdList><ArticleId IdType="pubmed">12938815</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl SM, Markowitz JS, Papadopoulos G., Sadik K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr Med Res Opin. 2004;20:517-524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15119989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18843265</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Effects of topiramate and other anti-glutamatergic drugs on the acute intoxicating actions of ethanol in mice: modulation by genetic strain and stress.</ArticleTitle><Pagination><StartPage>1454</StartPage><EndPage>1466</EndPage><MedlinePgn>1454-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/npp.2008.182</ELocationID><Abstract><AbstractText>Compounds with anti-glutamatergic properties currently in clinical use for various indications (eg Alzheimer's disease, epilepsy, psychosis, mood disorders) have potential utility as novel treatments for alcoholism. Enhanced sensitivity to certain acute intoxicating effects (ataxia, sedative) of alcohol may be one mechanism by which anti-glutamatergic drugs modulate alcohol use. We examined the effects of six compounds (memantine, dextromethorphan, haloperidol, lamotrigine, oxcarbazepine, and topiramate) on sensitivity to acute intoxicating effects of ethanol (ataxia, hypothermia, sedation/hypnosis) in C57BL/6J mice. Analysis of topiramate was extended to determine the influence of genetic background (by comparison of the 129S1, BALB/cJ, C57BL/6J, DBA/2J inbred strains) and prior stress history (by chronic exposure of C57BL/6J to swim stress) on topiramate's effects on ethanol-induced sedation/hypnosis. Results showed that one N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, but not another, dextromethorphan, potentiated the ataxic but not hypothermic or sedative/hypnotic effects of ethanol. Haloperidol increased ethanol-induced ataxia and sedation/hypnosis to a similar extent as the prototypical NMDAR antagonist MK-801. Of the anticonvulsants tested, lamotrigine accentuated ethanol-induced sedation/hypnosis, whereas oxcarbazepine was without effect. Topiramate was without effect per se under baseline conditions in C57BL/6J, but had a synergistic effect with MK-801 on ethanol-induced sedation/hypnosis. Comparing inbred strains, topiramate was found to significantly potentiate ethanol's sedative/hypnotic effects in BALB/cJ, but not 129S1, C57BL/6J, or DBA/2J strains. Topiramate also increased ethanol-induced sedation/hypnosis in C57BL/6J after exposure to chronic stress exposure. Current data demonstrate that with the exception of MK-801 and haloperidol, the compounds tested had either no significant or assay-selective effects on sensitivity to acute ethanol under baseline conditions in C57BL/6J. However, significant effects of topiramate were revealed as a function of co-treatment with an NMDAR blocker, genetic background, or prior stress history. These findings raise the possibility that topiramate and possibly other anti-glutamatergic drugs could promote the acute intoxicating effects of ethanol in specific subpopulations defined by genetics or life history.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Chyan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AA000411</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AA000411-04</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002492">Central Nervous System Depressants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018683">Excitatory Amino Acid Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H73WJJ391</RegistryNumber><NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance></Chemical><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance UI="D005632">Fructose</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3K9958V90M</RegistryNumber><NameOfSubstance UI="D000431">Ethanol</NameOfSubstance></Chemical><Chemical><RegistryNumber>7355X3ROTS</RegistryNumber><NameOfSubstance UI="D003915">Dextromethorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VZI5B1W380</RegistryNumber><NameOfSubstance UI="D000078330">Oxcarbazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000435" MajorTopicYN="N">Alcoholic Intoxication</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002492" MajorTopicYN="N">Central Nervous System Depressants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016292" MajorTopicYN="N">Conscious Sedation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003915" MajorTopicYN="N">Dextromethorphan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018683" MajorTopicYN="N">Excitatory Amino Acid Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005632" MajorTopicYN="N">Fructose</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007035" MajorTopicYN="N">Hypothermia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078330" MajorTopicYN="N">Oxcarbazepine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18843265</ArticleId><ArticleId IdType="mid">NIHMS69362</ArticleId><ArticleId IdType="pmc">PMC2669690</ArticleId><ArticleId IdType="doi">10.1038/npp.2008.182</ArticleId><ArticleId IdType="pii">npp2008182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad S, Fowler LJ, Whitton PS. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol. 2004a;142:136&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574927</ArticleId><ArticleId IdType="pubmed">15037514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res. 2004b;1029:41&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533314</ArticleId></ArticleIdList></Reference><Reference><Citation>Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312:1195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522999</ArticleId></ArticleIdList></Reference><Reference><Citation>Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology. 2004;29:921&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735132</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker HC, Lopez MF. Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res. 2004;28:1829&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608599</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijamini V, Skalisz LL, Joca SR, Andreatini R. The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur J Pharmacol. 1998;347:23&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9650844</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzung C. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav Pharmacol. 2001;12:451&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11742138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004;172:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530901</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay J, Palachick B, Hefner K, Karlsson RM, Millstein R, Harvey-White J, Holmes A. Desipramine potentiation of the acute depressant effects of ethanol: modulation by alpha2-adrenoreceptors and stress. Neuropharmacology. 2008a in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632577</ArticleId><ArticleId IdType="pubmed">18625256</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, Cameron HA, Holmes A. Chronic swim stress alters sensitivity to acute behavioral effects of ethanol in mice. Physiol Behav. 2007;91:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363014</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, Cunningham CL. The role of NMDA receptor binding sites in ethanol place conditioning. Behav Neurosci. 2004;118:822&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15301608</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, Holmes A. Functional roles of NMDA receptor NR2A and NR2B subunits in the acute intoxicating effects of ethanol in mice. Synapse. 2005;56:222&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803501</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, Holmes A. Ethanol-related behaviors in mice lacking the NMDA receptor NR2A subunit. Psychopharmacology (Berl) 2006;187:455&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835771</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce-Rustay JM, Janos AL, Holmes A. Effects of chronic swim stress on EtOH-related behaviors in C57BL/6J, DBA/2J and BALB/cByJ mice. Behav Brain Res. 2008b;186:133&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695676</ArticleId><ArticleId IdType="pubmed">17822784</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent J, Grahame NJ, Cunningham CL. Haloperidol prevents ethanol-stimulated locomotor activity but fails to block sensitization. Psychopharmacology (Berl) 1995;120:475&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8539330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody SA, Geyer MA, Large CH. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 2003;169:240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12698229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagetti E, Baicy KJ, Olsen RW. Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. Neuroreport. 2004;15:207&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15106859</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter-Hyland EP, Woodward JJ, Chandler LJ. Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. J Neurosci. 2004;24:7859&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729936</ArticleId><ArticleId IdType="pubmed">15356198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen C, Perrault G, Sanger DJ. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice. Neuropharmacology. 1997;36:1099&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9294975</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa ET, Soto EE, Cardoso RA, Olivera DS, Valenzuela CF. Acute effects of ethanol on kainate receptors in cultured hippocampal neurons. Alcohol Clin Exp Res. 2000;24:220&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10698375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowen MS, Djouma E, Lawrence AJ. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther. 2005;315:590&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowen MS, Schroff KC, Gass P, Sprengel R, Spanagel R. Neurobehavioral effects of alcohol in AMPA receptor subunit (GluR1) deficient mice. Neuropharmacology. 2003;45:325&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871650</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006;10:221&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17197372</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabbe JC. Current Protocols in Neuroscience. Wiley; 2007. Overview of Mouse Assays of Ethanol Intoxication.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428672</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabbe JC, Merrill CD, Belknap JK. Effects of convulsants on handling-induced convulsions in mice selected for ethanol withdrawal severity. Brain Res. 1991;550:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1888987</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabbe JC, Metten P, Ponomarev I, Prescott CA, Wahlsten D. Effects of genetic and procedural variation on measurement of alcohol sensitivity in mouse inbred strains. Behav Genet. 2006;36:536&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16619134</ArticleId></ArticleIdList></Reference><Reference><Citation>Croissant B, Diehl A, Klein O, Zambrano S, Nakovics H, Heinz A, Mann K. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol Clin Exp Res. 2006;30:630&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16573580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham CL, Malott DH, Dickinson SD, Risinger FO. Haloperidol does not alter expression of ethanol-induced conditioned place preference. Behav Brain Res. 1992;50:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1449638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology. 2000;39:2139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963757</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws LC, Montanez S, Munn JL, Owen AM, Baganz NL, Boyce-Rustay J, Millstein RA, Wiedholz L, Murphy DL, Holmes A. Ethanol inhibits clearance of brain serotonin by a serotonin transporter-independent mechanism. J Neurosci. 2006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674049</ArticleId><ArticleId IdType="pubmed">16775130</ArticleId></ArticleIdList></Reference><Reference><Citation>Erden BF, Ozdemirci S, Yildiran G, Utkan T, Gacar N, Ulak G. Dextromethorphan attenuates ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav. 1999;62:537&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080248</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31:775&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8:1481&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251991</ArticleId></ArticleIdList></Reference><Reference><Citation>Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol. 2007;42:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548369</ArticleId></ArticleIdList></Reference><Reference><Citation>Files FJ, Denning CE, Samson HH. Effects of the atypical antipsychotic remoxipride on alcohol self-administration. Pharmacol Biochem Behav. 1998;59:281&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9476971</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Franke H, Illes P. Effects of acute ethanol on the Ca2+ response to AMPA in cultured rat cortical GABAergic nonpyramidal neurons. Alcohol Alcohol. 2003;38:394&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12915512</ArticleId></ArticleIdList></Reference><Reference><Citation>Frye GD, Fincher A. Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons. Br J Pharmacol. 2000;129:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621129</ArticleId><ArticleId IdType="pubmed">10694206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel KI, Cunningham CL. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res. 2005;29:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654294</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75:218&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2239014</ArticleId><ArticleId IdType="pubmed">17706608</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6:521&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15995696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia. 2000;41(Suppl 1):S25&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10768296</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA, Saha TD, Smith SM, Pulay AJ, Pickering RP, Ruan WJ, Compton WM. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Mol Psychiatry. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766434</ArticleId><ArticleId IdType="pubmed">18427559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremel CM, Gabriel KI, Cunningham CL. Topiramate does not affect the acquisition or expression of ethanol conditioned place preference in DBA/2J or C57BL/6J mice. Alcohol Clin Exp Res. 2006;30:783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16634846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007;31:1900&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17877781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefner K, Holmes A. An investigation of the behavioral actions of ethanol across adolescence in mice. Psychopharmacology (Berl) 2007;191:311&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17206494</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111:855&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge CW, Miles MF, Sharko AC, Stevenson RA, Hillmann JR, Lepoutre V, Besheer J, Schroeder JP. The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl) 2006;183:429&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854492</ArticleId><ArticleId IdType="pubmed">16292590</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol. 1996;314:R1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957265</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61:905&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351769</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767733</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama. 2007;298:1641&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19:301&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888516</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson RM, Heilig M, Holmes A. Loss of glutamate transporter GLAST (EAAT1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and mGlu2/3 agonist. Biol Psychiatry. 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696047</ArticleId><ArticleId IdType="pubmed">18550032</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav. 2007a;87:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867456</ArticleId><ArticleId IdType="pubmed">17482246</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res. 2007b;31:582&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864137</ArticleId><ArticleId IdType="pubmed">17374037</ArticleId></ArticleIdList></Reference><Reference><Citation>Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkotter J, Niklewski G, Wodarz N, Klatt J, Burtscheidt W, Gaebel W, Markus Leweke F. Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res. 2007;31:1188&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17511748</ArticleId></ArticleIdList></Reference><Reference><Citation>Komanduri R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry. 2003;64:612.</Citation><ArticleIdList><ArticleId IdType="pubmed">12755670</ArticleId></ArticleIdList></Reference><Reference><Citation>Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 2003;27:232&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12605072</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, Tsoy M, Bespalov A, Slavina TY, Grinenko AA, Petrakis IL, Pittman B, Gueorguieva R, Zvartau EE, Krystal JH. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007a;164:519&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17329479</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007b;31:604&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374039</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther. 2003;99:79&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12804700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000;54:152&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10857388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuribara H. Potentiation of the ambulation-increasing effect induced by combined administration of MK-801 with ethanol in mice. Psychopharmacology (Berl) 1994;113:453&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7862858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 1993;612:190&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7687190</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Weiss F. Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J Pharmacol Exp Ther. 2002;300:882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez MF, Becker HC. Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice. Psychopharmacology (Berl) 2005;181:688&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16001125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 1989;243:1721&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2467382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DR, Gallagher MJ. Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther. 1996;279:154&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858988</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PJ, Phillips TJ. Bivalent effects of MK-801 on ethanol-induced sensitization do not parallel its effects on ethanol-induced tolerance. Behav Neurosci. 2003;117:641&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12802892</ArticleId></ArticleIdList></Reference><Reference><Citation>Millstein RA, Ralph RJ, Yang RJ, Holmes A. Effects of repeated maternal separation on prepulse inhibition of startle across inbred mouse strains. Genes Brain Behav. 2006;5:346&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716204</ArticleId></ArticleIdList></Reference><Reference><Citation>Moykkynen T, Korpi ER, Lovinger DM. Ethanol inhibits alpha-amino-3-hydyroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor function in central nervous system neurons by stabilizing desensitization. J Pharmacol Exp Ther. 2003;306:546&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulholland PJ, Chandler LJ. The thorny side of addiction: adaptive plasticity and dendritic spines. ScientificWorldJournal. 2007;7:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901136</ArticleId><ArticleId IdType="pubmed">17982573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nankai M, Fage D, Carter C. NMDA receptor subtype selectivity: eliprodil, polyamine spider toxins, dextromethorphan, and desipramine selectively block NMDA-evoked striatal acetylcholine but not spermidine release. J Neurochem. 1995;64:2043&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7722489</ArticleId></ArticleIdList></Reference><Reference><Citation>Newlin DB, Thomson JB. Alcohol challenge with sons of alcoholics: a critical review and analysis. Psychol Bull. 1990;108:383&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">2270234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse. 2007;61:150&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17146766</ArticleId></ArticleIdList></Reference><Reference><Citation>Norcross M, Mathur P, Enoch AJ, Karlsson RM, Brigman J, Cameron HA, Harvey-White J, Holmes A. Fluoxetine treatment during adolescence does not cause lasting deficits in fear-, anxiety- or stress-related behaviors in mice. Psychopharmacology (Berl) 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574726</ArticleId><ArticleId IdType="pubmed">18594797</ArticleId></ArticleIdList></Reference><Reference><Citation>Overstreet DH, Knapp DJ, Breese GR. Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007;31:1473&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010749</ArticleId><ArticleId IdType="pubmed">17624999</ArticleId></ArticleIdList></Reference><Reference><Citation>Palachick B, Chen Y-C, Enoch AJ, Karlsson RM, Mishina M, Holmes A. Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication. Alcohol Clin Exp Res. 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561332</ArticleId><ArticleId IdType="pubmed">18565157</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999;38:735&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10465680</ArticleId></ArticleIdList></Reference><Reference><Citation>Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol. 1998;354:135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306:81&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther. 1990;254:71&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">1694895</ArticleId></ArticleIdList></Reference><Reference><Citation>Risinger FO, Dickinson SD, Cunningham CL. Haloperidol reduces ethanol-induced motor activity stimulation but not conditioned place preference. Psychopharmacology (Berl) 1992;107:453&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1615143</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberto M, Bajo M, Crawford E, Madamba SG, Siggins GR. Chronic ethanol exposure and protracted abstinence alter NMDA receptors in central amygdala. Neuropsychopharmacology. 2006;31:988&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16052244</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio G, Lopez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8:289&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16696832</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">14750047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustay NR, Wahlsten D, Crabbe JC. Influence of task parameters on rotarod performance and sensitivity to ethanol in mice. Behav Brain Res. 2003;141:237&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742261</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;56:211&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12518536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Bachteler D, Gass P, Sprengel R, Spanagel R. Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse. J Neurosci. 2006;26:1231&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674564</ArticleId><ArticleId IdType="pubmed">16436610</ArticleId></ArticleIdList></Reference><Reference><Citation>Schik G, Wedegaertner FR, Liersch J, Hoy L, Emrich HM, Schneider U. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol. 2005;10:283&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16109591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuckit MA. Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry. 1994;151:184&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8296886</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008;62:149&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18000814</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry. 2005;10:877&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen EH, Phillips TJ. MK-801 potentiates ethanol's effects on locomotor activity in mice. Pharmacol Biochem Behav. 1998;59:135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitges M, Chiu LM, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology. 2007;52:598&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17070874</ArticleId></ArticleIdList></Reference><Reference><Citation>Smothers CT, Mrotek JJ, Lovinger DM. Chronic ethanol exposure leads to a selective enhancement of N-methyl-D-aspartate receptor function in cultured hippocampal neurons. J Pharmacol Exp Ther. 1997;283:1214&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399996</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell LD, Yi SJ, Johnson KM. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol. 1988;145:223&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3280329</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyka M, Bondy B, Eisenburg B, Schutz CG. NMDA receptor challenge with dextromethorphan - subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm. 2000;107:701&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10943910</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18262663</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzbay IT, Akarsu ES, Kayaalp SO. Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav. 1994;49:969&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7886115</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanover KE. Interaction of ethanol with excitatory amino acid receptor antagonists in mice. Eur J Pharmacol. 1999;368:137&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193649</ArticleId></ArticleIdList></Reference><Reference><Citation>Vengeliene V, Heidbreder CA, Spanagel R. The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology. 2007;53:951&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17976664</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology. 1995;45:1907&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport. 1996;7:3037&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport. 2001;12:2255&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447345</ArticleId></ArticleIdList></Reference><Reference><Citation>White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K, Sprengel R, Celikel T, Daws LC, Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and &#x2018;schizophrenia-related&#x2019; behaviors. Mol Psychiatry. 2008;13:631&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WR, Bosy TZ, Ruth JA. NMDA agonists and antagonists alter the hypnotic response to ethanol in LS and SS mice. Alcohol. 1990;7:389&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977412</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward JJ. Ethanol and NMDA receptor signaling. Crit Rev Neurobiol. 2000;14:69&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci. 2006;26:9967&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674480</ArticleId><ArticleId IdType="pubmed">17005860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18840035</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1172-7047</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.</ArticleTitle><Pagination><StartPage>963</StartPage><EndPage>973</EndPage><MedlinePgn>963-73</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given the number of antidepressants available and their rising costs, healthcare payers have initiated restrictive reimbursement policies for newer antidepressants, without consideration for differences in their effectiveness or tolerability.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to comprehensively compare medication adherence rates and associated healthcare utilization costs for patients using later-generation versus earlier-generation antidepressants in a managed care setting. Antidepressants launched after 2002 were deemed third-generation antidepressants, while antidepressants available prior to 2002 were deemed first-generation (TCAs and MAOIs) and second-generation (serotonin and noradrenaline [norepinephrine]-dopamine reuptake inhibitors).</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Retrospective database analysis using medical and pharmacy data from over 75 managed care plans covering 55 million lives.</AbstractText><AbstractText Label="SETTING/PATIENTS" NlmCategory="METHODS">All patients receiving an antidepressant between 1 January 2002 and 30 September 2004 were identified. The index date for patients was the date of their first antidepressant prescription within this time period. Patients had to (i) have a diagnosis of depression or anxiety disorder, or depression and anxiety disorder within 6 months prior to or 30 days after their index prescription; (ii) be at least 18 years of age, without having taken antidepressant therapy for 6 months prior to their index date; and (iii) be continuously eligible for 6 months prior to their index date and during their 6-month follow-up period. Patients were excluded if they had a diagnosis of psychosis-related disease, Alzheimer's or Parkinson's disease, or were initiated on psychosis-related medications. INTERVENTION/MAIN OUTCOME MEASURE: Patients meeting selection criteria were followed for 6 months to assess rates of antidepressant adherence, therapy change rates and medical healthcare costs.</AbstractText><AbstractText Label="STUDY POPULATION" NlmCategory="METHODS">A total of 266 665 patients met the study criteria. Approximately 66% were female, with a mean age of 39 years. About 63% had a diagnosis of depression, 31% had an anxiety disorder diagnosis and 6% had diagnoses for both an anxiety disorder and depression. Therapy change: Therapy change within 6 months occurred in 18% of patients receiving third-generation agents compared with 21% and 40% for second- and first-generation agents, respectively. The odds of a therapy change were significantly lower with third-generation antidepressants compared with both older agent cohorts. Adherence: Of patients receiving third-generation antidepressants, 33.6% were adherent compared with 29.3% and 12.4% of patients receiving second- and first-generation antidepressants, respectively. Newer agents also had better adherence rates across all diagnostic cohorts. After adjusting for baseline differences, the odds of being adherent to therapy were significantly lower for those taking second- and first-generation agents versus newer antidepressants. Among the newer agents, the proportion of patients adherent to their therapy was: venlafaxine extended release 38%, paroxetine controlled release (CR) 35%, escitalopram 34%, duloxetine 32% and bupropion extended release (XL) 31%. Healthcare utilization: Of the patients taking older antidepressants, 13% (second generation) and 21% (first generation) were hospitalized at least once for any reason compared with 12% of patients taking newer agents. Overall, the odds of all-cause hospitalization within 6 months of therapy initiation were significantly higher for patients taking older antidepressants. Among the newer agents, hospitalization rates ranged from 15.9% for duloxetine to 12.5% for paroxetine CR and bupropion XL. The unadjusted 6-month total medical costs (not including pharmacy costs) per patient were $US 3514 for second-generation, $US 5744 for first-generation and $US 3284 for newer antidepressants. After controlling for baseline differences, patients receiving second- and first-generation antidepressants incurred 12% and 44% higher costs, respectively. The unadjusted 6-month medical costs for the newer agents ranged from $US 2715 for paroxetine CR to $US 6042 for duloxetine.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of this study provide essential information for healthcare decision makers about the potential advantages of newer generation antidepressants versus older generation antidepressants, as well as the differences between the specific newer agents, with respect to improved rates of adherence and therapy change, reduced hospitalizations and healthcare costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>University of South Florida College of Medicine, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Eaddy</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Krulewicz</LastName><ForeName>Stan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006295" MajorTopicYN="N">Health Resources</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18840035</ArticleId><ArticleId IdType="doi">10.2165/00023210-200822110-00005</ArticleId><ArticleId IdType="pii">22115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 2003 Jun 18;289(23):3095-105</Citation><ArticleIdList><ArticleId IdType="pubmed">12813115</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Oct;11(12 Suppl):S362-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16236018</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2006 Apr;44(4):300-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16565629</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Mar 23;354(12):1231-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16554525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1997 May 24;349(9064):1498-504</Citation><ArticleIdList><ArticleId IdType="pubmed">9167458</ArticleId></ArticleIdList></Reference><Reference><Citation>Manag Care Interface. 2003 Dec;16(12):22-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14750459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Apr;58(1):19-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10760555</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chronic Dis. 1987;40(5):373-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2007 Feb;10(1):51-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16690006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Dec;64(12):1465-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14728109</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2005 Oct;21(10):1651-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16238905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1997 Jan;50(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9048695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2003 Mar;18(2):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12590404</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 Mar;31(2):122-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16575428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Jan;60(1):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10074873</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Aug;177:163-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11026957</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2002;62(11):1635-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12109925</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Oct;11(12 Suppl):S354-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16236017</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Dec;6(4):427-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14609440</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1992 Jun;45(6):613-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):110-117</Citation><ArticleIdList><ArticleId IdType="pubmed">15014608</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2005;22(2):68-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16094658</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2002 Oct;3(4):171-99</Citation><ArticleIdList><ArticleId IdType="pubmed">12516310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18838636</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study.</ArticleTitle><Pagination><StartPage>1193</StartPage><EndPage>1198</EndPage><MedlinePgn>1193-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archpsyc.65.10.1193</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Little is known about the population-based prevalence of neuropsychiatric symptoms in mild cognitive impairment (MCI).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To estimate the prevalence of neuropsychiatric symptoms in MCI and normal cognitive aging in a defined population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study derived from an ongoing population-based prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The Mayo Clinic Study of Aging.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">We studied a random sample of 1969 individuals without dementia from the target population of 9965 elderly persons residing in Olmsted County (Minnesota) on the prevalence date (October 1, 2004). Neuropsychiatric data were available for 319 of 329 subjects with MCI (97.0%) and 1590 of 1640 subjects with normal cognition (97.0%). Neurologic, cognitive, and neuropsychiatric data were obtained from the study participants. A classification of MCI, dementia, and normal cognitive aging was adjudicated by an expert consensus panel. Accordingly, 329 subjects were classified as having MCI and the remaining 1640 subjects were classified as having normal cognition.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Neuropsychiatric Inventory Questionnaire score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Multivariate logistic regression analyses were conducted after adjusting for age, sex, and educational status. By considering both the odds ratio (OR) and the frequency of a symptom, the most distinguishing features between the 2 groups were apathy (OR, 4.53; 95% confidence interval [CI], 3.11-6.60; P &lt; .001), agitation (3.60; 2.18-5.92; P &lt; .001), anxiety (3.00; 2.01-4.48; P &lt; .001), irritability 2.99; 2.11-4.22; P &lt; .001), and depression (2.78; 2.06-3.76; P &lt; .001). The OR was highest for delusion (8.12; 95% CI, 2.92-22.60; P &lt; .001); however, it was rare in both subjects with MCI (11 of 319 [3.4%]) and those with normal cognition (6 of 1590 [0.4%]). Thus, the population attributable risk for delusion was only 2.62% compared with 14.60% for apathy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nonpsychotic symptoms affected approximately 50% of subjects with MCI and 25% of subjects with normal cognition. In contrast, psychotic symptoms were rare.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. geda.yonas@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Christianson</LastName><ForeName>Teresa J H</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Vernon S</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Glenn E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>Eric G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS33978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH068351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R02AR30582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG028573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR030582-41</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786-14</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH68351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033978-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG028573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR030582</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG028573-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH068351-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008910" MajorTopicYN="N" Type="Geographic">Minnesota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Financial Disclosures:</b> No potential conflicts of interest relevant to this article were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18838636</ArticleId><ArticleId IdType="mid">NIHMS59491</ArticleId><ArticleId IdType="pmc">PMC2575648</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.65.10.1193</ArticleId><ArticleId IdType="pii">65/10/1193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732621</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook T, Bartus R, Ferris S, Whitehouse P, Cohen G, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change-Report of a National Institute of Mental Health Work Group. Dev Neuropsychol. 1986;2:261&#x2013;276.</Citation></Reference><Reference><Citation>Reisberg B, Ferris SH, de Leon MJ, Sinaiko E, Franssen E, Kluger A, Mir P, Borenstein J, George AE, Shulman E, Steinberg G, Cohen J. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res. 1988;15:101&#x2013;114.</Citation></Reference><Reference><Citation>Blackford R, LaRue A. Criteria for diagnosing age associated memory impairment. Dev Neuropsychol. 1989;5:295&#x2013;306.</Citation></Reference><Reference><Citation>Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">2067629</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9063278</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pubmed">9269213</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurland LT. Mayo's Older Americans Normative Studies: WAIS-R Norms for Ages 56 to 97. Clin Neuropsychol. 1992;65:1&#x2013;30.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994. Task Force on DSM-IV.</Citation></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Last JM International Epidemiological Association. A Dictionary of Epidemiology. 4th ed. New York: Oxford University Press; 2001.</Citation></Reference><Reference><Citation>Little RJ. Survey nonresponse adjustments for estimates of means. Int Stat Rev. 1986;54:139&#x2013;157.</Citation></Reference><Reference><Citation>Kessler RC, Little RJ, Groves RM. Advances in strategies for minimizing and adjusting for survey nonresponse. Epidemiol Rev. 1995;17:192&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521937</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agostino RB, Jr, Rubin DB. Estimating and using propensity scores with partially missing data. J Am Stat Assoc. 2000;95:749&#x2013;759.</Citation></Reference><Reference><Citation>Geda YE, Smith GE, Knopman DS, Boeve BF, Tangalos EG, Ivnik RJ, Mrazek DA, Edland SD, Petersen RC. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI) Int Psychogeriatr. 2004;16:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004;18:17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195459</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68:1596&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, Pilat J, Beckett LA, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29213584</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1980-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Dementia &amp; neuropsychologia</Title><ISOAbbreviation>Dement Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms in dementia is not a unitary concept: A critical review with emphasis on Alzheimer's disease.</ArticleTitle><Pagination><StartPage>272</StartPage><EndPage>277</EndPage><MedlinePgn>272-277</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1980-57642009DN20400007</ELocationID><Abstract><AbstractText Label="UNLABELLED">Behavioral and Psychological Symptoms of Dementia (BPSD) is an important feature of dementia. However, this definition comprises a large array of symptoms and syndromes. This hampers understanding of the behavior of patients with dementia and the devising of strategies to ameliorate these symptoms.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This review aimed to describe the main factors and syndromes that comprise BPSD, as well as neuroimaging, psychopharmacological, and genetic data derived from studies of these factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search on the Medline, Scielo, and ISI databases was performed using the keyword BPSD for articles published within the last five years. Selected publications were favored, so this review should not be regarded as a systematic study on the subject.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main factors and syndromes comprising BPSD were identified, namely psychosis, depression, and activity. Different ways of clustering symptoms were considered. The main manifestations of psychosis, apathy and depression were focused, relating phenomenology to neuroimaging and pharmacological issues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BPSD is a heterogeneous array of symptoms which can be better understood as clusters. At least three factors can be separated in BSPD, namely psychosis, depression, and activity. This division may offer guidance to clinicians regarding treatment management and follow up of the chosen therapeutic strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laks</LastName><ForeName>Jerson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease/ Institute of Psychiatry/Federal University of Rio de Janeiro; School of Medical Sciences, State University of Rio de Janeiro.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Eliasz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Neurology Deolindo Couto of the Federal University of Rio de Janeiro.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Dement Neuropsychol</MedlineTA><NlmUniqueID>101506587</NlmUniqueID><ISSNLinking>1980-5764</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="UNLABELLED">Os Sintomas Psicol&#xf3;gicos e do Comportamento na Dem&#xea;ncia (SPCD) s&#xe3;o uma caracter&#xed;stica importante das dem&#xea;ncias. Entretanto, essa defini&#xe7;&#xe3;o congrega uma ampla gama de sintomas e s&#xed;ndromes. Essa &#xe9; uma fonte de problemas no que tange o melhor conhecimento do comportamento dos pacientes e da&#xed; o desenvolvimento de estrat&#xe9;gias para aliviar esses sintomas.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Essa revis&#xe3;o objetiva descrever os principais fatores e s&#xed;ndromes que comp&#xf5;em os SPCD, al&#xe9;m de alguns dados de neuroimagem, psicofarmacol&#xf3;gicos e gen&#xe9;ticos derivados do estudo desses fatores.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Foi realizada busca nos bancos de dados Medline, Scielo e ISI utilizando a palavra chave BPSD (SPCD) compreendendo os cinco &#xfa;ltimos anos. Foram privilegiadas publica&#xe7;&#xf5;es selecionadas, de modo que a presente revis&#xe3;o n&#xe3;o deve ser vista como do tipo sistem&#xe1;tica sobre o assunto.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Os principais fatores e s&#xed;ndromes que comp&#xf5;em os SPCD foram identificados, compreendendo psicose, depres&#xe3;o e atividade. S&#xe3;o consideradas diferentes maneiras de se conglomerar os sintomas. As manifesta&#xe7;&#xf5;es principais, psicose, apatia e depress&#xe3;o s&#xe3;o focalizados, relacionando a fenomenologia &#xe0; aspectos de neuroimagem e farmacol&#xf3;gicos.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES" NlmCategory="UNASSIGNED">Os SPCD constituem um conjunto heterog&#xea;neo de sintomas que podem ser melhor compreendidos como conglomerados. Ao menos tr&#xea;s fatores podem ser separados nos SPCD, psicose, depress&#xe3;o e atividade. Essa divis&#xe3;o pode oferecer uma melhor orienta&#xe7;&#xe3;o para o cl&#xed;nico visando o tratamento e o seguimento da resposta a uma determinada estrat&#xe9;gia terap&#xea;utica escolhida.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BPSD</Keyword><Keyword MajorTopicYN="N">apathy</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29213584</ArticleId><ArticleId IdType="pmc">PMC5619079</ArticleId><ArticleId IdType="doi">10.1590/S1980-57642009DN20400007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finkel SL, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int J Geriatr Psychiatry. 1997;12:1060&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22:843&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">17193341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsch MF, Bottino CMC, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: Prevalence and relationship with dementia severity. Am J Geriatr Psychiatry. 2006;14(5):438&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">16670248</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallion P, McCarron M, Nickle T. Dementia and carer burnout: usefulness of the Maslach Burnout Inventory. J Appl Res Int Dis. 2006;19:230&#x2013;230.</Citation></Reference><Reference><Citation>Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics. 2005;23:227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer LS, Bay RC, Politis A, et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. Int J Geriatr Psychiatry. 2006;21:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">16955427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Intl Psychogeriatr. 2007;19:409&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">17346363</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006a;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2006b;294:1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part II: Relationships among behavioural sub-syndromes and the influence of clinical variables. Int J Geriatr Psychiatry. 2005;20:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920706</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovic M, Hurt C, Collins D, et al. Clustering of behavioural and psychological symptoms in dementia (BPSD): A European Alzheimer's disease consortium (EADC) study. Acta Clin Belg. 2007;62:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351187</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert PH, Frans RJ, Verhey E, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20:490&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Moskvina V, et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc. 2006;54:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Rabins PV, Breitner JCS. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746649</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11925273</ArticleId></ArticleIdList></Reference><Reference><Citation>Maertens K, Marien P, Vloeberghs E, et al. Behavioural and neuropsychological correlates of frontal lobe features in dementia. Psychol Med. 2006;36:1173&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16700962</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinno H, Inagaki T, Miyaoka T, et al. A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci. 2007;260:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">17540407</ArticleId></ArticleIdList></Reference><Reference><Citation>Morana EK, Becker JA, Satlin A, Lyoo K, Fischman AJ, Johnson KA. Psychosis of Alzheimer's disease: Gender differences in regional perfusion. Neurobiol Aging. 2008;29:1218&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">17408808</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Allozaa M, Gil-Beaa FJ, Diez-Arizaa M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia. 2005;43:442&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">15707619</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Hirst WD, Chen CPLH, Lasheras B, Francis PT, Ramirez MJ. Differential involvement of 5- HT1B/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology. 2004;29:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">14571255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, et al. Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging. 2008;29:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci. 2005;26:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629203</ArticleId></ArticleIdList></Reference><Reference><Citation>Miczek KA, Fish EW, De Bold JF. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav. 2003;44:242&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609546</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt E, Laks J, Cavalcanti JLS. O sistema glutamat&#xe9;rgico e a doen&#xe7;a de Alzheimer. Rev Bras Neurol. 2003;39:5&#x2013;20.</Citation></Reference><Reference><Citation>Lanct&#xf4;t KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int Psychogeriatr. 2007;19:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870038</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging. 2006;27:1110&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996794</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es HC, Levy R, Teixeira AL, Beato RG, Caramelli P. Neurobiology of apathy in Alzheimer's disease. Arq Neuropsiquiatr. 2008;66:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">18641892</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Barca ML, Selbaek G, Laks J, Engedal K. The pattern of depressive symptoms and factor analysis of the Cornell Scale among patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2008;23:1058&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457344</ArticleId></ArticleIdList></Reference><Reference><Citation>Skogseth R, Mulugeta E, Ballard C, et al. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;25:559&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536520</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18814807</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis.</ArticleTitle><Pagination><StartPage>78</StartPage><EndPage>85</EndPage><MedlinePgn>78-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610208007734</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms in Alzheimer disease (AD + P) identify a heritable phenotype associated with greater cognitive impairment. Knowing when the cognitive course of AD + P subjects diverges from that of subjects without psychosis would enhance understanding of how genetic variation results in AD + P and its associated cognitive burden. This study seeks to determine whether the degree of cognitive impairment and cognitive decline in early AD predicts subsequent AD + P onset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">361 subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis were evaluated every 6 months until psychosis onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Severity of cognitive dysfunction was a strong predictor of AD + P up to two years prior to psychosis onset. Cognition did not decline more rapidly prior to onset of AD + P.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals who will develop AD + P already demonstrate excess cognitive impairment during the mild stages of disease. Genetic variation and brain pathophysiology may lead to a cognitive risk phenotype which is present prior to dementia onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emanuel</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilkosz</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010414" MajorTopicYN="N" Type="Geographic">Pennsylvania</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Declaration</b>: The authors report no conflicts of interest. The sponsors had no part in formulation of the research questions, study design, data collection, data analysis, or decision to publish.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18814807</ArticleId><ArticleId IdType="mid">NIHMS103138</ArticleId><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="doi">10.1017/S1041610208007734</ArticleId><ArticleId IdType="pii">S1041610208007734</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Linkage analysis of Alzheimer disease with psychosis. Neurology. 2002;59:118&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, O'Brien JT, Coope B, Wilcock G. Psychotic symptoms in dementia and the rate of cognitive decline. Journal of the American Geriatrics Society. 1997;45:1031&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256862</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Boller F, Lopez OL, Saxton J, McGonigle KL. The natural history of Alzheimer's disease: description of study cohort and accuracy of diagnosis. Archives of Neurology. 1994;51:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8198470</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Boller F, Saxton J, McGonigle-Gibson KL. Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex. 1987;23:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53&#x2013;60.</Citation></Reference><Reference><Citation>Benton AL, Hamsher K, Varney NR, Spreen O. Contribution to Neuropsychological Assessment: A Clinical Manual. New York: Oxford University Press; 1983.</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135&#x2013;140.</Citation></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. Journal of the Neurological Sciences. 1987;78:151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Annals of Neurology. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biological Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of General Psychiatry. 2000;57:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10632234</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenette SY, Tanzi RE. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiology of Aging. 1999;20:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, O'Donovan MC, Sims R, Powell J, Lovestone S, Myers A, Devrieze FW, Hardy J, Goate A, Owen M, Williams J. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Wragg RE, Salmon DP, Harris MJ, Thal LJ. Cognitive deficits of patients with Alzheimer's disease with and without delusions. American Journal of Psychiatry. 1992;149:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Levy ML, Cummings J, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. American Journal of Psychiatry. 1996;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk WE, Saxton J, Hamilton RL, Kaufer D, Sweet RA, Cidis Meltzer C, Wisniewski SR, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades. II. Neurology. 2000a;55:1863&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk WE, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski SR, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology. 2000b;55:1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Archives of Neurology. 2003;60:1385&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E e4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology. 1997;49:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Archives of Neurology. 1999;56:1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Niendam TA, Bearden CE, Rosso IM, Sanchez LE, Hadley T, Nuechterlein KH, Cannon TD. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. American Journal of Psychiatry. 2003;160:2060&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">14594759</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Ready RE, Stout JC, Salmon DP, Thal LJ, Grant I, Jeste DV. Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society. 2000a;6:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105471</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal L, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology. 2000b;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tuson: Neuropsychology Press; 1993.</Citation></Reference><Reference><Citation>Rockwell E, Jackson E, Vilke G, Jeste DV. A study of delusions in a large cohort of Alzheimer's disease patients. American Journal of Geriatric Psychiatry. 1994;2:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">28530995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63:2341&#x2013;2347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623697</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology. 2005;62:1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiology of Aging. 2003;24:1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz BE, Macdonald AW, III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin. 2006;32:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632195</ArticleId><ArticleId IdType="pubmed">16166612</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life - Findings from the Nun Study. Jama-Journal of the American Medical Association. 1996;275:528&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:1649&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bergen SE, Sun Z, Marcsisin MJ, Sampson AR, Lewis DA. Anatomical evidence of impaired feedforward auditory processing in schizophrenia. Biological Psychiatry. 2007;61:854&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">17123477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Devlin B, Pollock BG, Sukonick DL, Kastango KB, Bacanu SA, Chowdari KV, DeKosky ST, Ferrell RE. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Molecular Psychiatry. 2005;10:1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002a;58:907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease. Archives of Neurology. 1998;55:1335&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer DI, DeKosky ST, Klunk WE. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging. 2002b;23:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y, Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. American Journal of Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. The Wechsler Memory Scale Manual-Revised. New York: The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Whalley LJ, Starr JM, Athawes R, Hunter D, Pattie A, Deary IJ. Childhood mental ability and dementia. Neurology. 2000;55:1455&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. American Journal of Geriatric Psychiatry. 2006;14:352&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18801019</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2008</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6712</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Scandinavian journal of caring sciences</Title><ISOAbbreviation>Scand J Caring Sci</ISOAbbreviation></Journal><ArticleTitle>Psychiatric and behavioural symptoms and the use of psychotropic medication in Special Care Units and Regular Units in Norwegian nursing homes.</ArticleTitle><Pagination><StartPage>568</StartPage><EndPage>573</EndPage><MedlinePgn>568-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1471-6712.2007.00576.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a number of countries Special Care Units (SCUs) have been established to meet the particular needs of patients with dementia. The criteria for SCUs are poorly defined and often not met.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the frequency distributions of dementia, psychiatric and behavioural symptoms and the use of psychotropic medication in SCUs and Regular Units (RUs) across different regions.</AbstractText><AbstractText Label="METHODS AND MATERIAL" NlmCategory="METHODS">By means of a structured interview, comprising the Neuropsychiatric Inventory, the Clinical Dementia Rating Scale and Lawton's Physical Self-maintenance scale, a representative sample of 1163 nonselected nursing home patients was assessed. In addition, information was collected from the patients' records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall SCU patients were significantly more likely to be younger, to have higher level of functioning, to have dementia, to exhibit clinically significant psychiatric and behavioural symptoms and to receive psychotropic medication. There were significant differences across regions in terms of psychiatric and behavioural symptoms and the use of psychotropic medication. The ratio of accommodation in SCUs to that in RUs varied across the regions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients in SCUs and patients in RUs are distinct nursing home populations. Regional differences, which might be due to diverse ratios of SCUs, are evident.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selbaek</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway. geir.selbaek@aldringoghelse.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkevold</LastName><ForeName>&#xd8;yvind</ForeName><Initials>&#xd8;</Initials></Author><Author ValidYN="Y"><LastName>Engedal</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Scand J Caring Sci</MedlineTA><NlmUniqueID>8804206</NlmUniqueID><ISSNLinking>0283-9318</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004992" MajorTopicYN="N">Ethics, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18801019</ArticleId><ArticleId IdType="doi">10.1111/j.1471-6712.2007.00576.x</ArticleId><ArticleId IdType="pii">SCS576</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18778191</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>14</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Using risperidone for Alzheimer's dementia-associated psychosis.</ArticleTitle><Pagination><StartPage>2537</StartPage><EndPage>2543</EndPage><MedlinePgn>2537-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.9.14.2537</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's dementia (AD) occurs in 6 - 8% of persons older than 65 years. The prevalence increases to 30% among those 85 years or older. Among AD patients, the incidence of psychosis is 30 - 50%. Safe and appropriate use of psychotropic agents is a relevant clinical concern for this population.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This review addresses risks and potential benefits when risperidone is used for treating AD-associated psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Through literature review and clinical experience, the authors discuss the clinical efficacy, safety, and regulatory issues concerning risperidone treatment for this group of patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite concerns about safety, risperidone remains a popular therapeutic choice for AD patients with psychosis. Subsets of these patients with more severe agitation and aggression may experience greater behavioral benefit.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNeal</LastName><ForeName>Karleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Alzheimer's Research and Clinical Programs, VA Medical Center and Medical University of South Carolina, Geriatrics and Extended Care, Charleston, SC, 29406-6076, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Renee P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Lukacs</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Senseney</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18778191</ArticleId><ArticleId IdType="doi">10.1517/14656566.9.14.2537</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18765932</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Lateralization of 17beta-hydroxysteroid dehydrogenase type 10 in hippocampi of demented and psychotic people.</ArticleTitle><Pagination><StartPage>193</StartPage><EndPage>198</EndPage><MedlinePgn>193-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000151778</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The multifunctional mitochondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10 could play a role in the development of Alzheimer disease via its high-affinity binding to amyloid-beta peptides and its overexpression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the specificity of alterations in mRNA/enzyme expression levels in human right and left hippocampi.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed a trend towards right/left laterality in nondemented nonpsychotic controls; however, the degree of asymmetry was higher for mRNA when compared to enzyme expression levels. In Alzheimer disease and schizophrenia, significant shifts to left/right asymmetry were found and the changes were associated with more marked increases in mRNA/enzyme expression in the left hemisphere. On the other hand, no alterations were observed in people with multi-infarct dementia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results support studies reporting an impairment of mitochondria in Alzheimer disease or schizophrenia and a higher vulnerability of the dominant hemisphere to pathological processes. Overexpression of the enzyme could be used to distinguish Alzheimer disease from multi-infarct dementia.</AbstractText><CopyrightInformation>Copyright 2008 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hovorkova</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Center, Prague Psychiatric Center, Prague, Czech Republic. kristofikova@pcp.lf3.cuni.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristofikova</LastName><ForeName>Zdena</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Horinek</LastName><ForeName>Ales</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ripova</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Majer</LastName><ForeName>Emerich</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zach</LastName><ForeName>Petr</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sellinger</LastName><ForeName>Pavel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ricny</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.-</RegistryNumber><NameOfSubstance UI="D015094">3-Hydroxyacyl CoA Dehydrogenases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.35</RegistryNumber><NameOfSubstance UI="C108634">HSD17B10 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015094" MajorTopicYN="N">3-Hydroxyacyl CoA Dehydrogenases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18765932</ArticleId><ArticleId IdType="doi">10.1159/000151778</ArticleId><ArticleId IdType="pii">000151778</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18758418</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2008</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>CR473</StartPage><EndPage>CR479</EndPage><MedlinePgn>CR473-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">AD is preceded by a lengthy preclinical period. Neural degeneration may lead to the appearance of behavioral and psychological symptoms, even before other clinical symptoms are manifest. We attempted to evaluate this symptomatology in preclinical AD.</AbstractText><AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">We recruited 291 care center residents who did not demonstrate dementia symptoms according to DSM-IV, whose MMSE score was at least 24, and who reached the first or second stage on the Global Deterioration Scale. Psychopathology was assessed using the AMDP, while the ADAS-cog was used to assess cognitive dysfunctions. Seven years later, 155 patients participated in the follow-up study (MMSE and ADAS-cog). If the MMSE was less than 24, a psychiatric workup was done to verify dementia. The AD group consisted of persons properly diagnosed with AD (n=25), while the control group consisted of persons in whom dementia had not developed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The AD and control groups differed in the level of psychopathological symptoms at baseline. The disparities related both to the global AMDP score and to every particular symptom category. The analysis did not disclose a pathognomonic symptom for preclinical AD, but there were many symptoms whose intensity differentiated AD patients from the controls. The degree of cognitive dysfunction seems to correlate with the clinical manifestation of some psychopathological symptoms in preclinical AD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The degeneration process before the clinical manifestation of dementia leads not only to the impairment of several cognitive functions, but also the intensification of behavioral and psychological symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Leszek</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Developmental, Psychotic, and Geriatric Psychiatry, Medical University of Gda&#x144;sk, Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachalska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grochmal-Bach</LastName><ForeName>Bozena</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Mariola</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cieslukowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pufal</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Med Sci Monit. 2008 Oct;14(10):LE15-6; author reply E16-7.</RefSource><PMID Version="1">18830201</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18758418</ArticleId><ArticleId IdType="pii">867965</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18696274</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1174</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Neuromolecular medicine</Title><ISOAbbreviation>Neuromolecular Med</ISOAbbreviation></Journal><ArticleTitle>Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>384</EndPage><MedlinePgn>377-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12017-008-8048-8</ELocationID><Abstract><AbstractText>Psychotic symptoms are common in Alzheimer's disease (AD) and have a negative impact on quality of life. It is suggested that psychotic symptoms may be attributed to genetic risk factors which are revealed during neurodegeneration. CHRNA7, the gene for the alpha 7 nicotinic acetylcholine receptor, has been associated with schizophrenia in linkage and association studies. Hence we investigated single SNPs and haplotypes in CHRNA7 in relation to AD with psychosis in a large, well-characterised and previously described cohort within the Northern Ireland population. A significant association between delusions and the T allele of rs6494223 (P = 0.014, OR = 1.63, CI = 1.22-2.17) was found. This suggests that the alpha 7 receptor may be a suitable target for the treatment of AD with psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Robyn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychiatry and Neuroscience, School of Medicine and Dentistry, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. robyn.carson@qub.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Francis A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>A Peter</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuromolecular Med</MedlineTA><NlmUniqueID>101135365</NlmUniqueID><ISSNLinking>1535-1084</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579167">Chrna7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18696274</ArticleId><ArticleId IdType="doi">10.1007/s12017-008-8048-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Feb;149(2):184-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2004 Sep;66(3):538-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15322245</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7):841-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1998 Sep;7(9):1507-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9700207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2008 Mar;29(3):341-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2003 Jun 30;61(1):1-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12788204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1998;9 Suppl 2:8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9718229</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Aug 28;57(4):613-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11524468</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Dec;59(12):1085-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12470124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1999 Jun 3;10(8):1779-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10501574</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2004 Dec;74(6):363-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15649582</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 May 23;54(10):1965-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2001 Jan 8;105(1):20-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11424985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 May;64(5):648-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1988 Feb 11;16(3):1215</Citation><ArticleIdList><ArticleId IdType="pubmed">3344216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2002 Apr;4(2):71-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12214130</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Jun;13(6):460-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15956265</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2007 Jun;85(8):1810-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17455307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Nov;10(11):1026-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):587-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9012828</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jul 15;60(2):115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16843094</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2007 Jan 5;144B(1):126-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16967466</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Jul 1;38(1):22-33</Citation><ArticleIdList><ArticleId IdType="pubmed">7548469</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2000 Apr 3;96(2):196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">10893497</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2008 Apr;45(4):244-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18057084</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2004 Sep 16;368(1):33-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15342129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):28-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Feb 1;49(3):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11230874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2005 Jan 15;21(2):263-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Apr;8(4):383-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(9):1006-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12399955</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1998 Oct;55(10):1335-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2007 Jun;321(3):1179-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17374745</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2007 Aug;28(8):1231-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16837108</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1998 Sep 1;52(2):173-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9782083</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2005;43(3):442-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15707619</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2 Suppl 1):S64-78</Citation><ArticleIdList><ArticleId IdType="pubmed">9581223</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2003;19(3):169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12814128</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Jun;63(6):630-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16754836</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2008 Jun;20(3):538-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18289451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2004 Jul;56(1):121-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15236409</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Jan 5;132B(1):5-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15690550</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jan;165(1):82-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17986678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Mar;9(3):227-36</Citation><ArticleIdList><ArticleId IdType="pubmed">14610524</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2004 May;1(2):135-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15975078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2006 Feb;127(2):158-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16297434</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Nov;19(11):1035-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15481075</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2022-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18691283</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications.</ArticleTitle><Pagination><StartPage>1644</StartPage><EndPage>1650</EndPage><MedlinePgn>1644-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1532-5415.2008.01839.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the potential mechanisms through which conventional antipsychotic medication (APM) might act, the specific causes of death in elderly patients newly started on conventional APM were compared with those of patients taking atypical APM.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">All British Columbia residents aged 65 and older who initiated a conventional or atypical APM between 1996 and 2004.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Cox proportional hazards models were used to compare risks of developing a specific cause of death within 180 days of APM initiation. Potential confounders were adjusted for using traditional multivariable, propensity-score, and instrumental-variable adjustments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study cohort included 12,882 initiators of conventional APM and 24,359 initiators of atypical APM. Of 3,821 total deaths within the first 180 day of use, cardiovascular (CV) deaths accounted for 49% of deaths. Initiators of conventional APM had a significantly higher adjusted risk of all CV death (hazard ratio (HR)=1.23, 95% confidence interval (CI)=1.10-1.36) and out-of-hospital CV death (HR=1.36, 95% CI=1.19-1.56) than initiators of atypical APM. Initiators of conventional APM also had a higher risk of death due to respiratory diseases, nervous system diseases, and other causes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that greater risk of CV deaths might explain approximately half of the excess mortality in initiators of conventional APM. The risk of death due to respiratory causes was also significantly higher in conventional APM use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Setoguchi</LastName><ForeName>Soko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA. ssetoguchi@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Alan Brookhart</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Canning</LastName><ForeName>Claire F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Kaci</LastName><ForeName>Liljana</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schneeweiss</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2009 May;12(2):58. doi: 10.1136/ebmh.12.2.58</RefSource><PMID Version="1">19395617</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="Y">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18691283</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2008.01839.x</ArticleId><ArticleId IdType="pii">JGS1839</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18625457</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1933-7213</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>469</EndPage><MedlinePgn>458-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nurt.2008.05.008</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. The neurochemical correlates of these clinical manifestations now appear to involve dysfunctions of multiple neurotransmitter pathways. Because of the extensive serotonergic denervation that has been observed in the AD brain and the important role played by serotonin (5-HT) in both cognition and behavioral control, this neurotransmitter system has become a focus of concerted research efforts to identify new treatments for AD. 5-HT exerts its diverse physiological and pharmacological effects through actions on multiple receptor subtypes. One of the newest members of this family is the 5-HT6 receptor, a subtype localized almost exclusively in the CNS, predominating in brain regions associated with cognition and behavior. With the subsequent development of selective 5-HT6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. These actions are largely underpinned by enhancements of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. A preliminary report that the cognitive enhancing properties of a 5-HT6 receptor antagonist (namely, SB-742457) extends into AD sufferers further highlights the therapeutic promise of this mechanistic approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Upton</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, United Kingdom. Neil_Upton@gsk.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Tsu Tshen</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Ann J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Virley</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097216">serotonin 6 receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18625457</ArticleId><ArticleId IdType="pmc">PMC5084247</ArticleId><ArticleId IdType="doi">10.1016/j.nurt.2008.05.008</ArticleId><ArticleId IdType="pii">S1878-7479(23)00498-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Zeigler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2007;3:186&#x2013;191. doi: 10.1016/j.jalz.2007.04.381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.04.381</ArticleId><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer&#x2019;s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821&#x2013;827. doi: 10.1124/jpet.102.041616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.102.041616</ArticleId><ArticleId IdType="pubmed">12805474</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer&#x2019;s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105&#x2013;2115. doi: 10.1016/S0140-6736(04)16499-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16499-4</ArticleId><ArticleId IdType="pubmed">15220031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez MJ, Aisa B, Garcia-Alloza M, Gil-Bea FJ, Marcos B. Involvement of the serotonergic system in cognitive and behavioral symptoms of Alzheimer&#x2019;s disease. Curr Psychiatry Rev. 2005;1:337&#x2013;343. doi: 10.2174/157340005774575073.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340005774575073</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang ATT, Foley A, Pugh PL, et al. 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2006;2:S631&#x2013;S632. doi: 10.1016/j.jalz.2006.05.2128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2006.05.2128</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruat M, Traiffort E, Arrang J-M, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization, and stimulation of cAMP accumulation. Biochem Biophys Res Commun. 1993;193:268&#x2013;276. doi: 10.1006/bbrc.1993.1619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1993.1619</ArticleId><ArticleId IdType="pubmed">8389146</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JC, Reavill C, East S, et al. The distribution of 5-HT6 receptors in rat brain: an autoradiographic radioligand binding study using the radiolabelled 5-HT6 receptor antagonist [6I]SB-258585. Brain Res. 2002;934:49&#x2013;57. doi: 10.1016/S0006-8993(02)02360-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(02)02360-0</ArticleId><ArticleId IdType="pubmed">11937069</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;rard C, el Mestikawy S, Lebrand C, et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 1996;23:164&#x2013;173. doi: 10.1002/(SICI)1098-2396(199607)23:3&lt;164::AID-SYN5&gt;3.0.CO;2-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2396(199607)23:3&lt;164::AID-SYN5&gt;3.0.CO;2-6</ArticleId><ArticleId IdType="pubmed">8807744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamon M, Doucet E, Lef&#xe8;vre K, et al. Antibodies and antisense oligonucleotides for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology. 1999;21(Suppl 2):68S&#x2013;76S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10432491</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley ML, Marsden CA, Fone KCF. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:59&#x2013;79. doi: 10.2174/1568007043482561.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007043482561</ArticleId><ArticleId IdType="pubmed">14965245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol. 2003;64:1295&#x2013;1308. doi: 10.1124/mol.64.6.1295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.64.6.1295</ArticleId><ArticleId IdType="pubmed">14645659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohen R, Metcalf MA, Khan N, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996;66:47&#x2013;56. doi: 10.1046/j.1471-4159.1996.66010047.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.66010047.x</ArticleId><ArticleId IdType="pubmed">8522988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther. 2005;108:320&#x2013;333. doi: 10.1016/j.pharmthera.2005.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2005.05.001</ArticleId><ArticleId IdType="pubmed">16005519</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth BL, Craigo SC, Choudray MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268:1403&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">7908055</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleight AJ, Boess FG, B&#xf6;s M, Levet-Trafit B, Riemer C, Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol. 1998;124:556&#x2013;562. doi: 10.1038/sj.bjp.0701851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0701851</ArticleId><ArticleId IdType="pmc">PMC1565407</ArticleId><ArticleId IdType="pubmed">9647481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromidge SM, Brown AM, Clarke SE, et al. 5-Chloro-N-(4-methoxy-3-piperazin-l-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective and orally bioavailable 5-HT6 receptor antagonist. J Med Chem. 1999;42:202&#x2013;205. doi: 10.1021/jm980532e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980532e</ArticleId><ArticleId IdType="pubmed">9925723</ArticleId></ArticleIdList></Reference><Reference><Citation>Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: a potent, selective, orally active 5-HT6 receptor antagonist. Br J Pharmacol. 2000;130:1606&#x2013;1612. doi: 10.1038/sj.bjp.0703457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0703457</ArticleId><ArticleId IdType="pmc">PMC1572216</ArticleId><ArticleId IdType="pubmed">10928964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109&#x2013;119. doi: 10.1016/j.ejphar.2006.09.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.09.049</ArticleId><ArticleId IdType="pubmed">17069795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonhaus DW, Martin R, Brothers J, et al. Ro4368554, a high affinity, selective, CNS penetrating 5-HT6 receptor antagonist. Soc Neurosci Abstr 2002;884.5 (abstract).</Citation></Reference><Reference><Citation>Schreiber R, Vivian J, Hedley L, et al. Effects of the novel 5-HT6 receptor antagonist Ro4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol. 2007;17:277&#x2013;288. doi: 10.1016/j.euroneuro.2006.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2006.06.009</ArticleId><ArticleId IdType="pubmed">16989988</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter LE, Smith DL, Zhang GM, et al. Pharmacological profile of a novel and selective 5-HT6 receptor agonist. Fundam Clin Pharmacol. 2004;18(Suppl 1):135&#x2013;151.</Citation></Reference><Reference><Citation>Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008;33:1323&#x2013;1335. doi: 10.1038/sj.npp.1301503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301503</ArticleId><ArticleId IdType="pubmed">17625499</ArticleId></ArticleIdList></Reference><Reference><Citation>Loiseau F, Dekeyne A, Millan MJ. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 2008;196:93&#x2013;104. doi: 10.1007/s00213-007-0934-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-007-0934-5</ArticleId><ArticleId IdType="pubmed">17922111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourson A, Borroni E, Austin RH, Monsma FJ, Sleight AJ. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther. 1995;274:173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley JC, Bourson A, Boess FG, et al. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol. 1999;126:1537&#x2013;1542. doi: 10.1038/sj.bjp.0702445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0702445</ArticleId><ArticleId IdType="pmc">PMC1565929</ArticleId><ArticleId IdType="pubmed">10323584</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer&#x2019;s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137&#x2013;147. doi: 10.1136/jnnp.66.2.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.66.2.137</ArticleId><ArticleId IdType="pmc">PMC1736202</ArticleId><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273&#x2013;280. doi: 10.1016/S0166-2236(98)01361-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(98)01361-7</ArticleId><ArticleId IdType="pubmed">10354606</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley JC, Sleight AJ, Marsden CA, Fone KCF. 5-HT6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding. J Psychopharmacol. 1997;11(3 Suppl):A64&#x2013;A64.</Citation></Reference><Reference><Citation>Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 2001;41:210&#x2013;219. doi: 10.1016/S0028-3908(01)00056-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(01)00056-9</ArticleId><ArticleId IdType="pubmed">11489457</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers DC, Hagan JJ. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 2001;158:114&#x2013;119. doi: 10.1007/s002130100840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002130100840</ArticleId><ArticleId IdType="pubmed">11702084</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell MGN, Dias R. Memories are made of this (perhaps): a review of serotonin 5-HT6 receptor ligands and their biological functions. Curr Top Med Chem. 2002;2:643&#x2013;654. doi: 10.2174/1568026023393877.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026023393877</ArticleId><ArticleId IdType="pubmed">12052198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner MD, Hodges DB, Hogan JB, et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther. 2003;307:682&#x2013;691. doi: 10.1124/jpet.103.056002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.056002</ArticleId><ArticleId IdType="pubmed">12975483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussey TJ, Muir JL, Aggleton JP. Functionally dissociating aspects of event memory: the effects of combined perirhinal and postrhinal cortex lesions on object and place memory in the rat. J Neurosci. 1999;19:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782353</ArticleId><ArticleId IdType="pubmed">9870977</ArticleId></ArticleIdList></Reference><Reference><Citation>King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation: an effect sensitive to NMDA receptor antagonism. Neuropharmacology. 2004;47:195&#x2013;204. doi: 10.1016/j.neuropharm.2004.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2004.03.012</ArticleId><ArticleId IdType="pubmed">15223298</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan PM, Ilch CP, Rowe WB, Tehim A. Characterization of the selective 5-HT6 receptor antagonist SB-271046 in behavioral models of cognition. Soc Neurosci Abstr 2004;776.19 (abstract).</Citation></Reference><Reference><Citation>Woolley ML, Marsden CA, Sleight AJ, Fone KC. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 2003;170:358&#x2013;367. doi: 10.1007/s00213-003-1552-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-003-1552-5</ArticleId><ArticleId IdType="pubmed">13680084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology. 2005;30:2169&#x2013;2179. doi: 10.1038/sj.npp.1300777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300777</ArticleId><ArticleId IdType="pubmed">15957009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirogi RV, Vishwakarma SL, Abraham R, Jayarajan P, Goyal RK, Shirsath VS. SUVN-507 reverses scopolamine induced amnesia in Morris water maze and novel object recognition task. Soc Neurosci Abstr 2006;162.12 (abstract).</Citation></Reference><Reference><Citation>Foley AG, Murphy KJ, Hirst WD, et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology. 2004;29:93&#x2013;100. doi: 10.1038/sj.npp.1300332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300332</ArticleId><ArticleId IdType="pubmed">14571256</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanski KV, Vivian JA, Dorsch K, et al. Procognitive effects of the 5-HT6 receptor antagonist Ro4368554 in rats. Soc Neurosci Abstr 2002;290.2 (abstract).</Citation></Reference><Reference><Citation>Perez-Garc&#xed;a G, Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 5;81:673&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher PD, Brown VJ, Tait DS, et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 2005;181:253&#x2013;259. doi: 10.1007/s00213-005-2261-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-005-2261-z</ArticleId><ArticleId IdType="pubmed">15846482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesolowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 2007;52:1274&#x2013;1283. doi: 10.1016/j.neuropharm.2007.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2007.01.007</ArticleId><ArticleId IdType="pubmed">17320917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiforuk A, Wesolowska A, Popik P. Effect of combined administration of the selective serotonin 6 receptor antagonist SB-399885 and antidepressants in the forced swim test in rats. Soc Neurosci Abstr 2007;709.7 (abstract).</Citation></Reference><Reference><Citation>Wesolowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol. 2007;18:439&#x2013;446. doi: 10.1097/FBP.0b013e3282d28f9c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FBP.0b013e3282d28f9c</ArticleId><ArticleId IdType="pubmed">17762512</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendharkar VV, Vishwakarma SL, Patel AS, Shirsath VS, Kambhampati SR, Nirogi RVS. Effect of selective 5-HT6 receptor antagonists on food-intake and body weight gain. Soc Neurosci Abstr 2005;533.7 (abstract).</Citation></Reference><Reference><Citation>Jackson HC, Cheetham SC, Dickinson K, et al. Effects of chronic administration and withdrawal of the novel 5-HT6 ligand, E-6837, in a rat model of dietary-induced obesity. Soc Neurosci Abstr 2006;62.2 (abstract).</Citation></Reference><Reference><Citation>Svartengren J, Axelsson-Lendin P, Multan U, et al. Characterization of a new selective BVT serotonin 5-HT6 receptor antagonist in animal models for feeding and body weight regulation. Soc Neurosci Abstr 2007;629.11 (abstract).</Citation></Reference><Reference><Citation>Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273&#x2013;1276. doi: 10.1021/jm021085c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm021085c</ArticleId><ArticleId IdType="pubmed">12646038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MY, Hughes ZA, Kerns EH, Lin Q, Beyer CE. Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J Pharm Biomed Anal. 2007;44:586&#x2013;593. doi: 10.1016/j.jpba.2007.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2007.02.024</ArticleId><ArticleId IdType="pubmed">17383138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson LA, Nguyen HQ, Li P. In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol. 2000;130:23&#x2013;26. doi: 10.1038/sj.bjp.0703288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0703288</ArticleId><ArticleId IdType="pmc">PMC1572041</ArticleId><ArticleId IdType="pubmed">10780993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662&#x2013;668. doi: 10.1016/S0893-133X(01)00265-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0893-133X(01)00265-2</ArticleId><ArticleId IdType="pubmed">11682249</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer&#x2019;s disease: investigative and therapeutic perspectives. J Neurochem. 1993;60:1589&#x2013;1604. doi: 10.1111/j.1471-4159.1993.tb13381.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb13381.x</ArticleId><ArticleId IdType="pubmed">8473885</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer AM. Neurochemical studies of Alzheimer&#x2019;s disease. Neurodegeneration. 1996;5:381&#x2013;391. doi: 10.1006/neur.1996.0051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1996.0051</ArticleId><ArticleId IdType="pubmed">9117551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of mono-amines in the rat medial prefrontal cortex. Synapse. 2004;51:158&#x2013;164. doi: 10.1002/syn.10288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.10288</ArticleId><ArticleId IdType="pubmed">14618683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb B. Functions of the frontal cortex of the rat: a comparative review. Brain Res. 1984;320:65&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">6440660</ArticleId></ArticleIdList></Reference><Reference><Citation>Passetti F, Chudasama Y, Robbins TW. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex. 2002;12:1254&#x2013;1268. doi: 10.1093/cercor/12.12.1254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/12.12.1254</ArticleId><ArticleId IdType="pubmed">12427677</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson LA, Li P. Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat. J Neural Transm. 2003;110:577&#x2013;590. doi: 10.1007/s00702-003-0812-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-003-0812-1</ArticleId><ArticleId IdType="pubmed">12768354</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos B, Gil-Bea FJ, Hirst WD, Garc&#xed;a-Alloza M, Ram&#xed;rez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299&#x2013;1306. doi: 10.1111/j.1460-9568.2006.05003.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2006.05003.x</ArticleId><ArticleId IdType="pubmed">16987217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerard C, Martres MP, Lef&#xe8;vre K, et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 1997;746:207&#x2013;219. doi: 10.1016/S0006-8993(96)01224-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(96)01224-3</ArticleId><ArticleId IdType="pubmed">9037500</ArticleId></ArticleIdList></Reference><Reference><Citation>Persohn E, Schachner M. Immunoelectron microscopic localization of the neural cell adhesion molecules L1 and N-CAM during postnatal development of the mouse cerebellum. J Cell Biol. 1987;105:569&#x2013;576. doi: 10.1083/jcb.105.1.569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.105.1.569</ArticleId><ArticleId IdType="pmc">PMC2114902</ArticleId><ArticleId IdType="pubmed">3301870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster T, Krug M, Stalder M, Hackel N, Gerardy-Schahn R, Schachner M. Immunoelectron microscopic localization of the neural recognition molecules L1, NCAM, and its isoform NCAM180, the NCAM-associated polysialic acid, beta1 integrin and the extracellular matrix molecule tenascin-R in synapses of the adult rat hippocampus. J Neurobiol. 2001;49:142&#x2013;158. doi: 10.1002/neu.1071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/neu.1071</ArticleId><ArticleId IdType="pubmed">11598921</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle E, Nolan PM, Bell R, Regan CM. Intraventricular infusions of anti-neural cell adhesion molecules in a discrete posttraining period impair consolidation of a passive avoidance response in the rat. J Neurochem. 1992;59:1570&#x2013;1573. doi: 10.1111/j.1471-4159.1992.tb08477.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1992.tb08477.x</ArticleId><ArticleId IdType="pubmed">1402906</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholey AB, Rose SP, Zamani MR, Bock E, Schachner M. A role for the neural cell adhesion molecule in a late, consolidating phase of glycoprotein synthesis six hours following passive avoidance training of the young chick. Neuroscience. 1993;55:499&#x2013;509. doi: 10.1016/0306-4522(93)90519-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(93)90519-L</ArticleId><ArticleId IdType="pubmed">8377940</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;thl A, Laurent JP, Figurov A, Muller D, Schachner M. Hippocampal long-term potentiation and neural cell adhesion molecules L1 and NCAM. Nature. 1994;372:777&#x2013;779. doi: 10.1038/372777a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/372777a0</ArticleId><ArticleId IdType="pubmed">7997264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoul R, Hirn M, Deagostini-Bazin H, Rougon G, Goridis C. Adult and embryonic mouse neural cell adhesion molecules have different binding properties. Nature. 1983;304:347&#x2013;349. doi: 10.1038/304347a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/304347a0</ArticleId><ArticleId IdType="pubmed">6877355</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran N, Bock E. Characterization of the kinetics of neural cell adhesion molecule homophilic binding. FEBS Lett. 1988;242:121&#x2013;124. doi: 10.1016/0014-5793(88)80998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(88)80998-0</ArticleId><ArticleId IdType="pubmed">3144464</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller D, Wang C, Skibo G, et al. PSA-NCAM is required for activity-induced synaptic plasticity. Neuron. 1996;7:413&#x2013;422. doi: 10.1016/S0896-6273(00)80174-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80174-9</ArticleId><ArticleId IdType="pubmed">8816705</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H, Schachner M. The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res. 1996;45:143&#x2013;152. doi: 10.1002/(SICI)1097-4547(19960715)45:2&lt;143::AID-JNR6&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19960715)45:2&lt;143::AID-JNR6&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">8843031</ArticleId></ArticleIdList></Reference><Reference><Citation>Venero C, Herrero AI, Touyarot K, et al. Hippocampal up-regulation of NCAM expression and polysialylation plays a key role on spatial memory. Eur J Neurosci. 2006;23:1585&#x2013;1595. doi: 10.1111/j.1460-9568.2006.04663.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2006.04663.x</ArticleId><ArticleId IdType="pubmed">16553622</ArticleId></ArticleIdList></Reference><Reference><Citation>Diyatev A, Dityateva G, Sytnyk V, et al. Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J Neurosci. 2004;24:9372&#x2013;9382. doi: 10.1523/JNEUROSCI.1702-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1702-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730092</ArticleId><ArticleId IdType="pubmed">15496673</ArticleId></ArticleIdList></Reference><Reference><Citation>Markram K, Gerardy-Schahn R, Sandi C. Selective learning and memory impairments in mice deficient for polysialylated NCAM in adulthood. Neuroscience. 2007;144:788&#x2013;796. doi: 10.1016/j.neuroscience.2006.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.10.024</ArticleId><ArticleId IdType="pubmed">17140740</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T, Arai Y. Highly polysialylated neural cell adhesion molecule (NCAM-H) is expressed by newly generated granule cells in the dentate gyrus of the adult rat. J Neurosci. 1993;13:2351&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576495</ArticleId><ArticleId IdType="pubmed">7684771</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T, Arai Y. Different polysialic acid-neural cell adhesion molecule expression patterns in distinct types of mossy fiber boutons in the adult hippocampus. J Comp Neurol. 1999;410:115&#x2013;125. doi: 10.1002/(SICI)1096-9861(19990719)410:1&lt;115::AID-CNE10&gt;3.0.CO;2-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(19990719)410:1&lt;115::AID-CNE10&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">10397399</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xed; Dh&#xfa;ill CM, Fox GB, Pittock SJ, O&#x2019;Connell AW, Murphy KJ, Regan CM. Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J Neurosci Res. 1999;55:99&#x2013;106. doi: 10.1002/(SICI)1097-4547(19990101)55:1&lt;99::AID-JNR11&gt;3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990101)55:1&lt;99::AID-JNR11&gt;3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">9890438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559&#x2013;566. doi: 10.1016/j.neuron.2007.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.05.002</ArticleId><ArticleId IdType="pmc">PMC2040308</ArticleId><ArticleId IdType="pubmed">17521569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Teng EM, Summers RG, Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci. 2006;26:3&#x2013;11. doi: 10.1523/JNEUROSCI.3648-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3648-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674324</ArticleId><ArticleId IdType="pubmed">16399667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee N, Teixeira CM, Wang AH, Frankland PW. Preferential incorporation of adult-generated granule cells into spatial memory networks in the dentate gyrus. Nat Neurosci. 2007;10:355&#x2013;362. doi: 10.1038/nn1847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1847</ArticleId><ArticleId IdType="pubmed">17277773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitabatake Y, Sailor KA, Ming GL, Song H. Adult neurogenesis and hippocampal memory function: new cells, more plasticity, new memories? Neurosurg Clin N Am. 2007;18:105&#x2013;113. doi: 10.1016/j.nec.2006.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nec.2006.10.008</ArticleId><ArticleId IdType="pmc">PMC5439504</ArticleId><ArticleId IdType="pubmed">17244558</ArticleId></ArticleIdList></Reference><Reference><Citation>Senkov O, Sun M, Weinhold B, Gerardy-Schahn R, Schachner M, Dityatev A. Polysialylated neural cell adhesion molecule is involved in induction of long-term potentiation and memory acquisition and consolidation in a fear-conditioning paradigm. J Neurosci. 2006;26:10888&#x2013;10898. doi: 10.1523/JNEUROSCI.0878-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0878-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674738</ArticleId><ArticleId IdType="pubmed">17050727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Femandez MA, Montaron MF, Varea E, et al. Upregulation of polysialylated neural cell adhesion molecule in the dorsal hippocampus after contextual fear conditioning is involved in long-term memory formation. J Neurosci. 2007;27:4552&#x2013;4561. doi: 10.1523/JNEUROSCI.0396-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0396-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673006</ArticleId><ArticleId IdType="pubmed">17460068</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CN, Roland A, Upton N. New symptomatic strategies in Alzheimer&#x2019;s disease. Drug Discov Today Ther Strateg. 2004;1:13&#x2013;20. doi: 10.1016/j.ddstr.2004.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddstr.2004.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley AG, Hirst WD, Gallagher HS, et al. The 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology. 2008;54:1166&#x2013;1174. doi: 10.1016/j.neuropharm.2008.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.03.012</ArticleId><ArticleId IdType="pubmed">18455201</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun HM, Kim S, Kim HJ, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem. 2007;282:5496&#x2013;5505. doi: 10.1074/jbc.M606215200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M606215200</ArticleId><ArticleId IdType="pubmed">17189269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9694&#x2013;9703. doi: 10.1523/JNEUROSCI.2980-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2980-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Thangavel R, Sharma VM, et al. Phosphorylation of tau by fyn: implications for Alzheimer&#x2019;s disease. J Neurosci. 2004;24:2351&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730442</ArticleId><ArticleId IdType="pubmed">14999081</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol. 2004;65:121&#x2013;129. doi: 10.1124/mol.65.1.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.65.1.121</ArticleId><ArticleId IdType="pubmed">14722243</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SG, O&#x2019;Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903&#x2013;1910. doi: 10.1126/science.1361685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1361685</ArticleId><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Yagi T, Watanabe S, Niki H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Mol Brain Res. 1994;27:179&#x2013;182. doi: 10.1016/0169-328X(94)90201-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-328X(94)90201-1</ArticleId><ArticleId IdType="pubmed">7877449</ArticleId></ArticleIdList></Reference><Reference><Citation>Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer&#x2019;s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(Suppl 1):S23&#x2013;S32. doi: 10.1002/gps.938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.938</ArticleId><ArticleId IdType="pubmed">12973747</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2006;l:CD001190&#x2013;CD001190.</Citation><ArticleIdList><ArticleId IdType="pubmed">16437430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Fallow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer&#x2019;s disease already receiving donepezil. JAMA. 2004;291:317&#x2013;324. doi: 10.1001/jama.291.3.317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.3.317</ArticleId><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider JA, Ridley RM. The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology. 2000;39:547&#x2013;552. doi: 10.1016/S0028-3908(99)00179-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(99)00179-3</ArticleId><ArticleId IdType="pubmed">10728875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter LE, Smith DL, Rosenzweig-Lipson S, et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther. 2005;314:1274&#x2013;1289. doi: 10.1124/jpet.105.086363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.086363</ArticleId><ArticleId IdType="pubmed">15951399</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Singla S, Toda H, Monje M, Palmer TD, Malenka RC. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron. 2004;42:535&#x2013;552. doi: 10.1016/S0896-6273(04)00266-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00266-1</ArticleId><ArticleId IdType="pubmed">15157417</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KJ, O&#x2019;Connell AW, Regan CM. Repetitive and transient increases in hippocampal neural cell adhesion molecule polysialylation state following multitrial spatial training. J Neurochem. 1996;67:1268&#x2013;1274. doi: 10.1046/j.1471-4159.1996.67031268.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67031268.x</ArticleId><ArticleId IdType="pubmed">8752135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox GB, O&#x2019;Connell AW, Murphy KJ, Regan CM. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. J Neurochem. 1995;65:2796&#x2013;2799. doi: 10.1046/j.1471-4159.1995.65062796.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.65062796.x</ArticleId><ArticleId IdType="pubmed">7595580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18597728</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>193</EndPage><MedlinePgn>187-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2007.12.004</ELocationID><Abstract><AbstractText>Aripiprazole is indicated for the treatment of schizophrenia in Europe and the United States, and for bipolar disorders in the latter. Nevertheless, a review of recent literature has shown that aripiprazole has been studied in many other disorders, notably resistant depression, anxiety, obsessive-compulsive disorder, borderline personality, Tourette syndrome, addiction, psychotic symptoms in children and adolescents, and neurological and psychiatric disorders in the elderly (late onset delusional disorders, Alzheimer, Parkinson, and delirium). The study of aripiprazole in these numerous indications is motivated by its excellent tolerance and original pharmacological effect (partial agonistic effect on the D2 and 5-HT1A receptors, and antagonistic effect on the 5-HT2A receptors). This paper reviews the recent literature, with particular attention paid to the level of proof provided by these various studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crocq</LastName><ForeName>M-A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Service de psychiatrie de l'adolescent, centre hospitalier, B.P. 29, 68250 Rouffach, France. ma.crocq@ch-rouffach.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Millet</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gliskman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Krebs</LastName><ForeName>M-O</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Limosin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Costentin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dal&#xe9;ry</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Potentialit&#xe9;s cliniques et perspectives d'utilisation de l'aripiprazole hors de ses champs classiques d'indication. Analyse critique des donn&#xe9;es de la litt&#xe9;rature r&#xe9;cente.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>53</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18597728</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2007.12.004</ArticleId><ArticleId IdType="pii">S0013-7006(08)00002-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18516510</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>258 Suppl 2</Volume><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The work of Emil Kraepelin and his research group in M&#xfc;nchen.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>11</EndPage><MedlinePgn>3-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00406-008-2001-6</ELocationID><Abstract><AbstractText>Emil Kraepelin is well known due to his development of the psychiatric classification. The ICD-10 and DSM-IV classification is based on the dichotomy of endogenous psychoses into affective psychoses and schizophrenia as early as 1899. Moreover, beside his classification system he put enormous impact on the development of psychiatry to an empirical field of science. The research activities of Kraepelin and his coworkers show that he was not only the most active researcher in the field of psychiatry in his time but also that his research activities included a lot of clinical and experimental work in different disciplines of psychiatry, including psychology, pharmacology and natural sciences as 'Hilfswissenschaften'. Due to his extraordinary position also in his time he brought together important researchers of this time, in particular after the foundation of a psychiatric research institute. Alois Alzheimer, Franz Nissl, Robert Gaupp, or Korbinian Brodman are only a few of his well known coworkers. Kraepelin tried to bring foreward the empirical knowledge in psychiatry, he did not want to have cessation in psychiatry in general and in the classification of psychiatric disorders in particular. He discussed and partly revisted his view and his theoretical approach in the different editions of his textbook according to the state of his empirical knowledge. This is also true for the dichotomy. More than twenty years after the 6th edition of his textbook, he wrote in an essay 'Die Erscheinungsformen des Irreseins' ('The manifestations of insanity') regarding the dichotomy: "No experienced diagnostician would deny that cases where it seems impossible to arrive to a clear decision, despite extremely careful observation, are unpleasantly frequent." and "....therefore, the increasingly obvious impossibility to separate the two respective illnesses satisfactorily should raise the suspicion that our question is wrong". This contribution shows that Kraepelin himself questioned his dichotomy of dementia praecox and manic depressive insanity, a discussion which is lively still today--more than 80 years later.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hippius</LastName><ForeName>Hanns</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hospital for Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit&#xe4;t, Nubbaumstr. 7, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D019477">Portrait</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013782" MajorTopicYN="N">Textbooks as Topic</DescriptorName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Kraepelin</LastName><ForeName>Emil</ForeName><Initials>E</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18516510</ArticleId><ArticleId IdType="doi">10.1007/s00406-008-2001-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1973 Jul;130(7):822</Citation><ArticleIdList><ArticleId IdType="pubmed">4576450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18591582</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Significance of findings in aripiprazole for treatment of psychoses in Alzheimer dementia.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>614</EndPage><MedlinePgn>613; author reply 614</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e318167aea2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31. doi: 10.1097/JGP.0b013e3181557b47</RefSource><PMID Version="1">17974864</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18591582</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318167aea2</ArticleId><ArticleId IdType="pii">16/7/613</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18591574</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.</ArticleTitle><Pagination><StartPage>537</StartPage><EndPage>550</EndPage><MedlinePgn>537-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e318165db77</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of aripiprazole treatment for psychotic symptoms associated with Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this parallel group, randomized, double-blind, placebo-controlled, flexible-dose trial, institutionalized subjects with AD and psychotic symptoms were randomized to aripiprazole (n = 131) or placebo (n = 125) for 10 weeks. The aripiprazole starting dose was 2 mg/day, and could be titrated to higher doses (5, 10, and 15 mg/day) based on efficacy and tolerability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in mean change [2 x SD] from baseline between aripiprazole (mean dose approximately 9 mg/day at endpoint; range = 0.7-15.0 mg) and placebo were detected in the coprimary efficacy endpoints of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) Psychosis score (aripiprazole, -4.53 [9.23]; placebo, -4.62 [9.56]; F = 0.02, df = 1, 222, p = 0.883 [ANCOVA]) and Clinical Global Impression (CGI)-Severity score (aripiprazole, -0.57 [1.63]; placebo, -0.43 [1.65]; F = 1.67, df = 1, 220, p = 0.198 [ANCOVA]) at endpoint. However, improvements in several secondary efficacy measures (NPI-NH Total, Brief Psychiatric Rating Scale Total, CGI - improvement, Cohen-Mansfield Agitation Inventory and Cornell Depression Scale scores) indicated that aripiprazole may confer clinical benefits beyond the primary outcome measures. Treatment-emergent adverse events (AEs) were similar in both groups, except for somnolence (aripiprazole, 14%; placebo, 4%). Somnolence with aripiprazole was of mild or moderate intensity, and not associated with accidental injury. Incidence of AEs related to extrapyramidal symptoms was low with aripiprazole (5%) and placebo (4%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In nursing home residents with AD and psychosis, aripiprazole did not confer specific benefits for the treatment of psychotic symptoms; but psychological and behavioral symptoms, including agitation, anxiety, and depression, were improved with aripiprazole, with a low risk of AEs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Streim</LastName><ForeName>Joel E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Section on Geriatric Psychiatry, University of Pennsylvania, Philadelphia, PA 19104-3309, USA. jstreim@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Breder</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Swanink</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18591574</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318165db77</ArticleId><ArticleId IdType="pii">16/7/537</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18537547</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1567-2050</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>Functional consequences of locus coeruleus degeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>342</StartPage><EndPage>345</EndPage><MedlinePgn>342-5</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is the most common cause of cognitive impairment in older patients, and its prevalence is expected to soar in coming decades. Neuropathologically, AD is characterized by beta-amyloid-containing plaques, tau-containing neurofibrillary tangles, and cholinergic neuronal loss. In addition to the hallmark of memory loss, the disease is associated with other neuropsychiatric and behavioral abnormalities, including psychosis, aggression, and depression. Although cholinergic cell loss is clearly an important attribute of the pathological process, another well-described yet underappreciated early feature of AD pathogenesis is degeneration of the locus coeruleus (LC), which serves as the main source of norepinephrine (NE) supplying various cortical and subcortical areas that are affected in AD. The purpose of this review is to explore the extent to which LC loss contributes to AD neuropathology and cognitive deficits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinshenker</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA. dweinshenker@genetics.emory.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18537547</ArticleId><ArticleId IdType="doi">10.2174/156720508784533286</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18536520</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>559</StartPage><EndPage>563</EndPage><MedlinePgn>559-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000137671</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to explore the relationship between cerebrospinal fluid biomarkers and neuropsychiatric symptoms in people with Alzheimer's disease. Psychosis, agitation, apathy and depression were assessed using standardised measures in 32 patients with mild Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The levels of the 42-amino-acid form of beta-amyloid (A beta(1-42)), tau and p-tau (phosphorylated at threonine 181) were quantified using the conventional enzyme-linked immunosorbent assay method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our result shows that apathy is significantly correlated with tau and p-tau but not with A beta(1-42). There were no significant correlations between indices of psychosis/agitation,or depression and cerebrospinal fluid A beta(1-42), tau or p-tau concentrations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our finding suggests that apathy is associated with the level of neurofibrillary tangles in people with mild Alzheimer's disease. In contrast, the overall levels of neurofibrillary tangles or amyloid plaques do not seem to be associated with depression or psychosis, indicating that other brain changes contribute to these symptoms.</AbstractText><CopyrightInformation>(c) 2008 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skogseth</LastName><ForeName>Ragnhild</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, School of Medicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulugeta</LastName><ForeName>Ezra</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nore</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Dement Geriatr Cogn Disord. 2008;26(3):290</RefSource><Note>Jones, Emma [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18536520</ArticleId><ArticleId IdType="doi">10.1159/000137671</ArticleId><ArticleId IdType="pii">000137671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18525126</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>50</EndPage><MedlinePgn>43-50</MedlinePgn></Pagination><Abstract><AbstractText>We studied the hypothesis that disturbances in 5-HT_{6} receptor function in the temporal cortex may contribute to clinical symptoms of Alzheimer's disease (AD). 5-HT_{6} density and 5-HT levels were significantly decreased in a cohort of AD patients prospectively assessed for cognitive/behavioral symptoms. cAMP formation after stimulation with the selective 5-HT_{6} receptor agonist E-6801 was significantly lower (p&lt;0.01) in AD (170.02 +/- 27.53 pmol/mg prot.) compared to controls (823.33 +/-196.67). In addition, the ratio cAMP formation after stimulation with E-6801/5-HT_{6} receptor density was significantly lower (p&lt; 0.01) in AD (6.67 +/- 0.83) compared to controls (16.67 +/- 3.33). Splitting these results by sex, 5-HT_{6} receptor activation was significantly lower (p&lt; 0.01) in AD females compared to males (121.67 +/- 30.02 vs. 231.67 +/- 34.17 pmol/mg prot). 5-HT_{6} density and 5-HT levels were significantly correlated (p &lt; or = 0.01) in both controls and AD patients, although in AD, this correlation was lost in females. Psychosis factor was the best predictor of reduced 5-HT levels or adenylate cyclase activity after E-6801 stimulation, the former result being due to females. It may be suggested that psychotic symptoms may be related to a dysregulation of 5-HT_{6} activation by 5-HT in the temporal cortex. These results are discussed in terms of purported influence of sex and therapeutical approaches to psychosis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Alloza</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gil-Bea</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Tsu T</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Shirley W T Y</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Mitchell K P</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097216">serotonin 6 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.6.1.1</RegistryNumber><NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18525126</ArticleId><ArticleId IdType="doi">10.3233/jad-2008-14104</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18519523</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.</ArticleTitle><Pagination><StartPage>844</StartPage><EndPage>854</EndPage><MedlinePgn>844-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2008.07111779</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) Alzheimer's disease effectiveness study included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician's discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this descriptive analysis of outpatients with Alzheimer's disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. dsultzer@ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><CollectiveName>CATIE-AD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00015548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH-9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2008 Jul;165(7):787-9. doi: 10.1176/appi.ajp.2008.08040517</RefSource><PMID Version="1">18593779</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2009 Feb;12(1):20. doi: 10.1136/ebmh.12.1.20</RefSource><PMID Version="1">19176779</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18519523</ArticleId><ArticleId IdType="mid">NIHMS102344</ArticleId><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2008.07111779</ArticleId><ArticleId IdType="pii">appi.ajp.2008.07111779</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's Disease: a review of 55 studies published from 1990&#x2013;2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2005;13:460&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates and causes. The Gerontologist. 1995;35:771&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference><Reference><Citation>Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol. 1996;9:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang M-X, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai W-Y. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;227:806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in Alzheimer's disease. Neurology. 2002;59:1721&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S, Katoma C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer's disease over 6 months. Am J Geriatr Psychiatry. 2005;13:976&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286441</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia. Archives of Internal Medicine. 2006;166:2182&#x2013;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101935</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">12517232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832078</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp MJ, Lindesay J, O'Brien JT, Wilcock GK, Katona C, Jones RW, DeCesare J, Rodger M. for the CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357:1382&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914039</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:190&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull. 2003;29:57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail S, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001;9:346&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739062</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3387516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Belle SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol. 1984;39:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699374</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, Richards M, Miller L, Folstein M, Albert M, Bylsma F, Lafleche G. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49:M216&#x2013;M222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL. The caregiver activity survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Kasper JD, Kleinman L, Black BS, Patrick DL. Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimer disease. J Ment Health Aging. 1999;5:33&#x2013;48.</Citation></Reference><Reference><Citation>Hochberg YA. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800&#x2013;802.</Citation></Reference><Reference><Citation>Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD): Baseline characteristics. Curr Alzheimer Res. 2007;4:325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Brown C, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 2003;160:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562582</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Tariot PN, Dagerman KS, Davis S, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. investigators ftC-A: A randomized trial of the cost-effectiveness of second generation antipsychotics and placebo in the treatment of psychosis and aggression in Alzheimer's disease. Arch Gen Psychiatry. 2007;64:1259&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18515692</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical characterization of late- and very late-onset first psychotic episode in psychiatric inpatients.</ArticleTitle><Pagination><StartPage>478</StartPage><EndPage>487</EndPage><MedlinePgn>478-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e31816c7b3c</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The goals of this study were to investigate the prevalence and initial symptoms of the late-onset schizophrenia (LOS: &gt;40 years) and very-late-onset schizophrenia-like psychosis (VLOSLP: &gt;60 years) nosological groups proposed by the International Late-Onset Schizophrenia Group.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a retrospective, cross-sectional, chart review study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The study was conducted at Centre Hospitalier Robert-Giffard (CHRG), Quebec City, Canada.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">The medical records of inpatients from the CHRG who presented with psychotic symptoms were analyzed.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Positive and negative symptoms were scored using the SAPS and SANS. Groups' symptoms were compared using chi(2), Fisher's exact tests, t tests, and exact Mann-Whitney tests. An exact conditional logistic regression analysis was performed to determine which clinical characteristics were the most predictive of the groups' classification.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 1,767 unique, first-admission medical records reviewed, 23 (1.3%) inpatients developed their first psychotic symptoms at the age of 40-59 years old (LOS), and 13 (0.7%) at the age of 60 years and above (VLOSLP). LOS patients were more apathetic and presented more abnormal psychomotor activity than the VLOSLP. Persecutory delusions, auditory hallucinations, inappropriate social behavior, formal thought disorders and anhedonia were frequent in the two groups. A logistic regression model including psychomotor abnormalities was statistically relevant to predict the belonging to LOS group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LOS and VLOSLP are rare. Abnormal psychomotor activity can properly differentiate VLOSLP and LOS. The nosological model proposed by the International Late-Onset Schizophrenia Group is at least partially supported by the present data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Psychology, Laval University, QC, Canada. caroline.girard.6@ulaval.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18515692</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e31816c7b3c</ArticleId><ArticleId IdType="pii">16/6/478</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18499932</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine and delirium: lesson from clinical practice.</ArticleTitle><Pagination><StartPage>433</StartPage><EndPage>434</EndPage><MedlinePgn>433-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Dhiren</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Forlano</LastName><ForeName>Rosaria</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6GOW6DWN2A</RegistryNumber><NameOfSubstance UI="D010076">Oxazepam</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010076" MajorTopicYN="N">Oxazepam</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013610" MajorTopicYN="N">Tachycardia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18499932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18489496</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2009</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4733</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>Sociodemographic and clinical correlates of utility scores in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1120</StartPage><EndPage>1130</EndPage><MedlinePgn>1120-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1524-4733.2008.00351.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the relationship between psychiatric symptoms, cognitive performance, functional capacity and quality of life in Alzheimer's disease (AD), and change in the Health Utilities Index (HUI)-Mark III, a widely used generic, multiattribute preference-based health-status classification system.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Follow-up data were obtained from caregiver proxy raters at 3, to 6, and 9-months postrandom assignment concerning 421 patients with AD, living with at least one caregiver in a noninstitutional setting, who participated in the Clinical Antipsychotic Trial of Intervention Effectiveness-AD of antipsychotic medication. Spearman rank correlations, multivariate linear regression, and mixed modeling were used to examine the correlates of change in the HUI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">HUI scores decreased by an average of -0.061 over 9 months. Analysis revealed weak bivariate, and largely, nonsignificant multivariate relationships between change in HUI scores and sociodemographic characteristics, psychiatric symptoms, and cognitive performance. There were highly significant associations between decreases in health utilities and change in the AD Cooperative Study for Activities of Daily Living scale (ADCS-ADL) and AD-Related Quality of Life (ADRQoL) (both P &lt; 0.001), even after controlling for other factors. Adjusted R(2) values ranged from 0.14 to 0.20.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In AD patients requiring antipsychotic treatment, only weak relationships were found between changes in the HUI and sociodemographic and clinical indicators. While functional capability and quality of life showed more significant associations, less than 20% of the variance in health utility could be explained. Significant cognitive impairment and the need to rely on proxy raters may limit the usefulness of utility measurement in AD patients with serious behavioral symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Edward Alan</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Brown University, Providence, RI 02912-1977, USA. edward_a_miller@brown.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Zbrozek</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="Y">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18489496</ArticleId><ArticleId IdType="doi">10.1111/j.1524-4733.2008.00351.x</ArticleId><ArticleId IdType="pii">S1098-3015(10)60594-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18441495</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-9173</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics</Title><ISOAbbreviation>Nihon Ronen Igakkai Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Advance prediction of Mild Cognitive Impairment (MCI) using (99m)Tc-ECD SPECT brain blood flow imaging].</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>212</EndPage><MedlinePgn>202-12</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Mild Cognitive Impairment (MCI) is considered as a precursor state of Alzheimer disease (AD). SPECT brain blood flow imaging was investigated in MCI and it's relevance to the prognosis of MCI was evaluated in an attempt define the characteristics of brain blood flow imaging of MCI (amnestic MCI; aMCI) converting to AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ninety-two patients over 60 years old with amnesia were studied. (99m)Tc-ECD SPECT brain blood flow examinations of the subject under drug-free conditions were conducted and imaging was analyzed according to the first clinical diagnosis. Patients given a diagnosis of MCI on the first clinical diagnosis, were examined again after 2 years and the SPECT imaging before 2 years previously was classified and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of them, there were 35 MCI patients, converting of 13 AD patients (37.1%; aMCI), 10 MCI patients (28.6%; non-converter), 4 depression patients (11.4%; Depression type MCI (dMCI)), 1 Geriatric psychosis patient, but 7 patients dropped out. In the aMCI group, relative hypoperfusion was recognized in the posterior cingulate and the precuneus. In the dMCI group, relative hypoperfusion was recognized in the dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate. In the non-converter group, relative hypoperfusion was recognized in the basal forebrain.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The hypoperfusion of the precuneus in aMCI, and the hypoperfusion of the right frontal lobe (DLPFC, dorsal-anterior cingulate) in dMCI were characteristic brain blood-flow abnormalities. We believe (99m)Tc-ECD SPECT brain blood flow imaging to be useful in the diagnosis of aMCI and in the early detection of depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawasaki</LastName><ForeName>Yohsuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyorin University, School of Medicine Department of Psychiatry, Kyosai Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Ronen Igakkai Zasshi</MedlineTA><NlmUniqueID>7507332</NlmUniqueID><ISSNLinking>0300-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015609">Organotechnetium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>H25WJA31XE</RegistryNumber><NameOfSubstance UI="C059659">technetium Tc 99m bicisate</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015609" MajorTopicYN="Y">Organotechnetium Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18441495</ArticleId><ArticleId IdType="doi">10.3143/geriatrics.45.202</ArticleId><ArticleId IdType="pii">JST.JSTAGE/geriatrics/45.202</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18289429</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0952-1941</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>European journal of anaesthesiology. Supplement</Title><ISOAbbreviation>Eur J Anaesthesiol Suppl</ISOAbbreviation></Journal><ArticleTitle>Long-term psychiatric disorders after traumatic brain injury.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>130</EndPage><MedlinePgn>123-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0265021507003250</ELocationID><Abstract><AbstractText>In the long term after traumatic brain injury, the most disabling problems are generally related to neuropsychiatric sequelae, including personality change and cognitive impairment, rather than neurophysical sequelae. Cognitive impairment after severe injury is likely to include impaired speed of information processing, poor memory and executive problems. Personality change may include poor motivation, and a tendency to be self-centred and less aware of the needs of others. Patients may be described as lazy and thoughtless. Some become disinhibited and rude. Agitation and aggression can be very difficult to manage. Anxiety and depression symptoms are quite frequent and play a role in the development of persistent post-concussion syndrome after milder injury. Depression may be associated with a deterioration in disability over time after injury. Psychosis is not unusual though it has been difficult to confirm that traumatic brain injury is a cause of schizophrenia. Head injury may, many years later, increase the risk of Alzheimer's disease. Good rehabilitation probably minimizes the risk of psychiatric sequelae, but specific psychological and pharmacological treatments may be needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleminger</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kings College London, Institute of Psychiatry, London, UK. s.fleminger@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Anaesthesiol Suppl</MedlineTA><NlmUniqueID>8804068</NlmUniqueID><ISSNLinking>0952-1941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006259" MajorTopicYN="N">Craniocerebral Trauma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015600" MajorTopicYN="N">Glasgow Coma Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18289429</ArticleId><ArticleId IdType="doi">10.1017/S0265021507003250</ArticleId><ArticleId IdType="pii">S0265021507003250</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18407715</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1173-2563</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>5</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>291</StartPage><EndPage>303</EndPage><MedlinePgn>291-303</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Antipsychotics have long been used to treat agitation and psychosis related to Alzheimer's disease, but in a limited fashion because of troubling adverse effects. The new atypical antipsychotics are thought to be at least as effective as first-generation drugs and to cause fewer adverse effects. These drugs, however, are currently not US FDA-approved for use among elderly demented subjects due to a slight increase in the risk of death and serious cardiovascular events within this population. However, their favourable adverse effect profile has led many physicians to prescribe these drugs as first-line therapy for behaviourally disturbed patients with Alzheimer's disease. Clinical trials to evaluate the use of atypical antipsychotics have produced varying results, and clarity has not yet been achieved. Thus, a quantitative summary of the risks and benefits may help inform complex decisions that must be made in this area. In this study we set out to compare the expected costs and outcomes for a community-dwelling cohort of patients with Alzheimer's disease with agitation and/or psychosis who are (a) untreated, or (b) treated with olanzapine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We constructed a Markov state-transition model using the best published data from several sources for Alzheimer's disease patient progression and treatment. This model allowed us to compare the expected costs and outcomes associated with olanzapine treatment compared with no treatment for a synthetic cohort of US adults aged &gt; or =65 years. The model cycles every 6 months and continues until all patients die from Alzheimer's disease progression or from co-morbid conditions. Outcome estimates included the incremental cost-effectiveness ratio (ICER) and cost per quality-adjusted life-year (QALY) gained. The robustness of the estimates was examined by sensitivity analyses of key parameters, including cost of care, olanzapine effectiveness and Alzheimer's disease progression rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results indicated that olanzapine was a cost-effective treatment for agitation and psychosis related to Alzheimer's disease when compared with no treatment (ICER &lt;$US50,000). In addition, sensitivity analyses demonstrated that olanzapine remained cost effective despite multiple variations of several parameters, both alone and concurrently.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Olanzapine treatment for agitation and psychosis related to Alzheimer's disease is cost effective when compared with no treatment. Further analysis should be performed as atypical antipsychotics become generic, as more information on health utilities in the Alzheimer's disease population becomes available, and to compare atypical antipsychotics with first-generation antipsychotics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirbach</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA. kirbach@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Kit</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nietert</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008390" MajorTopicYN="N">Markov Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18407715</ArticleId><ArticleId IdType="doi">10.2165/00044011-200828050-00003</ArticleId><ArticleId IdType="pii">2853</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Geriatr Psychiatry. 2006 May;21(5):449-59</Citation><ArticleIdList><ArticleId IdType="pubmed">16676288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2005;23(12):1271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16336020</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2006 Sep;7(3):165-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16896764</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2000 Apr;17(4):383-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10947493</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Sep-Oct;12(5):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Nov;13(11):976-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16286441</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2004;21(9):607-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15260515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Aug;13(8):722-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16085789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 1998 May;13(5 Pt 2):575-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17165324</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Drug Investig. 2006;26(8):447-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17163277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):134-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1989 Sep;39(9):1159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Mar;14(3):280-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16505133</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Oct 9;276(14):1172-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8827972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Oct;57(10):968-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Sep;152(9):1349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Oct 19;294(15):1934-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Sep;14(9):767-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16905684</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476</Citation><ArticleIdList><ArticleId IdType="pubmed">16437455</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Mar;54(3):257-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2003 Jul;51(7):953-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12834515</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Dec 10;59(11):1721-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12473759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2005;23(3):227-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15836005</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1999 Oct;56(10):1266-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2006;23(3):227-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16608378</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Sep 25;57(6):957-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11571317</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Care Manag Sci. 2001 Feb;4(1):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11315880</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Dec;163(12):2080-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17151158</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Fam Physician. 2003 Jun 1;67(11):2335-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12800962</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 1998 Mar;4(3):345-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10178497</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2005 Jan;Spec No:6-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17203561</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Pharmacother. 2005 Jun;3(2):77-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16129384</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):413-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11059474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1999 Apr;52(4):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10235167</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Oct 12;355(15):1525-38</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2005 Oct;62(10):1601-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):346-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Apr;150(4):643-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8465884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18405069</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0350-6134</ISSN><JournalIssue CitedMedium="Print"><Volume>32 Suppl 1</Volume><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Collegium antropologicum</Title><ISOAbbreviation>Coll Antropol</ISOAbbreviation></Journal><ArticleTitle>Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>122</EndPage><MedlinePgn>119-22</MedlinePgn></Pagination><Abstract><AbstractText>Post mortem brain studies indicate that alterations in serotonergic and catecholaminergic systems might be associated with Alzheimer's disease (AD). The aim of the study was to determine serotonin (5-HT) levels and monoamine oxidase type B (MAO-B) activity in platelets of psychotic and non-psychotic patients with AD, established according to the NINCDS-ADRDA and DSM-IV-TR criteria. Cognitive impairment and psychotic features were evaluated using Mini Mental Status Examination and Neuropsychiatric Inventory. Platelet 5-HT concentration and MAO-B activity were determined spectrofluorimetrically in 116 (51 male, 65 female) healthy subjects and 70 psychotic (10 male, 60 female) and 151 non-psychotic (32 male, 119 female) patients. Psychotic and non-psychotic female and psychotic male patients had significantly lower platelet 5-HT concentration than corresponding sex matched control subjects. Platelet MAO-B activity was significantly increased in both male and female non-psychotic patients compared to the sex matched controls. Non-psychotic female patients had significantly higher platelet MAO-B activity than psychotic female patients. Our data suggest that platelet MAO-B activity, but not platelet 5-HT concentration, could differentiate between psychotic and non-psychotic subtypes of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mimica</LastName><ForeName>Ninoslav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychiatric Hospital Vrapce, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ck-Seler</LastName><ForeName>Dorotea</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pivac</LastName><ForeName>Nela</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mustapi&#x107;</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dezeljin</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stipcevi&#x107;</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Presecki</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Radoni&#x107;</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Folnegovi&#x107;-Smalc</LastName><ForeName>Vera</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Coll Antropol</MedlineTA><NlmUniqueID>8003354</NlmUniqueID><ISSNLinking>0350-6134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18405069</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18402497</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis and agitation in dementia: should general psychiatrists care?</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>340</EndPage><MedlinePgn>339-40</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Memory Disorders Center, Banner Alzheimer's Institute, Phoenix, AZ 85006, USA. pierre.tariot@bannerhealth.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2008 Mar;69(3):341-8. doi: 10.4088/jcp.v69n0302</RefSource><PMID Version="1">18294023</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18402497</ArticleId><ArticleId IdType="doi">10.4088/jcp.v69n0301</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18378994</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>192</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Integrated multidisciplinary diagnostic approach for dementia care: randomised controlled trial.</ArticleTitle><Pagination><StartPage>300</StartPage><EndPage>305</EndPage><MedlinePgn>300-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.bp.107.035204</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An integrated multidisciplinary approach to dementia is often recommended but has rarely been evaluated.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To evaluate the clinical effects of an integrated multidisciplinary diagnostic facility for psychogeriatric patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients suspected of having complex psychogeriatric problems were randomly allocated to the intervention (n=137) or to treatment as usual (n=93). They were assessed at baseline, and at 6 months and 12 months follow-up by means of personal interviews with the patient's proxy. The primary outcome was health-related quality of life, assessed using the visual analogue scale (VAS) of the EuroQd measure, EQ-5D.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Health-related quality of life had improved at 6 months in the intervention group, whereas that of the control group had decreased. Furthermore, more patients in the intervention group experienced a clinically relevant improvement of 10 points or more on the VAS at both follow-up measurements.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An integrated multidisciplinary approach improves dementia care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolfs</LastName><ForeName>Claire A G</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, University Hospital of Maastricht/Alzheimer Centre Limburg, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessels</LastName><ForeName>Alfons</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dirksen</LastName><ForeName>Carmen D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Severens</LastName><ForeName>Johan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 2008 Jul;193(1):79; author reply 79. doi: 10.1192/bjp.193.1.79</RefSource><PMID Version="1">18700227</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 2008 Sep;193(3):257; author reply 257. doi: 10.1192/bjp.193.3.257a</RefSource><PMID Version="1">18757992</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18378994</ArticleId><ArticleId IdType="doi">10.1192/bjp.bp.107.035204</ArticleId><ArticleId IdType="pii">S0007125000234624</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18373228</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-3158</ISSN><JournalIssue CitedMedium="Print"><Volume>198</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>259</EndPage><MedlinePgn>251-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-008-1124-9</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Neuropsychiatric behaviours in Alzheimer's disease (AD) patients have been associated with neocortical alterations of presynaptic cholinergic and muscarinic M2 receptor markers. In contrast, it is unclear whether non-M2 muscarinic receptors have a role to play in AD behavioural symptoms.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To correlate the alterations of neocortical postsynaptic muscarinic receptors with clinical features of AD.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">[(3)H]4-DAMP were used in binding assays with lysates of Chinese hamster ovary (CHO) cells stably transfected with M1-M5 receptors. [(3)H]4-DAMP was further used to measure muscarinic receptors in the postmortem orbitofrontal cortex of aged controls and AD patients longitudinally assessed for cognitive decline and behavioural symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">[(3)H]4-DAMP binds to human postmortem brain homogenates and M1-, M3-, M4- and M5-transfected CHO lysates with subnanomolar affinity. Compared to the controls, the [(3)H]4-DAMP binding density is reduced only in AD patients with significant psychotic symptoms. The association between reduced [(3)H]4-DAMP binding and psychosis is independent of the effects of dementia severity or neurofibrillary tangle burden.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests that the loss of non-M2 muscarinic receptors in the orbitofrontal cortex may be a neurochemical substrate of psychosis in AD and provides a rationale for further development of muscarinic receptor ligands in AD pharmacotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>S W Y</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Outram Road, Outram Park 169608, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Esiri</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>P T H</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>C P L H</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>M K P</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043585">Receptor, Muscarinic M2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>81405-11-0</RegistryNumber><NameOfSubstance UI="C042375">4-diphenylacetoxy-1,1-dimethylpiperidinium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043585" MajorTopicYN="N">Receptor, Muscarinic M2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18373228</ArticleId><ArticleId IdType="doi">10.1007/s00213-008-1124-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 1991 Apr;41(4):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Methods. 1985 Nov;14(3):213-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3840547</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1999 Jan;174:39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10211149</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1991 Jun;14(6):220-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1716012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1991 Mar;29(3):256-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2042942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2006;21(3):144-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16391476</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47</Citation><ArticleIdList><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2006 Sep;27(9):1216-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16129514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1993 Feb;43(2):149-57</Citation><ArticleIdList><ArticleId IdType="pubmed">8429821</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2001 Apr 27;68(22-23):2605-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11392633</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1989 Aug 3;166(3):459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">2806372</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1996;8 Suppl 3:215-552</Citation><ArticleIdList><ArticleId IdType="pubmed">9221032</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2005;12(24):2915-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16305479</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1989 Dec;Suppl:50-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2694523</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Oct;47(4):876-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8857712</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Sep 11;57(5):805-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11552008</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Jul 2;13(9):1175-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12151764</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1995 Nov;54(6):783-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7595651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2003 Jun 6;974(1-2):82-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12742626</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Jun;28(6):1168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12700711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2001 Mar;49(3):355-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11261510</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1993 Mar-Apr;14(2):147-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8487917</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1997 Apr;54(4):465-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1985 May 31;228(4703):1115-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3992249</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Mar 5;215(4537):1237-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 Feb;22(1):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1574559</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13541-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8942969</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Dec;57(12):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Aug;34(6):1129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15554582</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Nov;12(11):1062-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9427090</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Jul 30;217(4558):408-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7046051</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Nov 28;55(10):1460-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11094098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm. 1985;61(3-4):253-64</Citation><ArticleIdList><ArticleId IdType="pubmed">3989524</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Mar;29(3):619-25</Citation><ArticleIdList><ArticleId IdType="pubmed">14694353</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1992 Feb;58(2):529-41</Citation><ArticleIdList><ArticleId IdType="pubmed">1729398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1993 Jun;58(3):319-79</Citation><ArticleIdList><ArticleId IdType="pubmed">7504306</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 1993 Sep-Oct;17(2):77-89</Citation><ArticleIdList><ArticleId IdType="pubmed">15374321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2000;920:315-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11193170</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1995 Apr;64(4):1888-91</Citation><ArticleIdList><ArticleId IdType="pubmed">7891119</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2 Suppl 1):S64-78</Citation><ArticleIdList><ArticleId IdType="pubmed">9581223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1976 Dec 25;2(8000):1403</Citation><ArticleIdList><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1995 Nov;21(3):285-300</Citation><ArticleIdList><ArticleId IdType="pubmed">8806017</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1992;51(12):955-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1325587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2000 Mar;10(3):243-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10731219</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1991 Jun;103(2):1561-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1884110</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Nov;12(11):1074-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9427091</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2007 Sep;28(9):1381-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16828202</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1998 Apr;13(4):248-56</Citation><ArticleIdList><ArticleId IdType="pubmed">9646153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18366366</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-5990</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Perspectives in psychiatric care</Title><ISOAbbreviation>Perspect Psychiatr Care</ISOAbbreviation></Journal><ArticleTitle>The art of prescribing: pharmacological management of psychosis in Alzheimer's disease: clinical challenges associated with second-generation antipsychotic medications.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>123</EndPage><MedlinePgn>120-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1744-6163.2008.00161.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antai-Otong</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fort Worth Outpatient Clinic, Department of Veterans Affairs in Fort Worth, TX, USA. deborah.antai-otong@va.gov &lt;deborah.antai-otong@va.gov&gt;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Perspect Psychiatr Care</MedlineTA><NlmUniqueID>0401133</NlmUniqueID><ISSNLinking>0031-5990</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>17</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18366366</ArticleId><ArticleId IdType="doi">10.1111/j.1744-6163.2008.00161.x</ArticleId><ArticleId IdType="pii">PPC161</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18351187</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1784-3286</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Acta clinica Belgica</Title><ISOAbbreviation>Acta Clin Belg</ISOAbbreviation></Journal><ArticleTitle>Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study.</ArticleTitle><Pagination><StartPage>426</StartPage><EndPage>432</EndPage><MedlinePgn>426-32</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This cross-sectional study investigated the relationships between behavioural and psychological symptoms of dementia (BPSD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 194 patients with dementia from the memory clinic practice of six European Alzheimer's Disease Consortium centres. BPSD were assessed using a pre-designed questionnaire comprising the Neuropsychiatric Inventory (NPI). BPSD scores were analysed by Spearman's correlation analysis and principal components factor analysis. Results were confirmed by performing Varimax rotation of the factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The NPI symptoms occurred very frequently: 96% of the patients displayed at least one symptom. Among them, apathy (59.6%) and depression (58.5%) were the most common abnormalities, followed by irritability (44.6%), anxiety (44%) and agitation (41.5%). Four NPI-based factors were identified (58% of the common variance): psychosis factor (irritability, agitation, hallucinations and anxiety), psychomotor factor (aberrant motor behaviour and delusions), mood liability factor (disinhibition, elation and depression) and instinctual factor (appetite disturbance, sleep disturbance and apathy).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Psychosis, psychomotor factor, mood liability factor and instinctual factor form four distinct behavioural syndromes in dementia. We report the novel observation that depression clusters together with disinhibition and elation within a mood liability factor. This finding highlights the nature of mood, and mood oscillations, from depression to disinhibition within the cluster, and has implications for treatment by taking into consideration the poles of the mood scale and any oscillation between them.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrovic</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geriatrics and Gerontology, Ghent University Hospital and Heymans Institute of Pharmacology, Ghent, Belgium. mirko.petrovic@ugent.be</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Liperoti</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Clin Belg</MedlineTA><NlmUniqueID>0370306</NlmUniqueID><ISSNLinking>1784-3286</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18351187</ArticleId><ArticleId IdType="doi">10.1179/acb.2007.062</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18339372</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2008</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0014-2999</ISSN><JournalIssue CitedMedium="Print"><Volume>583</Volume><Issue>2-3</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.</ArticleTitle><Pagination><StartPage>358</StartPage><EndPage>364</EndPage><MedlinePgn>358-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2008.01.001</ELocationID><Abstract><AbstractText>Neuropsychiatric disorders often involve considerable psychological stress and elevated cortisol activity. Glucocorticoid receptors have relatively low affinity for cortisol and are found distributed throughout the brain, particularly in the frontal cortex and hippocampus. In recent years, glucocorticoid receptors antagonists have been actively studied in both animal models of several disorders as well as a potential treatment in specific types of neuropsychiatric patients. Data from these various studies are reviewed with an emphasis on seven clinical disorders or problems: major depression with psychotic features, bipolar disorder, schizophrenia, cognitive disorders, (e.g., Alzheimer's disease and mild cognitive impairment), cognitive side effects of electroconvulsive therapy, and weight gain with atypical antipsychotic agents. Potential benefits and limitations are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schatzberg</LastName><ForeName>Alan F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, United States. afschatz@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindley</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 50604</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH47573</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Pharmacol. 2008 Sep 11;592(1-3):168</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007030" MajorTopicYN="N">Hypothalamo-Hypophyseal System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010913" MajorTopicYN="N">Pituitary-Adrenal System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011965" MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>61</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18339372</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2008.01.001</ArticleId><ArticleId IdType="pii">S0014-2999(08)00030-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">18311883</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1056-8751</ISSN><JournalIssue CitedMedium="Print"><Volume>148</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>ACP journal club</Title><ISOAbbreviation>ACP J Club</ISOAbbreviation></Journal><ArticleTitle>Second-generation antipsychotics did not improve outcomes and increased costs for patients with Alzheimer disease and psychosis.</ArticleTitle><Pagination><StartPage>53</StartPage><MedlinePgn>53</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seitz</LastName><ForeName>Dallas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Queen's University, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruneir</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rochon</LastName><ForeName>Paula A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACP J Club</MedlineTA><NlmUniqueID>9104824</NlmUniqueID><ISSNLinking>1056-8751</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Arch Gen Psychiatry. 2007 Nov;64(11):1259-68. doi: 10.1001/archpsyc.64.11.1259</RefSource><PMID Version="1">17984395</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18311883</ArticleId><ArticleId IdType="pii">ACPJC-2008-148-2-053</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18294023</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.</ArticleTitle><Pagination><StartPage>341</StartPage><EndPage>348</EndPage><MedlinePgn>341-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Long-standing evidence indicates that Alzheimer's disease patients with behavioral symptoms have a worse prognosis and a more rapid disease progression. The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A pooled analysis was conducted in people with agitation/aggression or psychosis from 3 large 6-month, randomized studies in moderately severe to severe Alzheimer's disease. The effect of memantine and placebo on these specific symptoms was evaluated using the Neuropsychiatric Inventory (NPI) subitem cluster of agitation and psychosis. Outcomes on global, cognitive, and functional measures were also analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty percent of the total patient group had baseline symptoms of agitation/aggression, delusions, or hallucinations on the NPI. At both 12 and 24/28 weeks, there was a significant treatment advantage for memantine over placebo for the proportion of patients showing improvement on the defined neuropsychiatric symptom cluster (55.6% vs. 44.4% at week 12, p = .008; 58.0% vs. 44.8% at week 24/28, p = .002) and specifically for the treatment of agitation/aggression (55.3% vs. 43.1% at week 12, p = .011; 61.0% vs. 45.0% at week 24/28, p &lt; .001). Placebo-treated patients in this population demonstrated an accelerated disease progression for global (Clinician's Interview-Based Impression of Change Plus Caregiver Input), cognitive (Severe Impairment Battery), and functional (Alzheimer Disease Cooperative Study Activities of Daily Living Inventory 19-item scale) outcomes, but memantine conferred statistically significant benefit for all measures. Tolerability in this population remained good, and fewer memantine-treated patients than placebo-treated patients withdrew due to adverse events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This post hoc analysis provides important evidence from placebo-controlled trials that memantine may be a safe and effective treatment in Alzheimer's disease patients with agitation/aggression or psychosis, who are otherwise prone to rapid progression. Memantine treatment provided benefits in cognitive, functional, and global outcomes in these patients and for their agitation/aggression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>From the Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK. Gordon.Wilcock@ndm.ox.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Loft</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 2008 Mar;69(3):339-40. doi: 10.4088/jcp.v69n0301</RefSource><PMID Version="1">18402497</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="Y">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18294023</ArticleId><ArticleId IdType="doi">10.4088/jcp.v69n0302</ArticleId><ArticleId IdType="pii">ej07m03515</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18227780</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2008</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>98</EndPage><MedlinePgn>89-98</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric symptoms are common in many neurologic diseases. Psychosis, depression, agitation, anxiety, irritability, and apathy occur in degenerative, traumatic, vascular, and demyelinating brain diseases.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Regulatory policies regarding approval of psychotropic agents for treatment of neuropsychiatric symptoms in neurologic disorders are reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Psychotropic agents previously received broad labeling such as treatment for psychosis or depression. Food and Drug Administration (FDA) policy now requires that labeling be limited to the population included in clinical trials providing the basis for the application. When applying for approval for use of psychotropic agents in neurologic disorders, pharmaceutical companies will be required to demonstrate efficacy in the neurologic disease of interest. Definitions of specific neuropsychiatric symptoms in neurologic diseases are required for study design. Approval will depend on demonstrating efficacy in two independent, randomized, controlled trials with symptom-focused and global outcome measures. Labeling for treatment of a nonspecific symptom (eg, agitation) can be approved if efficacy is demonstrated across several neurologic diseases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with neurologic diseases may have dosage ranges, side effects, or response profiles of psychotropic agents that differ from those of patients with idiopathic psychiatric disorders. FDA policy now requires demonstration of efficacy, safety, and tolerability of psychotropic agents within neurologic disorders, allowing clinicians to make more rational choices regarding treatment options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, UCLA School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR 00856</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004335" MajorTopicYN="Y">Drug and Narcotic Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18227780</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18204254</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in frontotemporal dementia: prevalence and review.</ArticleTitle><Pagination><StartPage>206</StartPage><EndPage>211</EndPage><MedlinePgn>206-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000113418</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Although most patients with frontotemporal dementia (FTD) present with neuropsychiatric symptoms, the frequency of psychotic symptoms is unclear. This study aims to determine the prevalence of psychotic symptoms in a large cohort of well-diagnosed and followed FTD patients compared to age-matched patients with Alzheimer's disease (AD) and to further review the literature on psychosis in FTD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Delusions, hallucinations and paranoia were evaluated among 86 patients who met consensus criteria for FTD, had frontotemporal changes on functional neuroimaging and were followed for 2 years. They were compared to 23 patients with early-onset AD on a caregiver-administered psychiatric questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the FTD patients, only 2 (2.3%) had delusions, 1 of whom had paranoid ideation; no FTD patient had hallucinations. This was significantly less than the AD patients, 4 (17.4%) of whom had delusions and paranoia. Other investigations fail to establish a significant association of psychosis with FTD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings, and a literature review, indicate that psychotic symptoms are rare in FTD, possibly due to limited temporal-limbic involvement in this disorder.</AbstractText><CopyrightInformation>Copyright 2008 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif., USA. mmendez@ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapira</LastName><ForeName>Jill S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Rochelle J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Licht</LastName><ForeName>Eliot A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Saul</LastName><ForeName>Ronald E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="Y">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="Y">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="Y">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>49</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18204254</ArticleId><ArticleId IdType="doi">10.1159/000113418</ArticleId><ArticleId IdType="pii">000113418</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18198970</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0888-5109</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</Title><ISOAbbreviation>Consult Pharm</ISOAbbreviation></Journal><ArticleTitle>The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>754</StartPage><EndPage>762</EndPage><MedlinePgn>754-62</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the literature for double-blind, placebo-controlled trials that examined the efficacy of cognitive enhancers in the psychopathology of Alzheimer's disease.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Literature searches were conducted using MEDLINE and EMBASE databases and clinicaltrials.gov.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Overall, 55 articles were reviewed for inclusion. Several open-label studies and case reports were found on this topic, but only those involving both tacrine and use of the Neuropsychiatric Inventory were included. Regarding other drugs, only double-blind, placebo-controlled trials were selected for inclusion.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Limited data suggest that the anticholinesterase inhibitors and memantine offer an alternative or adjunct to the antipsychotics for the treatment of moderate-to-severe behaviors. The author reviewed the literature for pharmacological management of behavioral and psychological symptoms of dementia (BPSD) using these cognitive enhancers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The majority of patients with Alzheimer's disease will experience behavioral disturbances during the course of their disease. Atypical antipsychotics are used routinely in these situations to treat the psychotic features and agitation. However, atypicals now carry a "black box" warning issued by the Food and Drug Administration on the basis of evidence that their use in geriatric patients with dementia-related psychosis may put patients at increased risk of mortality as a result of cardiovascular or infectious events. An alternative to the atypicals may be the acetylcholinesterase inhibitors and memantine, which have been shown to stabilize cognitive as well as behavioral issues in patients, utilizing the "gold standard" for behavior, the Neuropsychiatric Inventory. Efficacy varies among agents, with the greatest positive effects seen with donepezil, which also has the greatest number of studies. Drug benefits were harder to demonstrate for mild-to-moderate BPSD compared with moderate-to-severe symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas 77030, USA. lisaj.miller@med.va.gov</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Consult Pharm</MedlineTA><NlmUniqueID>9013983</NlmUniqueID><ISSNLinking>0888-5109</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Consult Pharm. 2008 May;23(5):357-8.</RefSource><PMID Version="1">18556821</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18198970</ArticleId><ArticleId IdType="doi">10.4140/tcp.n.2007.754</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18095783</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1936-2692</ISSN><JournalIssue CitedMedium="Internet"><Volume>13 Suppl 8</Volume><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of managed care</Title><ISOAbbreviation>Am J Manag Care</ISOAbbreviation></Journal><ArticleTitle>Current issues in dementia pharmacotherapy.</ArticleTitle><Pagination><StartPage>S198</StartPage><EndPage>S202</EndPage><MedlinePgn>S198-202</MedlinePgn></Pagination><Abstract><AbstractText>Diagnosis and treatment of dementia in nursing homes and assisted living facilities remains challenging since response to treatment and disease course varies for the common degenerative dementias. Four cholinesterase inhibitors and an N-methyl-D-aspartate glutamate receptor antagonist are approved by the US Food and Drug Administration for the treatment of Alzheimer's disease (AD). Treatment with AD medications is clinically efficacious and associated with reduced caregiver burden. Some controlled trials have reported that cholinesterase inhibitors and memantine ameliorate dementia-related behavioral symptoms. Antipsychotic therapy is often used for intractable behavioral symptoms or psychosis not responding to nonpharmacologic interventions and antidementia medications; however, the risk/benefit ratio for each patient should be critically evaluated, because treatment with atypical antipsychotics has been associated with serious adverse events, including increased risk for death in older adults with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daiello</LastName><ForeName>Lori A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Pharmacotherapy Solutions, 2115 Ivanhoe Rd, Orlando, FL 32804, USA. ldaiello@cox.net</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Manag Care</MedlineTA><NlmUniqueID>9613960</NlmUniqueID><ISSNLinking>1088-0224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>42</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18095783</ArticleId><ArticleId IdType="pii">6913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18173865</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Psychiatric consultations for nursing home residents: a perspective from Turkey and the implications for comparable countries.</ArticleTitle><Pagination><StartPage>752</StartPage><EndPage>763</EndPage><MedlinePgn>752-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610207006679</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">No specialized geriatric psychiatry consultation services are available for elderly people in the institutional care system in Turkey. Our aim was to evaluate psychiatric consultations among the residents of three homes for the elderly in a country with a rapidly aging population, and to investigate possible problems regarding psychiatric consultations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The residents of three homes for the elderly, which served partially as "care and rehabilitation centers" (equivalent to nursing homes), were chosen for the study. Data on the use of psychiatric services (mainly patient consultations with a visiting psychiatrist) were collected and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The percentage of patients in the three homes for the elderly who had psychiatric consultations between 2005 and 2007 was 31.8% (172/540). The main reasons for referral were forgetfulness (61%), depressive symptoms (37.7%), agitation and disruptive behavior (29.6%), and psychotic symptoms (27.9%). Of these patients, 46.5% were diagnosed with dementia, 20.9% with depression, 20.5% with behavioral and psychotic symptoms of dementia, and 18.6 % with primary psychotic disorders such as schizophrenia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Homes for the elderly in Turkey are not adequate in terms of consultations for psychiatric problems. Integration of these institutions with hospitals and organizing routine consultation visits from the psychiatry units would enhance the mental health of the elderly. Supporting the staff, maintaining good cooperation between them, and organizing educational programs in the field of mental health of the elderly are also required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cankurtaran</LastName><ForeName>Eylem Sahin</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Ankara Oncology Research and Training Hospital, Psychiatry Clinic, Ankara, Turkey. eylemcankurtaran@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutluer</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Senturk</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Erzin</LastName><ForeName>Gulten Bircan</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Gursoy</LastName><ForeName>Devrim</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tombak</LastName><ForeName>Eray</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="Y">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18173865</ArticleId><ArticleId IdType="doi">10.1017/S1041610207006679</ArticleId><ArticleId IdType="pii">S1041610207006679</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18166608</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>6</Issue><PubDate><MedlineDate>2007 Dec-2008 Jan</MedlineDate></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Medical management of frontotemporal dementia.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>498</EndPage><MedlinePgn>489-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533317507306654</ELocationID><Abstract><AbstractText>There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Arizona Alzheimer's Disease Consortium, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaari</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30AG19610-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002491">Central Nervous System Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002491" MajorTopicYN="N">Central Nervous System Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18166608</ArticleId><ArticleId IdType="pmc">PMC10846118</ArticleId><ArticleId IdType="doi">10.1177/1533317507306654</ArticleId><ArticleId IdType="pii">22/6/489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M. Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord. 2004;18:57-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M. Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease? PLoS Med. 2005;2:e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545200</ArticleId><ArticleId IdType="pubmed">15696217</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS Vitamin E and cognitive decline in older persons. Arch Neurol. 2002;59:1125-1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004;61:82-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732624</ArticleId></ArticleIdList></Reference><Reference><Citation>Commenges D. , Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartiques JF Intake of flavonoids and risk of dementia. Eur J Epidemiol. 2000. ;16:357-363.</Citation><ArticleIdList><ArticleId IdType="pubmed">10959944</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhart MJ , Geerlings MI, Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287:3223-3229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmijn S., Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol. 1997;145:33-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982020</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke R., Smith AD, Jobst KA, Refsum H., Sutton L., Ueland PM Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL A potential role of the curry spice cur-cumin in Alzheimer's disease . Curr Alzheimer Res. 2005;2:131-136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1702408</ArticleId><ArticleId IdType="pubmed">15974909</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Tang MX, Shea S., Mayeux R. Caloric intake and the risk of Alzheimer disease . Arch Neurol. 2002;59:1258-1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">12164721</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N. , Stern Y., Tang MX, Mayeux R., Luchsinger JA Mediterranean diet and risk for Alzheimer's disease. Ann Neurol. 2006;59:912-921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024594</ArticleId><ArticleId IdType="pubmed">16622828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A., van Swieten JC, Witteman JC, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet. 2002;359:281-286.</Citation><ArticleIdList><ArticleId IdType="pubmed">11830193</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Sabbagh M., Connor D., et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:78-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866915</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkenhager WH, Staessen JA Antihypertensives for prevention of Alzheimer's disease. Lancet Neurol. 2006. ;5:466-468.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun MK, Alkon DL Links between Alzheimer's disease and diabetes. Drugs Today (Barc). 2006;42:481-489.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894402</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann NY Acad Sci. 1996. ;777:213-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624086</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA , Legault C., Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA , Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291:2947-2958.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Farlow MR, Doody RS, Mohs R., Friedhoff LT A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology . 1998;50:136-145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443470</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;sler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27767</ArticleId><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881250</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B. , Doody R., St&#xf6;ffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti R., Torre P., Antonello RM, Cattaruzza T., Cazzato G., Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-937.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554751</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci. 2007;34(suppl 1):S118-S124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Shapira JS, McMurtray A., Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">17194818</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A., Greenberg SM, Growdon JH Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006; 57:513-533.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409164</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Doody RS, Pratt RD, Ieni JR Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10: 195-203.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793322</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Truyen L., Kershaw P., Damaraju CV The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61:252-256.</Citation><ArticleIdList><ArticleId IdType="pubmed">14967774</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H., Gauthier S., Hecker J., et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn ZJ, Cummings JL Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia Geriatr Cogn Disord. 2004;17:100-108.</Citation><ArticleIdList><ArticleId IdType="pubmed">14564129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tune LE Depression and Alzheimer's disease. Depress Anxiety. 1998;8(suppl 1):91-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenck CH, Mahowald MW, Kim SW, O'Connor KA, Hurwitz TD Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep. 1992;15:226-235.</Citation><ArticleIdList><ArticleId IdType="pubmed">1621023</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N. , Rabheru K., Wang J., Binder C. Galantamin treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials . Am J Geriatr Psychiatry. 2005;13:527-534.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956273</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer's disease . Eur Psychiatry. 2001;16 (suppl 1):25s-28s.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520475</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP Behavioral complications and their treatment in Alzheimer's disease. Geriatrics. 1997;52(suppl 2):S37-S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS , Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355: 1525-1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurlan R., Cummings J., Raman R., Thal L. for the ADCS. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology . 2007;68: 1356-1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PS, Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005. ;353:2335-2341.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62:742-748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367136</ArticleId><ArticleId IdType="pubmed">15007124</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP Behavioral complications and their treatment in Alzheimer's disease. Geriatrics. 1997;52(suppl 2):S37-S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307585</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton PS, Hocking LB Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother. 1997;31:319-322.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066939</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16:622-630.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadotani H. , Kadotani T., Young T., et al. Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults . JAMA. 2001;285:2888-2890.</Citation><ArticleIdList><ArticleId IdType="pubmed">11401610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb DJ , DeStefano AL, Foley DJ, et al. APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Neurology . 2004;63: 664-668.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR, Davies R., Xuereb J., Kril J., Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349-354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12913196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc. 2005;53:1658-1666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16181163</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules . Neurology. 1993;43:2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC , Stevens JC, Ganguli M., Tangalos EG, Cummings JL, DeKosky ST Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC , Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment&#x2014;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment . J Intern Med. 2004;256:240-246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubinsky RM , Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology . Neurology. 2000;54:2205-2211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881240</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ Visual syndromes as the presenting feature of degenerative brain disease . Semin Neurol. 2000;20:139-144.</Citation><ArticleIdList><ArticleId IdType="pubmed">10874783</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA , Swearer JM Driving and Alzheimer's disease: the risk of crashes. Neurology. 1993;43: 2448-2456.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255438</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Teri L., Larson EB Driving and Alzheimer's disease. J Gen Intern Med. 1992;7:583-588.</Citation><ArticleIdList><ArticleId IdType="pubmed">1453241</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitten LJ, Perryman KM, Wilkinson CJ, et al. Alzheimer and vascular dementias and driving. A prospective road and laboratory study. JAMA. 1995;273:1360-1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt LA, Murphy CF, Carr D., Duchek JM, Buckles V., Morris JC Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol. 1997;54:707-712.</Citation><ArticleIdList><ArticleId IdType="pubmed">9193205</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchek JM, Hunt L., Ball K., Buckles, V., Morris JC Attention and driving performance in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci. 1998;53:130-141.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebok GW, Keyl PM, Bylsma FW, Blaustein MJ, Tune L. The effects of Alzheimer disease on driving-related abilities. Alzheimer Dis Assoc Disord. 1994;8:228-240.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo M., Reinach S., McGehee D., Dawson J. Simulated car crashes and crash predictors in drivers with Alzheimer disease . Arch Neurol. 1997;54:545-551.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152111</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DJ, Quillian WC, Thorndike FP, Kovatchev BP, Hanna G. Evaluating driving performance of outpatients with Alzheimer disease . J Am Board Fam Pract. 1998;11:264-271.</Citation><ArticleIdList><ArticleId IdType="pubmed">9719348</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA, Swearer JM Driving and Alzheimer's disease: the risk of crashes. Neurology . 1993;43:2448-2456.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox GK, Bowden SC, Bashford GM, Smith DS Alzheimer's disease and driving: prediction and assessment of driving performance . J Am Geriatr Soc. 1997;45: 949-953.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF Dementia and guns. J Am Geriatr Soc. 1996;44:409-410.</Citation><ArticleIdList><ArticleId IdType="pubmed">8636586</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg KB, Wagner MT, Hendrix S., Bachman DL Firearm presence in households of patients with Alzheimer's disease and related dementias. J Am Geriatr Soc. 1999;47:1183-1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelman MS , Roth DL, Coon DW, Haley WE Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease . Am J Psychiatry. 2004;161:850-856.</Citation><ArticleIdList><ArticleId IdType="pubmed">15121650</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, Kokmen E., O'Brien PC Risk factors for nursing home placement in a population-based dementia cohort . J Am Geriatr Soc. 2000;48:519-525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler JE, Edwards AB, Femia EE, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. J Gerontol B Psychol Sci Soc Sci. 2000;55:247-255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584881</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D., Schneider L., Davis K., et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology. 1996;47:166-177.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710072</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher DS, Provenzano G., McRae T., Mastey V., Ieni JR Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R., O'Brien AT, Bookwala J., Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist. 1995. ;35: 771-791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19326737</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0260-1060</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Nutrition and health</Title><ISOAbbreviation>Nutr Health</ISOAbbreviation></Journal><ArticleTitle>Infantile autism: a chronic psychosis since infancy due to synaptic pruning of the supplementary motor area.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>317</EndPage><MedlinePgn>307-17</MedlinePgn></Pagination><Abstract><AbstractText>The rise in Infantile Autism, learning problems, cognitive decline with age, Alzheimer's, Parkinson's Diseases and the SIDS epidemic, has a common cause in the rising dietary deficit in Omega-3 brain-food. This paper suggests that aside from the wider concept of Autism Spectrum Disorders (ASD) and Pervasive Developmental Disorders (PDD), the rise in Infantile Autism (IA) in the last decade is the effect of deficient brain-food (Omega-3). The consequent delay of development prolongs the 2nd regressive event in infancy to pruning of the centre in the Medial Frontal Lobe System that connects Hippocampus and Cingulum. With a consequently defective Supplementary Motor Area (SMA), the Delayed Response Function is affected leading to persistent psychosis. Post-Pubertal Episodic Psychoses are associated with acute reduction of excitation, a risk of breakdown of circuitry, insufficient fill-in mechanisms, and silent spots. An acute psychosis occurs if the silent spots comprise of SMA. Only two brain areas have continuous neurogenesis, indicating their important functions: the Hippocampus and Olfactory Bulb that belongs to the Lateral Frontal Lobe System essential to survival. Concerned with necessity of action in response to the environment, it relies upon short-term memory and Acute Feedback Mechanisms influenced by emotion and motivation from the external world. In contrast, the Medial Frontal Lobe network is controlled by Feed-Forward Predictive Mechanisms related to storage of information. The Delayed Response Function is mastered at 7 months, when 2nd event occurs with pruning of axons and dendrites. An abolished or defective Delayed Response Function seriously incapacitates an individual: A defective "Social Brain" with an inability for conscious action and to communicate, predominates in IA. There is a near lack of speech, despite normal vision and hearing in the minority without marked adversity in pregnancy, at delivery or in infancy. I propose that the recent rise in IA despite no rise in adversity signifies a rising deficiency in brain-food. That this is so is suggested by a changing clinical picture: no Mental Retardation in an IA majority. Deficit in Olfaction is pathognomonic in schizophrenia since 30 yrs and distinguishes the Asperger Syndrome. If brain-food deficiency alone sufficiently prolongs pruning to cause absent activity in SMA in infancy, less mentally retarded IA from other causes might be observed. Deficit in brain-food was evident in the Sudden Infant Death Syndrome: birthweight averaged 200-300 g lower than sibs, Omega-3 levels in brainstem were lower than controls. Only 20 % SIDS died in first hypoxic episode, suggesting such episodes are more frequent than we imagined. Children with learning-behaviour problems have similarly depressed birthweight. A general deficiency in Omega-3 contributes to the lacking reduction in Schizophrenia, despite early puberty predominates. Olfactory Bulb is first affected in the Alzheimer's and Parkinson's Disease. Cognitive decline with age, Hippocampal dysfunctions rise markedly irrespective of disease, but the major mental illnesses and Infantile Autism in particular, benefit from "brain-food" that might also prevent a development of these disorders. To secure optimal brain function in the coming generations, there is a need to change the diet now from its emphasis on protein for body growth to food for the brain. This means there is a need to increase fish and sea food consumption.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saugstad</LastName><ForeName>Letten F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, University of Oslo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nutr Health</MedlineTA><NlmUniqueID>8306569</NlmUniqueID><ISSNLinking>0260-1060</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002659" MajorTopicYN="N">Child Development Disorders, Pervasive</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058870" MajorTopicYN="N">Food, Organic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017747" MajorTopicYN="N">Seafood</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>49</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19326737</ArticleId><ArticleId IdType="doi">10.1177/026010600801900406</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18090879</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2765</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Hypertension and cognitive function in the elderly.</ArticleTitle><Pagination><StartPage>533</StartPage><EndPage>554</EndPage><MedlinePgn>533-54</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is the most prevalent and common form of cognitive impairment, ie, dementia, in the elderly followed in second place by vascular dementia due to the microangiopathy associated with poorly-controlled hypertension. Besides blood pressure elevation, advancing age is the strongest risk factor for dementia. Deterioration of intellectual function and cognitive skills that leads to the elderly patient becoming more and more dependent in his, her, activities of daily living, ie, bathing, dressing, feeding self, locomotion, and personal hygiene. It has been known and demonstrated for many years that lowering of blood pressure from a previous hypertensive point can result in stroke prevention yet lowering of blood pressure does not prevent the microangiopathy that leads to white matter demyelinization which when combined with the clinical cognitive deterioration is compatible with a diagnosis of vascular dementia. It is known from many large studies, ie, SHEP, SCOPE, and HOPE, that lowering of blood pressure gradually will not and should not worsen the cognitive impairment. However, if the pressure is uncontrolled a stroke which might consequently occur would further worsen their cognitive derangement. So an attempt at slow reduction of blood pressure since cerebral autoregulation is slower as age increases is in the patient's best interest. It is also important to stress that control of blood glucose can also be seen as an attempt to prevent vascular dementia from uncontrolled hyperglycemia. Vascular dementia is not considered one of the reversible causes of dementia. Reversible causes of cognitive impairment are over medication with centrally acting drugs such as sedatives, hypnotics, antidepressants, and antipsychotics, electrolyte imbalance such as hyponatremia, azotemia, chronic liver disease, and poor controlled chronic congestive heart failure. Criteria for the clinical diagnosis of vascular dementia include cognitive decline in regards to preceding functionally higher level characterized by alterations in memory and in two or more superior cortical functions that include orientation, attention, verbal linguistic capacities, visual spacial skills, calculation, executive functioning, motor control, abstraction and judgment. Patients with disturbances of consciousness, delirium (acute confusional states), psychosis, serious aphasia, or sensory-motor alterations that preclude proper execution of neuro-psychological testing are also considered to have probably vascular dementia. Furthermore, these are ten of the other essential cerebral or systematic pathologies present that would be able to produce a dementia syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cherubini</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gerontology and Geriatrics, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowenthal</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Paran</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Leonard S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Senin</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>178</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18090879</ArticleId><ArticleId IdType="doi">10.1097/MJT.0b013e3180ed6b8f</ArticleId><ArticleId IdType="pii">00045391-200711000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18070853</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Phenomenological distinctions needed in DSM-V: delirium, subsyndromal delirium, and dementias.</ArticleTitle><Pagination><StartPage>468</StartPage><EndPage>470</EndPage><MedlinePgn>468-70</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meagher</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Midwestern Regional Hospital, Limerick, Ireland. meaghermob@eircom.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trzepacz</LastName><ForeName>Paula T</ForeName><Initials>PT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18070853</ArticleId><ArticleId IdType="doi">10.1176/jnp.2007.19.4.468</ArticleId><ArticleId IdType="pii">19/4/468</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18056823</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mental illness and use of home care nationally in the U.S. Department of Veterans Affairs.</ArticleTitle><Pagination><StartPage>1046</StartPage><EndPage>1056</EndPage><MedlinePgn>1046-56</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether patients with mental health diagnoses are more likely to utilize home-based primary care (HBPC), and to identify characteristics associated with HBPC admission among elderly and nonelderly veterans, specifically.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients receiving treatment during fiscal year (FY) 2003 and having no evidence of home care utilization during FY2002 were followed through FY2005 using administrative claims data of the Veterans Health Administration of the U.S. Department of Veterans Affairs (VA). Participants were 4,411,677 VA patients with no prior HBPC use. Cox proportional hazard models were developed to identify correlates of HBPC use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of VA patients with no prior use of HBPC, 24.2% received a mental health diagnosis, of whom 1.5% eventually used HBPC. Two in five new HBPC admissions were diagnosed with mental illness. Patients diagnosed with dementia were 66% more likely to be admitted. Patients diagnosed with nonschizophrenia psychoses (hazard ratio [HR]: 1.30), miscellaneous affective disorders (HR: 1.22), and schizophrenia (HR: 1.21) had the next highest probabilities. Risk of admission was highest for &gt; or = 3 outpatient medical visits (HR: 2.61), followed by any inpatient medical/surgical days (HR: 1.79) or outpatient mental health visits (HR: 1.30). Elderly patients with any inpatient mental health days were less likely to be admitted; younger patients with nursing home use, community residential care, and mental health intensive care management were more likely to be admitted.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Given that mental illness is independently associated with the likelihood of admission, it is critical that providers develop the skills and resources necessary to meet the psychiatric needs of home care recipients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Edward Alan</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>A. Alfred Taubman Center for Public Policy and American Institutions, Department of Community Health, Brown University, Providence, RI 02912, USA. edward_a_miller@brown.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006699" MajorTopicYN="N">Home Care Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18056823</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181462274</ArticleId><ArticleId IdType="pii">15/12/1046</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18046981</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Olfactory dysfunctions in patients with schizophrenia].</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>512</EndPage><MedlinePgn>503-12</MedlinePgn></Pagination><Abstract><AbstractText>Olfactory dysfunctions in patients with schizophrenia are becoming the aim of an increased number of studies. Smell identification deficits are well known but also other olfactory processes are examined, eg. sensitivity, discrimination, familiarity and edibility. Smell identification deficits are present in patients with schizophrenia and also in their non-psychotic siblings. Moreover, this dysfunction was reported in a group of children and adolescents with psychosis. Patients have also neuroanatomical abnormalites in brains structures linked with olfaction, e.g. olfactory bulb. Probably, there is no relationship between pathology of olfactory mucosa and olfactory dysfunction. However, correlation between smoking, neuroleptic treatment and olfactory deficits was not found, but it is unclear what is the role of long-term pharmacotherapy. There is a relationship between negative symptoms, IQ and olfactory processing. Smell identification deficits are not specific for schizophrenia. This disorder is well described in Alzheimer's disease. It is possible that olfactory deficits in schizophrenia are induced by pathology in cortical or subcortical regions which cannot be detected in neuropsychological tests. Currently it is difficult to use olfactory deficits as endophenotypical markers of schizophrenia, and further studies are necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Urban</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinika Zaburze&#x144; Afektywnych i Psychiatrii M&#x142;odziezy Katedry Psychiatrii UM w Lodzi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe-Jab&#x142;o&#x144;ska</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Dysfunkcje wechowe u chorych na schizofrenie.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009830" MajorTopicYN="N">Olfactory Bulb</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009831" MajorTopicYN="N">Olfactory Mucosa</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009833" MajorTopicYN="N">Olfactory Pathways</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="Y">Smell</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>44</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18046981</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18044110</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1176-9092</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Clinical interventions in aging</Title><ISOAbbreviation>Clin Interv Aging</ISOAbbreviation></Journal><ArticleTitle>Treatment of Alzheimer's disease across the spectrum of severity.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>142</EndPage><MedlinePgn>131-42</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is the most common cause of dementia affecting nearly 18 million people around the world and 4.5 million in the US. It is a progressive neurodegenerative condition that is estimated to dramatically increase in prevalence as the elderly population continues to grow. As the cognitive and neuropsychiatric signs and symptoms of AD progresses in severity over time, affected individuals become increasingly dependent on others for assistance in performing all activities of daily living. The burden of caring for someone affected by the disorder is great and has substantial impact on a family's emotional, social and financial well-being. In the US, the currently approved medications for the treatment of mild to moderate stages of AD are the cholinesterase inhibitors (ChEIs). Cholinesterase inhibitors have shown modest efficacy in terms of symptomatic improvement and stabilization for periods generally ranging from 6 to 12 months. There are additional data that have emerged, which suggest longer-term benefits. For the moderate to severe stages of AD, memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist is in widespread use and has shown modest benefit as monotherapy and in combination with ChEIs. The cost effectiveness of the currently available therapeutic agents for AD has undergone great scrutiny and remains controversial, especially outside the US. Neuropsychiatric symptoms such as agitation and psychosis are common in AD. Unfortunately, in the US there are no Food and Drug Administration (FDA)-approved agents for the treatment of these symptoms, although atypical antipsychotics have shown some efficacy and have been widely used. However, the use of these agents has recently warranted special caution due to reports of associated adverse effects such as weight gain, hyperlipidemia, glucose intolerance, cerebrovascular events, and an increased risk for death. Alternative agents used to treat neuropsychiatric symptoms include serotonergic antidepressants, benzodiazepines, and anticonvulsant medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shailaja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Correspondence: Shailaja Shah UMDNJ-RobertWood Johnson Medical School, 667 Hoes Lane, Piscataway, NJ 08854, USA. shahsk@umdnj.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichman</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Interv Aging</MedlineTA><NlmUniqueID>101273480</NlmUniqueID><ISSNLinking>1176-9092</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18044110</ArticleId><ArticleId IdType="pmc">PMC2695170</ArticleId><ArticleId IdType="doi">10.2147/ciia.2006.1.2.131</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>[AGS&#x2013;AAGP] American Geriatrics Society and American Association for Geriatric Psychiatry Consensus statement on improving the quality of mental health care in U.S. nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003;51:1287&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12919243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos G, Jeste D, Carpenter D, et al. Postgraduate Medicine Special Report. McGraw-Hill; 2005. Expert Consensus Guideline Series: Treatment of dementia and its behavioral disturbances.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG. Advances in the treatment of Alzheimer&#x2019;s disease: benefits of dual cholinesterase inhibition (review) Eur Neurol. 2002;47:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803198</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks JS, Melzer D. Donepezil for mild and moderate Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2000;4:CD001190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11034704</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with &#x201c;Advanced moderate&#x201d; Alzheimer&#x2019;s disease for at least 12 months. Dement Geriatr Cogn Disord. 2003;15:79&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566596</ArticleId></ArticleIdList></Reference><Reference><Citation>Brane G, Gottfries CG, Winblad B. The Gottfries-Brane-Steen scale: validity, reliability, and application in anti-dementia drug trials. Dement Geriatr Cogn Disord. 2001;12:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125236</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer&#x2019;s disease-results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10325453</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2004;19:243&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15027039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739063</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new cholinesterase inhibitor, in patients with mild to moderately severe Alzheimer&#x2019;s disease. Int Geriatr Psychopharmacol. 1998;2:55&#x2013;65.</Citation></Reference><Reference><Citation>Courtney C, Farrell D, Gray R, et al. AD 2000 Collaborative group Long term donepezil in 565 patients with Alzheimer&#x2019;s disease (AD 2000): randomized double-blind trial. Lancet. 2004;363:2105&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Alzheimer&#x2019;s disease: drug therapy. N Engl J Med. 2004;351:56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229308</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDeyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M, Anand R, Messina J, Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer&#x2019;s disease. Eur Neurol. 2000;244:236&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11096224</ArticleId></ArticleIdList></Reference><Reference><Citation>[FDA] Food and Drug Administration 2005FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disorders [online]Accessed 1 October 2005. URL: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm</Citation></Reference><Reference><Citation>Feldman H, Gauthier S, Hecker J, et al. Donepezil MSAD Study Investigators group 2001A 24-week randomized, double-blind study of donepezil in moderate to severe Alzheimer&#x2019;s disease Neurology 57613&#x2013;20.Correction in Neurology, 57:2153.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524468</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of behavioral manifestations of Alzheimer&#x2019;s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease. The Alzheimer&#x2019;s disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer&#x2019;s disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10500855</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Neurology. 2004;63:214&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasckow JW, Mulchahey JJ, Mohamed S. The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. J Am Med Dir Assoc. 2004;5:242&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15228634</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, et al. Risperidone study group Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kmietowicz Z. NICE proposes to withdraw Alzheimer&#x2019;s drugs from NHS. BMJ. 2005;330:495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552833</ArticleId><ArticleId IdType="pubmed">15746112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer&#x2019;s disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Reichman WE, Kershaw P. Long-term outcomes of galantamine treatment in patients with Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2004;12:473&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer&#x2019;s disease. Biol Psychiatry. 2001;49:279&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Doody RS, Morris JC, et al. 2001A 1-year placebo-controlled preservation of function survival study of donepezil in Alzheimer&#x2019;s disease patients Neurology 57481&#x2013;8.Correction in Neurology, 57:1942</Citation><ArticleIdList><ArticleId IdType="pubmed">11502917</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry. 1991;148:102&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1984692</ArticleId></ArticleIdList></Reference><Reference><Citation>[NIMH] National Institute of Mental Health . Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MA: 1986. pp. 217&#x2013;22.</Citation></Reference><Reference><Citation>Olin J, Schneider L. Galantamine for Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2002;3:CD001747.</Citation><ArticleIdList><ArticleId IdType="pubmed">12137632</ArticleId></ArticleIdList></Reference><Reference><Citation>Panisset M, Roudier M, Saxton J, et al. Severe Impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8274108</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Potkin SG, Pomara N, et al. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer&#x2019;s disease: a randomized, controlled trial [abstract] Eur J Neurol. 2004;11(Suppl 2):186.</Citation></Reference><Reference><Citation>Peterson RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Porteinsson AP, Tariot P, Erb R. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156753</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Wessel T, et al. Galantamine in Alzheimer&#x2019;s disease. A 6-month randomized placebo-controlled trial with a 6-month extension. The galantamine USA-1 Study group. Neurology. 2000;54:2261&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881250</ArticleId></ArticleIdList></Reference><Reference><Citation>Reissberg B, Doody R, Stoffler A, et al. Memantine in moderate to severe Alzheimer&#x2019;s disease. N Engl J Med. 2003;348:1333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2003;16(1):15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CW, Ames D, Clayton T. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2004;12:358&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Doody RS, Mohs R, et al. Donepezil improves cognition and global function in Alzheimer&#x2019;s disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study group. Arch Intern Med. 1998;158:1021&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9588436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer&#x2019;s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793322</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind placebo-controlled trial of donepezil in patients with Alzheimer&#x2019;s disease. Donepezil Study Group. Neurology. 1998;50:136&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer&#x2019;s disease: international randomized controlled trial. BMJ. 1999;318:633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27767</ArticleId><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry. 1993;1:82&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28530950</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer&#x2019;s disease cooperative study &#x2013; clinical global impression of change. The Alzheimer&#x2019;s disease Co-operative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl2):S22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer&#x2019;s disease. A randomized Placebo-controlled trial. Arch Neurol. 2004;61:1852&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596605</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton PS, Hocking LB. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother. 1997;31:319&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia, a review of the evidence. JAMA. 2005;293:596&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J, Clark S, Gannon K, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer&#x2019;s disease in nursing care facilities. Arch Gen Psychiatry. 2000;57:968&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, et al. Memantine Study Group Memantine treatment in patients with moderate to severe Alzheimer&#x2019;s disease already receiving donepezil, a randomized controlled trial. JAMA. 2004;291:317&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Rosemary RN, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9433339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Schneider L, Katz I. Quetiapine in nursing home residents with Alzheimer&#x2019;s dementia and psychosis. Am J Geriatr Psychiatry. 2002;10(Suppl 1):93.</Citation></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer&#x2019;s disease. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kam P, Mol F, Wimmers MF. Beoordelingsschaal voor oudere patienten (BOP) Van Loghum Slaterus; The Netherlands: 1971.</Citation></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Lilienfield S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer&#x2019;s disease: multicenter randomized controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27547</ArticleId><ArticleId IdType="pubmed">11110737</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Engedal K, Soininen H, et al. Donepezil Nordic Study A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer&#x2019;s disease. Neurology. 2001;57:489&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502918</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (Benefit and efficacy in severely demented patients during treatment with memantine) Int J Geriatr Psychiatry. 1999;14:135&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10885864</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18036286</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>166</EndPage><MedlinePgn>157-66</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia is frequently associated with behavioral disturbances, some of which have a significant impact on patient quality of life and the likelihood of institutionalization. Cholinergic systems, among other neurotransmitters in the brain, appear to be involved with different behaviors, such as psychosis, depression, agitation, and personality changes.</AbstractText><AbstractText Label="SCOPE" NlmCategory="METHODS">This paper reviews the clinical data on the effectiveness of rivastigmine, a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, in ameliorating behavioral disturbances in different patient populations. Relevant articles were identified through MEDLINE searches with no date restrictions.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">In particular, rivastigmine has shown efficacy in treating behavioral disturbances in patients with a wide range of dementias - Alzheimer's disease, vascular dementia, fronto-temporal dementia, mixed dementia, Lewy body dementia, Parkinson's disease with dementia, and schizophrenia with dementia. Most of the studies have been open-label clinical trials with behavior as a secondary endpoint. The behavior domains that most consistently showed improvement were apathy/indifference, anxiety, delusions (psychosis), and hallucinations. The major limitation of this review is that the effects on behavioral symptoms were usually secondary endpoints in clinical trials.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The efficacious effects of treatment with rivastigmine on various behavioral disturbances provide supporting evidence that cholinergic mechanisms, among other neurotransmitters, are involved in the manifestation of some behavioral and psychological symptoms of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Figiel</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Southeastern Geriatric Healthcare Group, Snellville, GA 30078, USA. GLFigiel@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>62</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18036286</ArticleId><ArticleId IdType="doi">10.1185/030079908x260961</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18033152</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>4 Pt 1</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?].</ArticleTitle><Pagination><StartPage>616</StartPage><EndPage>620</EndPage><MedlinePgn>616-20</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">While traumatic brain injury is a major public health issue, schizophrenia-like psychosis following traumatic brain injury is relatively rare and poorly studied. Yet the risk of developing schizophrenia-like psychosis after traumatic brain injury is 3 times more important than in the general population.</AbstractText><AbstractText Label="LITERATURE FINDINGS" NlmCategory="RESULTS">Risk factors associated with onset of psychosis after traumatic brain injury include: left hemispheric lesions, closed head injury and coma of duration superior to 24 hours. Most patients develop symptoms of psychosis after a moderate to severe traumatic brain injury and often have lesions of the frontal and temporal lobes. CHOLINERGIC HYPOTHESIS:</AbstractText><AbstractText Label="ARGUMENTS" NlmCategory="OBJECTIVE">Neuropathologic, electrophysiological and pharmacologic evidence show that cognitive impairment including attention, memory and executive functioning impairment may be related with cholinergic dysfunction in patients with traumatic brain injury. The cholinergic hypothesis is also incriminated in the genesis of schizophrenia. The same biochemical disorders found in schizophrenia which imply many neurotransmitters are often present immediately after traumatic brain injury. However in chronic cognitive disorders secondary to traumatic brain injury, the cholinergic system alone seems to be specifically implied. This is due to the fragility of the cholinergic fibres and a chronic yet reversible reduction of the cholinergic reserves after traumatic brain injury. Cholinergic function can be studied by the P50 evoked response to paired auditory stimuli.While this is disturbed in patients presenting with cognitive impairment after traumatic brain injury its normalisation can be obtained after administration of an acetylcholine esterase inhibitor. In schizophrenic patients there is also an abnormal P50 evoked response due in part to a low number of alpha 7 nicotinic receptors which are implicated in sensory filtering in the frontal lobe. Moreover in schizophrenia, post-mortem studies show a negative correlation between the activity of acetylcholine transferase in the parietal cortex and the severity of the cognitive deficits, as well as a lesser density of the muscarinic M1 and M4 receptors in the frontal lobe. The lower concentration of M1 receptors in the frontal cortex is correlated with the severity of the positive symptoms. THERAPEUTICAL PERSPECTIVES: Antipsychotics have emerged as the first line treatment of psychotic disorders. In research, their ability for enhancing cognitive function could result in the increase of acetylcholine in the medial prefrontal cortex. Acetylcholinesterase inhibitors have been widely used for treatment of cognitive impairment in Alzheimer's disease. Galantamine could be interesting in schizophrenia and psychosis following traumatic brain injury because it has a dual mechanism of action: selective competitive inhibition of acetylcholinesterase and allosteric potentialisation of nicotinic receptor response. Therefore Galantamine remains active in nicotine addicted schizophrenic patients who may smoke as an auto treatment. Galantamine has shown efficacy in adjunction to Risperidone in one patient presenting with psychosis following traumatic brain injury and in 3 case reports of schizophrenic patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further systematic studies are needed to confirm this hypothesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennouna</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Interne de sp&#xe9;cialit&#xe9;, CHS de Sarreguemines, 3e secteur, 1, rue Calmette, 57206 Sarreguemines, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>V B</ForeName><Initials>VB</Initials></Author><Author ValidYN="Y"><LastName>Defranoux</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Th&#xe9;orie cholinergique dans les psychoses apr&#xe8;s un traumatisme cr&#xe2;nien et dans la schizophr&#xe9;nie: un lien?</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>43</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18033152</ArticleId><ArticleId IdType="doi">10.1016/s0013-7006(07)92062-x</ArticleId><ArticleId IdType="pii">S0013-7006(07)92062-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18025783</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The aim of this study was to determine the consistency of neuropsychiatric subsyndromes of the Neuropsychiatric Inventory across several clinical and demographic subgroups (e.g. dementia subtypes, dementia severity, medication use, age and gender) in a large sample of outpatients with dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional data of 2,808 patients with dementia from 12 centres from the European Alzheimer's Disease Consortium were collected. Principal component analysis was used for factor analysis. Subanalyses were performed for dementia subtypes, dementia severity, medication use, age and gender.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed the relatively consistent presence of the 4 neuropsychiatric subsyndromes 'hyperactivity', 'psychosis', 'affective symptoms' and 'apathy' across the subanalyses. The factor structure was not dependent on dementia subtypes, age and gender but was dependent on dementia severity and cholinesterase use. The factors hyperactivity and affective symptoms were present in all subanalyses, but the presence of the factors apathy and psychosis was dependent on use of cholinesterase inhibitors and dementia severity, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study provided evidence of the relative consistency of neuropsychiatric subsyndromes across dementia subtypes, age and gender, thereby stressing the importance of thinking about neuropsychiatric subsyndromes instead of separate symptoms. However, the subsyndromes apathy and psychosis were dependent on use of cholinesterase inhibitors and dementia severity.</AbstractText><CopyrightInformation>(c) 2007 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aalten</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, Maastricht University Hospital, Maastricht, The Netherlands. p.aalten@np.unimaas.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Boziki</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brugnolo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Eleanor Jane</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Debby</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Elina</LastName><ForeName>Kazi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ousset</LastName><ForeName>Pierre Jean</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Reynish</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe H</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>32</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18025783</ArticleId><ArticleId IdType="doi">10.1159/000111082</ArticleId><ArticleId IdType="pii">000111082</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18020111</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.</ArticleTitle><Pagination><StartPage>630</StartPage><EndPage>646</EndPage><MedlinePgn>630-46</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To systematically review published clinical trials of the pharmacotherapy of neuropsychiatric symptoms of Alzheimer disease (AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We searched MEDLINE and EMBASE for published English-language medical literature. Our review focused on randomized controlled trials (RCTs) and corresponding metaanalyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The pharmacotherapy of neuropsychiatric symptoms of AD has been studied with numerous RCTs. The largest number of studies has focused on antipsychotics. Data are of reasonably high quality and indicate that risperidone and olanzapine are more effective than placebo for institutionalized patients with severe agitation, aggression, and psychosis. The efficacy of antipsychotics is counterbalanced by safety concerns that include cerebrovascular adverse events and mortality. Cholinesterase inhibitors and memantine appear to have modest benefits for patients with mildly to moderately severe symptoms. Antidepressants are effective for treating depression in AD, but more data are required to determine the efficacy of trazodone and citalopram for agitation and aggression. Carbamazepine appears to be efficacious, although side effects and concerns about drug-drug interactions limit its use. The data do not support the use of valproate. Benzodiazepines should only be used for short-term, as-needed use. There are insufficient data on other pharmacologic interventions, such as beta blockers, buspirone, and estrogen preparations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although there have been numerous well-designed studies of the pharmacotherapy of neuropsychiatric symptoms in AD, safer and more effective treatments are urgently needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Ontario. n.herrmann@utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanct&#xf4;t</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>157</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18020111</ArticleId><ArticleId IdType="doi">10.1177/070674370705201004</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18000814</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0887-4476</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Synapse (New York, N.Y.)</Title><ISOAbbreviation>Synapse</ISOAbbreviation></Journal><ArticleTitle>Memantine agonist action at dopamine D2High receptors.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>153</EndPage><MedlinePgn>149-53</MedlinePgn></Pagination><Abstract><AbstractText>Memantine is reported to improve symptoms in moderate cases of Alzheimer's disease and Parkinson's disease, but is also known to trigger psychosis in some Parkinson patients. Because these clinical features suggested a possible dopamine component of memantine action, we measured the potency of memantine on the functional high-affinity state of dopamine D2 receptors, or D2(High). Using [(3)H]domperidone to label D2 receptors, the memantine dissociation constant at D2(High) was 917 +/- 23 nM for rat striatal D2 receptors and 137 +/- 19 nM for human cloned D2Long receptors. The memantine dissociation constant for striatal N-methyl-D-aspartate (NMDA) receptors labeled by [(3)H]MK 801 was 2200 +/- 400 nM. Memantine stimulated the incorporation of [(35)S]GTP-gamma-S into D2-expressing Chinese Hamster Ovary cells with a dissociation constant of 1200 +/- 400 nM. Memantine, between 200 and 2000 nM, directly acted on D2(High) to inhibit the release of prolactin from isolated anterior pituitary cells in culture. Because the memantine potencies at NMDA receptors and dopamine D2(High) receptors are of a similar order of magnitude, it is likely that the clinical features of memantine can be attributed to its action at both types of receptors.</AbstractText><CopyrightInformation>(c) 2007 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeman</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8. philip.seeman@utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lasaga</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Synapse</MedlineTA><NlmUniqueID>8806914</NlmUniqueID><ISSNLinking>0887-4476</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007554">Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C113776">dopamine D2L receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>37589-80-3</RegistryNumber><NameOfSubstance UI="D016244">Guanosine 5'-O-(3-Thiotriphosphate)</NameOfSubstance></Chemical><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004294" MajorTopicYN="N">Domperidone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016244" MajorTopicYN="N">Guanosine 5'-O-(3-Thiotriphosphate)</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007554" MajorTopicYN="N">Isotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18000814</ArticleId><ArticleId IdType="doi">10.1002/syn.20472</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17989861</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0034-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>135</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Revista medica de Chile</Title><ISOAbbreviation>Rev Med Chil</ISOAbbreviation></Journal><ArticleTitle>[Charles Bonnet syndrome: report of three cases].</ArticleTitle><Pagination><StartPage>1034</StartPage><EndPage>1039</EndPage><MedlinePgn>1034-9</MedlinePgn></Pagination><Abstract><AbstractText>Charles Bonnet syndrome is characterized by the presence of visual hallucinations associated with loss of vision. We report three patients aged 74, 84 and 80 years (two women) with a severe loss of vision due to ocular diseases and silent visual hallucinations, that they recognized as unreal. Two patients felt that the hallucinations were ominous. Years later, two suffered a probable Alzheimer's disease (AD). One of them had a mild cognitive impairment when the syndrome appeared, that evolved into an AD with psychosis. This syndrome is not uncommon in older patients with loss of vision and it is probably underdiagnosed. Its pathogenesis is probably a cortical deafferentation. The content of the visual hallucinations (faces, landscaped, and so on) coincides with the activation of different areas of the visual association cortices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donoso S</LastName><ForeName>Archibaldo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico de la Universidad de Chile, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva R</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fuentes G</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gaete C</LastName><ForeName>Germ&#xe1;n</ForeName><Initials>G</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de Charles Bonnet: presentaci&#xf3;n de tres casos y revisi&#xf3;n de la literatura.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Rev Med Chil</MedlineTA><NlmUniqueID>0404312</NlmUniqueID><ISSNLinking>0034-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>16</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17989861</ArticleId><ArticleId IdType="doi">10.4067/s0034-98872007000800011</ArticleId><ArticleId IdType="pii">S0034-98872007000800011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17987049</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>68</EndPage><MedlinePgn>63-8</MedlinePgn></Pagination><Abstract><AbstractText>Emerging evidence suggests that psychosis in persons with Alzheimer's disease (AD) may be linked to the cholinergic deficit associated with the disease. This study sought to evaluate whether anticholinergic (ACH) drugs could be a risk factor for psychosis onset. A total of 230 patients affected with probable AD were recruited. Data on behavioral and psychological symptoms were collected using the Neuropsychiatric Inventory, and diagnosis of psychosis was performed. Patients were divided into those who used ACH drugs and those who used non-ACH drugs. Those using ACH drugs (18.3%) were more likely to have psychosis than those using non-ACH drugs (odds ratio (OR)=2.52; 95% confidence interval (CI), 1.27-5.00); this association remained significant even after adjusting for potential confounding variables (OR=2.13; 95% CI, 1.03-4.43). Our data suggest that patients with AD are frequently treated with ACH drugs and that ACH drug intake should be regarded as a potential risk factor for psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cancelli</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, "S. Maria della Misericordia" University Hospital, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentinis</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Merlino</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gigli</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018680" MajorTopicYN="N">Cholinergic Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17987049</ArticleId><ArticleId IdType="doi">10.1038/sj.clpt.6100435</ArticleId><ArticleId IdType="pii">6100435</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17986816</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>463</EndPage><MedlinePgn>457-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The aim of this study was to identify neuropsychiatric subsyndromes of the Neuropsychiatric Inventory in a large sample of outpatients with Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional data of 2,354 patients with AD from 12 centres from the European Alzheimer's Disease Consortium were collected. Principal component analysis was used for factor analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed the presence of 4 neuropsychiatric subsyndromes: hyperactivity, psychosis, affective symptoms and apathy. The subsyndrome apathy was the most common, occurring in almost 65% of the patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This large study has provided additional robust evidence for the existence of neuropsychiatric subsyndromes in AD.</AbstractText><CopyrightInformation>(c) 2007 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aalten</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, Maastricht University Hospital, Maastricht, The Netherlands. p.aalten@np.unimaas.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Boziki</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Eleanor Jane</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Debby</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Elina</LastName><ForeName>Kazi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Girtler</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ousset</LastName><ForeName>Pierre Jean</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Reynish</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe H</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>21</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId><ArticleId IdType="doi">10.1159/000110738</ArticleId><ArticleId IdType="pii">000110738</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17984395</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1259</StartPage><EndPage>1268</EndPage><MedlinePgn>1259-68</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To conduct a cost-benefit analysis of SGAs and placebo (taken to represent a "watchful waiting" treatment strategy) for psychosis and aggression in outpatients with AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized placebo-controlled trial of alternative SGA initiation strategies.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Forty-two outpatient clinics.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Outpatients with AD and psychosis, aggression, or agitation (N = 421). Intervention Participants were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind rerandomization to another antipsychotic or citalopram hydrobromide or open treatment over 9 months.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Monthly interviews documented health service use and costs. The economic perspective addressed total health care and medication costs. Costs of study drugs were estimated from wholesale prices with adjustment for discounts and rebates. Quality-adjusted life-years (QALYs) were assessed with the Health Utilities Index Mark 3 and were supplemented with measures of functioning, activities of daily living, and quality of life. Primary analyses were conducted using all available data. Secondary analyses excluded observations after the first medication change (ie, phase 1 only). Cost-benefit analysis was conducted using the net health benefits approach in a sensitivity analysis in which QALYs were valued at $50,000 per year and $100,000 per year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Average total health costs, including medications, were significantly lower for placebo than for SGAs, by $50 to $100 per month. There were no differences between treatments in QALYs or other measures of function. Phase 1-only analyses were broadly similar. Net-benefit analysis showed greater net health benefits for placebo as compared with other treatments, with probabilities ranging from 50% to 90%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00015548.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Northeast Program Evaluation Center (182), VA Connecticut Health Care System, West Haven, Connecticut 06516, USA. robert.rosenheck@yale.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Douglas L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Sindelar</LastName><ForeName>Jody L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffery A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><CollectiveName>Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00015548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2008 Mar-Apr;148(2):53.</RefSource><PMID Version="1">18311883</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17984395</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.64.11.1259</ArticleId><ArticleId IdType="pii">64/11/1259</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17974864</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.</ArticleTitle><Pagination><StartPage>918</StartPage><EndPage>931</EndPage><MedlinePgn>918-31</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy and safety of aripiprazole for psychosis associated with Alzheimer dementia (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this double-blind, multicenter study, 487 institutionalized patients with psychosis associated with AD were randomized to placebo or aripiprazole, 2, 5 or 10 mg/day. Primary efficacy assessment was the mean change from baseline to week 10 on the Neuropsychiatric Inventory-Nursing Home (NPI-NH) version Psychosis Subscale score. Secondary measures included NPI-NH Total, Clinical Global Impression-Severity of Illness (CGI-S), Brief Psychiatric Rating Scale (BPRS) Core and Total, and the Cohen-Mansfield Agitation Inventory (CMAI) scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS and CMAI scores. Aripiprazole 2 mg/day was not efficacious. Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N = 1; 5 mg/day, N = 2; 10 mg/day, N = 4; placebo, N = 0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 mg/day, 2%; 10 mg/day, 7%; placebo, 3%) were considered to be treatment-related.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Aripiprazole 10 mg/day was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms, agitation, and clinical global impression. However, clinicians should be aware of the safety considerations of atypical antipsychotic uses in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Alzheimer's Research &amp; Clinical Programs, Medical University of South Carolina, North Charleston, SC 29406-6076, USA. mintzerj@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tune</LastName><ForeName>Larry E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Breder</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Swanink</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Ronald N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Forbes</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Geriatr Psychiatry. 2008 Jul;16(7):613; author reply 614. doi: 10.1097/JGP.0b013e318167aea2</RefSource><PMID Version="1">18591582</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Psychiatry Rep. 2009 Feb;11(1):3-4.</RefSource><PMID Version="1">19187697</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007326" MajorTopicYN="Y">Institutionalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17974864</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181557b47</ArticleId><ArticleId IdType="pii">15/11/918</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17974863</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Agitation and psychosis in dementia.</ArticleTitle><Pagination><StartPage>913</StartPage><EndPage>917</EndPage><MedlinePgn>913-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019341" MajorTopicYN="N">Aromatherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17974863</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181584268</ArticleId><ArticleId IdType="pii">15/11/913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17943030</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-4348</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Southern medical journal</Title><ISOAbbreviation>South Med J</ISOAbbreviation></Journal><ArticleTitle>To prescribe or not to prescribe? Atypical antipsychotic drugs in patients with dementia.</ArticleTitle><Pagination><StartPage>961</StartPage><EndPage>963</EndPage><MedlinePgn>961-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry University of California, San Diego VA San Diego Healthcare System San Diego, CA 92161, USA. djeste@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH66248</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH071536</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019934</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>South Med J</MedlineTA><NlmUniqueID>0404522</NlmUniqueID><ISSNLinking>0038-4348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17943030</ArticleId><ArticleId IdType="doi">10.1097/SMJ.0b013e3181514c51</ArticleId><ArticleId IdType="pii">00007611-200710000-00002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17921754</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2007</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The many faces of psychosis in the elderly.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>558</EndPage><MedlinePgn>551-8</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">As the population ages, the number of older patients with psychosis will greatly rise. This review focuses on the etiology, biologic and clinical findings, and treatments of common causes of psychosis in the elderly.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent studies on psychosis related to Alzheimer's disease indicate that antipsychotic drugs have equivocal efficacy in improving psychotic symptoms and may have side effects or risks that outweigh their benefits. Behavioral interventions for agitation in dementia are showing some promise. In older adults with schizophrenia, intramuscular ziprasidone was found to be effective, and evidence is emerging for the use of hormone replacement therapy. For depression with psychosis, a recent study found that the combination of an antidepressant with an antipsychotic is no more effective than an antidepressant alone.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">There is support for the use of antipsychotic drugs for all types of psychosis in the elderly. While the atypical antipsychotics have a 'black box warning' on risk of death in elderly patients with dementia, the typical antipsychotics carry an even higher risk of death and adverse effects. Weighing the potential risks and benefits of treatment options is essential. Please refer to your country's regulations regarding the use of antipsychotic drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Broadway</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Adult and Geriatric Psychiatry, Medical University of South Carolina, Charleston, SC 29425, USA. reynol@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17921754</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e3282f0f09d</ArticleId><ArticleId IdType="pii">00001504-200711000-00006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17914184</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1535-1084</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Neuromolecular medicine</Title><ISOAbbreviation>Neuromolecular Med</ISOAbbreviation></Journal><ArticleTitle>Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4.</ArticleTitle><Pagination><StartPage>264</StartPage><EndPage>269</EndPage><MedlinePgn>264-9</MedlinePgn></Pagination><Abstract><AbstractText>In addition to cognitive impairment, behavioral changes such as aggressive behavior, depression, and psychosis accompany Alzheimer's Disease. Such symptoms may arise due to imbalances in neurotransmitters rather than overt neurodegeneration. Herein, we demonstrate that combined administration of N-acetyl cysteine (an antioxidant and glutathione precursor that protects against A beta neurotoxicity), acetyl-L-carnitine (which raises ATP levels, protects mitochondria, and buffers A beta neurotoxicity), and S-adenosylmethionine (which facilitates glutathione usage and maintains acetylcholine levels) enhanced or maintain cognitive function, and attenuated or prevented aggression, in mouse models of aging and neurodegeneration. Enhancement of cognitive function was rapidly reversed upon withdrawal of the formulation and restored following additional rounds supplementation. Behavioral abnormalities correlated with a decline in acetylcholine, which was also prevented by this nutriceutical combination, suggesting that neurotransmitter imbalance may contribute to their manifestation. Treatment with this nutriceutical combination was able to compensate for lack of dietary folate and vitamin E, coupled with administration of dietary iron as a pro-oxidant (which collectively increase homocysteine and oxidative damage to brain tissue), indicating that it provided antioxidant neuroprotection. Maintenance of neurotransmitter levels and prevention of oxidative damage underscore the efficacy of a therapeutic approach that utilizes a combination of neuroprotective agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Cellular Neurobiology &amp; Neurodegeneration Research, University of Massachusetts Lowell, Lowell, MA 01854, USA. Thomas_shea@uml.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuromolecular Med</MedlineTA><NlmUniqueID>101135365</NlmUniqueID><ISSNLinking>1535-1084</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>6DH1W9VH8Q</RegistryNumber><NameOfSubstance UI="D000108">Acetylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LP2MPO46S</RegistryNumber><NameOfSubstance UI="D012436">S-Adenosylmethionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>WYQ7N0BPYC</RegistryNumber><NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuromolecular Med. 2008;10(1):46</RefSource><Note>Chan, Amy [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000108" MajorTopicYN="N">Acetylcarnitine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012436" MajorTopicYN="N">S-Adenosylmethionine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>1999</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17914184</ArticleId><ArticleId IdType="doi">10.1007/s12017-007-8005-y</ArticleId><ArticleId IdType="pii">NMM:9:3:264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain Res. 2006 Sep 13;1109(1):201-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16872586</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2000 Nov 10;883(1):31-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11063985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tidsskr Nor Laegeforen. 1998 Feb 10;118(4):560-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9520584</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Exp Clin Res. 1994;20(4):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7813389</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2006 Nov;27(11):1595-603</Citation><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 May;20(5):459-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15852444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2003;(2):CD003158</Citation><ArticleIdList><ArticleId IdType="pubmed">12804452</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1990 Sep-Oct;11(5):499-506</Citation><ArticleIdList><ArticleId IdType="pubmed">2234280</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurobiol Exp (Wars). 2005;65(3):277-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16130802</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Jul 15;17(14):5573-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9204938</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ter. 1990 Mar 31;132(6 Suppl):479-510</Citation><ArticleIdList><ArticleId IdType="pubmed">2140973</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2000 Feb;7(1):9-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10671319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Nov;62(11):894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">11775050</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Health Aging. 2006 Nov-Dec;10(6):541-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17183426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Dec;10(4):353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17183144</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2004;6(2-3):93-103</Citation><ArticleIdList><ArticleId IdType="pubmed">15970627</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2002 Jan 25;318(2):103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11796196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2005 Jan;28(1):195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">15607954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2001 Dec;3(6):525-529</Citation><ArticleIdList><ArticleId IdType="pubmed">12214018</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pharmacol Res. 1990;10(1-2):65-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2387664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrition. 2000 Jul-Aug;16(7-8):544-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10906550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2003;4(3):197-202</Citation><ArticleIdList><ArticleId IdType="pubmed">14716026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1327-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15314125</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Apr;19(4):359-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15065229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2003 Mar;84(5):1173-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12603840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutagenesis. 2004 Nov;19(6):469-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15548759</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1998 Jun 19;249(2-3):111-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9682829</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2002 Nov;76(5):1158S-61S</Citation><ArticleIdList><ArticleId IdType="pubmed">12420702</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neurosci. 1997 Nov;92(1-2):79-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9522258</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2005;43(3):442-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15707619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Health Aging. 2008 Apr;12(4):252-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18373034</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2006 Feb;27(2):285-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16399213</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2005 Nov 9;1061(2):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16256963</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Feb 15;45(4):422-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10071711</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2004 Jul;26(7):980-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15336465</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2002 Dec;14(4):389-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12670060</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2005 Sep;29(7):1140-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16111797</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2004 Nov;311(2):677-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15192085</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2002 Jun;27(6):501-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12199155</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29213421</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1980-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Dementia &amp; neuropsychologia</Title><ISOAbbreviation>Dement Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Profile of caregivers of Alzheimer's disease patients attended at a reference center for cognitive disorders.</ArticleTitle><Pagination><StartPage>412</StartPage><EndPage>417</EndPage><MedlinePgn>412-417</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1980-57642008DN10400015</ELocationID><Abstract><AbstractText Label="UNLABELLED">This is a study on burden of caregivers of patients with Alzheimer's disease attended at a Reference Center for Cognitive Disorders.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the profile and burden on caregivers of patients with Alzheimer's disease attended at a Reference Center for Cognitive Disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collected demographic information and data on the relationship with the patient from caregivers, and measured burden with the Zarit scale. The patients were evaluated with the following scales: the Cambridge Cognitive Test (CAMCOG); Mini Mental State Examination, the Neuropsychiatric Inventory for neuropsychiatry symptoms, and Functional Activities Questionnaire - FAQ for functional impairment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 31 caregivers, 77.4% were female, predominantly, and daughters, having a mean age of 58.6 years, educational level of 8.1 years, 70% of caregivers co-resided with the patient and 71% did not work. The mean time as a caregiver was 3 years. Twenty-seven percent of the caregivers presented mild to severe burden. The variables presenting significant association with caregiver burden were scores on the NPI and CAMCOG.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The social demographic characteristics of the sample were similar to those of studies performed in other countries. The average time as a caregiver and the frequency of caregivers with mild to intense burden were lower than those reported in international studies. Neuropsychiatric symptoms and severity of cognitive decline were the main factors associated to burden in this sample of mostly mild to moderate demented AD patients. Further studies are necessary to verify whether the burden is indeed less intense in our milieu.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moscoso</LastName><ForeName>Marco Antonio</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Rita de C&#xe1;ssia Gomes</ForeName><Initials>RCG</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiz</LastName><ForeName>Salma Rose Imanari</ForeName><Initials>SRI</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Lysandra</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Diana Moitinho</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob Filho</LastName><ForeName>Wilson</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitrini</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottino</LastName><ForeName>C&#xe1;ssio Machado de Campos</ForeName><Initials>CMC</Initials><AffiliationInfo><Affiliation>CEREDIC (Reference Center for Cognitive Disorders); Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PROTER (Old Age Research Group), Institute of Psychiatry - Clinicas Hospital of the School of Medicine of the University of S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Dement Neuropsychol</MedlineTA><NlmUniqueID>101506587</NlmUniqueID><ISSNLinking>1980-5764</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="UNLABELLED">Trata-se de um estudo sobre a sobrecarga do cuidador dos pacientes com doen&#xe7;a de Alzheimer atendidos em Centro de Refer&#xea;ncia em Dist&#xfa;rbios Cognitivos.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Avaliar o perfil e a sobrecarga do cuidador dos pacientes com doen&#xe7;a de Alzheimer atendidos em Centro de Refer&#xea;ncia em Dist&#xfa;rbios Cognitivos.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Foram obtidos dados demogr&#xe1;ficos do cuidador e sobrecarga de acordo com a Escala de Sobrecarga de Zarit. Os pacientes foram avaliados com os seguintes testes e escalas: Teste Cognitivo Cambridge (CAMCOG); Mini-Exame do Estado Mental; Invent&#xe1;rio Neuropsiqui&#xe1;trico (NPI), para a presen&#xe7;a de sintomas neuropsiqui&#xe1;tricos; e o Question&#xe1;rio de Atividades Funcionais (QAF), de Pfeffer, para o comprometimento funcional.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Os 31 cuidadores eram predominantemente do sexo feminino, filhas, idade m&#xe9;dia 58,6 anos, escolaridade m&#xe9;dia de 8,1 anos; 70% dos cuidadores moravam com o paciente; 71% n&#xe3;o trabalhavam. O tempo m&#xe9;dio como cuidador foi de 3 anos. Vinte e sete por cento dos cuidadores apresentavam sobrecarga de intensidade leve a intensa. As vari&#xe1;veis que apresentaram associa&#xe7;&#xe3;o significativa com a sobrecarga do cuidador foram os escores do NPI e do CAMCOG.</AbstractText><AbstractText Label="CONCLUS&#xc3;O" NlmCategory="UNASSIGNED">As caracter&#xed;sticas sociodemogr&#xe1;ficas dos cuidadores foram semelhantes &#xe0;s de estudos feitos em outros pa&#xed;ses. Entretanto, sobrecarga foi menos freq&#xfc;ente do que em estudos internacionais. A intensidade dos transtornos neuropsiqui&#xe1;tricos e a gravidade do decl&#xed;nio cognitivo foram os principais fatores associados &#xe0; sobrecarga nesta amostra constitu&#xed;da principalmente por pacientes com DA, com dem&#xea;ncia leve a moderada. Mais estudos s&#xe3;o necess&#xe1;rios para verificar se a sobrecarga do cuidador &#xe9; menos intensa em nosso meio.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Zarit scale</Keyword><Keyword MajorTopicYN="N">behavioral symptoms</Keyword><Keyword MajorTopicYN="N">burden</Keyword><Keyword MajorTopicYN="N">caregivers</Keyword><Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword><Keyword MajorTopicYN="N">psychotic symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29213421</ArticleId><ArticleId IdType="pmc">PMC5619439</ArticleId><ArticleId IdType="doi">10.1590/S1980-57642008DN10400015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paleo Diaz N, Rodr&#xed;guez Paleo L. Por qu&#xe9; cuidar a los cuidadores de pacientes con enfermedad de
Alzheimer? 2005;7:13&#x2013;17. www.geriatrianet.com</Citation></Reference><Reference><Citation>Badia LX, Suri&#xf1;ach LN, Gamisans RM. Calidad de vida, tiempo de dedicaci&#xf3;n y carga percibida por el cuidador principal informal del enfermo de Alzheimer. Aten Primaria. 2004;34:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668642</ArticleId><ArticleId IdType="pubmed">15388064</ArticleId></ArticleIdList></Reference><Reference><Citation>George LK, Gwyther LP. Caregiver well-being: a multidimensional examination of family caregivers of demented adults. Gerontology. 1986;26:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">3721232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongomery RJV, Hooyman NR. Caregiving and the experience of subjective burden. Fam Relations. 1985;1:151&#x2013;158.</Citation></Reference><Reference><Citation>Cochrane JJ, Goering PN, Rogers JM. The mental health of informal caregivers in Otario: an epidemiological survey. Am J Public Health. 1997;87:2002&#x2013;2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1381244</ArticleId><ArticleId IdType="pubmed">9431291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez MI, Carrasco MA, Garc&#xed;a MM, Guti&#xe9;rrez Cuadra P, Gonzalo Jim&#xe9;nez E, L&#xf3;pez Fernandez LA. Cuidadores familiares de personas com enfermedad neurodegenerativa: perfil, aportaciones e impacto de cuidar. Aten Primaria. 2000;26:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683965</ArticleId><ArticleId IdType="pubmed">10996945</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco MM, Ballesteros RJ, Ibarra GN, et al. Sobrecarga del cuidador de pacientes com enfermedad de Alzheimer y distr&#xe9;s ps&#xed;quico. Uma asociaci&#xf3;n relegada em la valoraci&#xf3;n de las dem&#xea;ncias. Actas Esp Psiquiatr. 2002;30:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12217268</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso BA, Garrido BA, Diaz PA, Casquero RR, Riera PM. Perfil y sobrecarga de los cuidadores de pacientes com demencia incluidos em el programa ALOIS. Aten Primaria. 2004;33:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668908</ArticleId><ArticleId IdType="pubmed">14967121</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez TMJ, Abanto AJ, Labarta MJ. El s&#xed;ndrome del cuidador en los procesos com deterioro cognoscitivo (dem&#xea;ncia) Aten Primaria. 1996;18:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">8963001</ArticleId></ArticleIdList></Reference><Reference><Citation>Megido MJ, Espinas J, Carrasco RM, Copetti S, Caball&#xe9; E. La atencion de los cuidadores del paciente com dem&#xea;ncia. Aten Primaria. 1999;23:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">10394696</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez MJ. Efectos positivos de um estresor cr&#xf4;nico. El cuidador de un enfermo con demencia.Congreso Virtual. Interpsiquis. III. Universidad de Madrid. Facultad de psicologia; Espana: 2000.</Citation></Reference><Reference><Citation>D&#xed;ez Espino J, Redondo Valdivielso ML, Arroniz Fern&#xe1;ndez de Gaceo C, Giacchi Urzainqui A, Zabal C, Salaberri Nieto A. Malestar ps&#xed;quico em cuidadores familiares de personas confinadas em su domicilio. MEDIFAM. 1995;3:124&#x2013;130.</Citation></Reference><Reference><Citation>Vitaliano PP, Russo J, Young HM, Teri L, Maiuro RD. Predictors of burden in spouse caregivers of individuals with Alzheimer's disease. Psychol Aging. 1991;6:392&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">1930756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feeling of burden. Gerontologist. 1980;20:649&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Scazufca M. Vers&#xe3;o brasileira da escala Burden Interview para avalia&#xe7;&#xe3;o de sobrecarga em cuidadores de indiv&#xed;duos com doen&#xe7;as mentais. Rev Bras Psiquiatr. 2002;24:12&#x2013;17.</Citation></Reference><Reference><Citation>Garrido R, Menezes PR. Impacto em cuidadores de idosos com dem&#xea;ncia atendidos em um servi&#xe7;o psicogeri&#xe1;trico. Rev Sa&#xfa;de P&#xfa;blica. 2004;38:835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608902</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-IV) Fourth ed . Washington (DC): American Psychiatric Association; 1994. pp. 143&#x2013;147.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth M, Tym E, Mountjoy CO, et al. CAMDEX: a standardized instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia. Br J Psychiatry. 1986;149:698&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">3790869</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filis S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz PN, Rodriguez PL. Por que cuidar a los cuidadores de pacientes con enfermedad de
Alzheimer. 2005;7:1&#x2013;9. www.geriatrianet.com</Citation></Reference><Reference><Citation>Schultz R, Willianson GM. A 2-year longitudinal study of depression among Alzheimer caregivers. Psychol Aging. 1991;6:569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">1777145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin ED, HAUT MW, Keefover RW. Clinical assessment of family caregivers in dementia. Gerontologist. 1992;32:813&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">1478501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou KR, Lamontagne LL, Hepworth JT. Burden experienced by caregivers of relatives with dementia in Taiwan. Nur Res. 1999;48:206&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10414683</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallicchio L, Siddiqui N, Langenberg P. Gender differences in burden and depression among informal caregivers of demented elders in the community. Int J Geriatr Psychiatry. 2002;17:154&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton L, Haan M, Geller S, Mungas Neurosychiatric Symptoms in latino Elders with Dementia or cognitive Impairment without Dementia and factors that modify their association with caregiver depression. Gerontologist. 2003;43:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570963</ArticleId></ArticleIdList></Reference><Reference><Citation>Schene AH. Objective and subjective dimensions of family burden: towards an integrative framework for research. Soc Psychiatry Psychiatr Epidemiol. 1990;25:289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">2291131</ArticleId></ArticleIdList></Reference><Reference><Citation>Croog SH, Sudilovsky A, Burelenson J, Baurne RB. Vulnerability of husband and wife caregivers of Alzheimer disease patients to caregiving stressors. Alzheimer Dis Assoc Disord. 2001;4:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11723371</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody EM, Litvin SJ, Hoffman C. Marital status of caregiving daughters and co- residence with dependent parents. Gerontologist. 1995;25:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19595959</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Clinical practice guidelines for severe Alzheimer's disease.</ArticleTitle><Pagination><StartPage>385</StartPage><EndPage>397</EndPage><MedlinePgn>385-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2007.07.007</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although severe Alzheimer's disease (AD) represents a prevalent, serious, and costly public health problem, few practice guidelines exist to help physicians manage this disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search of English language medical databases was performed from 1996 to the present for articles pertaining to the management of AD. The focus of this review was on studies that included patients with severe disease. Studies were assessed by considering the subjects, trial design, analysis, and results. Recommendations were based on the best available evidence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Severe AD can be defined and diagnosed reliably by using measures of cognition, function, behavior, and global staging. Specific assessments would also include medical status, safety issues, and the health status of the caregiver. Disease-specific management would include treatment with cholinesterase inhibitors and/or memantine. Treatment of neuropsychiatric symptoms begins with nonpharmacologic behavioral and environmental approaches. Severe agitation, aggression, and psychosis that are potentially dangerous to the patient, caregiver, and others in the environment can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular adverse events and mortality. All pharmacologic approaches require careful monitoring and regular periodic reassessments to determine whether ongoing treatment is necessary.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Evidence-based guidelines for the management of severe AD have the potential to improve the quality of life for the patient and their caregiver. More randomized controlled trials aimed specifically at this phase of illness are still urgently required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. n.herrmann@utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lysy</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19595959</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2007.07.007</ArticleId><ArticleId IdType="pii">S1552-5260(07)00552-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17896234</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0954-0261</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International review of psychiatry (Abingdon, England)</Title><ISOAbbreviation>Int Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain imaging research: does the science serve clinical practice?</ArticleTitle><Pagination><StartPage>541</StartPage><EndPage>558</EndPage><MedlinePgn>541-58</MedlinePgn></Pagination><Abstract><AbstractText>Brain imaging represents a potent tool to characterize biomarkers, biological traits that are pathognomonic for specific neurological and neuropsychiatric disorders. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are imaging techniques used to identify alterations in the density and distribution of neurotransmitters, neuroreceptors, and transporters in specific regions of the brains of people with these disorders. Brain imaging research currently facilitates the elucidation of dysfunction of dopamine, serotonin, acetylcholine, and other substances in people with Alzheimer's and Parkinson's diseases, schizophrenia, alcoholism and other substance abuse disorders, attention deficit/hyperactivity disorder, and the syndromes of restless legs, Lesch-Nyhan, Rett, and Tourette. Thus, brain imaging research offers great potential for the diagnosis, treatment, prevention, and cure of neurological and neuropsychiatric disorders. Brain imaging research also facilitates new drug development and helps establish therapeutic doses of novel drugs. In particular, studies of specific receptors, such as the dopamine D2 receptor, before and after the administration of doses of drugs that occupy these D2 receptors, provide the means to determine receptor occupancy. For example, an optimal dose of D2 antagonist antipsychotics produces occupancy of 65% to 80% of D2 receptors, while a greater dose carries a risk of extrapyramidal side effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Dean F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0807, USA. dfwong@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;nder</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Brasic</LastName><ForeName>James Robert</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR017219</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA12839</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS38927</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24DA00412</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH078175</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DA000412</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DA11080</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD24448</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DA000412-09</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR11996</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Psychiatry</MedlineTA><NlmUniqueID>8918131</NlmUniqueID><ISSNLinking>0954-0261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030342" MajorTopicYN="N">Genetic Diseases, Inborn</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012586" MajorTopicYN="N">Science</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>106</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17896234</ArticleId><ArticleId IdType="doi">10.1080/09540260701564849</ArticleId><ArticleId IdType="pii">782454861</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17896233</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0954-0261</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International review of psychiatry (Abingdon, England)</Title><ISOAbbreviation>Int Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical trials: bridging the gap between efficacy and effectiveness.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>539</EndPage><MedlinePgn>531-9</MedlinePgn></Pagination><Abstract><AbstractText>The need for clinical psychiatry research to provide practical information to clinicians, families, and consumers has led to the development of new approaches to clinical trials. Efficacy trials, the historical backbone of clinical research, have many shortcomings in delivering practical information to stakeholders. The 'effectiveness' or 'public-health' model of intervention research targets a diverse group of patients across multiple settings that are outside of academic medical centres, with study design and outcomes that are selected on the basis of their potential to produce clinically meaningful information. The National Institute of Mental Health has funded three such clinical trials in recent years, respectively targeting schizophrenia and Alzheimer's disease, depression, and bipolar disorder. Each of these studies has made a major impact, and provided new insights into the challenges of public health orientated trials in psychiatry. In this review, we describe the underlying principles and practical considerations in efficacy and effectiveness-orientated trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Depp</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, California 92161, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH64722</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH66248</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Psychiatry</MedlineTA><NlmUniqueID>8918131</NlmUniqueID><ISSNLinking>0954-0261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003256" MajorTopicYN="N">Community Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009315" MajorTopicYN="N">National Institute of Mental Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012109" MajorTopicYN="N">Research Support as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17896233</ArticleId><ArticleId IdType="doi">10.1080/09540260701563320</ArticleId><ArticleId IdType="pii">782450431</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17890863</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Relationship between behavioural and psychological symptoms of dementia and cognition in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>347</EndPage><MedlinePgn>343-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behavioural and psychological symptoms of dementia (BPSDs) are common. It is unclear whether associations are stronger with the absolute cognitive level or that relative to premorbid mental ability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Neuropsychiatric Inventory (NPI) was administered to carers of patients with Alzheimer's disease (AD). Patients underwent cognitive testing with the National Adult Reading Test (NART) to estimate premorbid IQ and 6 tests of current cognitive function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">556 patients, mean age 77.3 years, had NPI scores. The total NPI score correlated significantly with most cognitive test scores, but multi-linear regression identified NART-IQ as the only significant cognitive predictor (beta=-0.17, p=0.008). Principal component analysis of the 10 NPI domains extracted 3 components corresponding to mood, frontal and psychotic factors. The NPI mood factor correlated significantly with NART-IQ (rho=-0.14, p=0.014) and lexical verbal fluency (rho=-0.09, p=0.034) only. The NPI frontal factor correlation with NART-IQ approached significance (rho=-0.11, p=0.053). The NPI psychotic factor correlated significantly with the Mini-Mental State Examination (rho=-0.15, p&lt;0.001) and the Hopkins verbal learning test (rho=-0.11, p=0.013) scores.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The relationship between BPSDs and cognition in AD is weak and largely explained by premorbid IQ. There is a stronger relationship between current cognition and psychotic symptoms.</AbstractText><CopyrightInformation>Copyright (c) 2007 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Geriatric Medicine Unit, Royal Victoria Hospital, Edinburgh, UK. John.Starr@ed.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonie</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17890863</ArticleId><ArticleId IdType="doi">10.1159/000108632</ArticleId><ArticleId IdType="pii">000108632</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17879256</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>400</EndPage><MedlinePgn>393-400</MedlinePgn></Pagination><Abstract><AbstractText Label="SETTING" NlmCategory="METHODS">Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events with newer atypical agents. Quetiapine is an atypical antipsychotic agent that warrants further investigation.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess tolerability, safety, and clinical benefit of quetiapine in AD patients with BPSD.</AbstractText><AbstractText Label="PARTICIPANTS AND DESIGN" NlmCategory="METHODS">AD patients with BPSD participated in a 6-week randomized, double-blind, placebo-controlled trial. Quetiapine was increased on the basis of clinical response and tolerability. Primary efficacy assessments included the Neuropsychiatric Inventory (NPI) and Clinical Global Impression of Change (CGI-C). Secondary efficacy measures included the Mini-Mental State Examination (MMSE), the Simpson-Angus Scale (SAS) and the Abnormal Involuntary Movement Scale (AIMS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty patients (26 women), mean age 82.2 (SD 6.4) years were enrolled, 27 completed treatment. Median dose of quetiapine was 200 mg/day. Significant NPI total scores reductions (79% for placebo and 68.5% for quetiapine) were observed. The CGI-C score decreased significantly in the quetiapine group (p = 0.009 at 6 weeks) and did not change significantly in the placebo group (p = 0.48). The MMSE, AIMS, SAS scores and adverse events did not differ significantly between the two arms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Quetiapine did not significantly improve psychosis scores. It did not cause cognitive and motor deterioration. These results might possibly be due to small sample size.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paleacu</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Service and Memory Clinic, Abarbanel Mental Health Center, Bat-Yam, Israel. paleacu@post.tau.ac.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barak</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mirecky</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mazeh</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17879256</ArticleId><ArticleId IdType="doi">10.1002/gps.1892</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17851196</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Genetics of Alzheimer's disease. A rapidly evolving field.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>92</EndPage><MedlinePgn>73-92</MedlinePgn></Pagination><Abstract><AbstractText>Genetic factors have a variable impact on Alzheimer's Disease (AD), ranging from familial forms that are transmitted in an autosomal dominant fashion to sporadic AD, where a polygenic component is present. Most genes conferring susceptibility to AD are related to amyloid-beta deposition (APP; PS1; PS2; APOE; Cystatin-C; ubiquilin-1), oxidative stress (NOS2; NOS3) and inflammatory response (IL-1 alpha; IL-1 beta; IL-6; TNF-alpha). Genome-wide analyses, transcriptomics and proteomics approaches have pointed also to proapoptotic genes as increasing AD liability. Depression and psychotic symptoms that occur in a large proportion of AD patients have been associated with monoamine genes coding for metabolic enzymes (COMT), transporters (5-HTTLPR) and receptors (DRD1; DRD3). Genetic testing may be useful to confirm the diagnosis of AD in individuals with clinical signs of dementia, while it is generally not recommended as a predictive testing for AD in asymptomatic individuals. Drugs currently in use to treat AD are effective in only 20% of patients; their therapeutic effect is predominantly under genetic control (CYP26 gene; APOE). Environmental factors have been shown to moderate the effects of genes on psychiatric disorders such as depression, schizophrenia and ADHD. The study of gene-environment interactions in AD, that are still poorly understood, is essential to predict disease-risk in asymptomatic individuals. Genomics will provide a dynamic picture of biological processes in AD and new targets for the forthcoming anti-AD drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Bologna, Italy. alessandro.serretti@unibo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olgiati</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Ronchi</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525030">CST3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015891">Cystatins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="N">Cystatin C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015891" MajorTopicYN="N">Cystatins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>296</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17851196</ArticleId><ArticleId IdType="doi">10.3233/jad-2007-12108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17691947</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0929-8673</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>19</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Current medicinal chemistry</Title><ISOAbbreviation>Curr Med Chem</ISOAbbreviation></Journal><ArticleTitle>HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies.</ArticleTitle><Pagination><StartPage>2053</StartPage><EndPage>2069</EndPage><MedlinePgn>2053-69</MedlinePgn></Pagination><Abstract><AbstractText>Variants at the gene encoding for the 5-hydrosytryptamine (serotonin) receptor 2A (HTR2A) have been associated with many psychiatric disorders such as schizophrenia, mood disorders, attention deficit hyperactivity disorder, suicide, anxiety disorders, obsessive-compulsive disorder, eating disorders, and Alzheimer's disease. The studied SNPs differ across studies, in the present review we focused on available evidence with the aim of identifying the overall phenotypic profile of HTR2A variant carriers. We then extensively analyzed all SNPs of the HTR2A gene with criteria of frequency, haplotype blocks, previous evidence, functionality in order to obtain a list of suitable SNPs for future studies that properly cover all possible genetic control of the HTR2A gene. Genetic association studies report conflicting and generally negative results. Most replicated data suggest C allele of the 102 T/C and Tyr452 variants as risk factor for psychosis and antipsychotic response, but the number of not replicating studies does not allow to draw any definite conclusion. Moreover their impact as risk factors is very small. In the other investigated psychiatric fields, evidence shows no involvement or at least a small and not replicated role for HTR2A gene variants. Conflicting and negative results could be due to a real marginal role of this receptor gene variants, or it could be caused by a lack of gene coverage of investigated SNPs. We suggest a wider investigation of the HTR2A gene to better understand its role in psychiatric disorders, preferably complemented with the use of proteomic or metabolomic approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Bologna, Italy. alessandro.serretti@unibo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drago</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>De Ronchi</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Med Chem</MedlineTA><NlmUniqueID>9440157</NlmUniqueID><ISSNLinking>0929-8673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>256</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17691947</ArticleId><ArticleId IdType="doi">10.2174/092986707781368450</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17691220</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1400</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Acta neurobiologiae experimentalis</Title><ISOAbbreviation>Acta Neurobiol Exp (Wars)</ISOAbbreviation></Journal><ArticleTitle>Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>139</EndPage><MedlinePgn>131-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55782/ane-2007-1640</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1640</ELocationID><Abstract><AbstractText>Cholinesterase inhibitors are currently the mainstream of symptomatic treatment of patients with Alzheimer's disease. The response to treatment with cholinesterase inhibitors is clinically difficult to predict. Several demographic, clinical and biological variables have been proposed as pretreatment predictors of long-term therapy efficacy. In this paper, consistently with previous reports, we confirm that higher initial disease severity and faster progression of cognitive impairment increase the chance of a clinically meaningful response to cholinesterase inhibitor therapy in a carefully selected population of patients with Alzheimer's disease. Moreover, for the first time we demonstrate the association between the increase in the concentration of plasma Abeta(1-42) peptide after 2 weeks of treatment with an initial dose of rivastigmine and the likelihood of a positive response to treatment after 6 months. A change in plasma Abeta(1-42) level might constitute a novel biochemical predictor of rivastigmine treatment efficacy in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland. tmsobow@csk.umed.lodz.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kloszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Acta Neurobiol Exp (Wars)</MedlineTA><NlmUniqueID>1246675</NlmUniqueID><ISSNLinking>0065-1400</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17691220</ArticleId><ArticleId IdType="doi">10.55782/ane-2007-1640</ArticleId><ArticleId IdType="pii">1640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17690552</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients.</ArticleTitle><Pagination><StartPage>201</StartPage><EndPage>206</EndPage><MedlinePgn>201-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Alzheimer disease (AD) patients commonly suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in AD has been demonstrated. This is an investigation of whether the linked polymorphic region and variable number tandem repeat variants of the serotonin transporter (SERT) are associated with BPSD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The longitudinal measures of BPSD of our large cohort of 367 AD patients were assessed by the Neuropsychiatric Inventory. Measures with good evidence of serotonergic involvement (delusions, hallucinations, depression, anxiety, agitation/aggression and irritability) were related to genotype and allele frequencies of the linked polymorphic region and variable number tandem repeat variants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis revealed significant relationships between the linked polymorphic region variant long allele with irritability and the variable number tandem repeat 10-repeat allele with psychosis, but no associations were found with depression, anxiety or agitation/aggression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data and review of previous studies suggest SERT could play a minor role in development of psychosis and aggressive/irritable tendencies; however, further investigations are required in large, well-characterized cohorts.</AbstractText><CopyrightInformation>2007 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Antonia L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Molecular Psychiatry Group, Queensland Institute of Medical Research, Herston, Brisbane, Australia. Antonia.Pritchard@qimr.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018598" MajorTopicYN="N">Minisatellite Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17690552</ArticleId><ArticleId IdType="doi">10.1159/000107081</ArticleId><ArticleId IdType="pii">000107081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17663455</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0887-4476</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Synapse (New York, N.Y.)</Title><ISOAbbreviation>Synapse</ISOAbbreviation></Journal><ArticleTitle>Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.</ArticleTitle><Pagination><StartPage>903</StartPage><EndPage>911</EndPage><MedlinePgn>903-11</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies (DLB) is a progressive dementia frequently accompanied by psychotic symptoms. Similar symptoms can occur in Alzheimer's disease (AD) to a lesser extent. The use of neuroleptic medication to treat psychosis in both diseases is of modest efficacy and can induce severe adverse reactions in DLB. Dopamine D2 receptors in the cerebral cortex are the putative target for the antipsychotic action of these drugs, but the status of these receptors in DLB is unknown. Autoradiography was used to examine the density D2 receptors in postmortem temporal cortex tissue from prospectively assessed patients with neuropathologically confirmed DLB and AD. D2 receptors were substantially (over 40%) and significantly (P &lt; 0.001) reduced in temporal cortex in DLB, and in DLB with concomitant Alzheimer pathology, but was not significantly changed in AD. This reduction correlated with greater cognitive decline (P &lt; 0.01), but was not significantly related to visual or auditory hallucinations or delusions. D2 receptor density was inversely correlated with cortical Lewy body pathology in the neocortex (P &lt; 0.001). The specific loss of D2 receptors associated with Lewy body pathology, in conjunction with our previous finding of low D2 receptors in striatum in DLB, provides a possible explanation for neuroleptic intolerance. That the reduction of D2 receptors correlated with cognitive decline suggests that neuroleptics, as dopamine D2 receptor antagonists, may have a deleterious effect on cognition in DLB.</AbstractText><CopyrightInformation>(c) 2007 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piggott</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle-upon-Tyne NE4 6BE, United Kingdom. m.a.piggott@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Jaros</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Elaine K</ForeName><Initials>EK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Synapse</MedlineTA><NlmUniqueID>8806914</NlmUniqueID><ISSNLinking>0887-4476</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007456">Iodine Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>107188-87-4</RegistryNumber><NameOfSubstance UI="C063525">epidepride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007456" MajorTopicYN="N">Iodine Isotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17663455</ArticleId><ArticleId IdType="doi">10.1002/syn.20441</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17659476</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1472-4472</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current opinion in investigational drugs (London, England : 2000)</Title><ISOAbbreviation>Curr Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>569</EndPage><MedlinePgn>563-9</MedlinePgn></Pagination><Abstract><AbstractText>Corcept Therapeutics Inc is developing mifepristone (as C-1073, Corlux), an orally available progesterone and glucocorticoid antagonist originally launched as an abortifacient by Aventis Pharma AG, for the potential treatment of the psychotic features of psychotic major depression (PMD) and for Alzheimer's disease (AD). In August 2004, a pivotal phase III trial was initiated in the US for psychotic features of PMD, a second trial began in October 2004 and these were followed by a European phase III trial in May 2005. However, in August 2006, September 2006 and March 2007, respectively, these phase III trials failed to meet their endpoints. A further phase III trial was to commence later in 2007. By August 2006, Corcept expected to file an NDA for PMD in 2007. In addition, in March 2005 a phase II study of mifepristone as a cognitive enhancer in AD was underway, and in May 2006 a proof-of-concept study in alleviating the weight gain associated with olanzapine had begun.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nihalani</LastName><ForeName>Nikhil D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>State University of New York, Upstate Medical University, Department of Psychiatry, Syracuse, New York, NY 13210-2375, USA. nihalann@upstate.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Investig Drugs</MedlineTA><NlmUniqueID>100965718</NlmUniqueID><ISSNLinking>1472-4472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006727">Hormone Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>320T6RNW1F</RegistryNumber><NameOfSubstance UI="D015735">Mifepristone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006727" MajorTopicYN="N">Hormone Antagonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015735" MajorTopicYN="N">Mifepristone</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>68</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17659476</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17633594</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1086-5462</ISSN><JournalIssue CitedMedium="Print"><Volume>90</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Medicine and health, Rhode Island</Title><ISOAbbreviation>Med Health R I</ISOAbbreviation></Journal><ArticleTitle>Atypical antipsychotics for the treatment of dementia-related behaviors: an update.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>194</EndPage><MedlinePgn>191-4</MedlinePgn></Pagination><Abstract><AbstractText>Atypical antipsychotics will continue to be prescribed for the behavioral symptoms of dementia in the absence of more effective, better tolerated, and safer alternatives. The evidence base, although incomplete, suggests that modest treatment effect sizes are offset by risk of considerable adverse effects. How might this information be best applied to clinical practice? Non-pharmacologic strategies should be implemented in routine clinical practice. Placebo-controlled clinical trials of individual antipsychotic agents have historically reported high placebo response rates; CATIE-AD reported that the sum total of the risk/benefit equation of atypical antipsychotic therapy was no greater than that achieved by placebo. CATIE-AD was designed to study the effectiveness of atypical antipsychotic treatment in community dwelling patients with AD. It is uncertain whether the results can be generalized to the populations of dementia patients residing in nursing homes with more severe cognitive and behavioral impairment. There is some suggestion that nursing home patients with dementia complicated by severe behavioral symptoms, particularly agitation and aggression without accompanying psychosis, might achieve greater benefit from atypical antipsychotic treatment than patients with milder behavioral symptoms. The finding that dementia patients without psychosis may respond more robustly to antipsychotic treatment seems counterintuitive, but may support the hypothesis that the neurobiology of the "psychosis of AD" differs from the psychosis of schizophrenia or bipolar disease. Adverse effects associated with antipsychotic therapy should be aggressively monitored throughout therapy. Treatment-emergent sedation was associated with all of the atypical antipsychotics in CATIE-AD and is probably an important mediator of mortality risk in patients with dementia. Sedation exacerbates pre-existing cognitive impairment and increases the risk of complications such as aspiration pneumonia, so concomitant use of benzodiazepines should be discouraged or limited to short periods with careful observation.' Once initiated, the effectiveness and tolerability of antipsychotic therapy should be evaluated routinely. In Alzheimer's disease, the severity and frequency of behavioral symptoms often decreases as illness progresses. In a stable patient, it is prudent to attempt to taper and discontinue the antipsychotic after 2-8 months of therapy. Better understanding of the potential adverse effects of antipsychotic therapy has increased interest in the effects of the dementia-specific medications on behavioral symptoms. Reductions in neuropsychiatric symptoms have been reported from trials of individual cholinesterase inhibitors, memantine monotherapy, and memantine combined with donepezil in AD patients. Studies of small numbers of patients in open trials of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and one double-blind placebo controlled trial (rivastigmine) have reported varying degrees of improvement of behavioral symptoms and psychosis of dementia with Lewy bodies (DLB). Delusions, hallucinations, apathy, and agitation/aggression are cited as the symptom categories most likely to show significant improvement. Since few of these studies were prospectively designed to study behavioral symptoms, results must be interpreted cautiously. Treatment of behavioral symptoms in AD and other dementias is challenging. The limitations of current approaches drive the search for effective, well tolerated therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daiello</LastName><ForeName>Lori A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>The Warren Alpert Medical School of Brown University, USA. ldaiello@lifespan.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Health R I</MedlineTA><NlmUniqueID>9603446</NlmUniqueID><ISSNLinking>1086-5462</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17633594</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17627490</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1567-2050</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>335</EndPage><MedlinePgn>325-35</MedlinePgn></Pagination><Abstract><AbstractText>CATIE-AD was a multicenter effectiveness trial of atypical antipsychotics in patients with agitation and psychosis associated with AD who resided in the community. The study enrolled 421 participants. In this paper we present and discuss baseline characteristics of participants (demographics, cognitive, behavioral, and functional assessments), caregivers (demographics and caregiver burden) and settings at randomization. Those enrolled suffered from a wide range of cognitive impairment, were medically complex and experienced acute psychopathology requiring intervention with atypical antipsychotics. Family members providing the equivalent of institutional care experienced significant depression and caregiver burden. With the increasing prevalence of AD, clinicians and health care planners should look into future needs of those AD sufferers who are residing in community.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>University of Rochester Medical Center, Program in Neurobehavioral Therapeutics, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA. saleem_ismail@urmc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Abbott</LastName><ForeName>Shana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kavanagh</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009315" MajorTopicYN="N">National Institute of Mental Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17627490</ArticleId><ArticleId IdType="doi">10.2174/156720507781077214</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17614196</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>422</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>231</EndPage><MedlinePgn>228-31</MedlinePgn></Pagination><Abstract><AbstractText>Psychiatric disorders are common in Parkinson's disease (PD) and hallucinations are observed in nearly 40% of PD patients. The involvement of dopaminergic system in the pathogenesis of psychosis has been sustained by most of the authors even if several evidences indicate that multiple neurochemical substrates might underlie psychosis in PD. In PD there is an extensive loss of serotoninergic raphe neurons and serotonin dysfunction had been implicated in the pathogenesis of many psychiatric disorders such as depression, schizophrenia, and in psychosis of patients with Alzheimer disease. The association of a serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the 5-HT2A receptor T102C polymorphism with psychosis in a group of patients with PD was investigated. No significant differences in the distribution of allele and genotype frequencies of the 5-HTTLPR (p&gt;0.01) and 5-HT2A T102C (p&gt;0.05) were found between patients and controls as well as between the patients' subgroups without and with psychosis. These data might suggest that 5-HTTLPR and 5-HT2A polymorphisms are not major susceptibility factors of psychotic symptoms in PD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiferle</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Pisa, via Roma 67, 56127 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceravolo</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Petrozzi</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Frosini</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044348">Receptors, Serotonin, 5-HT2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044348" MajorTopicYN="N">Receptors, Serotonin, 5-HT2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17614196</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2007.06.028</ArticleId><ArticleId IdType="pii">S0304-3940(07)00731-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17606529</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Season>Jun-Jul</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Associations between AQT processing speed and neuropsychological tests in neuropsychiatric patients.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>210</EndPage><MedlinePgn>202-10</MedlinePgn></Pagination><Abstract><AbstractText>Associations between A Quick Test of Cognitive Speed (AQT) perceptual and cognitive speed and neuropsychological tests, including the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III), Mini Mental State Examination (MMSE), and the Trail Making Test (TMT), were evaluated in 41 neuropsychiatric patients. Neuropsychological and neurological tests, including CT scan, were administered to all of the patients. AQT was also administered to 75 controls. All AQT means differed significantly for patients and controls. Dual-dimension naming time means in the patient group were in the atypical range and indicated generally reduced cognitive speed, whereas controls performed in the normal range. In the patient group, WAIS-III verbal, performance, and full-scale IQ means were in the normal range. AQT perceptual and cognitive speed correlated negatively with WAIS-III P IQ and MMSE scores, and the relationships were nonlinear. The findings support that AQT dual-dimension naming evaluates cognitive speed (i.e., attention, set shifting, working memory) and can be used for first-line or complementary screening for mild or progressive cognitive impairments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Niels Peter</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hvidovre Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringstr&#xf6;m</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wiig</LastName><ForeName>Elisabeth H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17606529</ArticleId><ArticleId IdType="pmc">PMC10846251</ArticleId><ArticleId IdType="doi">10.1177/1089253206300417</ArticleId><ArticleId IdType="pii">22/3/202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiig EH , Nielsen NP , Minthon L. , Warkentin S. A Quick Test of Cognitive Speed (AQT). San Antonio, Tx: : Harcourt Assessment/PsychCorp; 2002.</Citation></Reference><Reference><Citation>Wiig EH , Nielsen NP , Minthon L. , Warkentin S. AQT: Assessment of parietal function. Svensk Version &amp; Norsk Versjon. Stockholm: Psykologif&#xf6;rlaget AB; ; 2003.</Citation></Reference><Reference><Citation>Reitan RM , Wolfson D. Category test and trail making test as measures of frontal lobe functions . Clin Neuropsychol. 1995;9: 50-56 .</Citation></Reference><Reference><Citation>Stroop JR Studies of interference in serial verbal reactions . Psychol Monogr. 1935;50: 38-48 .</Citation></Reference><Reference><Citation>Salthouse TA The processing speed theory of adult age differences in cognition . Psychol Rev. 1996;103: 403-428 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8759042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson JM , Nielsen NP , Minthon L. , Warkentin S. , Wiig EH Multiple rapid automatic naming measures of cognition: Normal performance and effects of aging . Percept Mot Skills. 2004;98: 739-753 .</Citation><ArticleIdList><ArticleId IdType="pubmed">15209286</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzer R. , Stern Y. , Rakitin BC Predicting age-related dual-task effects with individual differences on neuropsychological tests . Neuropsychologia. 2005;19: 18-27 .</Citation><ArticleIdList><ArticleId IdType="pubmed">15656759</ArticleId></ArticleIdList></Reference><Reference><Citation>Londos E. , Warkentin S. , Minthon L. &#x201c; AQT&#x201d;&#x2014;a measure of cognitive speed&#x2014;is a useful tool in the diagnosis of dementia with Lewy bodies . Int Psychogeriatr . 2005;17: 151 .</Citation></Reference><Reference><Citation>Nielsen NP , Wiig EH , Warkentin S. , Minthon L. Clinical utility of color-form naming in Alzheimer's disease: Preliminary evidence . Percept Mot Skills. 2004;99: 1201-1204 .</Citation><ArticleIdList><ArticleId IdType="pubmed">15739845</ArticleId></ArticleIdList></Reference><Reference><Citation>Vendrell P. , Junque C. , Pujol J. , Jurado MA , Molet J. , Grafman J. The role of prefrontal regions in the Stroop task . Neuropsychologia. 1995;33: 341-352 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7792000</ArticleId></ArticleIdList></Reference><Reference><Citation>Warkentin S. , Tsantali E. , Kiosseoglou G. , et al. (2005. June). The AQT as a useful short screening test for dementia. Evidence from two European cultures . Int Psychogeriatr. 2005;17: 160 .</Citation></Reference><Reference><Citation>Warkentin S. , Nielsen NP , Erikson C. , Minthon L. , Wiig EH Brain imaging validation of a screening test for cognitive speed . Presented at: Alzheimer's Association International Conference on Prevention of Dementia, Washington, DC, September 2005.</Citation></Reference><Reference><Citation>Downing PE Interactions between working memory and selective attention . Psych Sci. 2000;11: 467&#x2014;473 .</Citation><ArticleIdList><ArticleId IdType="pubmed">11202491</ArticleId></ArticleIdList></Reference><Reference><Citation>de Fockert JW , Rees G. , Rith CD , Lavie N. The role of working memory in selective visual attention . Science. 2001;291: 1803-1806 .</Citation><ArticleIdList><ArticleId IdType="pubmed">11230699</ArticleId></ArticleIdList></Reference><Reference><Citation>Furey M. , Pietrini P. , Haxby JV Cholinergic enhancement and increased selectivity of perceptual processing during working memory . Science. 2000;290: 2315-2319 .</Citation><ArticleIdList><ArticleId IdType="pubmed">11125148</ArticleId></ArticleIdList></Reference><Reference><Citation>Malapani C. , Pillon B. , Dubois B. , Agid Y. Impaired simultaneous cognitive task performance in Parkinson's disease: A dopamine-related dysfunction . Neurology . 1994;44: 319-326 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8309583</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell S. , Whyte J. , D'Esposito, M. Working memory impairments in traumatic brain injury: Evidence from a dual-task paradigm . Neuropsychologia. 1997;35: 1341-1353 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9347480</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun PA , O'Kane G. , Wingfield A. Distraction by competing speech in younger and older adult listeners . Psych Aging. 2002;17: 453-467 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12243387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen NP , Wiig EH Alzheimer's quick test screening criteria for West African speakers of Krio . Age Ageing, 2006;35: 503-507 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16807311</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association Press; 1994.</Citation></Reference><Reference><Citation>Who Icd-10. Psykiske lidelser og adf&#xe6;rdsm&#xe6;ssige forstyrrelser: Klassifikation og diagnostiske kriterier (revideret oplag). Copenhagen: , Denmark: Munksgaard; 2003.</Citation></Reference><Reference><Citation>Petersen RD , Stevens JC , Ganguli M. , Tangalos EG , Cummings JL , DeKosky ST (2001). Practice parameter. Early detection of dementia: Mild cognitive impairment (an evidence review) . Neurology. 2001;56: 1133-1142 .</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler adult intelligence scale &#x2014; III. Svensk version. Stockholm: , Sweden: Psykologif&#xf6;rlaget AB; ; 2003.</Citation></Reference><Reference><Citation>Folstein MF , Folstein SE , McHugh PR &#x201c; Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician . J Psychiat Res, 1975;12: 189-198 .</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL , Hamsher K. , Sivan AB Multilingual Aphasia Examination. 3rd ed. Iowa City, Iowa: AJA; ; 1994.</Citation></Reference><Reference><Citation>Nordgren J. Kliniska normer till Cronholm-Molanders minnesprov. Stockholm: : Psykologif&#xf6;rlaget AB; ; 1978.</Citation></Reference><Reference><Citation>Meyers JE , Meyers KR Rey complex figure test and recognition trial. Odessa, Fl: Psychological Assessment Resources, Inc; .; 1995.</Citation></Reference><Reference><Citation>Strauss E. , Sherman Ems , Spreen O. A Compendium of Neuropsychological Tests. 3rd ed. New York: Oxford University Press; 2006.</Citation></Reference><Reference><Citation>Kawas C. , Katzman R. Epidemiology of dementia and Alzheimer disease. In: RD Terry, R Katzman , KL Bick, SS Sisodia , eds. Alzheimer disease. New York: Raven Press; ; 1999.</Citation></Reference><Reference><Citation>Baillon S. , Muhommad S. , Marudkar M. , et al. Neuropsychological performance in Alzheimer's disease and vascular dementia: Comparisons in a memory clinic population. Intl J Geriatr Psychiatr. 2003;18: 602-608 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12833304</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner MI , Walker JA , Friedrich FJ , Rafal RD Effects of parietal injury on covert orienting of attention . J Neurosci. 1984;4: 1863-1874 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564871</ArticleId><ArticleId IdType="pubmed">6737043</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CR , Delis DC , Norman MA , Tecoma ES , Iragui-Madoz VJ Is impairment in set-shifting specific to frontal-lobe dysfunction: Evidence from patients with frontal-lobe or temporal-lobe epilepsy . J Int Neuropsychol Soc. 2005;11: 477-481 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16209428</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuss DT , Bischop SM , Alexander MP , Levine B. , Katz D. , Izukawa D. The trail making test: A study of focal lesion patients . Psychol Assess. 2001;13: 230-239 .</Citation><ArticleIdList><ArticleId IdType="pubmed">11433797</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll J. , de Oliveira-Souza R. , Moll FT , Bramati IE , Andreiuolo PA The cerebral correlates of set shifting: An fMRI study of the trail making test . Arq Neuropsiquiatr. 2002;60: 900-905 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12563376</ArticleId></ArticleIdList></Reference><Reference><Citation>Messerli P. , Seron X. , Tissot R. Quelques aspects des troubles de la programmation dans le syndrome frontale . Schweiz Arch Neurol Neurochir Psychiatr . 1979;125: 23-25 .</Citation><ArticleIdList><ArticleId IdType="pubmed">545685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon B. Troubles visuo-constructifs et methods de compensation: Resultants de 85 patients atteints de lesions c&#xe9;r&#xe9;brales . Neuropsychologia. 1981;19: 375-383 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7266830</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry JD , Crawford JR A meta-analytic review of verbal fluency performance following focal cortical lesions . Neuropsychology. 2004;18: 284-295 .</Citation><ArticleIdList><ArticleId IdType="pubmed">15099151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17587584</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0967-5868</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>850</StartPage><EndPage>855</EndPage><MedlinePgn>850-5</MedlinePgn></Pagination><Abstract><AbstractText>To assess the possible neurological basis of behavioral and psychological symptoms of dementia (BPSD), the relationships between BPSD and cognitive function were evaluated in 40 patients with Alzheimer's disease (AD). BPSD was assessed using the Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW) for behavioral symptoms and psychological symptoms separately, and cognitive function was also assessed using the Cognitive Abilities Screening Instrument (CASI). We found that only behavioral symptoms were associated with cognitive function based on the CASI total score and the score for the CASI attention domain. Administration of risperidone, an atypical anti-psychotic drug, for one month, improved the behavioral symptoms and the scores for the CASI attention and orientation domains. Our data suggest that BPSD in AD may reflect two largely independent pathophysiological processes: one associated with behavioral symptoms partly overlapping with attention, and the other associated with psychological symptoms predominantly unrelated to cognitive function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, and The Kawasaki Kokoro Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meguro</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Akanuma</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Meguro</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kasuya</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17587584</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2006.06.010</ArticleId><ArticleId IdType="pii">S0967-5868(06)00399-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17563253</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Management of the behavioral aspects of Parkinson's disease.</ArticleTitle><Pagination><StartPage>711</StartPage><EndPage>725</EndPage><MedlinePgn>711-25</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease is a progressive and debilitating movement disorder that is diagnosed by its motor signs. The behavioral manifestations of Parkinson's disease are prevalent and frequently complicate the course of the disease. These may be due to the illness itself or its treatment and are often more disabling than the motor symptoms. This review focuses on the management of the most common behavioral symptoms of Parkinson's disease, including depression, anxiety, psychosis, dementia, delirium, sleep disorders, fatigue, apathy, emotionalism and compulsive behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borek</LastName><ForeName>Leora L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Neurohealth Alzheimer's Disease and Movement Disorders Center, and Department of Geriatric Psychiatry, Butler Hospital, Warren Alpert Medical School of Brown University, RI, USA. leolisa@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Kelvin L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>214</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17563253</ArticleId><ArticleId IdType="doi">10.1586/14737175.7.6.711</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17562697</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>The neuropharmacology of psychosis.</ArticleTitle><Pagination><StartPage>937</StartPage><EndPage>946</EndPage><MedlinePgn>937-46</MedlinePgn></Pagination><Abstract><AbstractText>Antipsychotic drugs (APDs) are therapeutic in psychotic disorders. They are not specific treatments for schizophrenia (SZ) but useful in bipolar disorder (BD), psychotic depression, Alzheimers disease, and other psychotic diagnoses. In this perspective, we discuss the actions of APDs for the treatment of both SZ and bipolar-1 disorder (BD-1) with a specific focus on the implications of these data for the whole group of psychotic diagnoses. Both schizophrenic and BD-1 are characterized by several symptom dimensions, some overlapping and some distinctive. We discuss a dimensional approach to the diagnosis of BD and SZ and suggest that psychosis is an important dimension of each. In order to define the dimension of psychosis more carefully would require additional research to fill in the gaps in our knowledge. We propose that psychosis is a dimension that cuts through many psychiatric disorders, and the use of this dimension may be useful for clinical and research progress. We discuss the kinds of data necessary to further support the dimensional aspects of psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamminga</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, NE5 110F, Dallas, TX 75390 9127, USA. Carol.Tamminga@UTSouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17562697</ArticleId><ArticleId IdType="pmc">PMC2632319</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbm063</ArticleId><ArticleId IdType="pii">sbm063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gardner DM. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1150265</ArticleId><ArticleId IdType="pubmed">15967975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman SE. Medicine: what are the right targets for psychopharmacology? Science. 2003;299:350&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12532001</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder SR. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72:5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15531402</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter WT., Jr Schizophrenia [Review] N Engl J Med. 1994;330:681&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">8107719</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminga CA. Principles of the pharmacotherapy of schizophrenia. In: Charney DS, editor. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999. pp. 272&#x2013;285.</Citation></Reference><Reference><Citation>American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154:1&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9090368</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM. Dose response and dose equivalence of antipsychotics. [see comment] J Clin Psychopharmacol. 2004;24:192&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15206667</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM. Review of antipsychotic drug literature. In: Klein DF, editor. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Md: The Williams and Wilkins Company; 1969. pp. 52&#x2013;138.</Citation></Reference><Reference><Citation>Davis JM. A meta-analysis of the efficacy of second-generation antipsychotics. [see comment] Arch Gen Psychiatry. 2003;60:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796218</ArticleId></ArticleIdList></Reference><Reference><Citation>Leucht S. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988841</ArticleId></ArticleIdList></Reference><Reference><Citation>Leucht S. Amisulpride, an unusual &#x201c;atypical&#x201d; antipsychotic: a meta-analysis of randomized controlled trials. [see comment] Am J Psychiatry. 2002;159:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823257</ArticleId></ArticleIdList></Reference><Reference><Citation>Leucht S. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. [see comment] Lancet. 2003;361:1581&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">12747876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlbeck K. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172203</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16585434</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">16585435</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder SR, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon R, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophr Res. 2006;84:77&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper S, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane JM, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">12363115</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayeh HG. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006 CD004578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11361475</ArticleId><ArticleId IdType="pubmed">16625607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodzimierz KC. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 2006;189:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17058105</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan RW. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry. 1992;32:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">1356490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 1984;41:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">6143506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura J. Life events and schizophrenic relapse after withdrawal of medication. Br J Psychiatry. 1992;161:615&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">1422609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry. 2000;61(suppl 14):33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11154015</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RSE. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202565</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163:1918&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane J. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">3046553</ArticleId></ArticleIdList></Reference><Reference><Citation>Glick ID. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry. 2006;67:1261&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16965205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord. 2005;7:307&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16026484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehret MJ. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy. 2006;26:1134&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16863489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajwani P. Acute treatment of mania: an update on new medications. Curr Psychiatry Rep. 2006;8:504&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17094930</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherk MD. Second-generation antipsychotic agents in the treatment of acute mania. Arch Gen Psychiatry. 2007;64:442&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17404121</ArticleId></ArticleIdList></Reference><Reference><Citation>Seemuller F, et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf. 2005;4:849&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111448</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67:e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17201046</ArticleId></ArticleIdList></Reference><Reference><Citation>McElroy SL. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48:539&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">11018226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunner DL. Atypical antipsychotics: efficacy across bipolar disorder subpopulations. J Clin Psychiatry. 2005;66(suppl 3):20&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15762831</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15762832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry. 1999;60(suppl 5):43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192407</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig TJ, et al. Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features. Bipolar Disord. 2004;6:406&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383133</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CL, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67:1501&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">17107240</ArticleId></ArticleIdList></Reference><Reference><Citation>Oral TE. Treatment of acute mania. Neuro Endocrinol Lett. 2005;26:9&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohen M, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000;48:467&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">11018220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. J Clin Psychiatry. 2004;65:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554791</ArticleId></ArticleIdList></Reference><Reference><Citation>Marken PA. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother. 2006;40:276&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">16403851</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein DF. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Md: Williams &amp; Wilkins; 1969.</Citation></Reference><Reference><Citation>Calabrese JR, et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry. 2006;59:1061&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769295</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PE, Jr, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">16669728</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM. Overview: maintenance therapy in psychiatry: II. Affective disorders. Am J Psychiatry. 1976;133:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1108674</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM. Chapter 10: Lithium Maintenance of Unipolar Depression. In: Bauer M, editor. Lithium in Neuropsychiatry: The Comprehensive Guide. Abingdon, Oxon, England: Informa UK Ltd; 2006. pp. 99&#x2013;108.</Citation></Reference><Reference><Citation>Baldessarini RJ. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17042835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohen M, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohen M, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:1263&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12832240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15762830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry. 2005;66(suppl 1):3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15693745</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese JR, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15994719</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao K. Newer treatment studies for bipolar depression. Bipolar Disord. 2005;7(suppl 5):13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16225556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao K. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry. 2005;66:1376&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420074</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PE, Jr, et al. Double-Blind, Placebo-Controlled Study of Quetiapine in Bipolar I Depression. Munich, Germany: 2005.</Citation></Reference><Reference><Citation>Pande AC. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11249802</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson A. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963;20:140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">14060771</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994;15:264&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">7940991</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman II. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb HH. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry. 1996;153:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8540590</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong MR. Primate models of movement disorders of basal ganglia origin [Review] Trends Neurosci. 1990;13:281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">1695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirakawa O. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol. 1994;127:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">8200438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9265914</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter WT., Jr Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 1993;50:825&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">8215806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17525976</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-485X</ISSN><JournalIssue CitedMedium="Internet"><Volume>144B</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism.</ArticleTitle><Pagination><StartPage>1054</StartPage><EndPage>1062</EndPage><MedlinePgn>1054-62</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms in Alzheimer disease (AD + P) identify a heritable phenotype associated with a more severe course. We recently found an association of AD + P with depression symptom severity. Reports have shown an association of a serotonin-2A receptor (HTR2A) gene T102C polymorphism with AD + P and with depression during AD. We examined the interaction of this common genetic polymorphism with depression and increased psychosis risk. Subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis at study entry were genotyped for the HTR2A T102C polymorphism and reassessed every 6 months until psychosis onset. Psychotic and depressive symptoms were rated using the CERAD behavioral rating scale (CBRS). Cox proportional hazard models with time-dependent covariates were used to examine associations with psychosis onset. A total of 324 Caucasian subjects completed at least one follow-up exam. Depressive symptom severity was a strong predictor of psychosis onset. Neither psychosis onset nor depression severity was associated with the HTR2A genotype. Genotype interacted with depression severity to moderate the risk of AD + P onset. This did not result from an interaction of HTR2A genotype with antidepressant use. Psychosis onset in AD is strongly associated with severity of depressive symptoms, an association that may be modified by HTR2A genotype.</AbstractText><CopyrightInformation>2007 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilkosz</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodavali</LastName><ForeName>Chowdari</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>Vishwajit L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-01A2</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17525976</ArticleId><ArticleId IdType="mid">NIHMS124114</ArticleId><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30549</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DSM-IV: Diagnostic and Statistical Manual of Mental Health Disorders. Washington, D.C: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res. 2004;67:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741324</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias B, Gasto C, Catalan R, Gutierrez B, Pintor L, Fananas L. THe 5-HT(2A) receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. Am J Med Genetics. 2001a;105:801&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803534</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias B, Gutierrez B, Pintor L, Gasto C, Fananas L. Variability in the 5-HT(2A) receptor gene is associated with seasonal pattern in major depression. Mol Psychiatry. 2001b;6:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11317230</ArticleId></ArticleIdList></Reference><Reference><Citation>Arranz B, Blennow K, Eriksson A, M&#xe5;nsson JE, Marcusson J. Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biol Psychiatry. 1997;41:1000&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">9129780</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Linkage analysis of Alzheimer disease with psychosis. Neurology. 2002;59:118&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, O'Brien JT, Coope B, Wilcock G. Psychotic symptoms in dementia and the rate of cognitive decline. J Am Geriatr Soc. 1997;45:1031&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Rosenblatt A, Baker A, Steinberg M, Steele CD, Sheppard J, Lyketsos CG. The relationship between delusions and depression in Alzheimer's disease. Int J Geriatr Psychiatry. 2002;17:549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112179</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Boller F, Lopez OL, Saxton J, McGonigle KL. The natural history of Alzheimer's disease: description of study cohort and accuracy of diagnosis. Arch Neurol. 1994;51:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8198470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Wijsman EM, NOchlin D, Leehey M, Sumi SM, Payami H, Poorkaj P, Nemens E, Rafkind M, Schellenberg GD. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology. 1997;48:950&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109883</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 2001;69:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235314</ArticleId><ArticleId IdType="pubmed">11443544</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Agosti C, Archetti S, Costanzi C, Bonomi S, Ghianda D, Lenzi GL, Caimi L, Di Luca M, Padovani A. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci Lett. 2004;370:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488308</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, Archetti S, Costanzi C, Cornali C, Caltagirone C, Caimi L, Di Luca M, Padovani A. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582043</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, Costanzi C, Archetti S, Franzoni S, Caltagirone C, Di Luca M, Caimi L, Padovani A. Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia. Arch Gen Psychiatry. 1999;56:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry. 2004;9:962&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">15124004</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull. 2006;32:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632175</ArticleId><ArticleId IdType="pubmed">16319375</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett. 2004;368:33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342129</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Go RC, Perry RT, Wiener H, Bassett SS, Blacker D, Devlin B, Sweet RA. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gormley N, Rizwan MR. Prevalence and clinical correlates of psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13:410&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">9658277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamshere ML, Bennett P, Williams N, Segurado R, Cardno A, Norton N, Lambert D, Williams H, Kirov G, Corvin A, Holmans P, Jones L, Jones I, Gill M, O'Donovan MC, Owen MJ, Craddock N. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry. 2005;62:1081&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">16203953</ArticleId></ArticleIdList></Reference><Reference><Citation>Handoko HY, Nyholt DR, Hayward NK, Nertney DA, Hannah DE, Windus LC, McCormack CM, Smith HJ, Filippich C, James MR, Mowry BJ. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry. 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">15505638</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RJ, Ellison D, Hardy J, Hutton M, Roques PK, Collinge J, Fox NC, Rossor MN. Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine--&gt;serine (L250S) substitution at codon 250 of the presenilin 1 gene. J Neurol Neurosurg Psychiatry. 1998;64:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169918</ArticleId><ArticleId IdType="pubmed">9436726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere M, Holmans P, Jones L, O'Donovan M, Myers A, Hardy J, Goate A, Lovestone S, Owen M, Williams J. Familiality and Linkage Analysis of Behavioral Symptoms and Age at Disease Onset in Late-Onset Alzheimer's Disease. Alzheimer's &amp; Dementia. 2006;2:S194.</Citation></Reference><Reference><Citation>Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's Disease: The Effect of Serotonin Receptor Gene Variation. American Journal of Medical Genetics Part B (Neuropsyciatric Genetics) 2003;119B:40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707936</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Arranz MJ, Powell JF, Collier D, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genetics. 1998;7:1507&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700207</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, Lovestone S. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737623</ArticleId><ArticleId IdType="pubmed">11723200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Wragg RE, Salmon DP, Harris MJ, Thal LJ. Cognitive deficits of patients with Alzheimer's disease with and without delusions. Am J Psychiatry. 1992;149:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001;158:848&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler KS, Karkowski LM, Walsh D. The structure of psychosis: latent class analysis of probands from the Roscommon Family Study. Arch Gen Psychiatry. 1998;55:492&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler KS, Mcguire M, Gruenberg AM, Walsh D. Schizotypal Symptoms and Signs in the Roscommon Family Study - Their Factor Structure and Familial Relationship with Psychotic and Affective-Disorders. Arch Gen Psychiatry. 1995;52:296&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7702446</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings J, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry. 1996;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003;73:34&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180588</ArticleId><ArticleId IdType="pubmed">12802786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Brenner RP, Rosen J, Bajulaiye OI, Reynolds CF. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology. 1991;41:906&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">2046938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk WE, Saxton J, Hamilton RL, Kaufer D, Sweet RA, Cidis Meltzer C, Wisniewski SR, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades. II. Neurology. 2000a;55:1863&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk WE, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski SR, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology. 2000b;55:1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E &#x3b5;4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology. 1997;49:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack JL, Patterson MB, Tariot PN. Behavior Rating Scale for Dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's disease. J Geriatr Psychiatry Neurol. 1999;12:211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616870</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Keene J, Gedling J, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997;314:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2125727</ArticleId><ArticleId IdType="pubmed">9022490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi R, Starkstein SE, Jorge R, Robinson RG. Phenomenology and Clinical Correlates of Delusions in Alzheimer Disease. Am J Geriatr Psychiatry. 2006;14:573&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, Ortenzi L, Petruzzi C, Serio A, Marcon G, Sorbi S. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry. 2001;50:472&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566166</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimgaonkar VL. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry. 2006;60:570&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893532</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen MJ, Craddock N, O'Donovan MC. Schizophrenia: genes at last? Trends Genet. 2005;21:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009449</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Ready RE, Stout JC, Salmon DP, Thal LJ, Grant I, Jeste DV. Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society. 2000a;6:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105471</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal L, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology. 2000b;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Polesskaya O, Sokolov B. Differential Expression of the "C" and "T" Alleles of the 5-HTR2A Receptor Gene in the Temporal Cortex of Normal Individuals and Schizophrenics. J Neurosci Res. 2002;67:812&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891796</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope HGJ, Yurgelun-Todd D. Schizophrenic individuals with bipolar first-degree relatives: analyses of two pedigrees. J Clin Psychiatry. 1990;51:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">2307666</ArticleId></ArticleIdList></Reference><Reference><Citation>Potash JB, Zandi PP, Willour VL. Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry. 2003;160:680&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, Bentham P. Role of 5HT(2A) and 5HT(2C) polymorphisms in behavioral and psychological symptoms of Alzheimer's Disease. Neurobiol Aging. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice J, Reich T, Andreasen NC. The familial transmission of bipolar illness. Arch Gen Psychiatry. 1987;44:441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">3579495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rippon GA, Crook R, Baker M, Halvorsen E, Chin S, Hutton M, Houlden H, Hardy J, Lynch T. Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia. Arch Neurol. 2003;60:884&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">12810495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, Murri L. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): Association studies with psychosis in Alzheimer disease. Genetic Testing. 2003;7:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15000807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwell E, Jackson E, Vilke G, Jeste DV. A study of delusions in a large cohort of Alzheimer's disease patients. Am J Geriatr Psychiatry. 1994;2:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">28530995</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher J, Jamra RA, Becker T. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BNDF) locus and major depression. Biol Psychiatry. 2005;58:307&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005437</ArticleId></ArticleIdList></Reference><Reference><Citation>Shifman S, Bronstein MSM, Pisante-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002;71:1296&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378567</ArticleId><ArticleId IdType="pubmed">12402217</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, St Clair D. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet. 2003;72:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420015</ArticleId><ArticleId IdType="pubmed">12478479</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou MD, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378543</ArticleId><ArticleId IdType="pubmed">12145742</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:1649&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Devlin B, Pollock BG, Sukonick DL, Kastango KB, Bacanu S-A, Chowdari KV, DeKosky ST, Ferrell RE. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry. 2005;10:1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA, DeKosky ST. Alterations of striatal dopamine receptor binding in Alzheimer's disease are associated with lewy body pathology and with antemortem psychosis. Arch Neurol. 2001;58:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002a;58:907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease. Arch Neurol. 1998;55:1335&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer DI, DeKosky ST, Klunk WE. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002b;23:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, Varma PG, Prasad S, Semwal P, Bhatia T, Deshpande S, Devlin B, Thelma BK, Nimgaonkar V. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry. 2006;60:570&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893532</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang MT, Faraone SV, Lyons MJ. Identification of the phenotype in psychiatric genetics. European Archives of Psychiatry and Clinical Neuroscience. 1993;243:131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">8117756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang MT, Winokur G, Crowe RR. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression, and surgical conditions. Br J Psychiatry. 1980;137:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">7214104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunstall N, Fraser L, Lovestone S, Owen MJ, Williams J, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V. Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. Br J Psychiatry. 2000;176:156&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755053</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JT, Peacock ML, Rodriguez LC, Fink JK. An Mspi Polymorphism in the Hyman Serotonin Receptor Gene (Htr2) - Detection by Dgge and Rflp Analysis. Hum Mol Genetics. 1993;2:338&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">7684645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams NM, Norton N, Williams H. A systematic genomewide linkage study in 353 sib pairs with schizophrenia. Am J Hum Genet. 2003a;73:1355&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180400</ArticleId><ArticleId IdType="pubmed">14628288</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S, O'Donovan MC, Owen MJ. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry. 2003b;8:485&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, Zhou M, Zhang HY, Kong QM, Liu C, Zhang DR, Yu YQ, Liu SZ, Ju GZ, Shu L, Ma DL, Zhang D. Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry. 2003;8:706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17522557</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2007</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1527-4160</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>152</EndPage><MedlinePgn>143-52</MedlinePgn></Pagination><Abstract><AbstractText>In 2005, responding to several studies, the FDA issued a black box warning on atypical (second generation) antipsychotic medications, noting that the drugs may increase the risk of cerebrovascular adverse events in elderly patients with dementia-related behavior disturbances. The black box warning has raised concern for clinicians, among whom atypical antipsychotics have gained favor for having a more tolerable side-effect profile than many other pharmacological treatment options. Complicating this concern are studies suggesting that other medications may have similar risks and a dearth of unbiased head-to-head studies comparing different treatment options. To effectively manage risk when treating elderly patients with dementia-related psychosis, physicians, patients, and caregivers must consider both acute risks (such as danger of bodily harm to the patient and others) and long-term risks (such as placement in a restrictive nursing home). If an atypical antipsychotic is chosen, additional risk management may be warranted. This paper presents a brief overview of relevant concerns and suggests some techniques to help minimize and manage risk, such as increased monitoring, informed consent, and thorough documentation. A sample clinical risk management form and a sample letter to the primary care physician are provided to help guide clinicians in improving their risk management practices when working with elderly patients suffering from dementia-related psychosis and related behavioral difficulties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Recupero</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Brown Medical School and Butler Hospital, Providence, RI 02906, USA. Patricia_Recupero@Brown.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainey</LastName><ForeName>Samara E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004282" MajorTopicYN="N">Documentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007258" MajorTopicYN="N">Informed Consent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011356" MajorTopicYN="N">Product Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="N">Risk Management</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17522557</ArticleId><ArticleId IdType="doi">10.1097/01.pra.0000271655.02093.49</ArticleId><ArticleId IdType="pii">00131746-200705000-00002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17492769</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>144B</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis.</ArticleTitle><Pagination><StartPage>841</StartPage><EndPage>848</EndPage><MedlinePgn>841-8</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms are common in Alzheimer's disease (AD) and are associated with increased cognitive impairment and earlier institutionalization. One study has suggested that they are genetically modified and two genome screens have been performed to search for susceptibility loci for AD with psychosis (AD + P). The aim of this study was to further investigate the familial aggregation of AD + P and perform a genome screen for AD, conditioning on the presence or absence of psychotic symptoms. Samples from the UK and US were combined, providing data from 374 families in which at least two members met criteria for AD and had complete data regarding psychotic symptoms. Generalized estimating equations (GEE) were used to assess the relationship of psychotic symptoms between siblings. A total of 321 affected relative pairs (ARPs) were genotyped for linkage. There was a significant association between proband psychosis status and the occurrence of AD + P in siblings in the UK (OR = 4.17, P = 0.002) and US (OR = 3.2, P &lt; 0.001) samples. Chromosomewide and genomewide significant linkage peaks were observed on chromosomes 7 (LOD = 2.84) and 15 (LOD = 3.16), respectively, with the strongest evidence coming from pairs concordant for AD without psychosis. A LOD score of 2.98 was observed close to a previously reported AD + P linkage region on chromosome 6, however the increase in LOD attributable to psychosis was not significant. These findings support the hypothesis that psychotic symptoms in AD are genetically modified and that a gene/s implicated in their aetiology may be located on chromosome 7 and 15.</AbstractText><CopyrightInformation>(c) 2007 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom. hollingworthp@cardiff.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamshere</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>DeVrieze</LastName><ForeName>F W</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 MH 46281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH 46290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 5681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 MH 46373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30515</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17492420</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor].</ArticleTitle><Pagination><StartPage>1052</StartPage><EndPage>1057</EndPage><MedlinePgn>1052-7</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy Bodies (DLB) is the second most common form of dementia in the elderly. Core features of the DLB are fluctuating cognitive symptoms, visual hallucinations and spontaneous parkinsonism. The clinical diagnostic criteria are very useful in the differentiation between DLB and Alzheimer's disease. The deficits in cholinergic neurotransmission are pronounced and associated with cognitive and psychotic symptoms. An 83 years old patient with DLB showed well formed recurrent visual hallucinations and fluctuating cognition and attention. There was no response to treatment with atypical neuroleptics. The patient responded within few days to treatment with Donepezil. Both cognitive and behavioural symptoms were improved significantly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Omerovic</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Psychiatrie und Psychotherapie der Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Nussbaumstrasse 7, 80336, M&#xfc;nchen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teipel</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Demenz mit Lewy-K&#xf6;rperchen. Besserung unter Therapie mit einem Acetylcholinesteraseinhibitor.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17492420</ArticleId><ArticleId IdType="doi">10.1007/s00115-007-2277-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1998 Aug;13(8):516-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9733331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):243-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9069479</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Dec 10;59(11):1714-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12473758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2000 Dec;48(6):868-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11117543</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1990 Summer;4(2):87-95</Citation><ArticleIdList><ArticleId IdType="pubmed">2357341</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1998 Apr;152(4):879-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1991;640:197-202</Citation><ArticleIdList><ArticleId IdType="pubmed">1723256</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1998 Sep;10(3):229-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9785144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 Dec 16;356(9247):2031-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11145488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2000 Nov-Dec;11(6):314-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11044776</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 May;16(5):528-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11376470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2002;13(3):183-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11893841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Oct;43(10):1927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">8105420</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Jun 10;52(9):1839-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10371532</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Sep;15(9):794-802</Citation><ArticleIdList><ArticleId IdType="pubmed">10984725</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropathol. 1999 Jul-Aug;18(4):214-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10442465</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Jun;15(6):548-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10861923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):209-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10406992</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2004 Fall;16(4):409-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15616167</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Nov;47(5):1113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Apr;15(4):338-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10767734</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 Nov;22(4):911-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1362617</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Dec 27;65(12):1863-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2005 Nov;34(6):561-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16267179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17471598</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.</ArticleTitle><Pagination><StartPage>475</StartPage><EndPage>484</EndPage><MedlinePgn>475-84</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia typically includes behavioral and psychological symptoms of dementia (BPSD) as well as cognitive decline. Psychosis of Alzheimer's disease (AD) is a specific component of AD, characterized by delusions, misidentifications, and hallucinations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia. Three trials included patients diagnosed with heterogeneous symptoms of BPSD (those with psychosis of AD were included in this analysis), while one trial included only those diagnosed with psychosis of AD. Efficacy was measured using the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression (CGI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Primary analyses in the psychosis of AD population demonstrated that risperidone significantly improved scores on the BEHAVE-AD Psychosis subscale and CGI scale compared with placebo. Secondary analyses demonstrated that patients with more severe symptoms showed a more pronounced response to treatment with risperidone compared with placebo than those patients with less severe symptoms. Extrapyramidal symptoms and somnolence were more frequent with risperidone than placebo (p=0.04). Cerebrovascular adverse events and all-cause mortality were observed more frequently, although not statistically significantly, with risperidone versus placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This meta-analysis of psychosis of AD showed improvement in psychotic symptoms and general clinical improvement in patients with psychosis of AD treated with risperidone compared with placebo. The benefits of treatment were most significant in patients with severe symptoms. The safety profile of risperidone in this psychosis of AD population was similar to the more general BPSD population.</AbstractText><CopyrightInformation>Copyright (c) 2007 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA, and Department of Neurology, Memory Clinic, Middelheim Hospital, ZNA, Wilrijk-Antwerp, Belgium. katzi@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Deyn</LastName><ForeName>Peter-Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Young</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId><ArticleId IdType="doi">10.1002/gps.1792</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17469686</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0317-1671</ISSN><JournalIssue CitedMedium="Print"><Volume>34 Suppl 1</Volume><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title><ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Assessment of behavioural and psychological symptoms associated with dementia.</ArticleTitle><Pagination><StartPage>S67</StartPage><EndPage>S71</EndPage><MedlinePgn>S67-71</MedlinePgn></Pagination><Abstract><AbstractText>Neuropsychiatric symptoms (mood, psychotic, and behavioural) are very common in dementia and do not necessarily correlate well with other measures of cognition. However, these symptoms are of great importance, as they are a major source of excess disability, patient distress and caregiver burden and have great impact on the level of care required, and the associated costs. This paper is a review of the most useful outcome measures for behaviour and mood symptoms. Investigators who require a comprehensive instrument to measure neuropsychiatric symptoms in studies of patients with dementia should consider using the Neuropsychiatric Inventory (NPI), the Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-BRSD) or, possibly, the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD). The Cornell Scale for Depression in Dementia and the Dementia Mood Assessment Scale (DMAS) are recommended for evaluating depressive symptoms and the Cohen-Mansfield Agitation Inventory (CMAI) is very useful for evaluating the full range of agitation symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conn</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorpe</LastName><ForeName>Lilian</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Neurol Sci</MedlineTA><NlmUniqueID>0415227</NlmUniqueID><ISSNLinking>0317-1671</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="Y">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17469686</ArticleId><ArticleId IdType="doi">10.1017/s0317167100005606</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17452579</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>17</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.</ArticleTitle><Pagination><StartPage>1356</StartPage><EndPage>1363</EndPage><MedlinePgn>1356-63</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multicenter randomized, double-blind, placebo-controlled parallel groups clinical trial involving 40 patients with dementia with Lewy bodies (n = 23), Parkinson disease (PD) with dementia (n = 9), or Alzheimer disease with parkinsonian features (n = 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified PD Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Quetiapine was well-tolerated and did not worsen parkinsonism. Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating agitation or psychosis in patients with dementia and parkinsonism. These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurlan</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mt. Hope Professional Building, Rochester, NY 14620, USA. Roger_Kurlan@urmc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Cooperative Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020086</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015990" MajorTopicYN="N">Placebo Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17452579</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000260060.60870.89</ArticleId><ArticleId IdType="pii">68/17/1356</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17449111</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>152</Volume><Issue>2-3</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Family assessment in early psychosis.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>102</EndPage><MedlinePgn>95-102</MedlinePgn></Pagination><Abstract><AbstractText>Some caregiver burden scales designed for chronic schizophrenia may be inappropriate for use with families of individuals who are experiencing a first-episode of psychosis (FEP). The aims of the study were to determine the usefulness for FEP families of the Caregiver Burden Inventory (CBI), a scale originally designed for use with family members of Alzheimer's patients. The CBI, Experience of Caregiving Scale (ECI) and the Psychological General Well-Being Scale (PGWB) were administered to the relatives of 113 individuals with a FEP at admission to an early psychosis program and again at 6-, 12-, and 24-month follow-ups. Ratings on the CBI improved significantly over the follow-up period. The CBI was significantly associated with the ECI and with ratings of psychological distress. The most significant predictor of psychological distress was ratings on the CBI and not the severity of symptoms or impaired functioning. Overall, the CBI appeared to be a reliable and valid measure for use with FEP families. This short and easy to score measure may be useful for families of young people presenting with FEP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCleery</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addington</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Addington</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011361" MajorTopicYN="N">Professional Competence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17449111</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2006.07.002</ArticleId><ArticleId IdType="pii">S0165-1781(06)00202-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="HSR"><PMID Version="1">17413135</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0898-2643</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of aging and health</Title><ISOAbbreviation>J Aging Health</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment, psychiatric disorders, and problematic behaviors in a tribal nursing home.</ArticleTitle><Pagination><StartPage>260</StartPage><EndPage>274</EndPage><MedlinePgn>260-74</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Residents' cognitive, psychiatric, and behavioral statuses were examined as part of a larger study of care in a nursing home (NH) owned and operated by a Northern Plains American Indian tribe.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Reviews of 45 medical records and semistructured interviews with 36 staff were completed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Creekside residents had considerable psychiatric and behavioral morbidity. High prevalences of non-Alzheimer's disease dementia, cognitive impairment, anxious symptomatology, and resistance to care were met with psychopharmacotherapy, reorientation, and informal techniques for behavior management. Significant depressive, anxious, psychotic, and behavioral symptoms remained. Staff interpretations of resident problems consisted of an ethnopsychological schema emphasizing resident loneliness, grumpiness, and propensity to "fight" rather than formal psychiatric nosology.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Tribal NH residents were likely underdiagnosed for dementia and anxiety. Residual behavioral and psychiatric symptomatology suggest room for improvement in the NH's behavioral management regimen. Need for greater attention to conceptual, diagnostic, clinical, and documentation processes in the NH setting is noted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jervis</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>American Indian and Alaska Native Programs, University of Colorado at Denver and Health Sciences Center, Nighthorse Campbell Native Health Building, Room 349, PO Box 6508, Mail Stop F800, Aurora, CO 80045-0508, USA. lori.jervis@uchsc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>Spero M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG20232-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Aging Health</MedlineTA><NlmUniqueID>8912686</NlmUniqueID><ISSNLinking>0898-2643</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007198" MajorTopicYN="Y">Indians, North American</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008485" MajorTopicYN="N">Medical Audit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="Y">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016312" MajorTopicYN="N">Treatment Refusal</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17413135</ArticleId><ArticleId IdType="doi">10.1177/0898264306297191</ArticleId><ArticleId IdType="pii">19/2/260</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17408808</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer's disease: Gender differences in regional perfusion.</ArticleTitle><Pagination><StartPage>1218</StartPage><EndPage>1225</EndPage><MedlinePgn>1218-25</MedlinePgn></Pagination><Abstract><AbstractText>We sought to determine whether the presence of psychotic symptoms in patients with Alzheimer's disease is associated with abnormal regional cerebral function. Perfusion single photon emission computed tomography images from 51 AD patients with psychotic symptoms were compared to images of 52 AD patients without such symptoms. Group comparisons were made with a voxel-based method, Statistical Parametric Mapping. We found that perfusion was lower in female patients with psychotic symptoms in right infero-lateral prefrontal cortex and in inferior temporal regions compared to female patients without such symptoms. In contrast, perfusion was higher in male patients with psychotic symptoms in the right striatum compared to male patients without such symptoms. Comparison groups did not differ in age or in dementia severity, as estimated by the Mini-Mental State Examination (MMSE). These results support the role of right hemisphere prefrontal and lateral temporal cortex in the psychosis of AD in women but not in men, and raise the possibility that these dysfunctional processes have a gender-specific regional pathophysiology in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>E K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, 55 Fruit St., Tilton 201, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Satlin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>In Kyoon</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Fischman</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014768" MajorTopicYN="N">Virginia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17408808</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.024</ArticleId><ArticleId IdType="pii">S0197-4580(07)00080-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19300554</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1176-6328</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuropsychiatric disease and treatment</Title><ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation></Journal><ArticleTitle>Rivastigmine in the treatment of patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>218</EndPage><MedlinePgn>211-8</MedlinePgn></Pagination><Abstract><AbstractText>Impairment of attention and memory in patients with Alzheimer's disease (AD) is associated with significantly lower levels of acetylcholine. Inhibition of the breakdown of acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with rivastigmine improves this cholinergic depletion. Thus rivastigmine administration provides established, effective, long-term symptomatic treatment in AD and Parkinson's disease (PD) patients with dementia. A sustained treatment with cholinesterase inhibitors in general may also induce a certain deterioration of fine motor behavior, which may play a crucial role in the treatment of PD patients with dementia. Recent studies show that this altered balance between dopamine and acetylcholine due to cholinesterase inhibition, with its possible negative impact on motion behaviour, does not present a major problem in clinical practice in AD patients and may be compensated for by modification of dopaminergic substitution in PD patients with dementia. However, progression of neurodegeneration increases the vulnerability for psychosis in AD and PD patients with dementia in combination with dehydration and often requires additional application of neuroleptics. Since classical neuroleptics increase extrapyramidal symptoms, atypical neuroleptics are used. Out of these, quetiapine shows a distinct lower anticholinergic (muscarinergic) potency with beneficial effects on cognition. This favors its use in combination with rivastigmine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neuropsychiatr Dis Treat</MedlineTA><NlmUniqueID>101240304</NlmUniqueID><ISSNLinking>1176-6328</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">movement</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">rivastigmine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19300554</ArticleId><ArticleId IdType="pmc">PMC2654625</ArticleId><ArticleId IdType="doi">10.2147/nedt.2007.3.2.211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alva G, Potkin SG. Alzheimer disease and other dementias. Clin Geriatr Med. 2003;19:763&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024811</ArticleId></ArticleIdList></Reference><Reference><Citation>Belle SH, Zhang S, Czaja SJ, et al. Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer&#x2019;s Caregiver Health (REACH) project. Am J Geriatr Psychiatry. 2004;12:250&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126225</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002;17:314&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12106000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnen N, Kaufer D, Hendrickson R, et al. Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol. 2004;24:354&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15118497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am. 2002;86:657&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12171061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer&#x2019;s disease over a 2-year period. Curr Med Res Opin. 2005;21:1317&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16083542</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer&#x2019;s disease. A systematic review. Int J Technol Assess Health Care. 2002;18:497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391943</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer&#x2019;s disease. Int J Geriatr Psychopharmacol. 1998;1:55&#x2013;65.</Citation></Reference><Reference><Citation>Cummings JL. Cholinesterase inhibitors: expanding applications. Lancet. 2000;356:2024&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145482</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer&#x2019;s disease. CNS Spectr. 2005;10(Suppl 18):22&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273027</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology. 2002;594:563&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196650</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, et al. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer&#x2019;s disease patients. J Neurochem. 2004;885:1102&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009666</ArticleId></ArticleIdList></Reference><Reference><Citation>Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4:131&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12563284</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Oliviero A, Pilato F, et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2004;75:555&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739006</ArticleId><ArticleId IdType="pubmed">15026495</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M. Dementia in Parkinson&#x2019;s disease:cause and treatment. Curr Opin Neurol. 2004;174:399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247534</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Skoog I, Lane R, et al. Rivastigmine in patients with Alzheimer&#x2019;s disease and concurrent hypertension. Int J Clin Pract. 2002;5610:791&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12510954</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer&#x2019;s plaques and tangles. Brain Res. 2005;1060:144&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16212945</ArticleId></ArticleIdList></Reference><Reference><Citation>Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson&#x2019;s disease:results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16:135&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11215574</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M, Anand R, Messina J, Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer&#x2019;s disease. Eur Neurol. 2000;44:236&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11096224</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol. 2003;60:843&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12810489</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR. Do cholinesterase inhibitors slow progression of Alzheimer&#x2019;s disease? Int J Clin Pract. 2002;(Suppl):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139366</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001;58:417&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255445</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR, Lilly ML. Rivastigmine:an open-label, observational study of safety and effectiveness in treating patients with Alzheimer&#x2019;s disease for up to 5 years. BMC Geriatr. 2005;5:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548267</ArticleId><ArticleId IdType="pubmed">15659242</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer&#x2019;s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon) Eur J Neurol. 1999;6:423&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362894</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankfort SV, Appels BA, de Boer A, et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry. 2005;20:1167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315150</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankfort SV, Appels BA, de Boer A, et al. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer&#x2019;s disease in an outpatient geriatric setting. Int J Clin Pract. 2006;60:646&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805746</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E. Cholinesterase inhibitors stabilize Alzheimer&#x2019;s disease. Ann NY Acad Sci. 2000;920:321&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193171</ArticleId></ArticleIdList></Reference><Reference><Citation>Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson&#x2019;s disease. Acta Neurol Scand. 2003;108:368&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">14616309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11:e274&#x2013;e85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604527</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase:an important new target in Alzheimer&#x2019;s disease therapy. Int Psychogeriatr. 2002;14(Suppl 1):77&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12636181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegerl U, Mergl R, Henkel V, et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol. 2003;23:214&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640228</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinze M, Andreae D, Grohmann R. Rivastigmin and impaired motor function. Pharmacopsychiatry. 2002;35:79&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11951151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioffe ME. Brain mechanisms for the formation of new movements during learning:the evolution of classical concepts. Neurosci Behav Physiol. 2004;34:5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15109077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Cosentino SA, Ball SK, et al. Errors produced on the mini-mental state examination and neuropsychological test performance in Alzheimer&#x2019;s disease, ischemic vascular dementia, and Parkinson&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2002;14:311&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154156</ArticleId></ArticleIdList></Reference><Reference><Citation>Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson&#x2019;s disease. Mov Disord. 2004;19:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14743357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz A, Farlow M, Quarg P, et al. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord. 2004;18:123&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494617</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson&#x2019;s disease. Int J Geriatr Psychiatry. 2004;19:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716693</ArticleId></ArticleIdList></Reference><Reference><Citation>Liepert J, Bar KJ, Meske U, et al. Motor cortex disinhibition in Alzheimer&#x2019;s disease. Clin Neurophysiol. 2001;112:1436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459683</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson AJ, Lamb HM. Quetiapine&#x2013;A review of its clinical potential in the management of psychotic symptoms in Parkinson&#x2019;s disease. CNS Drugs. 2000;14:157&#x2013;72.</Citation></Reference><Reference><Citation>Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson&#x2019;s disease. J Neural Transm. 2004;111:1447&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15480845</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319699</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhlack S, Przuntek H, M&#xfc;ller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer&#x2019;s disease. Pharmacopsychiatry. 2006;39:16&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16453249</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T, Kuhn W, Schulte T, et al. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson&#x2019;s disease. Neurosci Lett. 2003a;339:25&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12618292</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T, Meisel M, Russ H, et al. Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson&#x2019;s disease patients. J Neurol Sci. 2003b;213:61&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873756</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T, Schafer S, Kuhn W, et al. Correlation between tapping and inserting of pegs in Parkinson&#x2019;s disease. Can J Neurol Sci. 2000;27:311&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11097522</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal PK, Lee CS, Samii A, et al. Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson&#x2019;s disease and correlates with PET. Parkinsonism Relat Disord. 2001;7:305&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11344014</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson&#x2019;s disease. N Engl J Med. 1999;340:757&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072410</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson&#x2019;s disease:an active treatment extension study. Mov Disord. 2006;21:456&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16229010</ArticleId></ArticleIdList></Reference><Reference><Citation>Polinsky RJ. Clinical pharmacology of rivastigmine:a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer&#x2019;s disease. Clin Ther. 1998;20:634&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9737824</ArticleId></ArticleIdList></Reference><Reference><Citation>Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders:impact on the elderly. Drugs Aging. 2006;23:357&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16823990</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard IH, Justus AW, Greig NH, et al. Worsening of motor function and mood in a patient with Parkinson&#x2019;s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol. 2002;25:296&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12469000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer&#x2019;s disease: international randomised controlled trial. BMJ. 1999;318:633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27767</ArticleId><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Saft C, Andrich J, Meisel NM, et al. Assessment of complex movements reflects dysfunction in Huntington&#x2019;s disease. J Neurol. 2003;250:1469&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">14673581</ArticleId></ArticleIdList></Reference><Reference><Citation>Saft C, Andrich J, Meisel NM, et al. Congruent deterioration of complex and simple movements in patients with Huntington&#x2019;s disease. J Neural Transm. 2004;(Suppl):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15354394</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer&#x2019;s disease. Drugs Aging. 1998;13:391&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829166</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2006;21:17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16323253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN. Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Alzheimer Dis Assoc Disord. 2001;15(Suppl 1):S26&#x2013;S33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10668703</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH. Understanding the latest advances in pharmacologic interventions for Alzheimer&#x2019;s disease. CNS Spectr. 2004;9(Suppl 5):24&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15241297</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hilten JJ, Middelkoop HA, Kuiper SI, et al. Where to record motor activity:an evaluation of commonly used sites of placement for activity monitors. Electroencephalogr Clin Neurophysiol. 1993;89:359&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691576</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vugt JP, Siesling S, Piet KK, et al. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington&#x2019;s disease. Mov Disord. 2001;16:481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391742</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock M. Selectivity of cholinesterase inhibition&#x2013;Clinical implications for the treatment of Alzheimer&#x2019;s disease. CNS Drugs. 1999;12:307&#x2013;23.</Citation></Reference><Reference><Citation>Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson&#x2019;s disease and dementia. J Neural Transm. 2001;108:1319&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11768630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer&#x2019;s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21:453&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15132713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer&#x2019;s disease. Int J Clin Pract. 2002;56:441&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12166542</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Beusterien KM, Thomas SK, et al. Caregivers prefer patches to capsules: results from a 24-week placebo-controlled study of rivastigmine (IDEAL trial) Hot topic session ICAD 2006 2006</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17388995</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Cognitive and behavioural predictors of progression rates in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>440</StartPage><EndPage>446</EndPage><MedlinePgn>440-6</MedlinePgn></Pagination><Abstract><AbstractText>Cognitive and functional decline in Alzheimer's disease (AD) may show different, yet correlated, rates of progression. Over a 2-year period we investigated the predictive role of neuropsychological and behavioural variables on the cognitive and functional decline of 43 patients with AD. Slow and fast decliners were defined on the basis of cognitive and functional indexes of disease progression. We found that cognitive decline was predicted by diffuse cognitive impairment and functional progression by visuospatial deficits. Psychotic symptoms predicted faster disease progression in both cognitive and functional dimensions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buccione</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy. i.buccione@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perri</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Carlesimo</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Scalmana</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0700704</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17388995</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01693.x</ArticleId><ArticleId IdType="pii">ENE1693</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17384319</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients.</ArticleTitle><Pagination><StartPage>354</StartPage><EndPage>356</EndPage><MedlinePgn>354-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the rate of adverse medical outcomes for elderly exposed to antipsychotic treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective evaluation of psychiatric inpatients records. Age, gender, diagnosis, treatment with antipsychotics, and duration of treatment were analyzed. An acute cardiac or cerebrovascular event necessitating transfer to a general hospital or resulting in death was the outcome measure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 15 years (1990 to 2005), 3,111 elderly were hospitalized. Their mean age was 73.5 +/- 6.1 years, 1,220 were male (39%), and 1,891 were female (61%). Most patients (2,583 [83%]) were exposed to antipsychotics, of which 1,402 (54%) were exposed to second-generation antipsychotics (SGAs). Antipsychotic-treated patients did not have a higher rate of adverse medical outcomes compared with patients who had not received antipsychotics. No significant differences were noted between patients exposed to typical antipsychotics or SGAs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment of elderly psychiatric inpatients with antipsychotics did not increase their risk of adverse medical outcomes. Thus, regulating the use of conventional antipsychotics or SGAs for all elderly patients in all indications may be premature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barak</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Abarbanel Mental Health Center, Bat-Yam, Israel. mdybarak@netvision.net.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baruch</LastName><ForeName>Yehuda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mazeh</LastName><ForeName>Doron</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Paleacu</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Aizenberg</LastName><ForeName>Dov</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17384319</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318030253a</ArticleId><ArticleId IdType="pii">15/4/354</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17374745</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3565</ISSN><JournalIssue CitedMedium="Print"><Volume>321</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.</ArticleTitle><Pagination><StartPage>1179</StartPage><EndPage>1182</EndPage><MedlinePgn>1179-82</MedlinePgn></Pagination><Abstract><AbstractText>Cholinergic receptors (AChR) are reported altered in brains from schizophrenic patients, and a growing body of evidence suggests that muscarinic receptor agonists exhibit antipsychotic potential. Centrally acting selective muscarinic receptor agonists are currently not available for clinical use, but acetylcholinesterase (AChE) inhibitors, which indirectly stimulate AChR by blocking the breakdown of acetylcholine by AChE, are widely used in the clinic against Alzheimer's disease. AChE inhibitors have been reported to exhibit antipsychotic efficacy in Alzheimer's disease patients, and these compounds have also been investigated as adjunctive treatment to antipsychotic medication in schizophrenic patients with varying results. However, monotherapy with AChE inhibitors in schizophrenic patients has not been evaluated. We wanted to investigate the antipsychotic potential of the AChE inhibitor galantamine, which also allosterically potentiates nicotinic receptor stimulation. To this end, we investigated its ability to antagonize d-amphetamine-induced psychotic-like behavior in extrapyramidal side effects (EPS)-primed Cebus monkeys. Galantamine inhibited d-amphetamine-induced unrest, arousal, and stereotypy. Side effects such as emesis, sedation, and EPS were minor or not existing. The results indicate that AChE inhibitors have antipsychotic potentials and suggest that clinical trials investigating antipsychotic effects of AChE inhibitors as monotherapy would be of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Maibritt B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Research Institute of Biological Psychiatry, Sct. Hans Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werge</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fink-Jensen</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>TZ47U051FI</RegistryNumber><NameOfSubstance UI="D003913">Dextroamphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002428" MajorTopicYN="N">Cebus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003913" MajorTopicYN="N">Dextroamphetamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018476" MajorTopicYN="N">Hypokinesia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013239" MajorTopicYN="N">Stereotyped Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17374745</ArticleId><ArticleId IdType="doi">10.1124/jpet.107.119677</ArticleId><ArticleId IdType="pii">jpet.107.119677</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17356347</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1543-3633</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology</Title><ISOAbbreviation>Cogn Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Educational level as a modulator of cognitive performance and neuropsychyatric features in Parkinson disease.</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>72</EndPage><MedlinePgn>68-72</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To test a possible association between the educational level (EL), cognitive performance, and neuropsychiatric features in Parkinson disease (PD).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An inverse association has been reported between EL and cognitive dysfunction in patients with senile dementia of Alzheimer type but it is yet unsettled whether education has a similar effect on cognition in PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Seventy-two PD patients (45 males, mean age 68.7+/-11.6 y) underwent a detailed neurologic examination, a battery of neuropsychologic tests, and questionnaires for the evaluation of psychosis, sleep disturbances, and depression. According to the number of educational years, patients were divided into 3 groups: low EL (0 to 8 y), (15 patients), intermediate EL (9 to 12 y) (28 patients), and high EL (&gt;/=13 y) (29 patients).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with a higher EL had a better cognitive function and an association was found between the patients' EL and their scores in various neuropsychologic tests mainly those sensitive to frontal lobe dysfunction. Low education was associated with an increased risk for hallucinations and a trend for more depression, delusions, and sleep disturbances.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The association between high educational attainment and the lower risk of cognitive dysfunction suggest that education might modulate cognitive performance in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Oren S</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>Parkinson's disease and Movement Disorders Clinic, Chaim Sheba Medical Center, Tel-Hashomer, Israel. oren.cohen@sheba.health.gov.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vakil</LastName><ForeName>Eli</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Tanne</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nitsan</LastName><ForeName>Zeev</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Roseline</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hassin-Baer</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cogn Behav Neurol</MedlineTA><NlmUniqueID>101167278</NlmUniqueID><ISSNLinking>1543-3633</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17356347</ArticleId><ArticleId IdType="doi">10.1097/WNN.0b013e3180335f8e</ArticleId><ArticleId IdType="pii">00146965-200703000-00012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17356308</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>251</EndPage><MedlinePgn>247-51</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and risperidone for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type (DAT). Twenty-eight patients with DAT were randomly assigned to treatment with either amisulpride or risperidone for 8 weeks. The effectiveness of the treatments was assessed with the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression-Severity of Illness (CGI-S) scale. The Simpson-Angus Rating Scale, the Barnes Akathisia Rating Scale and the Abnormal Involuntary Movement Scale were used for the assessment of side effects. The NPI and CGI-S scores were significantly decreased over time in both treatment groups without any significant group difference and time by treatment group interaction effect (F=71.85, p&lt;0.0001). There were no serious adverse events in both groups. This study showed that either amisulpride or risperidone would be effective and tolerable for treating patients with DAT. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion.</AbstractText><CopyrightInformation>(c) 2006 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Hyun-Kook</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kangnam St. Mary's Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pae</LastName><ForeName>Chi-Un</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chul</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chang-Uk</ForeName><Initials>CU</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7MNE9M8287</RegistryNumber><NameOfSubstance UI="D013469">Sulpiride</NameOfSubstance></Chemical><Chemical><RegistryNumber>8110R61I4U</RegistryNumber><NameOfSubstance UI="D000077582">Amisulpride</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077582" MajorTopicYN="N">Amisulpride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013469" MajorTopicYN="N">Sulpiride</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17356308</ArticleId><ArticleId IdType="doi">10.1159/000100779</ArticleId><ArticleId IdType="pii">000100779</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17322133</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Premorbid personality and behavioral and psychological symptoms in probable Alzheimer disease.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>213</EndPage><MedlinePgn>202-13</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Previous research investigating the influence of premorbid personality on behavioral and psychological symptoms in dementia (BPSD) has produced mixed findings. Addressing some limitations of previous studies, the authors aimed to investigate whether some of the common individual symptoms of BPSD (depression, anxiety, irritability, and aggression) were associated with key aspects of previous personality (neuroticism and agreeableness); and also to perform an exploratory investigation into the broader influence of personality factors on behavioral and psychological syndromes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred eight patients with a diagnosis of probable Alzheimer disease were assessed for the presence of BPSD over the disease course using the caregiver-rated Neuropsychiatric Inventory (NPI). One or two knowledgeable informants rated patients' midlife personalities using a retrospective version of the NEO-FFI questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Premorbid neuroticism was correlated with anxiety and total NPI score, although not with depression. Premorbid agreeableness was negatively correlated with agitation and irritability. Principal components analysis of the 10 NPI behavioral domains identified three syndromes: "agitation/apathy," "psychosis," and "affect." In stepwise linear regression analyses, including personality domains from the Five-Factor Model and a range of potential confounders as independent variables; the only significant personality predictor of a behavioral syndrome was "agitation/apathy," predicted by lower premorbid agreeableness.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lower premorbid agreeableness is associated with agitation and irritability symptoms in Alzheimer disease and also predicts an "agitation/apathy" syndrome. The relationship between premorbid neuroticism and BPSD is less straightforward, and premorbid neuroticism does not appear to be associated with depression in Alzheimer disease or predict an "affect" syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>King's College London, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, London, UK. N.Archer@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Richard G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Suzanne J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Boothby</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="Y">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17322133</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000232510.77213.10</ArticleId><ArticleId IdType="pii">15/3/202</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17310040</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2007</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Steroid dementia: a follow-up.</ArticleTitle><Pagination><StartPage>622</StartPage><MedlinePgn>622</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sacks</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, New York, NY, USA. mail@oliversacks.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2005 Feb 22;64(4):707-9. doi: 10.1212/01.WNL.0000151977.18440.C3</RefSource><PMID Version="1">15728296</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17310040</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000254625.14676.48</ArticleId><ArticleId IdType="pii">68/8/622</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17284093</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1172-7047</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>115</EndPage><MedlinePgn>101-15</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis of Alzheimer's disease (PAD) forms part of the behavioural and psychological symptoms of dementia (BPSD). PAD includes symptoms of psychosis such as hallucinations or delusions, and may be associated with agitation, negative symptoms or depression. Even though the US FDA has not approved any medication for the treatment of PAD, atypical antipsychotics have been widely used and favoured by geriatric experts in the management of the condition in view of their modest efficacy and relative safety. However, the recent FDA warnings regarding the cardiac, metabolic, cerebrovascular and mortality risks associated with the use of these drugs in elderly patients with dementia have caused serious concerns regarding their use. Nevertheless, until an effective and safe medication is approved by the regulatory agencies for PAD, clinicians do not have a better choice than atypical antipsychotics for the management of the serious symptoms of this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madhusoodanan</LastName><ForeName>Subramoniam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St John's Episcopal Hospital, 327 Beach 19th Street, Far Rockaway, New York 11691, USA. sdanan@ehs.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Payal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>87</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17284093</ArticleId><ArticleId IdType="doi">10.2165/00023210-200721020-00002</ArticleId><ArticleId IdType="pii">2122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Geriatr Psychiatry. 2001 Winter;9(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">11156753</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2001 Summer;9(3):283-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11481137</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Sep;14(9):767-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16905684</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18 Suppl 1:S9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15249843</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jul;157(7):1150-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10873925</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Jul 27;63(2):214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15277611</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jun 27;54(12):2269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Manag Care Interface. 2003 May;16(5):64-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12789866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Oct;57(10 ):968-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2005 Nov;10(11 Suppl 18):22-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16273027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):134-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Aug 28;57(4):613-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11524468</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2241</Citation><ArticleIdList><ArticleId IdType="pubmed">14638601</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Apr 16;330(7496):874</Citation><ArticleIdList><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15220031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Jun;85(6):453-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1642129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Forensic Sci. 2002 Jul;47(4):893-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12137003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1997 Fall;9(4):591-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9447502</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Jan 21;291(3):317-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Aug;66(8):1071</Citation><ArticleIdList><ArticleId IdType="pubmed">16086625</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Mar;14 (3):191-210</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Jan;155(1):54-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9433339</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Winter;8(1):29-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 May;146(5):577-87</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Oct 19;294(15):1934-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2001 Dec;49(12):1590-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11843990</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 Dec;16(12):1156-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11748775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2002;(2):CD002852</Citation><ArticleIdList><ArticleId IdType="pubmed">12076456</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26</Citation><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Aug;13(8):722-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16085789</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Jun;161(6):1113-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15169702</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2005 Jan;Spec No:6-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17203561</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Oct;149(10):1390-2</Citation><ArticleIdList><ArticleId IdType="pubmed">1530076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11606667</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Oct 12;355(15):1525-38</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Oct;61(10 ):742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11078035</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2004 Feb;27(2):596-601</Citation><ArticleIdList><ArticleId IdType="pubmed">14747245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Oct;59(10):550-61; quiz 562-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9818639</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1999 Jun;47(6):716-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10366172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2002 Jul;22(7):841-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12126218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 May;48 Suppl:9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1988 Feb 1;23(3):271-84</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 2003 Sep-Oct;10 (5):348-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12975719</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1996 Jan-Feb;37(1):12-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8600488</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2001 Fall;9(4):400-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11739066</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 May;38(5):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Apr 3;348(14):1333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):434-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12837672</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2002 Apr;26(4):494-504</Citation><ArticleIdList><ArticleId IdType="pubmed">11927174</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1989 Jan;25(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Oct;65(10):1329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15491235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol A Biol Sci Med Sci. 2005 May;60(5):622-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15972615</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Nov 14;55(9):1271-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11087767</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Mar 11;340(10 ):757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10072410</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2006;21(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16244481</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Oct 15;44(8):778-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9798083</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2003 Jan-Feb;26(1):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12567158</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Sep 22;53(5):946-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Jan;19(1):9-18</Citation><ArticleIdList><ArticleId IdType="pubmed">14716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Mar;159(3):460-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 May;20(5):459-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15852444</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Nov;13(11):942-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16286437</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2003;20(11):833-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12964889</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1991 Feb 1;29(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2015329</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1990 Oct 23;187(3):435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">2127400</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Feb 2;293(5):596-608</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jan 8;289(2):210-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12517232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17267378</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><MedlineDate>2006 Dec-2007 Jan</MedlineDate></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>453</EndPage><MedlinePgn>448-53</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral symptoms start to appear in mild and moderate dementia and become increasingly severe with the progression of the disease. Agitation, aggressiveness, and psychosis can be seen in Alzheimer's disease, and in particular are common manifestations in Lewy body dementia. It is the behavioral disturbances rather than the cognitive disorders that are more often the cause of the institutionalization of these patients because of the heavy assistance and emotional burden they represent for caregivers. Traditionally, these kinds of symptoms were controlled by classical antipsychotic agents, which after long-term use cause severe extrapyramidal effects, late dyskinesia, sedation, orthostatic hypotension, and cognitive function impairment. More recently, atypical antipsychotic agents have shown a better tolerability profile, with a reduced incidence of extrapyramidal effects, orthostatic hypotension, sedation, and a reduced impact on cognitive function. The aim of this study is to evaluate the efficacy and tolerability of quetiapine in a group of patients with a diagnosis of dementia and concomitant psychotic disorders. The response to treatment was evaluated by the Neuropsychiatric Inventory (NPI) and the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). The NPI and BEHAVE-AD were administered at baseline and after 4 weeks and 12 weeks of therapy. Tolerability was assessed by the incidence of clinically evident side effects. The results show that quetiapine is effective in reducing behavioral symptoms, deliria and hallucinations, aggressiveness, and sleep disturbances. Quetiapine tolerability proved to be satisfactory. The only side effect of clinical significance was orthostatic hypotension, which was, however, partially preventable by a slower drug titration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onor</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Clinical, Morphological and Technological Science, University of Trieste, Italy. marialuisa.onor@libero.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saina</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Aguglia</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004361" MajorTopicYN="N">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17267378</ArticleId><ArticleId IdType="doi">10.1177/1533317506294775</ArticleId><ArticleId IdType="pii">21/6/448</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17257504</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2008</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Quetiapine for psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>6</EndPage><MedlinePgn>5-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>Raymond L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17257504</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17254747</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0753-3322</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>2-3</Issue><PubDate><Year>2007</Year><Season>Feb-Apr</Season></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Dietary omega-3 fatty acids for women.</ArticleTitle><Pagination><StartPage>105</StartPage><EndPage>112</EndPage><MedlinePgn>105-12</MedlinePgn></Pagination><Abstract><AbstractText>This review details the specific needs of women for omega-3 fatty acids, including alpha linoleic acid (ALA) and the very long chain fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omega-3 fatty acid (dietary or in capsules) ensures that a woman's adipose tissue contains a reserve of these fatty acids for the developing fetus and the breast-fed newborn infant. This ensures the optimal cerebral and cognitive development of the infant. The presence of large quantities of EPA and DHA in the diet slightly lengthens pregnancy, and improves its quality. Human milk contains both ALA and DHA, unlike that of other mammals. Conditions such as diabetes can alter the fatty acid profile of mother's milk, while certain diets, like those of vegetarians, vegans, or even macrobiotic diets, can have the same effect, if they do not include seafood. ALA, DHA and EPA, are important for preventing ischemic cardiovascular disease in women of all ages. Omega-3 fatty acids can help to prevent the development of certain cancers, particularly those of the breast and colon, and possibly of the uterus and the skin, and are likely to reduce the risk of postpartum depression, manic-depressive psychosis, dementias (Alzheimer's disease and others), hypertension, toxemia, diabetes and, to a certain extend, age-related macular degeneration. Omega-3 fatty acids could play a positive role in the prevention of menstrual syndrome and postmenopausal hot flushes. The normal western diet contains little ALA (less than 50% of the RDA). The only adequate sources are rapeseed oil (canola), walnuts and so-called "omega-3" eggs (similar to wild-type or Cretan eggs). The amounts of EPA and DHA in the diet vary greatly from person to person. The only good sources are fish and seafood, together with "omega-3" eggs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bourre</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>INSERM U 705, CNRS UMR 7157, Universit&#xe9;s Paris 7 et 5, H&#xf4;pital Fernand Widal, 200 rue du Faubourg Saint Denis, 75745 Paris cedex 10, France. jean-marie.bourre@fwidal.inserm.fr</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RBV727H71</RegistryNumber><NameOfSubstance UI="D017962">alpha-Linolenic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>25167-62-8</RegistryNumber><NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>AAN7QOV9EA</RegistryNumber><NameOfSubstance UI="D015118">Eicosapentaenoic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015118" MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047109" MajorTopicYN="N">Fetal Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018673" MajorTopicYN="N">Nutrition Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009751" MajorTopicYN="Y">Nutritional Requirements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009753" MajorTopicYN="N">Nutritive Value</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017747" MajorTopicYN="N">Seafood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="N">Women's Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017962" MajorTopicYN="N">alpha-Linolenic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>103</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17254747</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2006.09.015</ArticleId><ArticleId IdType="pii">S0753-3322(06)00346-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17242775</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0104-4230</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Revista da Associacao Medica Brasileira (1992)</Title><ISOAbbreviation>Rev Assoc Med Bras (1992)</ISOAbbreviation></Journal><ArticleTitle>[Brief cognitive evaluation and diagnosis of dementia, depression, and psychosis in the elderly].</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>404</EndPage><MedlinePgn>401-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the cognitive performance of the elderly with psychosis, depression and dementia in a mental health outpatient unit.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Mini-Mental State Examination (MMSE) and the Cambridge Cognitive Examination (CAMCOG) were applied to 86 patients above 60 years of age referred for evaluation due to memory complaints. Patients were diagnosed according to DSM IV criteria. Socio-demographic data were expressed as means (standard deviation); MMSE and CAMCOG score of patients with psychosis, dementia and mood disorders were compared using Student's T test and ANOVA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the total sample (age: 70.87 (sd=6.61); male=32; female=54; illiterate=41, educated=45; 17 (19.7%) had dementia, 11 (12.8%) psychosis and 58 (67.4%) mood disorders. The MMSE of the total sample was 21.07 (sd=6.61) and the CAMCOG = 61.50 (sd=19.78). MMSE/CAMCOG of each diagnosis: Dementia: 16.76 (sd=6.25)/48(sd=20.49); Psychosis: 20.9 (sd=5.87)/60.09 (sd=13.54); mood disorders: 22.36 (sd=5.49)/66.03 (sd=18.88). The MMSE and CAMCOG scores of patients with dementia were significantly lower than those of patients with mood disorders (ANOVA p &lt; 0.01). The score of patients with psychosis was not different from scores of those with dementia and mood disorders (p &gt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A brief cognitive evaluation permits a differentiation between dementia and depression but not between psychosis and depression in elderly patients of a psychiatric outpatient unit, who had complained of memory impairment. These data may be useful to develop an easy and low cost protocol to attend the population of public health services.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reys</LastName><ForeName>Bruno Netto dos</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Centro para Doen&#xe7;a de Alzheimer, Instituto de Psiquiatria, UFRJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Ana Beatriz</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Vilela</LastName><ForeName>Ana Lucia de Sousa</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Keusen</LastName><ForeName>Alexandre Lins</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Marinho</LastName><ForeName>Valeska</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Paula</LastName><ForeName>Estev&#xe3;o de</ForeName><Initials>Ed</Initials></Author><Author ValidYN="Y"><LastName>Laks</LastName><ForeName>Jerson</ForeName><Initials>J</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Diagn&#xf3;stico de dem&#xea;ncia, depress&#xe3;o e psicose em idosos por avalia&#xe7;&#xe3;o cognitiva breve.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Assoc Med Bras (1992)</MedlineTA><NlmUniqueID>9308586</NlmUniqueID><ISSNLinking>0104-4230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17242775</ArticleId><ArticleId IdType="doi">10.1590/s0104-42302006000600018</ArticleId><ArticleId IdType="pii">S0104-42302006000600018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17211052</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1419-8711</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacol Hung</ISOAbbreviation></Journal><ArticleTitle>[New formulations of olanzapine in the treatment of acute agitation].</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>178</EndPage><MedlinePgn>171-8</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Agitation is common in patients with acute schizophrenia or bipolar mania, and when severe can result in aggressive or violent behaviour. Pharmacotherapy for acute psychotic agitation includes the use of antipsychotic and benzodiazepine drugs, either alone or in combination. Although oral treatment is preferred, options in the pharmacotherapy of acute agitation include the parenteral administration of antipsychotics in order to facilitate onset of drug action and quickly alleviate symptoms. Until recently only conventional antipsychotic and benzodiazepine drugs were available as intramuscular injections. Olanzapine has been one of the first atypical antipsychotics available for intramuscular administration. Four randomized placebo and comparator controlled , double-blind clinical trials have demonstrated the efficacy of olanzapine in reducing acute agitation in patients with schizophrenia, bipolar mania and Alzheimer and vascular dementia. Evidence from these clinical trials has shown that IM olanzapine associated with faster onset of action and more favorable profile of adverse events, than monotherapy with IM haloperidol. Current clinical experience and one naturalistic study with intramuscular olanzapine suggest that it is efficacious and can be safely used in "real world" patients with severe agitation. Intramuscular olanzapine have shown ease of transition to same agent oral therapy once the acute agitation has diminished. The orally disintegrating tablet formulation of olanzapine was effective rapidly reducing psychopathology, while improving medication compliance, attitudes and behaviours. This new formulation of olanzapine may offer an alternative strategy in the treatment of acutely ill, noncompliant schizophrenic patients. Evidence suggests that the new formulations of olanzapine should be among the first-line choices in the treatment of agitation in acute psychosis.</AbstractText><AbstractText Label="KEYWORDS" NlmCategory="BACKGROUND">olanzapine, intramuscular, orally disintegrating tablet, agitation, psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartk&#xf3;</LastName><ForeName>Gy&#xf6;rgy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Jahn Ferenc D&#xe9;l-pesti Psychiatric Hospital, Budapest, Hungary. bartkogy@jahndelpest.hu</Affiliation></AffiliationInfo></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Az olanzapin &#xfa;j gy&#xf3;gyszerform&#xe1;i az akut agit&#xe1;ci&#xf3; kezel&#xe9;s&#xe9;ben.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Neuropsychopharmacol Hung</MedlineTA><NlmUniqueID>100961631</NlmUniqueID><ISSNLinking>1419-8711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001290" MajorTopicYN="N">Attitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>20</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17211052</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17203561</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2007</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0032-5481</ISSN><JournalIssue CitedMedium="Print"><Volume>Spec No</Volume><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Postgraduate medicine</Title><ISOAbbreviation>Postgrad Med</ISOAbbreviation></Journal><ArticleTitle>The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.</ArticleTitle><Pagination><StartPage>6</StartPage><EndPage>22</EndPage><MedlinePgn>6-22</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">New treatment options for dementia and its behavioral disturbances have become available since publication of The Expert Consensus Guidelines on the Treatment of Agitation in Older Persons with Dementia in 1998. While only 2 cholinesterase inhibitors, donepezil and tacrine, were available in 1998, 3 new cognitive-enhancing agents have been introduced since that time as well as several new atypical antipsychotics and antidepressants. However, there are still limited data from controlled studies to guide clinicians in choosing among these agents and sequencing and combining treatments. We therefore conducted a new survey study of expert opinion on the treatment of cognitive impairment and behavioral disturbances associated with dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Based on a literature review, a 61-question survey was developed with 1,225 options. Most options were scored using a modified version of the RAND 9-point scale for rating appropriateness of medical decisions. For other options, the experts were asked to write in answers. The survey was sent to 50 North American experts on dementia, 100% of whom completed it. In analyzing responses to items rated on the 9-point scale, consensus was defined as a nonrandom distribution of scores by chi-square "goodness-of-fit" test. Based on the 95% confidence interval around the mean, we assigned a categorical rank (first line/preferred, second line/alternate, third line/usually inappropriate) to each option. Guidelines indicating preferred treatment strategies were then developed for selected clinical situations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For patients at risk for dementia, the experts recommended control of hypertension and diabetes. They also recommended aspirin and would consider a lipid-lowering agent in patients at risk for vascular dementia. Cholinesterase inhibitors were an option for patients with mild cognitive impairment (i.e., at risk for Alzheimer's dementia [AD]). To slow cognitive impairment in mild/moderate AD, the experts recommended a cholinesterase inhibitor alone or combined with vitamin E. Donepezil and galantamine were the preferred cholinesterase inhibitors. The experts recommended combining a cholinesterase inhibitor with a N-methyl-D-aspartate (NMDA) antagonist (e.g., memantine) if a patient with mild/moderate dementia has an inadequate response to monotherapy. Control of hypertension and diabetes was the treatment of choice, in patients with mild/moderate vascular or mixed AD/vascular dementia, with aspirin another first-line option. Cholinesterase inhibitors were also a first-line option for mild/moderate mixed AD/vascular dementia. Among nonpharmacological interventions for mild/moderate dementia, the experts recommended caregiver education, supportive therapy for caregivers, referral to day treatment, exercise programs, and respite care. For moderate/severe AD or mixed AD/vascular dementia, the experts recommended combining an NMDA antagonist with a cholinesterase inhibitor. For moderate/severe vascular or mixed AD/vascular dementia, they recommended control of hypertension and diabetes. The experts' ratings underscore the importance of nonpharmacological strategies aimed at reducing caregiver burden in more severe dementia. Management of agitation and other behavioral disturbances was another focus of this study. The experts recommended using an atypical antipsychotic for agitation associated with delirium, psychosis, aggression, or anger. They would also consider divalproex to manage anger with a risk of physical aggression. Selective serotonin reuptake inhibitors were recommended for the treatment of depression or anxiety in patients with dementia. Benzodiazepines or atypical antipsychotics were viewed as short-term options for acute anxiety. Trazodone was recommended for insomnia. The experts also gave recommendations concerning dosage levels, duration of treatment, and choice of medications for patients with different complicating conditions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The experts reached high levels of consensus on key steps in treating dementia and associated behavioral disturbances. Within the limits of expert opinion and with the expectation that new research data will take precedence, these guidelines may provide direction for clinicians offering care to patients with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Docherty</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Postgrad Med</MedlineTA><NlmUniqueID>0401147</NlmUniqueID><ISSNLinking>0032-5481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Psychiatr Pract. 2007 May;13(3):207-16. doi: 10.1097/01.pra.0000271667.53717.9f</RefSource><PMID Version="1">17522567</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17203561</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29213374</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1980-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Dementia &amp; neuropsychologia</Title><ISOAbbreviation>Dement Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Reports by caregivers of behavioral and psychological symptoms of dementia.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>103</EndPage><MedlinePgn>97-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1980-57642008DN10100015</ELocationID><Abstract><AbstractText Label="UNLABELLED">Behavioral and Psychological Symptoms of Dementia (BPSD) are relevant since they are frequent and cause distress to caregivers. However, they may not be reported by physicians due to the priority usually attributed to cognitive symptoms.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To verify whether BPSD is being systematically investigated by physicians even in specialized settings and whether their records on medical files are accurate.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Assessment of records on medical files of BPSD reported by caregivers to 182 patients (57.1% men, mean age 67.6&#xb1;13.5 years) assisted in a tertiary-care behavioral neurology outpatient clinic (BNOC) who also had appointments in other clinics of the same hospital. Alzheimer's disease (37.9%) and vascular disease (19.2%) were the most frequent causes of dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Report/appointment ratios were 0.58 in BNOC, 0.43 in other neurological, 0.93 in psychiatric and 0.20 in non-neurological, non-psychiatric clinics. BPSD most frequently recorded in BNOC were insomnia, aggressiveness, agitation/hyperactivity, visual hallucinations, apathy, inadequate behavior and ease of crying. Sorted by psychiatrists, categories associated to more BPSD were affect/mood, thought and personality/behavior. affect/mood and sensoperception symptoms were the most frequently reported. Sorted according to Neuropsychiatric Inventory (NPI), categories associated to more BPSD were depression/dysphoria, delusion and apathy/indifference. depression/dysphoria and agitation/ aggression symptoms were the most frequently reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BPSD reported by caregivers were very diverse and were not systematically investigated by physicians. Notes in medical files often contained non-technical terms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>do Vale</LastName><ForeName>Francisco de Assis Carvalho</ForeName><Initials>FAC</Initials><AffiliationInfo><Affiliation>Neurologist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarnieri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Psychiatrist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liboni</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatrist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balieiro</LastName><ForeName>Ari Pedro</ForeName><Initials>AP</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Psychologist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva-Filho</LastName><ForeName>Jos&#xe9; Humberto</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Psychologist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Miranda</LastName><ForeName>St&#xea;nio Jos&#xe9; Correia</ForeName><Initials>SJC</Initials><AffiliationInfo><Affiliation>Neurologist, Behavioral Neurology Group, Clinics Hospital of the Ribeir&#xe3;o Preto Faculty of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Dement Neuropsychol</MedlineTA><NlmUniqueID>101506587</NlmUniqueID><ISSNLinking>1980-5764</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="UNLABELLED">Sintomas Comportamentais e Psicol&#xf3;gicos de Dem&#xea;ncia (SCPD) s&#xe3;o relevantes, pois s&#xe3;o freq&#xfc;entes e causam estresse aos cuidadores. Contudo, podem n&#xe3;o ser relatados pelos m&#xe9;dicos devido &#xe0; prioridade usualmente atribu&#xed;da aos sintomas cognitivos.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Verificar que SCPD podem n&#xe3;o ser sistematicamente investigados pelos m&#xe9;dicos mesmo em ambientes especializados e que seus registros nos prontu&#xe1;rios podem ser imprecisos.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Avalia&#xe7;&#xe3;o dos registros nos prontu&#xe1;rios m&#xe9;dicos dos SCPD de relatos de cuidadores de 182 pacientes (57,1% homens, idade m&#xe9;dia 67,6&#xb1;13,5 anos) assistidos em um ambulat&#xf3;rio de neurologia comportamental (ANCP), que tamb&#xe9;m tiveram consultas em outras cl&#xed;nicas neurol&#xf3;gicas, psiqui&#xe1;tricas, n&#xe3;o-neurol&#xf3;gicas e n&#xe3;o-psiqui&#xe1;tricas do mesmo hospital. Doen&#xe7;a de Alzheimer (37,9%) e doen&#xe7;a vascular (19,2%) foram as causas mais freq&#xfc;entes de dem&#xea;ncia.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">As raz&#xf5;es relato/consulta foram 0,58 no ANCP, 0,43 em outros ambulat&#xf3;rios neurol&#xf3;gicos, 0,93 em ambulat&#xf3;rios psiqui&#xe1;tricos e 0,20 em outros ambulat&#xf3;rios n&#xe3;o-neurol&#xf3;gicos e n&#xe3;o-psiqui&#xe1;tricos. SCPD mais freq&#xfc;entemente anotados no ANCP foram ins&#xf4;nia, agressividade, agita&#xe7;&#xe3;o/ hiperatividade, alucina&#xe7;&#xf5;es visuais, apatia, comportamento inadequado e choro f&#xe1;cil. Classificados por psiquiatras, as categorias reunindo mais SCPD foram afeto/humor, pensamento e personalidade/comportamento. sintomas de afeto/humor e sensopercep&#xe7;&#xe3;o foram os mais freq&#xfc;entemente relatados. Classificados de acordo com o Invent&#xe1;rio Neuropsiqui&#xe1;trico (INP), as categorias reunindo mais SCPD foram depress&#xe3;o/disforia, del&#xed;rio e apatia/indiferen&#xe7;a. sintomas de depress&#xe3;o/disforia e agita&#xe7;&#xe3;o/agress&#xe3;o foram os mais freq&#xfc;entemente relatados.</AbstractText><AbstractText Label="CONCLUS&#xd5;ES" NlmCategory="UNASSIGNED">SCPD relatados pelos cuidadores eram muito diversos e n&#xe3;o eram sistematicamente investigados pelos m&#xe9;dicos. Anota&#xe7;&#xf5;es nos prontu&#xe1;rios eram freq&#xfc;entemente feitas com termos n&#xe3;o t&#xe9;cnicos.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BPSD</Keyword><Keyword MajorTopicYN="N">behavioral symptoms</Keyword><Keyword MajorTopicYN="N">caregiver</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">mood disorders</Keyword><Keyword MajorTopicYN="N">personality disorders</Keyword><Keyword MajorTopicYN="N">psychotic disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29213374</ArticleId><ArticleId IdType="pmc">PMC5619390</ArticleId><ArticleId IdType="doi">10.1590/S1980-57642008DN10100015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Psychogeriatric Association . Behavioral and Psychological Symptoms of Dementia (BPSD) Educational Pack; 1998.</Citation></Reference><Reference><Citation>Sultzer DL, Brown CV, Mandelkern MA. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 2003;160:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562582</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Baldinetti F, Buccione I. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. J Neurol. 2004;251:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311344</ArticleId></ArticleIdList></Reference><Reference><Citation>Derouesne C, Piquard A, Thibault S, Baudouin-Madec V, Lacomblez L. Noncognitive symptoms in Alzheimer's disease. A study of 150 community-dwelling patients using a questionnaire completed by the caregiver. Rev Neurol (Paris) 2001;157:162&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Ames D, Prince M. Dementia Research Group Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr. 2004;16:441&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715360</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Draper BM, Low LF. Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. Med J Aust. 2003;178:231&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemels MEH, Lanct&#xf4;t KL, Iskedjian M, Einarson TR. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging. 2001;18:527&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11482746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto C, Seethalakshmi R. Behavioral and psychological symptoms of dementia in an Indian population: comparison between Alzheimer's disease and vascular dementia. Int Psychogeriatr. 2006:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16466592</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccininni M, Carlo AD, Baldereschi M, Zaccara G, Inzitari D. Behavioral and psychological symptoms in Alzheimer's disease: Frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord. 2005;19:276&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15775717</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro J, Awata S, Matsuoka H. Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients. Psychiatry Clin Neurosci. 2005;59:274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart DJ, Craig D, Compton SA. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">14618556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow TW, Liu CK, Fuh JL. Neuropsychiatric symptoms of Alzheimer&#xb4;s disease differ in Chinese and American patients. Int J Geriatr Psychiatry. 2002;17:22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr. 2001;13:121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352329</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde G, Quiroga P, Fasce M, Fasce F. Noncognitive symptoms in Alzheimer disease and caregivers distress in Chile. Brain Cogn. 2002;49:253&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15259404</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang FC, Chow TW, Cummings JL. Effect of neuropsychiatric symptoms of Alzheimer&#xb4;s disease on Chinese and American caregivers. Int J Geriatr Psychiatry. 2002;17:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802227</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguglia E, Onor ML, Trevisiol M, Negro C, Saina M, Maso E. Stress in the caregivers of Alzheimer's patients: an experimental investigation in Italy. Am J Alzheimers Dis Other Demen. 2004;19:248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833810</ArticleId><ArticleId IdType="pubmed">15359564</ArticleId></ArticleIdList></Reference><Reference><Citation>Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:248&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12468899</ArticleId></ArticleIdList></Reference><Reference><Citation>Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59:1721&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale FAC, Miranda SJC. Clinical and demographic features of patients with dementia attended in a tertiary outpatient clinic. Arq Neuropsiquiatr. 2002;60:548&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">12244388</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TK, Erkinjuntti T. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups, editor. J Neurol Neurosurg Psychiatry. 1994;57:416&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072868</ArticleId><ArticleId IdType="pubmed">8163988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia AL, Godinho C, Ferreira ED, et al. Application of the Brazilian version of the CDR scale in samples of dementia patients. Arq Neuropsiquiatr. 2006;64:485&#x2013;4899.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917624</ArticleId></ArticleIdList></Reference><Reference><Citation>Montano MB, Ramos LR. Validity of the Portuguese version of Clinical Dementia Rating. Rev Saude Publica. 2005;39:912&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. The Neuropsychiatric Inventory assessing psychopathogy in dementia patients. Neurology. 1997;44(Suppl 6):S10&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17194816</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2006</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Heterogeneity in risk factors for cognitive impairment, no dementia: population-based longitudinal study from the Kungsholmen Project.</ArticleTitle><Pagination><StartPage>60</StartPage><EndPage>69</EndPage><MedlinePgn>60-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objectives of this study were to investigate the relation of vascular, neuropsychiatric, social, and frailty-related factors with "Cognitive impairment, no dementia" (CIND) and to verify their effect independently of future progression to Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Seven hundred eighteen subjects aged 75+ years who attended baseline, 3- and 6-year follow-up examinations of the Kungsholmen Project, a Swedish prospective cohort study, were studied. CIND was defined according to the performance on the Mini-Mental State Examination. Potential risk factors were collected at baseline and clustered according to four research hypotheses (frailty, vascular, neuropsychiatric, and social hypothesis), each representing a possible pathophysiological mechanism of CIND independently of subsequent development of AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a mean 3.4 years of follow up, 82 participants (11.4%) developed CIND. When the population was subsequently followed for a mean of 2.7 years, subjects with CIND had a threefold increased risk to progress to AD. After multiple adjustments, including adjustment for the development of AD at the 6-year follow up, risk factors for CIND were hip fracture, polypharmacy, and psychoses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results suggest that not only the AD-type neurodegenerative process, but also neuropsychiatric- and frailty-related factors may induce cognitive impairment in nondemented elderly. These findings may have relevant preventive and therapeutic implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monastero</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Aging Research Center, Division of Geriatric Epidemiology, Department for Neurobiology, Health Care Sciences, and Society, Karolinska Institutet, Stockholm Gerontology Research Center, Stockholm, Sweden. roberto.monastero@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Chengxuan</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="N">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17194816</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000229667.98607.34</ArticleId><ArticleId IdType="pii">15/1/60</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17192763</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.</ArticleTitle><Pagination><StartPage>46</StartPage><EndPage>50</EndPage><MedlinePgn>46-50</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The behavioral and psychological symptoms of dementia present a major challenge in the management of these patients. There is no Food and Drug Administration-indicated medication for the management of these symptoms. Even though atypical antipsychotics are considered safer than conventional antipsychotics, safety concerns have emerged.</AbstractText><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The FDA has issued warnings regarding the cardiac and metabolic side effects, cerebrovascular events, and, most recently, mortality risk. This study was conducted in 2003 when physicians were notified of the cerebrovascular risks of risperidone. Since then, similar warnings have been issued for olanzapine and aripiprazole.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The medical records of 58 elderly dementia patients who were taking risperidone and were abruptly switched to olanzapine were reviewed. Clinical Global Impressions scale at assigned retrospectively at switch, and weeks 4-6 assessed treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline and follow-up Clinical Global Impressions scale scores were essentially unchanged. Adverse events were mild to moderate in severity. Mean risperidone dose at switch was 1.54 mg/day (range: 0.25-6 mg/day). Mean olanzapine dose after the switch was 5.69 mg/day (range: 2.52-27.5 mg/day).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Most of the 58 patients were switched from risperidone to olanzapine without any deterioration in their clinical status. Even though it is generally not recommended in elderly patients, abrupt switching did not have any negative consequences in this group of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madhusoodanan</LastName><ForeName>Subramoniam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Peninsula Hospital Center, USA. sdanan@ehs.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogunovic</LastName><ForeName>Olivera</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17192763</ArticleId><ArticleId IdType="doi">10.1017/s1092852900020514</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17186187</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[A pilot project with clowns in psychiatric clinics].</ArticleTitle><Pagination><StartPage>571</StartPage><EndPage>574</EndPage><MedlinePgn>571-4</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This project examines whether visits of specially trained clinic clowns, as established in pediatrics, would also be useful in psychiatry.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We describe the effects of a 6-week phase with one clown visit per week in a ward for acutely ill geriatric patients. The patients and medical team were also questioned about their attitudes towards the clowns.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found more positive attitudes in patients after this phase.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We interpret this result as an indication of positive effects and sufficient reason to initiate similar projects in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>bawild@med.uni-tuebingen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetzel</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gottwald</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Buchkremer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wormstall</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Clowns in der Psychiatrie? Ein Pilotprojekt.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027641" MajorTopicYN="Y">Laughter Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="Y">Psychiatric Department, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014925" MajorTopicYN="Y">Wit and Humor as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17186187</ArticleId><ArticleId IdType="doi">10.1007/s00115-006-2076-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Bull. 2001 Jul;127(4):504-19</Citation><ArticleIdList><ArticleId IdType="pubmed">11439709</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2003 Oct;126(Pt 10):2121-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12902310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17184138</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1936-5764</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Geriatrics</Title><ISOAbbreviation>Geriatrics</ISOAbbreviation></Journal><ArticleTitle>Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options.</ArticleTitle><Pagination><StartPage>14</StartPage><EndPage>20</EndPage><MedlinePgn>14-20</MedlinePgn></Pagination><Abstract><AbstractText>Approximately 50% to 80% of persons diagnosed with Alzheimer's disease (AD) have some type of behavioral or psychiatric condition (eg, agitation, psychosis, and/or disinhibition). Agitation is defined in the context of restlessness, irritability, and resistiveness. Psychosis is recognized as a disturbance in the perception of objective reality. Disinhibition means a chronic loss of social restraint. In the case of AD, disinhibition can present as aggression, hyperactivity, and socially intrusive behavior. Such conditions can be burdensome for physicians and caregivers to manage. Consequences may include caregiver burnout or illness, patient abuse, and even institutionalization for the patient. Management of behavioral disturbances is no longer primarily handled by psychiatrists, but is now entering the realm of family practice and primary care. This article provides evaluation methods and treatment options for the aforementioned behavioral disturbances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesser</LastName><ForeName>Jary M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Geropsychiatry Clinic, University of Texas Medical School, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatrics</MedlineTA><NlmUniqueID>2985102R</NlmUniqueID><ISSNLinking>0016-867X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>25</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17184138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17183148</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease.</ArticleTitle><Pagination><StartPage>371</StartPage><EndPage>378</EndPage><MedlinePgn>371-8</MedlinePgn></Pagination><Abstract><AbstractText>Patients with Alzheimer disease (AD) often exhibit psychiatric symptoms associated with cognitive impairment. The serotoninergic system may be involved in the development of depressive symptoms in AD patients, as suggested by the evidence that antidepressant drugs having the serotonin transporter as their target are effectively used to treat depressive AD patients. The aim of this study was to investigate the role of serotonin in depression, searching for association of two serotoninergic polymorphisms (T102C of serotonin receptor 5-HT2A and serotonin transporter linked polymorphic region -5-HTTLPR- of SLC6A4 gene) with depressive symptoms and considering their possible interactions with Apolipoprotein E (ApoE) and between themselves, in a sample of 208 sporadic AD patients and 116 normal controls from Italy. 5-HTTLPR and T102C are not associated with AD when separately analysed. However, we found out an interaction between the two polymorphisms in L/L and C/C genotype carriers increasing the risk for the disease (p=0.015, OR=8.048; 95% CI: 1.497-43.262). No association of the polymorphisms was detected with depression linked to AD. No interaction between 5-HTTLPR and T102C was detected in depressive AD subjects, even after stratification according to the presence of ApoE4 allele. These results suggest that the serotoninergic system may be not involved in the pathogenesis of depressive symptoms in AD patients, and it may be involved in other aspects of disease pathophysiology like cognitive symptoms and psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Micheli</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Neurological Clinic, University of Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonvicini</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ceravolo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tognoni</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gennarelli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17183148</ArticleId><ArticleId IdType="doi">10.3233/jad-2006-10405</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17180865</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0260-1060</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Nutrition and health</Title><ISOAbbreviation>Nutr Health</ISOAbbreviation></Journal><ArticleTitle>Are neurodegenerative disorder and psychotic manifestations avoidable brain dysfunctions with adequate dietary omega-3?</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>215</EndPage><MedlinePgn>203-15</MedlinePgn></Pagination><Abstract><AbstractText>The present mismatch between what our brain needs, and the modern diet neglects our marine heritage. Last century, the priority in nutrition and food production was to achieve a high protein diet and somatic growth and function. The dietary content of omega-3 (N-3) required by the brain was neglected although evidence for the essentiality of certain fatty acids was published in 1929 and specifically re-affirmed for omega 3 in the brain in the 1970s. Cognitive decline with age and neurodegenerative disorder with dementia are now rising. This review describes signs of N-3 deficit in Alzheimer and Parkinson Disease, where maximum change involves the primary sites: olfactory cortex and the hippocampus. The olfactory agnosia observed in schizophrenia supports an N-3 deficit as does a reduction of key ologodendrocyte- and myelin-related genes in this disorder and affective disorder, where a rise in dementia accords with a deficit of N-3 also in this disorder. N-3 normalizes cerebral excitability at all levels. That the two disorders are localized at the extremes of excitability, is supported by their opposing treatments: convulsant neuroleptics and anti-epileptic antidepressants. An adequate N-3 diet will probably prevent most psychotic episodes and prove that neurodegenerative disorder with dementia is also to a large extent not only preventable but avoidable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saugstad</LastName><ForeName>Letten F</ForeName><Initials>LF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nutr Health</MedlineTA><NlmUniqueID>8306569</NlmUniqueID><ISSNLinking>0260-1060</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ReprintOf"><RefSource>Nutr Health. 2006;18(2):89-101. doi: 10.1177/026010600601800201</RefSource><PMID Version="1">16859172</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17180865</ArticleId><ArticleId IdType="doi">10.1177/026010600601800302</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17157125</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0149-2918</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.</ArticleTitle><Pagination><StartPage>1695</StartPage><EndPage>1700</EndPage><MedlinePgn>1695-700</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In addition to cognitive decline, 30% to 40% of patients with Alzheimer's disease (AD) experience concomitant psychiatric and behavioral complications, such as hallucinations, delusions, and aggression. Atypical antipsychotics (AAs) are used to treat psychosis and aggressive behaviors in these patients; however, data regarding their early effects on cognition are conflicting. Based on a literature search, the cognitive effects of long-term treatment with AAs in outpatients with AD have not been studied.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to describe and compare the rate of cognitive decline with longterm AA use in adult patients with AD receiving concomitant treatment with cholinesterase inhibitors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was conducted at the Department of Neurology, The Ohio State University, Columbus, Ohio. Data were collected from the charts of adult outpatients who (1) received care at Memory Disorders Clinic, Columbus, Ohio, between April 2003 and June 2005; (2) were aged &gt; or =55 years with a diagnosis of mild to severe definite or probable AD; (3) received an AA for &gt; or =6 months or did not receive any AA; and (4) received a cholinesterase inhibitor during the entire evaluation period. Cognitive function, as measured using the Mini-Mental State Examination (MMSE), was compared between those who received AA treatment and those who did not. The end point was the rate of decline in cognitive function, defined as annualized change in mean MMSE score from baseline to the end of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-two outpatients were included in the final analysis (67 women, 25 men; mean age, 72.4 years). Thirty-four patients received treatment with an AA for 6 &gt; or =months (mean duration of treatment, 421 days) and 58 did not receive any AA treatment. Quetiapine (mean dose, 67 mg/d) was prescribed to 28 (82 %) of the patients receiving an AA. The AAs were prescribed for psychosis (15 [44%] patients), psychosis/agitation (11 [32%]), and agitation/aggression (8 [24%]). The baseline mean MMSE scores in patients receiving and not receiving an AA were 14.65 and 17.88, respectively (P = 0.021), with mean (SD) annual rates of cognitive decline of 3.03 (1.84) and 2.24 (1.27), respectively (P = NS).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results from this retrospective study of data from a small, selected group of outpatients with AD did not find a significant difference in the rate of cognitive decline between those who received an AA for &gt; or =6 months and those who did not.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caballero</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitchcock</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Beversdorf</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nahata</LastName><ForeName>Milap C</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA05734</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS045222</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17157125</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2006.10.008</ArticleId><ArticleId IdType="pii">S0149-2918(06)00248-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17146727</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2720</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Psychiatric quarterly</Title><ISOAbbreviation>Psychiatr Q</ISOAbbreviation></Journal><ArticleTitle>Measuring patient quality of life: is the health utility index useful?</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>62</EndPage><MedlinePgn>53-62</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this paper is to report Health Utility Index Mark 3 (HUI3) scores, at baseline and at one year, for patients with psychotic disorders. Eighty two randomly selected outpatients from a Montreal teaching hospital completed the HUI3 and other measures of symptoms and side-effects. At baseline, the average Global Utility score was 0.64, which is rated in the "dysfunctional" health status range. Improvements were seen at one year follow-up in the Global, Dexterity, Cognition, and Pain Utility scores. The proportion of individuals rated in the "healthy" health status range improved by 32% from baseline to one year. HUI3 scores were negatively related to measures of psychotic symptoms and side-effects. We propose that the HUI3 should be used to assess health-related quality of life (HRQOL) in patients with psychotic disorders. Scores could be compared with other populations affected with chronic conditions (e.g., Alzheimer dementia, cancer, arthritis, etc.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tempier</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, Canada, S7N 0W8. raymond.tempier@usask.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawliuk</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Q</MedlineTA><NlmUniqueID>0376465</NlmUniqueID><ISSNLinking>0033-2720</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003266" MajorTopicYN="N">Continuity of Patient Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="Y">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006784" MajorTopicYN="N">Hospitals, Teaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018434" MajorTopicYN="Y">Sickness Impact Profile</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17146727</ArticleId><ArticleId IdType="doi">10.1007/s11126-006-9026-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Diabetes Care. 2004 Jun;27(6):1306-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15161780</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2002 Sep;11(6):545-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12206575</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2005 Mar;56(3):292-300</Citation><ArticleIdList><ArticleId IdType="pubmed">15746503</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1997 Jul;22(4):267-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9262049</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2000 Mar;38(3):290-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10718354</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2005 May;14(4):1045-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16041900</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1997 Jan;6(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9062438</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 Feb;180:101-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11823316</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2000;9(6):591-601</Citation><ArticleIdList><ArticleId IdType="pubmed">11236850</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2002 Feb;40(2):113-28</Citation><ArticleIdList><ArticleId IdType="pubmed">11802084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chronic Dis. 1987;40(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3818871</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2005 Apr;60(7):1571-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15652688</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2001 Jun;39(6):562-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11404641</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Public Health. 2000 Nov-Dec;91(6):465-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11200741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2005 Feb;58(2):138-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15680746</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1997 Jan;6(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9062437</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2004 Feb;35(2):607-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14726549</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2000 Oct 27;45(3):175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11042435</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1995 Jun;4(3):249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">7613535</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2000;9(6):667-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11236856</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2002 Nov;32(8):1345-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12455933</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2001 Aug 5;103(1):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">11472791</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 Jan;28(1):165-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9483693</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2003 Feb;12(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12625514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17146092</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>Recognition and management of neuropsychiatric complications in Parkinson's disease.</ArticleTitle><Pagination><StartPage>1545</StartPage><EndPage>1552</EndPage><MedlinePgn>1545-52</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease is primarily considered a motor disease characterized by rest tremor, rigidity, bradykinesia and postural disturbances. However, neuropsychiatric complications, including mood and anxiety disorders, fatigue, apathy, psychosis, cognitive impairment, dementia, sleep disorders and addictions, frequently complicate the course of the illness. The pathophysiologic features of these complications are multifaceted and include neuropathophysiologic changes of a degenerative disease, exposure to antiparkinsonian treatments and emotional reactions to having a disabling chronic illness. Changes in mental status have profound implications for the well-being of patients with Parkinson's disease and of their caregivers. Treatment is often efficacious but becomes a challenge in advanced stages of Parkinson's disease. In this article, we review the key clinical features of neuropsychiatric complications in Parkinson's disease as well as what is known about their epidemiologic characteristics, risk factors, pathophysiologic features and management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreri</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agbokou</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005715" MajorTopicYN="N">Gambling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019529" MajorTopicYN="N">Sexuality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17146092</ArticleId><ArticleId IdType="pmc">PMC1660590</ArticleId><ArticleId IdType="doi">10.1503/cmaj.060542</ArticleId><ArticleId IdType="pii">175/12/1545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003;168(3):293-301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140472</ArticleId><ArticleId IdType="pubmed">12566335</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736593</ArticleId><ArticleId IdType="pubmed">10486397</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606910</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (text revision). Washington: American Psychiatric Association; 2001.</Citation></Reference><Reference><Citation>Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988;145:1020-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">3394854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005;76(Suppl 1): i48-52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765679</ArticleId><ArticleId IdType="pubmed">15718222</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens AF, Verhey FR, Luijckx GJ, et al. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000;15:1221-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11104209</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery&#x2013; Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000;15:644-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10918346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001;6:350-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">11326308</ArticleId></ArticleIdList></Reference><Reference><Citation>Maricle RA, Nutt JG, Valentine RJ, et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7675241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson's disease: a literature review. Parkinsonism Relat Disord 2005;11:269-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15970452</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1989731</ArticleId><ArticleId IdType="pubmed">15954137</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999;14:155-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9918360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendis T, Suchowersky O, Lang A, et al. Management of Parkinson's disease: a review of current and new therapies. Can J Neurol Sci 1999;26:89-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10352867</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48:1070-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109902</ArticleId></ArticleIdList></Reference><Reference><Citation>Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998;10:187-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9608407</ArticleId></ArticleIdList></Reference><Reference><Citation>Fregni F, Simon DK, Wu A, et al. Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 2005;76:1614-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739437</ArticleId><ArticleId IdType="pubmed">16291882</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993;37:753-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426416</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996;8:383-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116473</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003;18:646-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12784267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986;9:373-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2873889</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard IH, Frank S, McDermott MP, et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 2004; 17:201-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15622015</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005;252:753-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15999234</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10734005</ArticleId></ArticleIdList></Reference><Reference><Citation>Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737419</ArticleId><ArticleId IdType="pubmed">11385005</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitz C, Moses H III, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">655276</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56 (Suppl 5):S1-S88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402154</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15889951</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18:510-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722164</ArticleId></ArticleIdList></Reference><Reference><Citation>Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14743357</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10752567</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005;20(Suppl 12):S77-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16092095</ArticleId></ArticleIdList></Reference><Reference><Citation>Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004;31:7-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15038467</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with PD and dementia: Frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry [Epub ahead of print 2006 July 4]. Available: http://jnnp.bmjjournals.com/cgi/rapidpdf/jnnp.2005.083113v1.pdf (accessed 2006 Oct 6).</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Camicioli R, Gauthier S. Guidelines for randomized clinical studies in Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469693</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716693</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6732189</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium [published erratum in Neurology 2005;65:1992]. Neurology 2005;65:1863-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Gauthier S, Chertkow H, et al. Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 2006;33:6-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16583717</ArticleId></ArticleIdList></Reference><Reference><Citation>Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia [review]. Cochrane Database Syst Rev 2006;(1):CD004747.</Citation><ArticleIdList><ArticleId IdType="pubmed">16437494</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737925</ArticleId><ArticleId IdType="pubmed">12023410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739697</ArticleId><ArticleId IdType="pubmed">15965198</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">14533126</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology 2005;64(Suppl 3):S12-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15994219</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9:185-200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893249</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Lang AE, Massicotte-Marquez J, et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: Reward systems gone awry? Lancet Neurol 2003;2:595-604.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505581</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocchi F. Pathological gambling in Parkinson's disease. Lancet Neurol 2005;4:590-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168925</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs [letter]. Arch Neurol 2006;63:298-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006;63:298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009751</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. CMAJ 1969;101:59-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1946468</ArticleId><ArticleId IdType="pubmed">4903690</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 1998;13:597-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9613761</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 2002;25:234-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151912</ArticleId></ArticleIdList></Reference><Reference><Citation>Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2061539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17117394</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The incidence of first-onset psychotic symptoms and paranoid ideation in a representative population sample followed from age 70-90 years. Relation to mortality and later development of dementia.</ArticleTitle><Pagination><StartPage>520</StartPage><EndPage>528</EndPage><MedlinePgn>520-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Limited data are available on the incidence of psychotic symptoms in the elderly.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To elucidate the incidence of first-onset psychotic symptoms in the elderly and their relation to mortality and later development of dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A population-sample (n = 392) born 1901-1902 was assessed from age 70-90 with psychiatric examinations, medical record reviews and from age 85, also with key-informant interviews. Individuals developing dementia were excluded.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">The cumulative incidence of first-onset psychotic symptoms was 4.8% (8.0% including key-informant reports in the total sample) and 19.8 % in those who survived to age 85. Sixty-four percent of those with first-onset hallucinations later developed dementia, compared to 30% of those with delusions and 25% of those without psychotic symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">One fifth of non-demented elderly who survives up to age 85 develops first-onset psychotic symptoms. Hallucinations predict dementia, but most elderly individuals with first-onset psychotic symptoms do not develop dementia.</AbstractText><CopyrightInformation>Copyright 2006 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostling</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Sahlgrenska Academy at G&#xf6;teborg University, Institute of Clinical Neuroscience and Physiology, Psychiatry Section, Unit of Epidemiology, Sahlgrenska University Hospital, G&#xf6;teborg, Sweden. svante.ostling@neuro.gu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;lsson</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17117394</ArticleId><ArticleId IdType="doi">10.1002/gps.1696</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17110812</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Mortality in elderly dementia patients treated with risperidone.</ArticleTitle><Pagination><StartPage>566</StartPage><EndPage>570</EndPage><MedlinePgn>566-70</MedlinePgn></Pagination><Abstract><AbstractText>Agitation, aggression, and psychosis are among the most troublesome behavioral and psychological symptoms of dementia (BPSD) and impair the lives of dementia patients and their caregivers. Atypical antipsychotics have been widely prescribed to improve these BPSD. However, in a number of trials with atypical antipsychotics, a consistent increase in overall mortality has been observed. The US Food and Drug Administration issued a warning for all atypical antipsychotics as a result of a meta-analysis of 17 placebo-controlled clinical trials using various atypical antipsychotics for the treatment of BSPD. To evaluate this mortality risk specifically for risperidone, 6 phase-2/3 double-blind trials comparing risperidone with placebo were analyzed. Data were obtained from Johnson &amp; Johnson Pharmaceutical Research and Development. Hazard ratios with 95% confidence intervals were calculated to compare the relative mortality risk between patients treated with risperidone and those treated with placebo. In this meta-analysis, 1721 patients were included. In the pooled sample, the mortality was 4.0% with risperidone versus 3.1% with placebo (relative risk, 1.21; 95% confidence interval, 0.71-2.06) during treatment or within 30 days after treatment discontinuation. The most common adverse events associated with death were pneumonia, cardiac failure or arrest, or cerebrovascular disorder. No relationship was found between risperidone dose and mortality. In conclusion, this meta-analysis found a nonsignificant increase in mortality during treatment with risperidone in dementia patients. Larger studies would be needed to rule out a small increase in mortality in these patients. Careful assessments of potential benefits and risks should be made before prescribing risperidone for the treatment of BPSD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cognitive Disorders, Neurologic Research Institute, Neuro-Centrum D&#xfc;sseldorf, D&#xfc;sseldorf, Germany. m.haupt@alzheimer-praxis-duesseldorf.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Jentoft</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17110812</ArticleId><ArticleId IdType="doi">10.1097/01.jcp.0000239796.21826.39</ArticleId><ArticleId IdType="pii">00004714-200612000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17098333</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>341</StartPage><EndPage>347</EndPage><MedlinePgn>341-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Alzheimer's disease (AD) patients suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in AD has been demonstrated. Polymorphisms within serotonin receptors 5HT(2A) and 5HT(2C) have been previously investigated in a few interesting studies reviewed here, however, their role remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our large cohort of 394 patients had longitudinal information on the BPSD (Neuropsychiatric Inventory), which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period and give each patient a severity score. These measures were related to the 5HT(2A) T102C and 5HT(2C) cys23ser genotype and allele frequencies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our data supports previous reports of an increased frequency of the C allele and CC genotype of the T102C variant of 5HT(2A) with hallucinations, delusions, psychosis and aberrant motor behaviour, however, we dispute previous associations with depression and aggression. We describe for the first time an increase in the C allele and CC genotype frequencies of the cys23ser variant of 5HT(2C) with anxiety and support previous associations with appetite disturbances in females.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This review and extension of previous data presents support for the role of 5HT(2A) and 5HT(2C) in the development of certain symptoms, although the effect size may be small.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Antonia L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, G Floor CBCRC Building, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane 4006, Australia. Antonia.Pritchard@qimr.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Sayeed</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044405">Receptor, Serotonin, 5-HT2C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044405" MajorTopicYN="N">Receptor, Serotonin, 5-HT2C</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.10.011</ArticleId><ArticleId IdType="pii">S0197-4580(06)00388-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17090702</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3565</ISSN><JournalIssue CitedMedium="Print"><Volume>320</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2.</ArticleTitle><Pagination><StartPage>819</StartPage><EndPage>827</EndPage><MedlinePgn>819-27</MedlinePgn></Pagination><Abstract><AbstractText>The effect of ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) on cognitive impairment in mice, previously treated with methamphetamine (METH) at a dose of 1 mg/kg for 7 days, was investigated. ZSET1446 showed a significant ameliorating effect on METH-induced impairment of recognition memory, although it had no effect on exploratory behavior. ZSET1446 (1 microg/kg) recovered the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the prefrontal cortex (PFC) of METH-treated mice. The compound increased phosphorylated ERK1/2 levels in the hippocampus but not PFC of naive mice without affecting the total ERK1/2 levels. The ameliorating effect of ZSET1446 on recognition memory in METH-treated mice was negated by pretreatment with a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor, SL327 (alpha-[amino-(4-aminophenylthio)methylene]-2-(trifluoromethyl)phenylacetonitrile). Furthermore, the dopamine D1 receptor antagonist, SCH23390 [R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine], and N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 [5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)], blocked the ameliorating effect of ZSET1446 on METH-induced memory impairment, whereas the D2 receptor antagonist, raclopride, had no effect. These results suggest that the ameliorative effect of ZSET1446 on METH-induced memory impairment is associated with indirect activation of ERK1/2 following stimulation with dopamine D1 and NMDA receptors of the PFC. ZSET1446 would be a potential candidate for further preclinical study aimed at the treatment of cognitive deficits in Alzheimer's disease and schizophrenia, as well as METH psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takuma</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mizoguchi</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Taku</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kiyofumi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C511224">spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>44RAL3456C</RegistryNumber><NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008694" MajorTopicYN="N">Methamphetamine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17090702</ArticleId><ArticleId IdType="doi">10.1124/jpet.106.114108</ArticleId><ArticleId IdType="pii">jpet.106.114108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17090210</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis.</ArticleTitle><Pagination><StartPage>e428</StartPage><MedlinePgn>e428</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e428</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosis is a severe mental condition that is characterized by a loss of contact with reality and is typically associated with hallucinations and delusional beliefs. There are numerous psychiatric conditions that present with psychotic symptoms, most importantly schizophrenia, bipolar affective disorder, and some forms of severe depression referred to as psychotic depression. The pathological mechanisms resulting in psychotic symptoms are not understood, nor is it understood whether the various psychotic illnesses are the result of similar biochemical disturbances. The identification of biological markers (so-called biomarkers) of psychosis is a fundamental step towards a better understanding of the pathogenesis of psychosis and holds the potential for more objective testing methods.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Surface-enhanced laser desorption ionization mass spectrometry was employed to profile proteins and peptides in a total of 179 cerebrospinal fluid samples (58 schizophrenia patients, 16 patients with depression, five patients with obsessive-compulsive disorder, ten patients with Alzheimer disease, and 90 controls). Our results show a highly significant differential distribution of samples from healthy volunteers away from drug-na&#xef;ve patients with first-onset paranoid schizophrenia. The key alterations were the up-regulation of a 40-amino acid VGF-derived peptide, the down-regulation of transthyretin at approximately 4 kDa, and a peptide cluster at approximately 6,800-7,300 Da (which is likely to be influenced by the doubly charged ions of the transthyretin protein cluster). These schizophrenia-specific protein/peptide changes were replicated in an independent sample set. Both experiments achieved a specificity of 95% and a sensitivity of 80% or 88% in the initial study and in a subsequent validation study, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that the application of modern proteomics techniques, particularly mass spectrometric approaches, holds the potential to advance the understanding of the biochemical basis of psychiatric disorders and may in turn allow for the development of diagnostics and improved therapeutics. Further studies are required to validate the clinical effectiveness and disease specificity of the identified biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jeffrey T-J</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leweke</LastName><ForeName>F Markus</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Oxley</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Koethe</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gerth</LastName><ForeName>Christoph W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Nolden</LastName><ForeName>Brit M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bahn</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C510637">VGF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests:</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17090210</ArticleId><ArticleId IdType="pmc">PMC1630717</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0030428</ArticleId><ArticleId IdType="pii">06-PLME-RA-0182R3</ArticleId><ArticleId IdType="sici">plme-03-11-02</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thaker GK, Carpenter WT., Jr Advances in schizophrenia. Nat Med. 2001;7:667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11385502</ArticleId></ArticleIdList></Reference><Reference><Citation>Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs. schizophrenia. Sex and sociocultural setting. Arch Gen Psychiatry. 1994;51:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8161289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PF. The genetics of schizophrenia. PLoS Med. 2005;2:e212.  doi: 10.1371/journal.pmed.0020212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020212</ArticleId><ArticleId IdType="pmc">PMC1181880</ArticleId><ArticleId IdType="pubmed">16033310</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev. 2004;23:34&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14625891</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet. 2003;361:1258&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699953</ArticleId></ArticleIdList></Reference><Reference><Citation>Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868&#x2013;1875.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912167</ArticleId></ArticleIdList></Reference><Reference><Citation>Swatton JE, Sellers LA, Faull RL, Holland A, Iritani S, et al. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur J Neurosci. 2004;19:2711&#x2013;2719.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147305</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, et al. Targeted deletion of the VGF gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron. 1999;23:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433265</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23:10800&#x2013;10808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374594</ArticleId><ArticleId IdType="pubmed">14645472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol. 2005;196:273&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154129</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci. 2004;2:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517953</ArticleId><ArticleId IdType="pubmed">15341658</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001;310:173&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005;95:1461&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1540444</ArticleId><ArticleId IdType="pubmed">16313519</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics. 2003;3:1486&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923774</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi A, Ferri GL, Watson E, Possenti R, Salton SR. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol. 2004;24:517&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233376</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, et al. VGF: A novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol. 2000;21:199&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Succu S, Cocco C, Mascia MS, Melis T, Melis MR, et al. Pro-VGF-derived peptides induce penile erection in male rats: Possible involvement of oxytocin. Eur J Neurosci. 2004;20:3035&#x2013;3040.</Citation><ArticleIdList><ArticleId IdType="pubmed">15579158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisor JP, Takahashi JS. Regulation of the VGF gene in the golden hamster suprachiasmatic nucleus by light and by the circadian clock. J Comp Neurol. 1997;378:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120062</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, et al. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test&#x2014;A functional magnetic resonance imaging study. Eur Psychiatry. 1999;14:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10572321</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5:267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">11865311</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E, Tsang TM, Huang TJ, Leweke FM, Koethe D, et al.  Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006;3:e327.  doi: 10.1371/journal.pmed.0030327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030327</ArticleId><ArticleId IdType="pmc">PMC1551919</ArticleId><ArticleId IdType="pubmed">16933966</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684&#x2013;697. 643.</Citation><ArticleIdList><ArticleId IdType="pubmed">15098003</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson E, Hahm S, Mizuno TM, Windsor J, Montgomery C, et al. VGF ablation blocks the development of hyperinsulinemia and hyperglycemia in several mouse models of obesity. Endocrinology. 2005;146:5151&#x2013;5163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141392</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol. 2002;175:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379491</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell BR, Duan W, Alcorn D, Brack C, Richardson SJ, et al. Thyroxine transport to the brain: Role of protein synthesis by the choroid plexus. Endocrinology. 1993;133:2116&#x2013;2126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8404661</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Shafer RB. Thyroid function screening in new psychiatric admissions. Arch Intern Med. 1982;142:591&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">7065794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan WG, Roddam RF, Grizzle WE. Thyroid function screening in newly admitted psychiatric inpatients. Ann Clin Psychiatry. 1994;6:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7951647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol. 1998;138:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall RCW, Stickney S, Beresford TP. Endocrine disease and behavior. Integr Psychiatry. 1986;4:122&#x2013;135.</Citation></Reference><Reference><Citation>Chen ML, Chen CH. Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment. J Psychiatr Res. 2005. E-pub 31 May 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, et al. Low cerebrospinal fluid transthyretin levels in depression: Correlations with suicidal ideation and low serotonin function. Biol Psychiatry. 2006;60:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">16487493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17067184</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-229X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Drugs &amp; aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>Management of Parkinson's disease dementia : practical considerations.</ArticleTitle><Pagination><StartPage>807</StartPage><EndPage>822</EndPage><MedlinePgn>807-22</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease dementia (PDD) ultimately develops in about 80% of patients with Parkinson's disease (PD), and cross-sectional studies have found that some 30% of these patients will experience neuropsychiatric symptoms, such as visual hallucinations and psychosis. The most consistently reported risk factors for dementia in PD are age, severe parkinsonism and mild cognitive impairment. In PDD, both subcortical cognitive and cortical cognitive profiles are described. Specific disorders of sleep, such as rapid eye movement sleep behaviour disorder, excessive daytime sleepiness and sleep attacks, occur frequently. Alzheimer and Lewy body pathology coexist, but the Lewy body pathology in limbic and cortical areas seems to be the main cause of dementia. Neurochemical changes in the biogenic amines and acetylcholine are common, and magnetic resonance imaging studies have shown cortical atrophy in wide cortical areas, including the hippocampus. All PD patients should be screened for mild cognitive impairment and dementia. A large randomised clinical trial showed that the cholinesterase inhibitor rivastigmine has desirable effects on cognition and neuropsychiatric symptoms in PDD patients. Atypical antipsychotic agents may improve psychosis in PDD, but the evidence for this is poor and adverse effects from such therapy are common and may be severe. Non-pharmacological interventions can also be effective but require further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Haugesund County Hospital, Haugesund, Norway University of Bergen, Bergen, Norway. arvid.rongve@helse-fonna.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009493" MajorTopicYN="N">Neurosurgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>140</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17067184</ArticleId><ArticleId IdType="doi">10.2165/00002512-200623100-00004</ArticleId><ArticleId IdType="pii">23104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Geriatr Psychiatry. 1999 Oct;14(10):866-74</Citation><ArticleIdList><ArticleId IdType="pubmed">10521886</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Dec 13;65(11):1716-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16344512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 1995;46:423-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8821078</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 1986 Mar;73(3):295-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3521185</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2000 Sep;100(3):285-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10965798</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Mar;46(3):678-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8618666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Feb;20(2):212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15390044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Aug;20(8):958-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15800937</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Jun 28;64(12):2069-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15985574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1996 Dec;119 ( Pt 6):2121-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9010015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2002 Nov;8(7):907-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12405541</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 May 23;54(10):1916-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10822429</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2004 Apr;127(Pt 4):791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">14749292</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2006 Mar;35(2):154-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16414964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Jun;21 Suppl 14:S305-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16810676</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2005 Dec;8(3):289-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16340086</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin North Am. 2002 May;86(3):641-56, viii</Citation><ArticleIdList><ArticleId IdType="pubmed">12168563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Apr;59(4):591-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16566021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2006 Oct 25;248(1-2):266-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16814808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Sep;21(9):1375-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16705684</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1991 Dec;14(6):540-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 2005 Dec;112(6):386-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16281921</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2004 Mar;127(Pt 3):550-60</Citation><ArticleIdList><ArticleId IdType="pubmed">14691062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Dec;20(12):1571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16116613</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Sep;177:252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11040887</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2005 Sep;18(3):149-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16100104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2000 Jul;15(4):613-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10928571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2004 Sep;17(3):146-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15312278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2002 May;61(5):413-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12030260</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Mar;14 (3):191-210</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Oct;20(10):1255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16041803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2003 Apr;2(4):229-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12849211</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2000 Summer;12(3):364-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10956570</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Dec 10;59(11):1714-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12473758</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2003 Dec;60(12 ):1745-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14676050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Nov;20(11):1413-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16007620</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Aug 9;65(3):481-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16087923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 May;66(5):633-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15889951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Sep;20(9):1161-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15954137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1990 Mar;27(3):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">2158268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2005 Nov;252(11):1345-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15995795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Med Rev. 2005 Jun;9(3):185-200</Citation><ArticleIdList><ArticleId IdType="pubmed">15893249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15312280</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2005 May;34(3):268-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15863411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Jun 27;66(12):1830-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16801645</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 May 24;64(10):1696-703</Citation><ArticleIdList><ArticleId IdType="pubmed">15911793</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2000 May;16(5):365-79</Citation><ArticleIdList><ArticleId IdType="pubmed">10917074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2004 Sep;17(3):172-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15312281</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1998 Mar;12(1):45-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9539410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):492-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10486397</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Sep 26;275(2):321-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6626985</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1998 Mar-Apr;19(2):145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9558151</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2001 Aug;14(4):499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">11470967</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2005 Sep;112(3):201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16095475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2003 Jul;18(7):784-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12815657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Apr;21(4):456-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16229010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2005 Nov;58(5):773-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16240351</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2004 Jan-Feb;27(1):4-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15090928</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Nov;43(11):2227-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8232934</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 31;302(5646):841</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Mar 14;54(5):1050-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Mar 27;56(6):730-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11274306</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;82(4):239-59</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Feb;20(2):190-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15551331</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S47-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15885629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1260-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15314111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):629-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12438461</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2005 May-Jun;28(3):111-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15965308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2003 May;18(5):510-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12722164</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 Oct;20(10):938-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16163744</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2005 Feb;252(2):139-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15729517</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1987 Jan;37(1):42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3796837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2004 Oct;318(1):121-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16820421</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2003 Jan;56(1):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12589871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2004 Sep;17(3):137-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15312277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747</Citation><ArticleIdList><ArticleId IdType="pubmed">16437494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jan;64(1):63-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12590626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakartidningen. 2004 Jun 3;101(23):2003-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15232837</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2003 Jul;10(4):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">12823492</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Aug;51(2):363-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9710004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2002 Feb;51(2):156-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11835371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2002 Jul;17(4):676-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12210856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Sep;21(9):1343-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16721732</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Sep 28;63(6):975-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15452286</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2005 Jan;12(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15613141</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Dec 9;351(24):2509-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2002 Nov;17(6):1221-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12465060</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 Aug;20(8):776-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16035122</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Nov 12;59(9):1427-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12427897</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1995 Dec;45(12):2143-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8848182</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Feb 26;330(7489):445</Citation><ArticleIdList><ArticleId IdType="pubmed">15668211</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Aug;51(2):526-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9710029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 1990;5(3):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2388638</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2002 Jan;59(1):102-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11790237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Feb;21(2):223-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16161159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Jun 12;353(9169):2041-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10376627</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2005 Aug;7(4):285-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16131729</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Jun 27;66(12):1811-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16801642</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999;52(7 Suppl 3):S10-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10227604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 1990;5(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">2325678</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Jan 10;66(1):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16401843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2002 Mar;109(3):329-39</Citation><ArticleIdList><ArticleId IdType="pubmed">11956955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):214-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15939976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Behav Neurol. 2003 Jun;16(2):85-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12799594</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2006 Mar;12(2):119-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16337163</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Mar 11;340(10 ):757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10072410</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 Sep;20(9):872-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16116579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2006 Jan 15;240(1-2):15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16199056</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2003;26(9):643-59</Citation><ArticleIdList><ArticleId IdType="pubmed">12814332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Jul 16;23(15):6351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12867520</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Mar 8;344(10):710-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11236774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol B Psychol Sci Soc Sci. 1997 Jul;52(4):P159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">9224439</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Nov 22;65(10):1654-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16301500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1989 Feb;25(2):152-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2645825</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 May;50(5):1456-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9596005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):37-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15764870</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Jan 27;62(2):181-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14745051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Mar;21(3):337-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16211595</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Sep 26;55(6):870-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10994012</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2000 Apr;57(4):470-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10768619</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1999 Jan;28(1):39-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10203203</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2003 Mar;60(3):387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12633150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2006 Feb;253(2):242-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16133720</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Dec 27;65(12):1863-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2005 Feb;62(2):281-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15710857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2003 Aug;54(2):235-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12891676</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Dec 24;59(12):1976-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12499496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Jul;20(7):873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15809995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2003 Dec 15;26(8):1049-54</Citation><ArticleIdList><ArticleId IdType="pubmed">14746389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17054574</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>11-12</Issue><PubDate><Year>2006</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>High CSF Tau-protein concentration in delirium induced by high dose psychiatric medication.</ArticleTitle><Pagination><StartPage>1039</StartPage><EndPage>1041</EndPage><MedlinePgn>1039-41</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Windhagen</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wurster</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Kropp</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ziegenbein</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2U1W68TROF</RegistryNumber><NameOfSubstance UI="D008376">Maprotiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008318" MajorTopicYN="N">Malpractice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008376" MajorTopicYN="N">Maprotiline</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17054574</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1614.2006.01933.x</ArticleId><ArticleId IdType="pii">ANP1933</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17048808</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0968-7912</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Down's syndrome, research and practice : the journal of the Sarah Duffen Centre</Title><ISOAbbreviation>Downs Syndr Res Pract</ISOAbbreviation></Journal><ArticleTitle>Mental health, behaviour and intellectual abilities of people with Down syndrome.</ArticleTitle><Pagination><StartPage>37</StartPage><EndPage>43</EndPage><MedlinePgn>37-43</MedlinePgn></Pagination><Abstract><AbstractText>The mental health, adaptive behaviour and intellectual abilities of people with Down syndrome (n=129) were evaluated in a population-based survey of social and health care records. Females had better cognitive abilities and speech production compared with males. Males had more behavioural problems than females. Behaviour suggestive of attention deficit hyperactivity disorder was often seen in childhood. Depression was diagnosed mainly in adults with mild to moderate intellectual disability. Autistic behaviour was most common in individuals with profound intellectual disability. Elderly people often showed decline of adaptive behaviour associated with Alzheimer's disease. Case descriptions are presented to illustrate the multitude of mental health and behavioural issues seen from childhood to old age in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xe4;&#xe4;tt&#xe4;</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service Centre of Kuusanm&#xe4;ki, University of Oulu, Finland. tuomo.maatta@kainuu.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tervo-M&#xe4;&#xe4;tt&#xe4;</LastName><ForeName>Tuula</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Taanila</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaski</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iivanainen</LastName><ForeName>Matti</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Downs Syndr Res Pract</MedlineTA><NlmUniqueID>9508122</NlmUniqueID><ISSNLinking>0968-7912</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011153" MajorTopicYN="N">Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17048808</ArticleId><ArticleId IdType="doi">10.3104/reports.313</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17035647</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>355</Volume><Issue>15</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1525</StartPage><EndPage>1538</EndPage><MedlinePgn>1525-38</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo. Doses were adjusted as needed, and patients were followed for up to 36 weeks. The main outcomes were the time from initial treatment to the discontinuation of treatment for any reason and the number of patients with at least minimal improvement on the Clinical Global Impression of Change (CGIC) scale at 12 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences among treatments with regard to the time to the discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 8.0 weeks) (P=0.52). The median time to the discontinuation of treatment due to a lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002). The time to the discontinuation of treatment due to adverse events or intolerability favored placebo. Overall, 24% of patients who received olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo discontinued their assigned treatment owing to intolerability (P=0.009). No significant differences were noted among the groups with regard to improvement on the CGIC scale. Improvement was observed in 32% of patients assigned to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=0.22).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00015548 [ClinicalTrials.gov].).</AbstractText><CopyrightInformation>Copyright 2006 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>T Scott</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><CollectiveName>CATIE-AD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00015548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2006 Oct 12;355(15):1604-6. doi: 10.1056/NEJMe068163</RefSource><PMID Version="1">17035654</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2007 Jan 25;356(4):416; author reply 417-8. doi: 10.1056/NEJMc063094</RefSource><PMID Version="1">17251541</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2007 Jan 25;356(4):416-7; author reply 417-8.</RefSource><PMID Version="1">17256186</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2007 Mar-Apr;146(2):35.</RefSource><PMID Version="1">17335158</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Clin Pract Neurol. 2007 May;3(5):248-9. doi: 10.1038/ncpneuro0472</RefSource><PMID Version="1">17389878</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2007 May;10(2):58. doi: 10.1136/ebmh.10.2.58</RefSource><PMID Version="1">17459989</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Fam Pract. 2007 Jan;56(1):14.</RefSource><PMID Version="1">17607819</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Neurol Neurosci Rep. 2007 Sep;7(5):363-5. doi: 10.1007/s11910-007-0056-9</RefSource><PMID Version="1">17764624</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa061240</ArticleId><ArticleId IdType="pii">355/15/1525</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17012935</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The neurobiology of neuropsychiatric syndromes in dementia.</ArticleTitle><Pagination><StartPage>581</StartPage><EndPage>586</EndPage><MedlinePgn>581-6</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Neuropsychiatric disturbances in dementia are prevalent, and research is uncovering their neurobiological correlates.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Late-onset depression appears to be associated with Alzheimer's disease pathology at autopsy, and lifetime depression episodes may worsen Alzheimer's disease pathology in the hippocampus. Vascular disease and elevated homocysteine increase risk for both late-onset depression and Alzheimer's disease and may partly mediate their relationship. Monoamine changes are robust finding in Alzheimer's disease and may account for many observed depression symptoms. Risk of psychosis of Alzheimer's disease appears to be increased by several genes also implicated in schizophrenia (e.g., catechol-O-methyltransferase, neuregulin-1). Psychosis in dementia with Lewy bodies appears to be related to cholinergic deficits. Alzheimer's disease is associated with changes in the circadian sleep-wake cycles, including decreased night-time melatonin. Sleep apnea may be related to apolipoprotein E genotype and impact cognition in Alzheimer's disease. Rapid eye movement sleep behavior disorder is intricately related to synucleinopathies, such as dementia with Lewy bodies, but synuclein changes may not totally explain this relationship.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Neuropsychiatric disturbances are a core feature of dementia and worsen many clinical outcomes. Among the most validated syndromes are depression, psychosis, and sleep disturbance of Alzheimer's disease. Neuropathology, neuroimaging, and genetic studies increasingly provide insight into the origins of these psychiatric symptoms in dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, Department of Psychiatry, University of California, San Diego, and Veterans Affairs San Diego Healthcare System, San Diego, California 92161, USA. tmeeks@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ropacki</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH19934-13</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009446" MajorTopicYN="N">Neurobiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009484" MajorTopicYN="N">Neuropsychology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>72</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17012935</ArticleId><ArticleId IdType="doi">10.1097/01.yco.0000245746.45384.0e</ArticleId><ArticleId IdType="pii">00001504-200611000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16970641</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1348</StartPage><EndPage>1354</EndPage><MedlinePgn>1348-54</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate behavioral components of Alzheimer's disease (AD) and to analyze behavioral components in relation to disease severity, apolipoprotein E genotype (APOE), sex, years of education, age at onset, and cognitive impairment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Data were collected from community-dwelling individuals and those residing in nursing homes.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 1,120 individuals meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for late-onset probable AD.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Behavioral symptoms were assessed using the Neuropsychiatric Inventory. First-order polychoric correlations, controlling for disease severity, between the 12 symptom domain scores were estimated, and the resulting matrix underwent principal components analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four interpretable components were identified: behavioral dyscontrol (euphoria, disinhibition, aberrant motor behavior, and sleep and appetite disturbances), psychosis (delusions and hallucinations), mood (depression, anxiety, and apathy), and agitation (aggression and irritability). Scores on the four components were associated with severity of cognitive impairment. Higher behavioral dysfunction, agitation, and mood component scores were associated with lower age at onset. Behavioral dysfunction and mood component scores were associated with sex. None of the components were associated with age at assessment, years of education, or number of APOE epsilon4 alleles.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Four behavioral components were identified that were comparable with those observed previously. Future analysis of these components will strengthen understanding of the underlying pathology of behavioral symptoms and AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamshere</LastName><ForeName>Marian L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Moskvina</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dowzell</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9810900</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2006.00854.x</ArticleId><ArticleId IdType="pii">JGS854</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16967466</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>144B</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>128</EndPage><MedlinePgn>126-8</MedlinePgn></Pagination><Abstract><AbstractText>Although the aetiology of psychotic symptoms in Alzheimer's disease (AD) is multi-factorial, alterations in serotonergic neurotransmission are often implicated. Polymorphisms of the serotonin receptor 5HT-2A are associated with hallucinatory symptoms and delusions in demented and non-demented cohorts. This study examined the role of the 5HT-2A T102C polymorphism in influencing psychotic symptoms in a large Northern Ireland AD population (n = 406, mean MMSE 13/30). Forty-eight percent of patients experienced delusional symptoms and 28% experienced hallucinations during the course of their dementia. No significant association was found either in frequency of genotype or allelic variation for either set of symptoms. Furthermore, the mean delusional and hallucinatory severity scores did not differ significantly among the three genotype groups. The lack of influence of the T102C polymorphism of the 5HT-2A receptor on the emergence of psychotic symptoms in AD contrasts with previous reports in other cohorts involving smaller numbers of subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Division of Psychiatry and Neuroscience, Queen's University, Belfast, Northern Ireland. david.craig@qub.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Robyn</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009660" MajorTopicYN="N" Type="Geographic">Northern Ireland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16967466</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30409</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16937350</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9762</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of clinical psychology</Title><ISOAbbreviation>J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Assessment and treatment of persistent pain in persons with cognitive and communicative impairment.</ArticleTitle><Pagination><StartPage>1379</StartPage><EndPage>1387</EndPage><MedlinePgn>1379-87</MedlinePgn></Pagination><Abstract><AbstractText>Pain management is a challenge when working with persons who have cognitive impairment that affects their ability to understand and communicate. This article focuses on pain assessment and treatment in persons who have dementia, but the challenges and principles are relevant to the spectrum of cognitive impairment. Fundamental principles guiding pain assessment and treatment in this population are (1) that behavioral disturbance is the result of an unmet need that causes discomfort, (2) that the behavioral disturbances that result from the unmet need of uncontrolled pain may be identical to those caused by other unmet needs (e.g., thirst, needing to toilet, understimulation, overstimulation, depression, psychosis, uncomfortable clothing), and therefore (3) that any pain treatment protocol for this population must target discomfort behaviors in general and then attempt to determine their causes. Pain assessment and treatment approaches based on these principles are outlined, and then two cases are presented to illustrate the application of these approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snow</LastName><ForeName>A Lynn</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Center for Mental Health and Department of Psychology, University of Alabama and Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa, AL 35487, USA. lsnow@bama.ua.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuster</LastName><ForeName>John L</ForeName><Initials>JL</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychol</MedlineTA><NlmUniqueID>0217132</NlmUniqueID><ISSNLinking>0021-9762</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="Y">Disabled Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007326" MajorTopicYN="Y">Institutionalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="Y">Pain Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16937350</ArticleId><ArticleId IdType="doi">10.1002/jclp.20317</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16910626</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>2 Pt 1</Issue><PubDate><Year>2006</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Oxidative stress involvement in schizophrenia pathophysiology: a review].</ArticleTitle><Pagination><StartPage>244</StartPage><EndPage>252</EndPage><MedlinePgn>244-52</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Schizophrenia is a devastating psychiatric disorder with a broad range of behavioural and biologic manifestations. There are several clinical characteristics of the illness that have been consistently associated with poor premorbid adjustment, long duration of psychosis prior to treatment and prominent negative symptoms. The etiopathogenic mechanisms of lack of insight in patients with schizophrenia are to date unknown, although several hypotheses have been suggested. A point of convergence for the theoretical models occurs with regard to the neuronal membrane. Neuronal membrane contains a high proportion of polyunsaturated fatty acid and is the site for oxidative stress. Oxidative stress is a state when there is unbalance between the generation of reactive oxygen species and antioxidant defence capacity of the body. It is closely associated with a number of diseases including Parkinson's disease, Alzheimer-type dementia and Huntington's chorea. Accumulating evidence points to many interrelated mechanisms that increase production of reactive oxygen or decrease antioxidant protection in schizophrenic patients.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This review aims to summarize the perturbations in antioxidant protection systems during schizophrenia, their interrelationships with the characteristic clinics and therapeutics and the implications of these observations in the pathophysiology of schizophrenia are discussed.</AbstractText><AbstractText Label="LITERATURE FINDINGS" NlmCategory="RESULTS">In schizophrenia there is evidence for deregulation of free radical metabolism, as detected by abnormal activity of critical antioxidant enzymes (superoxide dismutase, glutathione peroxidase and catalase). Many studies conclude in the decrease in the activity of key antioxidant enzymes in schizophrenia. A few studies have examined levels of non enzymatic antioxidants such as plasma antioxidant proteins (albumin, bilirubine, uric acid) and trace elements. How showed decreased levels in schizophrenic patients. Others studies have provided evidence of oxidative membrane damage by examining levels of lipid peroxidation products. Such abnormalities have been associated with certain clinical symptoms and therapeutic features. Negative symptoms have been associated with low levels of GSH-Px. Positive symptoms have been positively correlated with SOD activity. Plasma TAS was significantly lower in drug-free and haloperidol treated patients with schizophrenia. A low erythrocyte SOD activity has been found in never-treated patients, but with haloperidol treatment, SOD activity increased.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">These results demonstrate altered membrane dynamics and antioxidant enzyme activity in schizophrenia. Membrane dysfunction can be secondary to free a radical-mediated pathology, and may contribute to specific aspects of the schizophrenia symptomatology. Membrane defects can significantly alter a broad range of membrane functions and presumably modify behavior through multiple downstream biological effects. Phospholipid metabolism in the brain may be perturbed in schizophrenia, with reduced amounts of phosphatidylcholins and phosphatidylethanolamine in post-mortem brain tissue from schizophrenic patients, and large amounts of lipofuscin-like materiel in the oligodendrocytes. The existence of these products within cell membranes results in an unstable membrane structure, altered membrane fluidity and permeability and impaired signal transduction. Recent findings suggest that multiple neurotransmitter systems may be faulty. CNS cells are more vulnerable to the toxic effects of free radicals because they have a high rate of catecholamine oxidative metabolic activity. Neurotransmitters, like glutamate, can induce the same metabolic processes that increase free radical production and can lead to impaired dopamine-glutamate balance. These results question the role of this imbalance in the biochemical basis evoked in the etipathogenic mechanisms of schizophrenia, as well as the role of antioxidants in the therapeutic strategy and their implication in preventive and early intervention approaches in populations at risk for schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fendri</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Recherche en Sant&#xe9; mentale (01/UR/08.08), Service de Psychiatrie, Centre hospitalo-universitaire Fattouma Bourguiba de Monastir, rue du 1er juin 5000, Monastir, Tunisie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mechri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Khiari</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Othman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kerkeni</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gaha</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Implication du stress oxydant dans la physiopathologie de la schizophr&#xe9;nie: revue de la litt&#xe9;rature.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16910626</ArticleId><ArticleId IdType="doi">10.1016/s0013-7006(06)76151-6</ArticleId><ArticleId IdType="pii">S0013-7006(06)76151-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16908972</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1660-2854</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Neuro-degenerative diseases</Title><ISOAbbreviation>Neurodegener Dis</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>43</EndPage><MedlinePgn>38-43</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosis frequently occurs in Alzheimer's disease (AD), being associated with more severe cognitive decline, but the underlying mechanisms are unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of centrally administered beta-amyloid peptide, a model for AD, in the locomotor response to amphetamine, caffeine and MK-801, which are psychoactive drugs related to neurochemical changes occurring in psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Mice were intracerebroventricularly injected with beta-amyloid (25-35), and after 1 week they were tested in the passive avoidance, spontaneous alternation and locomotor tasks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Besides impaired performance in inhibitory avoidance and spontaneous alternation tasks, beta-amyloid-treated mice showed increased spontaneous locomotion, augmented response to amphetamine (1.5 mg/kg), blunted response to caffeine (30 mg/kg) and no difference in MK-801 (0.25 mg/kg)-induced locomotor activation when compared to its respective control.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results are compatible with the hypothesis that beta-amyloid peptide may predispose to psychotic symptoms of AD by increasing sensitivity of the dopaminergic system, possibly related to a decreased adenosinergic inhibitory tone.</AbstractText><CopyrightInformation>Copyright (c) 2004 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dall'Igna</LastName><ForeName>Oscar P</ForeName><Initials>OP</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica, Instituto de Ciencias Basicas da Saude, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. oscar.dalligna@ufrgs.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Anselmo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Adriana L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Diogo O</ForeName><Initials>DO</Initials></Author><Author ValidYN="Y"><LastName>Lara</LastName><ForeName>Diogo R</ForeName><Initials>DR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurodegener Dis</MedlineTA><NlmUniqueID>101189034</NlmUniqueID><ISSNLinking>1660-2854</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RH81L854J</RegistryNumber><NameOfSubstance UI="D005973">Glutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018663" MajorTopicYN="N">Adrenergic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16908972</ArticleId><ArticleId IdType="doi">10.1159/000076668</ArticleId><ArticleId IdType="pii">76668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16905684</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>767</StartPage><EndPage>776</EndPage><MedlinePgn>767-76</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objectives of this study were to evaluate the efficacy, safety, and tolerability of quetiapine for treating psychosis in patients with probable/possible Alzheimer disease and assess its impact on other psychopathology and social and daily functioning.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol. Primary outcomes were change in total Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impressions-Severity of Illness (CGI-S) scores at week 10. Secondary outcomes included BPRS factors, Neuropsychiatric Inventory (NPI), Multidimensional Observation Scale for Elderly Subjects (MOSES), and Physical Self-Maintenance Scale (PSMS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two hundred eighty-four participants (mean age: 83.2 years) were randomized; 63.4% completed; and mean Mini-Mental State Examination score was 12.8. Median of the mean daily dose was 96.9 mg for quetiapine and 1.9 mg for haloperidol. No differential benefit was seen on any psychosis measure. BPRS agitation factor scores improved with quetiapine versus placebo and not quetiapine versus haloperidol. BPRS anergia scores worsened with haloperidol versus quetiapine but not quetiapine versus placebo. No NPI factors showed change, including the agitation factor. MOSES Withdrawal Subscale and PSMS total scores worsened with haloperidol versus quetiapine. Somnolence occurred in 25.3%, 36.2%, and 4.1% of the quetiapine, haloperidol, and placebo groups, respectively; parkinsonism was most prevalent in the haloperidol group; other safety and tolerability measures differed little among groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">All treatment groups showed improvement in measures of psychosis without significant differences between them when planned comparisons were performed. Participants treated with quetiapine or haloperidol showed inconsistent evidence of improvement in agitation. Tolerability was better with quetiapine compared with haloperidol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Memory Disorders Center, Banner Alzheimer's Disease Institute, Phoenix, Arizona, USA. pierre.tariot@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Street</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Copenhaver</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams-Hughes</LastName><ForeName>Celeste</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Geriatr Psychiatry. 2006 Nov;14(11):988</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004361" MajorTopicYN="N">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16905684</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000196628.12010.35</ArticleId><ArticleId IdType="pii">S1064-7481(12)60711-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16902281</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Treatment of delusions in Alzheimer's disease--response to pharmacotherapy.</ArticleTitle><Pagination><StartPage>260</StartPage><EndPage>266</EndPage><MedlinePgn>260-6</MedlinePgn></Pagination><Abstract><AbstractText>Delusions are commonly encountered symptoms in patients with Alzheimer's disease and may lead to significant morbidity. The purpose of this article is to review all clinical trials to date focusing on the management of delusions in patients with Alzheimer's disease to determine the level of evidence for treatment. To achieve this objective, Medline was searched using the key words delusions, dementia, Alzheimer's disease and psychosis. Three main categories of treatment were identified: atypical antipsychotics, cholinesterase inhibitors, and other miscellaneous treatments. It was concluded that all forms of treatment were effective although the greatest burden of evidence existed for risperidone and donepezil. Side effects were noted in all forms of treatment and included somnolence and extrapyramidal effects for antipsychotic medications, whereas gastrointestinal effects were more prevalent in studies involving cholinesterase inhibitors. Further large scale, double-blind, randomized, controlled studies are required before a definitive conclusion can be reached. To our knowledge this is the only systematic review of this area.</AbstractText><CopyrightInformation>Copyright (c) 2006 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>St. Michael's Hospital, Toronto, Ont., Canada. fischerc@smh.toronto.on.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozanovic</LastName><ForeName>Radenka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Atkins</LastName><ForeName>Jana H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Rourke</LastName><ForeName>Sean B</ForeName><Initials>SB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16902281</ArticleId><ArticleId IdType="doi">10.1159/000094975</ArticleId><ArticleId IdType="pii">94975</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16880358</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Research agenda for DSM-V: diagnostic categories and criteria for neuropsychiatric syndromes in dementia.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>171</EndPage><MedlinePgn>160-71</MedlinePgn></Pagination><Abstract><AbstractText>Neuropsychiatric symptoms in dementia represent a major health burden for older adults. These symptoms are often more distressing, impairing, and costly than cognitive symptoms in dementia, yet they have been less coherently categorized in the various versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM). The preponderance of literature on psychiatric symptoms in dementia has been in patients with Alzheimer's disease. Diagnostic criteria have been proposed for psychosis, depression, and sleep disturbance in Alzheimer's disease. "Agitation" also appears to be a clinically important behavioral complication of dementia that warrants further study. Beginning with further validation of these proposed diagnostic criteria, future research can guide a more clinically meaningful description of these syndromes in DSM-V. Advancing biotechnology offers promise for discoveries related to the etiology and treatment of these syndromes. New research in this field should encompass diverse populations and different types of dementia. The high emotional and economic costs of neuropsychiatric symptoms in dementia implore diagnostic refinement to facilitate improved treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, Department of Psychiatry, University of California, San Diego, CA 92161, USA. djeste@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Zubenko</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH19934-13</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH47346</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16880358</ArticleId><ArticleId IdType="doi">10.1177/0891988706291087</ArticleId><ArticleId IdType="pii">19/3/160</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16879763</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.</ArticleTitle><Pagination><StartPage>227</StartPage><EndPage>240</EndPage><MedlinePgn>227-40</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD) among patients with psychosis of Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Post hoc exploratory analysis of data on 479 nursing-home patients with psychosis of AD from three 12-week, double-blind, placebo-controlled clinical trials. Criteria for psychosis of AD were a diagnosis of AD or mixed dementia and a rating of &gt;/= 2 on any delusion or hallucination item of the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) rating scale when entering the trial. Mean changes from baseline to endpoint were examined for items on the Cohen-Mansfield Agitation Inventory (CMAI) and BEHAVE- AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On the CMAI, risperidone was significantly more effective than placebo in treating cursing or verbal aggression (p = 0.004), hitting (p &lt; 0.001), performing repetitious mannerisms (p &lt; 0.001), pacing, aimless wandering (p = 0.017), hoarding things (p = 0.02), hiding things (p = 0.02) and repetitive sentences or questions (p = 0.025). On the BEHAVE-AD, risperidone was significantly more effective than placebo in treating physical threats and/or violence (p = 0.001), agitation (other) (p = 0.001) and verbal outbursts (p = 0.026). Although analysis on individual hallucination and delusional items did not demonstrate specific responses, analyses of a composite of delusional items revealed significant drug-placebo differences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that risperidone is effective in treating a variety of symptoms associated with psychosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabinowitz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bar Ilan University, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="Y">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16879763</ArticleId><ArticleId IdType="doi">10.1017/S1041610206003942</ArticleId><ArticleId IdType="pii">S1041610206003942</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16877235</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0929-6646</ISSN><JournalIssue CitedMedium="Print"><Volume>105</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the Formosan Medical Association = Taiwan yi zhi</Title><ISOAbbreviation>J Formos Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychologic symptoms in different types of dementia.</ArticleTitle><Pagination><StartPage>556</StartPage><EndPage>562</EndPage><MedlinePgn>556-62</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/PURPOSE" NlmCategory="OBJECTIVE">Behavioral and psychologic symptoms of dementia (BPSD) are major sources of a caregiver's burden and also the most important factor when considering the need for institutionalization of dementia patients. BPSD occur in about 90% of patients with dementia. Studies comparing the BPSD in the major types of dementia using unitary behavioral rating scales are limited. We studied BPSD in patients with four major types of dementias from a memory clinic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited patients with dementia from our memory clinic from January 2003 to February 2004. The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) was used to measure BPSD severity. Clinical Dementia Rating and Mini Mental State Examination were used to determine dementia severity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 137 patients with four major types of dementia were recruited from 155 patients with dementia who attended the clinic during the study period. The main dementia types identified were Alzheimer's dementia (AD) in 54.8%, vascular dementia (VaD) in 20.6%, frontotemporal dementia (FTD) in 8.4%, dementia with Lewy bodies (DLB) in 4.5%, and other dementias in 11.6%. BPSD were found in 92.0% of the patients but only 43.1% received psychotropic treatment. The relative risk of receiving psychotropic treatment for BPSD subscales paralleled the extent of caregivers' burden as assessed by the BEHAVE-AD global rating. Type-specific BPSD, e.g. hallucination was identified for DLB, activity disturbances for FTD, anxiety and phobias for AD and affective disturbance for VaD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A strategy of targeting type-specific BPSD may be beneficial, such as environmental stimulus control for DLB patients who are prone to have hallucinations, design of a pacing path for patients with FTD who need support for symptoms of wandering and emotional support for patients with VaD who are susceptible to depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Ming-Jang</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan. mjchiu@ntumc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ta-Fu</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Ping-Keung</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Mau-Sun</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Li-Yu</ForeName><Initials>LY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>J Formos Med Assoc</MedlineTA><NlmUniqueID>9214933</NlmUniqueID><ISSNLinking>0929-6646</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16877235</ArticleId><ArticleId IdType="doi">10.1016/S0929-6646(09)60150-9</ArticleId><ArticleId IdType="pii">S0929-6646(09)60150-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16859172</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0260-1060</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Nutrition and health</Title><ISOAbbreviation>Nutr Health</ISOAbbreviation></Journal><ArticleTitle>Are neurodegenerative disorder and psychotic manifestations avoidable brain dysfunctions with adequate dietary omega-3?</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>101</EndPage><MedlinePgn>89-101</MedlinePgn></Pagination><Abstract><AbstractText>The present mismatch between what our brain needs, and the modern diet neglects our marine heritage. Last century, the priority in nutrition and food production was to achieve a high protein diet and somatic growth and function. The dietary content of omega-3 (N-3) required by the brain was neglected although evidence for the essentiality of certain fatty acids was published in 1929 and specifically re-affirmed for omega 3 in the brain in the 1970s. Cognitive decline with age and neurodegenerative disorder with dementia are now rising. This review describes signs of N-3 deficit in Alzheimer and Parkinson Disease, where maximum change involves the primary sites: olfactory cortex and the hippocampus. The olfactory agnosia observed in schizophrenia supports an N-3 deficit as does a reduction of key ologodendrocyte- and myelin-related genes in this disorder and affective disorder, where a rise in dementia accords with a deficit of N-3 also in this disorder. N-3 normalizes cerebral excitability at all levels. That the two disorders are localized at the extremes of excitability, is supported by their opposing treatments: convulsant neuroleptics and anti-epileptic anti-depressants. An adequate N-3 diet will probably prevent most psychotic episodes and prove that neurodegenerative disorder with dementia is also to a large extent not only preventable but avoidable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saugstad</LastName><ForeName>Letten F</ForeName><Initials>LF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nutr Health</MedlineTA><NlmUniqueID>8306569</NlmUniqueID><ISSNLinking>0260-1060</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ReprintIn"><RefSource>Nutr Health. 2006;18(3):203-15. doi: 10.1177/026010600601800302</RefSource><PMID Version="1">17180865</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009751" MajorTopicYN="N">Nutritional Requirements</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>72</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16859172</ArticleId><ArticleId IdType="doi">10.1177/026010600601800201</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16841077</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0893-133X</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>179</EndPage><MedlinePgn>171-9</MedlinePgn></Pagination><Abstract><AbstractText>The apolipoprotein E (ApoE) epsilon4 allele is a well-documented genetic risk factor for sporadic Alzheimer's disease (AD). Its association with psychopathology among AD patients has been the subject of discrepant reports. We aimed to determine whether ApoE epsilon4+ and epsilon4- AD patients exhibit a different risk profile for psychotic symptoms and other behavioral disturbances. The Neuropsychiatric Inventory (NPI) was administered to determine the frequency and severity of psychotic and other behavioral symptoms in a sample of n=266 AD patients who had been genotyped for ApoE. Multiple logistic regression models were used to calculate the association between the ApoE epsilon4 allele and the presence of psychotic symptoms (delusions or hallucinations). Exploratory analyses were also conducted to determine the impact of disease severity on epsilon4 effects and to examine the association between epsilon4 and other behavioral symptoms. ApoE epsilon4 was significantly associated with psychotic symptoms (odds ratio (OR)=1.87, 95% CI=1.07-3.29, P=0.029), adjusting for age, sex, education, and MMSE score. More stringent definitions of clinically significant psychosis yielded similar results. Exploratory analyses suggested that this effect accrued specifically from patients with severe-stage AD and primarily from an association between epsilon4 and delusions. The epsilon4 allele did not appear to influence the development of most other behavioral symptoms in our sample. In conclusion, AD patients who carry the ApoE epsilon4 allele are at greater risk than noncarriers for developing psychotic symptoms, particularly as the severity of their dementia progresses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zdanys</LastName><ForeName>Kristina F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleiman</LastName><ForeName>Timothy G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Benjamin T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Rightmer</LastName><ForeName>Tracy E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Grey</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Garman</LastName><ForeName>Katherine S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Tampi</LastName><ForeName>Rajesh R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Gelernter</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0001237</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30-MH30929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9439390</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600986</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K24--DA15105</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="Y">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16841077</ArticleId><ArticleId IdType="doi">10.1038/sj.npp.1301148</ArticleId><ArticleId IdType="pii">1301148</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16837108</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1231</StartPage><EndPage>1238</EndPage><MedlinePgn>1231-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The gene encoding catechol-O-methyltransferase (COMT) has been suggested as a candidate for Alzheimer-related psychosis (AD-P) susceptibility, and an association between AD-P and a functional valine to methionine polymorphism has been reported.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to assess the genetic contribution of other COMT variants to the risk of AD-P.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred and forty-six AD patients underwent clinical and neuropsychological examination as well as an evaluation of behavioural and psychiatric disturbances. They were subsequently divided into two subgroups according to the presence (AD-P) or the absence (AD-nP) of psychotic symptoms. Four single-nucleotide polymorphisms (SNPs) within COMT gene were evaluated, i.e. rs737865, rs737864, intron 1 C2754delC, and the well-known valine/methionine variant (rs4680). Analyses were performed on the single locus and pairwise disequilibrium of loci, and multi-locus haplotype.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The individual SNP analysis confirmed an association for the valine/methionine variant with AD-P. Haplotype analyses revealed that the alleles at four loci (rs737865, rs737864, intron 1 C2754delC, rs4680) interacted to create the risk of psychosis in AD, as A-C-C-G haplotype (OR=2.08, 95% CI=1.02-4.27, P=0.044) and G-C-delC-G haplotype (OR=2.54, 95% CI=1.32-4.90, P=0.006) in respect to the most common and not-at-risk A-C-C-A haplotype which was significantly overrepresented in AD-P.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present findings provide evidence of COMT genetic variations' role in the susceptibility to AD-related psychosis. The observation of a haplotype effect of different polymorphisms within the COMT gene puts emphasis on the usefulness of haplotype analysis in better defining individualized genetic risk profiles in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Italy. bborroni@inwind.it &lt;bborroni@inwind.it&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zanetti</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Archetti</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Franzoni</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Caimi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>AE28F7PNPL</RegistryNumber><NameOfSubstance UI="D008715">Methionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="Y">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008715" MajorTopicYN="N">Methionine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="Y">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16837108</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.027</ArticleId><ArticleId IdType="pii">S0197-4580(06)00184-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16831414</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0014-2999</ISSN><JournalIssue CitedMedium="Print"><Volume>545</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>New targets for pharmacological intervention in the glutamatergic synapse.</ArticleTitle><Pagination><StartPage>2</StartPage><EndPage>10</EndPage><MedlinePgn>2-10</MedlinePgn></Pagination><Abstract><AbstractText>Excitotoxicity is thought to be a major mechanism in many human disease states such as ischemia, trauma, epilepsy and chronic neurodegenerative disorders. Briefly, synaptic overactivity leads to the excessive release of glutamate that activates postsynaptic cell membrane receptors, which upon activation open their associated ion channel pore to produce ion influx. To date, although molecular basis of glutamate toxicity remain uncertain, there is general agreement that N-methyl-d-aspartate (NMDA) subtype of ionotropic glutamate receptors plays a key role in mediating at least some aspects of glutamate neurotoxicity. On this view, research has focused in the discovery of new compounds able to either reduce glutamate release or activation of postsynaptic NMDA receptors. Although NMDA receptor antagonists prevent excitotoxicity in cellular and animal models, these drugs have limited usefulness clinically. Side effects such as psychosis, nausea, vomiting, memory impairment, and neuronal cell death accompany complete NMDA receptor blockade, dramatizing the crucial role of the NMDA receptor in normal neuronal processes. Recently, however, well-tolerated compounds such as memantine has been shown to be able to block excitotoxic cell death in a clinically tolerated manner. Understanding the biochemical properties of the multitude of NMDA receptor subtypes offers the possibility of developing more effective and clinically useful drugs. The increasing knowledge of the structure and function of this postsynaptic NMDA complex may improve the identification of specific molecular targets whose pharmacological or genetic manipulation might lead to innovative therapies for brain disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gardoni</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center of Excellence on Neurodegenerative Diseases and Department of Pharmacological Sciences, University of Milano, via Balzaretti 9, 20133 Milano, Italy. Fabrizio.Gardoni@unimi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000151" MajorTopicYN="N">congenital</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>68</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16831414</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2006.06.022</ArticleId><ArticleId IdType="pii">S0014-2999(06)00642-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16823890</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1053-8569</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Adverse events among nursing home residents with Alzheimer's disease and psychosis.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>774</EndPage><MedlinePgn>763-74</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The objective of this study was to quantify rates of adverse events in a high-risk multi-morbid population of institutionalized patients with Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study among nursing home residents diagnosed with AD and psychosis during January 1998 to October 1999. Using the Medicare Minimum Data Set (MDS) and Medicare inpatient claims (ICD-9 codes), 7728 nursing home residents aged 55-95 years with AD and psychosis were identified for study. Potential adverse events of interest were identified from the MDS and Medicare inpatient claims (ICD-9 codes). We estimated the incidence rate (IR) and 95% confidence interval (CI) for each adverse event during a 2-year follow-up period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 7728 residents studied, nearly 30% were considered 'dependent' by the activities of daily living (ADL) score and approximately 15% exhibited severe cognitive impairment at baseline. At least 90% had comorbid psychiatric disorders. The most common adverse event was accidental injury, occurring at a rate of 97.7 per 100 person-years (95%CI = 94.7-100.7). Other common adverse events were death (IR = 44.6/100 person-years; 95%CI = 42.9-46.4), infection (IR = 41.8/100 person-years; 95%CI = 39.7-43.8), pain (IR = 43.5/100 person-years; 95%CI = 41.2-45.9), anorexia (41.3/100 person-years; 95%CI = 39.1-43.6), and weight change (IR = 40.2/100 person-years; 95%CI = 38.7-41.7).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This information on the occurrence of adverse outcomes among nursing home patients with AD and psychosis provides useful context for any safety event observed among patients treated for psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveria</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Episource, Hamden, CT, USA. oliveri1@mskcc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liperoti</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>L'italien</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pugner</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Safferman</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lapane</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007344" MajorTopicYN="N">Insurance Claim Reporting</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008484" MajorTopicYN="N">Medicaid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017751" MajorTopicYN="N">Safety Management</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16823890</ArticleId><ArticleId IdType="doi">10.1002/pds.1274</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16816014</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.</ArticleTitle><Pagination><StartPage>605</StartPage><EndPage>612</EndPage><MedlinePgn>605-12</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to conduct exploratory analyses of data pertaining to the efficacy of donepezil treatment of patients with severe behavioral disturbances. Preliminary studies suggest that cholinesterase inhibitors, including donepezil, may reduce behavioral disturbances in patients with Alzheimer disease (AD). Most patients included in clinical trials have had low levels of psychopathology at baseline, and the effect of cholinesterase inhibitors on patients with more severe behavioral disturbances is unknown. The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a hypothesis-driven secondary analysis of a three-phase study involving donepezil and sertraline. In phase 1, psychotropic agents were withdrawn; in phase 2, patients were treated in an open-label fashion with donepezil for 8 weeks; and in phase 3, patients on donepezil were randomized to receive placebo or sertraline for an additional 12 weeks. The data set analyzed is comprised of the patient population treated with donepezil (without sertraline) for 20 weeks. One hundred twenty patients were included in the analyses. Mean age was 76 years, average Mini-Mental State Examination Score was 18, and mean Neuropsychiatric Inventory (NPI) total score was 30. Primary efficacy assessments were the NPI, the Clinical Global Impression-Improvement, and the Clinical Global Impression-Severity scales. Secondary measures included the Behavioral Pathology in Alzheimer's Disease Rating Scale, The Hamilton Depression Rating Scale, and the Alzheimer's Disease Functional Assessment and Change Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Excellent concurrent validity was noted between the NPI and the Behavioral Pathology in Alzheimer's Disease Rating Scale. The total score of the NPI was significantly reduced over the 20 weeks of therapy with donepezil. Sixty-two percent of patients had at least a 30% reduction in the total NPI score (significantly greater than the number with no meaningful response). Likewise, more patients had total or partial resolution of depression and delusions than those who had no meaningful change. Factor analysis of baseline NPI data revealed five factors, including a psychosis factor, an agitation factor, mood factor, frontal lobe function factor, and appetite and eating disorders factor. Clinically meaningful treatment effect sizes were notable for the delusion factor (0.340) and the mood factor (0.39). There were significant correlations between the Clinical Global Impression-Improvement and reductions in mood and agitation scores.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of these analyses suggest that donepezil reduces behavioral symptoms, particularly mood disturbances and delusions, in patients with AD with relatively severe psychopathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. jcummings@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McRae</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>Donepezil-Sertraline Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 16570</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020280" MajorTopicYN="N">Sertraline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16816014</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000221293.91312.d3</ArticleId><ArticleId IdType="pii">S1064-7481(12)60558-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16816010</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Phenomenology and clinical correlates of delusions in Alzheimer disease.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>581</EndPage><MedlinePgn>573-81</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objectives of this study were to determine whether anosognosia, depression, and elevated mood are associated with delusions in Alzheimer disease (AD), and to examine the validity of standardized diagnostic criteria for psychosis of dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors assessed a consecutive series of 771 patients with AD attending a dementia clinic with a comprehensive neuropsychologic and psychiatric evaluation that included specific measures of delusions, hallucinations, anosognosia, depression, and elevated mood.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Delusions were found in one-third of the patients and hallucinations in 7%. Most patients with hallucinations also had delusions. A principal component analysis of the Psychosis Dementia Scale, which rates the presence and severity of delusions, produced the factors of paranoid misidentification and expansive delusions. Paranoid, but not expansive, delusions increased across the stages of the illness. Anosognosia and depression were significantly and independently associated with the presence of delusions, whereas elevated mood was significantly associated with expansive, but not paranoid, delusions. A multiple logistic regression analysis demonstrated that delusions in AD were significantly associated with depression, anosognosia, overt aggression, and agitation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anosognosia, depression, global cognitive deficits, and elevated mood are the main psychiatric correlates of paranoid misidentification and expansive delusions in AD, whereas overt aggression and agitation are the most frequent behavioral concomitants of psychosis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mizrahi</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PET Center for Addiction and Mental Health, Clarke Division, Toronto, Canada. romina.mizrahi@camhpet.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starkstein</LastName><ForeName>Sergio E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Jorge</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002194" MajorTopicYN="N">Capgras Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16816010</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000214559.61700.1c</ArticleId><ArticleId IdType="pii">S1064-7481(12)60554-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16808321</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Polskie Archiwum Medycyny Wewnetrznej</Title><ISOAbbreviation>Pol Arch Med Wewn</ISOAbbreviation></Journal><ArticleTitle>[Music application in the therapy of psychic and somatic diseases].</ArticleTitle><Pagination><StartPage>808</StartPage><EndPage>812</EndPage><MedlinePgn>808-12</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jonderko</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Katedra i Oddzial Kliniczny Chor&#xf3;b Wewnetrznych Wydzia&#x142;u Opieki i O&#x15b;wiaty Zdrowotnej Slaskiej Akademii Medycznej w Katowicach.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcisz</LastName><ForeName>Czes&#x142;aw</ForeName><Initials>C</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Zastosowanie muzyki w leczeniu chor&#xf3;b psychicznych i somatycznych.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol Arch Med Wewn</MedlineTA><NlmUniqueID>0401225</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009147" MajorTopicYN="N">Music Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011602" MajorTopicYN="N">Psychophysiologic Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="N">Somatoform Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16808321</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16806095</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Galantamine improves cognition in schizophrenic patients stabilized on risperidone.</ArticleTitle><Pagination><StartPage>530</StartPage><EndPage>533</EndPage><MedlinePgn>530-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognition in schizophrenia is impaired in a variety of cognitive domains. Galantamine, a cholinesterase inhibitor with putative nicotinic agonist-like effects, improves cognition in Alzheimer's patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixteen schizophrenic or schizoaffective patients stabilized on risperidone were administered galantamine (n=8) or placebo (n=8) in a randomized, double-blind trial. The Repeatable Battery for Assessment of Neuropsychological Status (RBANS) assessed changes in cognitive performance over an eight-week treatment interval.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical symptoms improved in both groups during the trial with no evidence that galantamine exacerbated extrapyramidal symptoms. Patients treated with galantamine experienced an overall improvement in cognitive performance (RBANS Total scale score; galantamine = 12.1 +/- 12.8 SD, placebo = .5 +/- 13.5, t = 2.32, p &lt; .04). Confidence intervals suggest that RBANS Attention and Delayed Memory subscale performance was robustly improved in galantamine patients by approximately one standard deviation, effectively normalizing cognitive performance in these domains.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adjunctive treatment with galantamine improves memory and attention in patients with schizophrenia who are stabilized on risperidone, providing the opportunity to improve functional outcome in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>Max H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science, Neuropsychiatry Research Program, Texas A&amp;M University System Health Science Center College of Medicine, Central Texas Veterans Health Care System, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Curr Psychiatry Rep. 2007 Apr;9(2):133-4.</RefSource><PMID Version="1">17389124</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16806095</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2006.04.006</ArticleId><ArticleId IdType="pii">S0006-3223(06)00468-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16805717</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities.</ArticleTitle><Pagination><StartPage>1305</StartPage><EndPage>1321</EndPage><MedlinePgn>1305-21</MedlinePgn></Pagination><Abstract><AbstractText>The objective of this paper is to synthesise extant studies describing the neurotherapeutic effects of antidiabetic agents in neuropsychiatric disorders. The authors conducted a MedLine search of all English-language articles published between 1966 and March 2006. The search terms were the nonproprietary names of established and putative antidiabetic agents (e.g., insulin, insulin secretagogues and sensitisers) cross-referenced with the individual names of Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R/IV/-TR-defined mood, psychotic, anxiety and dementing disorders. The search was augmented with a manual review of article reference lists. Contemporary models of disease pathophysiology in major depressive disorder, bipolar disorder and several dementing disorders (e.g., Alzheimer's disease) emphasise alterations in cellular plasticity and cytoarchitecture, with associated regional abnormalities in neuronal and glial density and morphology. Antidiabetic treatments (e.g., thiazolidinediones) may be capable of attenuating this pathological process via disparate mechanisms (e.g., neuroprotective, neurotrophic, anti-inflammatory). Enhanced insulin signalling with antidiabetic treatments may preserve and/or augment cognitive function in several neuropsychiatric disorders. Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street-Toronto, ON, M5T 2S8, Canada. roger.mcintyre@uhn.on.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soczynska</LastName><ForeName>Joanna K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Gary F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>MacQueen</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Konarski</LastName><ForeName>Jakub Z</ForeName><Initials>JZ</Initials></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Sidney H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010848">Picolinic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>QZV2W997JQ</RegistryNumber><NameOfSubstance UI="C030614">picolinic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010848" MajorTopicYN="N">Picolinic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="N">Thioctic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16805717</ArticleId><ArticleId IdType="doi">10.1517/14656566.7.10.1305</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16793187</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>8</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications.</ArticleTitle><Pagination><StartPage>1369</StartPage><EndPage>1380</EndPage><MedlinePgn>1369-80</MedlinePgn></Pagination><Abstract><AbstractText>Two members of the family of low-density lipoprotein receptors (i.e., very low-density lipoprotein [VLDL] receptor and apolipoprotein E [apoE] type 2 receptor) are expressed in brain, where they bind and transduce reelin, a secreted glycoprotein that shares structural analogies with extracellular matrix proteins. In the developing fetal brain, reelin-signal transduction is critical for the correct positioning of neurons and the formation of appropriate synaptic connections, whereas in the mature brain, reelin participates in the mediation of experience-dependent synaptic plasticity. An important "downstream" consequence of the reelin-signal transduction cascade is inhibition of the phosphorylation of tau, a protein that regulates microtubule assembly and stability. Importantly, hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease; hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders. Isoforms of apoE may affect the binding of reelin to its cell surface receptors and, thereby, influence tau phosphorylation, whereas insulin, insulin-like growth factor-1, and the lithium ion have actions within the cell at the level of the specific tyrosine kinases involved in the phosphorylation of tau. These data support the exploration of pharmacotherapeutic interventions designed to prevent or reduce the burden of hyperphosphorylated tau. Impaired reelin-signal transduction due to an actual deficiency of reelin expression may occur in at least some patients with psychotic disorders, especially schizophrenia; conceivably, hyperphosphorylation of tau would result from deficient transduction of reelin in schizophrenia. Schizophrenia has been conceptualized as a neurodevelopmental disorder of impaired synaptic "connectivity", whose consequence does not become fully apparent until late adolescence or early adulthood. In summary, hyperphosphorylation of tau may be an underlying point of pathological convergence for several neuropsychiatric disorders, and prevention of tau hyperphosphorylation may be an important therapeutic target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Stephen I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Mental Health Service Line and Research Service, Department of Veterans Affairs Medical Center, 50 Irving Street, NW, Washington, DC 20422, United States. Stephen.Deutsch@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosse</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Lakshman</LastName><ForeName>Raj M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091042">Reelin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717127">RELN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16793187</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2006.04.007</ArticleId><ArticleId IdType="pii">S0278-5846(06)00162-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16720796</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>White matter changes associated with psychotic symptoms in Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>198</EndPage><MedlinePgn>191-8</MedlinePgn></Pagination><Abstract><AbstractText>This study explored the relationship between white matter changes seen on magnetic resonance imaging (MRI) and neuropsychiatric symptoms of Alzheimer's disease patients. Fifty-five probable Alzheimer's disease patients were assessed with Behavioral Rating Scale for Dementia (BRSD) and MRI. White matter changes in the bilateral frontal or parieto-occipital region and left basal ganglia significantly corresponded with the score of the Psychotic Symptoms subscale of BRSD. Secondary analyses revealed that white matter changes were not associated with paranoid delusion and hallucination, but only with delusional misidentification. Our results suggest that white matter changes in Alzheimer's disease patients probably contribute to the development of specific psychotic symptoms, namely delusional misidentification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choo</LastName><ForeName>Il Han</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Woong</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Jhoo</LastName><ForeName>Jin Hyeong</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Jong Choul</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Un Young</ForeName><Initials>UY</Initials></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Jong Inn</ForeName><Initials>JI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002194" MajorTopicYN="N">Capgras Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007089" MajorTopicYN="Y">Image Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16720796</ArticleId><ArticleId IdType="doi">10.1176/jnp.2006.18.2.191</ArticleId><ArticleId IdType="pii">18/2/191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16716829</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0361-9230</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Brain research bulletin</Title><ISOAbbreviation>Brain Res Bull</ISOAbbreviation></Journal><ArticleTitle>Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain.</ArticleTitle><Pagination><StartPage>626</StartPage><EndPage>630</EndPage><MedlinePgn>626-30</MedlinePgn></Pagination><Abstract><AbstractText>Abnormalities of NMDA receptor-mediated neurotransmission are involved in the pathophysiology of schizophrenia, Alzheimer's disease, substance abuse and seizure disorders. The NMDA receptor is implicated in schizophrenia because phencyclidine (PCP), a noncompetitive NMDA receptor antagonist, binds to a hydrophobic domain within the channel, precipitating a schizophreniform psychosis in susceptible persons. Pharmacological, environmental, and genetic variables alter NMDA receptor-mediated neurotransmission. Inbred mouse strains differ in their sensitivity to some of the behavioral effects of MK-801 (dizocilpine), a PCP analogue. The NMDA receptor complex in the BALB/c strain could reflect a unique stoichiometric combination of receptor subunits resulting in a higher proportion of the channels in the open configuration, a higher affinity of MK-801 for its hydrophobic channel domain, and/or a combination of the above. The BALB/c mouse strain, "stressed" mice, and behavioral consequences of MK-801 administration represent models of altered glutamatergic neural transmission. We were interested in examining the effect of stress on the modulatory properties of d-serine and sarcosine. d-Serine is a naturally occurring glycine agonist that modulates the ability of l-glutamate to influence the opening of the NMDA receptor-associated ionophore, and sarcosine is a naturally occurring glycine reuptake inhibitor. The data suggest that 24h after stress, d-serine and sarcosine interact synergistically to reduce MK-801's ability to antagonize electrically precipitated tonic hindlimb extension. Under conditions of stress, modulatory effects of d-serine and sarcosine on the antiseizure effect of MK-801 are observed that are not apparent in the nonstress condition. The results could be relevant to the development of glycinergic interventions for the treatment of neuropsychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Katrice D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Mental Health Service Line, Department of Veterans Affairs Medical Center, 50 Irving Street NW, Washington, DC 20422, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastropaolo</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosse</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Manaye</LastName><ForeName>Kebreten F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Stephen I</ForeName><Initials>SI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Res Bull</MedlineTA><NlmUniqueID>7605818</NlmUniqueID><ISSNLinking>0361-9230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z711V88R5F</RegistryNumber><NameOfSubstance UI="D012521">Sarcosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004597" MajorTopicYN="N">Electroshock</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012521" MajorTopicYN="N">Sarcosine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16716829</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2006.03.007</ArticleId><ArticleId IdType="pii">S0361-9230(06)00086-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16700962</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>8</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Behavioural and neuropsychological correlates of frontal lobe features in dementia.</ArticleTitle><Pagination><StartPage>1173</StartPage><EndPage>1182</EndPage><MedlinePgn>1173-82</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In order to characterize frontal lobe features and their behavioural and cognitive correlates across diagnostic categories, we performed a cross-sectional analysis of behavioural and neuropsychological data from a large, prospective Belgian study on behavioural and psychological signs and symptoms of dementia (BPSD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with probable Alzheimer's disease (AD) (n=170), frontotemporal dementia (FTD) (n=28), mixed dementia (MXD) (n=29) and dementia with Lewy bodies (DLB) (n=21) were included and underwent neuropsychological and behavioural assessment by means of a battery of tests and scales. Frontal lobe symptoms were quantified by means of the Middelheim Frontality Score (MFS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In AD (and to a lesser extent in MXD), MFS total scores were negatively correlated with scores on MMSE (Spearman: r=-0.36, p&lt;0.001) and a Verbal Fluency Task (r=-0.38, p&lt;0.001) and were associated with increased severity and frequency of psychosis (r=0.24, p&lt;0.01), activity disturbances (r=0.44, p&lt;0.001) and aggressiveness (r=0.43, p&lt;0.001). In DLB, MFS total scores were negatively correlated with MMSE scores (r=-0.50, p=0.020). No associations were found in FTD patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A cross-sectional analysis of frontal lobe features, behavioural characteristics and neuropsychological data demonstrated that, in AD (and to a lesser extent in MXD) patients, frontal lobe symptoms were associated with more pronounced cognitive deficits (of frontal origin), with increased severity and frequency of agitated and aggressive behaviour, and with increased severity of psychosis and depressive symptoms. Given the small sample sizes of the DLB and FTD patient groups, negative findings in these patient groups should be interpreted cautiously.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Memory Clinic, Middelheim General Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maertens</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mari&#xeb;n</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Vloeberghs</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Somers</LastName><ForeName>Nore</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Nagels</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16700962</ArticleId><ArticleId IdType="doi">10.1017/S003329170600777X</ArticleId><ArticleId IdType="pii">S003329170600777X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16669138</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-4079</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Bulletin de l'Academie nationale de medecine</Title><ISOAbbreviation>Bull Acad Natl Med</ISOAbbreviation></Journal><ArticleTitle>[Early clinical signs of dementia in the elderly].</ArticleTitle><Pagination><StartPage>1383</StartPage><EndPage>1391</EndPage><MedlinePgn>1383-90; discussion 1390-1</MedlinePgn></Pagination><Abstract><AbstractText>Clinical signs and symptoms preceding the onset of dementia are sometimes acute, such as mood disorders often associated with hypochondriacal traits and cognitive slowing, sudden and serious suicide attempts, character and conduct disorders contrasting with the previous state, and psychotic disorders presenting as pathological mistrust, or ill-structured prejudice or persecution. Most forerunning symptoms reflect a progressive deterioration of cognitive functions over a long period, that have been masked by various coping strategies used by the patient with the spouse's help. Progressive cognitive deficits may develop over years before dementia can be diagnosed with confidence. Quantitative tools can help to detect dementia incipiens, such as the Folstein Mini Mental Test, the Mattis Dementia Scale, the five-word learning test, the clock drawing test, and the brief cognitive battery. The profile of early cognitive deterioration varies according to the type of dementia (Alzheimer's disease, fronto-temporal dementia, Lewy body dementia, and vascular dementia). The symptoms of dementia may be interlinked with symptoms of other disorders. Neuropsychological tests and brain imaging are needed to validate the diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf4;o</LastName><ForeName>Henri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>L'Acad&#xe9;mie Nationale de M&#xe9;decine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallarda</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Amado</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Olie</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les signes cliniques pr&#xe9;curseurs d'un processus d&#xe9;mentiel chez le sujet ag&#xe9;.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Bull Acad Natl Med</MedlineTA><NlmUniqueID>7503383</NlmUniqueID><ISSNLinking>0001-4079</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>15</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16669138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16634465</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>108</EndPage><MedlinePgn>101-8</MedlinePgn></Pagination><Abstract><AbstractText>The behavioral and psychological symptoms of dementia (BPSD), such as psychosis, agitation, or aggression have a considerable negative impact on the quality of life of both patients and their caregivers. Multiple studies have demonstrated that atypical antipsychotics are efficacious in the treatment of the aggressive and psychotic symptom clusters, and here we review their use in this indication. Because of the safety concerns associated with the use of atypical antipsychotics in this population, these drugs must be used judiciously. For patients with severe BPSD such as psychosis, agitation, or aggression, for whom there are few options, atypical antipsychotics, particularly risperidone and olanzapine, should be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aupperle</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16634465</ArticleId><ArticleId IdType="pmc">PMC10833293</ArticleId><ArticleId IdType="doi">10.1177/153331750602100209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>1. Finkel SI: Introduction to behavioral and psychological symptoms of dementia (BPSD). Int JGeriatrPsychiatry. 2000; 15(Suppl 1): S2-S4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767742</ArticleId></ArticleIdList></Reference><Reference><Citation>2. Small GW, Rabins PV, Barry PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAAM. 1997; 278: 1363-1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343469</ArticleId></ArticleIdList></Reference><Reference><Citation>3. Finkel SI: Behavioral and psychological symptoms of dementia: A current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001; 62(Suppl 21): 3-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584987</ArticleId></ArticleIdList></Reference><Reference><Citation>4. Hemels ME, Lanctot KL, Iskedjian M, et al.: Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs Aging. 2001; 18: 527-550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11482746</ArticleId></ArticleIdList></Reference><Reference><Citation>5. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>6. Cohen-Mansfield J: Nonpharmacologic interventions for inappropriate behaviors in dementia. Am J Geriatr Psychiatry. 2001; 9: 361-381.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739063</ArticleId></ArticleIdList></Reference><Reference><Citation>7. McShane RH: What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychogeriatr. 2000; 12(Suppl 1): 147-153.</Citation></Reference><Reference><Citation>8. Tariot PN, Blazina L: The psychopathology of dementia. In Morris TC (ed): Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994.</Citation></Reference><Reference><Citation>9. Steele C, Rovner B, Chase GA, et al.: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Ain J psychiatry. 1990; 147: 1049-1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>10. Balestreri L, Grossberg A, Grossberg GT: Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. nt Psychogeriatr. 2000; 12(Suppl 1): 59-62.</Citation></Reference><Reference><Citation>11. Teri L, Rabins P. Whitehouse P. et al.: Management of behavior disturbance in Alzheimer disease: Current knowledge and future directions. Alzheimer Dis Assoc Disord. 1992; 6: 77-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1389083</ArticleId></ArticleIdList></Reference><Reference><Citation>12. Herrmann N, Lanctot KL, Naranjo CA: Behavioural disorders in demented elderly patients. CNS Drugs. 1996; 6: 280-300.</Citation></Reference><Reference><Citation>13. De Deyn PP, Wirshing WC: Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001; 62(Suppl 21): 19-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584983</ArticleId></ArticleIdList></Reference><Reference><Citation>14. Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48(Suppl): 9-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>15. Cohen-Mansfield J: Conceptualization of agitation: Results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996; 8(Suppl 3): 309-315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154580</ArticleId></ArticleIdList></Reference><Reference><Citation>16. Dahlke F, Lohaus A, Gutzmann H: Reliability and clinical concepts underlying global judgments in dementia: Implications for clinical research. Psychopharmacol Bull. 1992; 28: 425-432.</Citation><ArticleIdList><ArticleId IdType="pubmed">1296220</ArticleId></ArticleIdList></Reference><Reference><Citation>17. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10: 799-812.</Citation></Reference><Reference><Citation>18. Herrmann N: Recommendations for the management of behavioral and psychological symptoms of dementia. Can JNeurol Sci. 2001; 28(Suppl 1): S96-S107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237317</ArticleId></ArticleIdList></Reference><Reference><Citation>19. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005; 293: 596-608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>20. Gauthier S, Feldman H, Hecker J, et al.: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002; 14: 389-404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670060</ArticleId></ArticleIdList></Reference><Reference><Citation>21. Paleacu D, Mazeh D, Mirecki I, et al.: Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol. 2002; 25: 313-317.</Citation><ArticleIdList><ArticleId IdType="pubmed">12469005</ArticleId></ArticleIdList></Reference><Reference><Citation>22. Weiner MF, Martin-Cook K, Foster BM, et al.: Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry. 2000; 61: 487-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10937606</ArticleId></ArticleIdList></Reference><Reference><Citation>23. Tariot PN, Cummings JL, Katz IR, et al.: A randomized, doubleblind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. JAm Geriatr Soc. 2001; 49: 1590-1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">11843990</ArticleId></ArticleIdList></Reference><Reference><Citation>24. Wilcock G, Howe I, Coles H, et al.: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003; 20: 777-789.</Citation><ArticleIdList><ArticleId IdType="pubmed">12875613</ArticleId></ArticleIdList></Reference><Reference><Citation>25. Suh GH, Yeon Jung H, Uk Lee C, et al.: A prospective, doubleblind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Therap. 2004; 26: 1608-1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598477</ArticleId></ArticleIdList></Reference><Reference><Citation>26. Cummings JL, Schneider L, Tariot PN, et al.: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am JPsychiatry. 2004; 161: 532-538.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992980</ArticleId></ArticleIdList></Reference><Reference><Citation>27. Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-IO Study Group. Neurology. 2000; 54: 2269-2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>28. Schneider LS, Pollock VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. JAm Geriatr Soc. 1990; 38: 553-563.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>29. Zaudig M: A risk-benefit assessment of risperidone for the treatment of behavioral and psychological symptoms in dementia. Drug Safety. 2000; 23: 183-195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11005702</ArticleId></ArticleIdList></Reference><Reference><Citation>30. Lawlor B, Bhriain SN: Psychosis and behavioral symptoms of dementia: Defining the role of neuroleptic interventions. IntJGeriatr Psychiatry. 2001; 16(Suppl 1): S2-S6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748783</ArticleId></ArticleIdList></Reference><Reference><Citation>31. Jeste DV, Rockwell E, Harris MJ, et al.: Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999; 7: 70-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9919323</ArticleId></ArticleIdList></Reference><Reference><Citation>32. Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999; 60: 107-115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>33. De Deyn PP, Rabheru K, Rasmussen A, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999; 53: 946-955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>34. Chan WC, Lam LC, Choy CN, et al.: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. IntJ Geriatr Psychiatry. 2001; 16: 1156-1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748775</ArticleId></ArticleIdList></Reference><Reference><Citation>35. Brodaty H, Ames D, Snowdon J, et al.: A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64: 134-143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>36. Suh GH, Son HG, Ju YS, et al.: A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. 2004; 12: 509-516.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353389</ArticleId></ArticleIdList></Reference><Reference><Citation>37. De Deyn PP, Katz IR, Brodaty H, et al.: Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005; 107: 497-508.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922506</ArticleId></ArticleIdList></Reference><Reference><Citation>38. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebocontrolled trial. Arch Gen Psychiatry. 2000; 57: 968-976.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>39. De Deyn PP, Carrrasco MM, Deberdt W, et al.: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004; 9: 115-126.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId></ArticleIdList></Reference><Reference><Citation>40. Clark WS, Street JS, Feldman PD, et al.: The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2001; 62: 34-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11235926</ArticleId></ArticleIdList></Reference><Reference><Citation>41. Rainer MK, Mucke HA, Kruger-Rainer C, et al.: Zotepine for behavioral and psychological symptoms in dementia: An open-label study. CNS Drugs. 2004; 18: 49-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">14731059</ArticleId></ArticleIdList></Reference><Reference><Citation>42. Fujikawa T, Takahashi T, Kinoshita A, et al.: Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004; 49: 201-204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15118358</ArticleId></ArticleIdList></Reference><Reference><Citation>43. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002; 16: 128-130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040309</ArticleId></ArticleIdList></Reference><Reference><Citation>44. McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999; 60: 292-298.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362435</ArticleId></ArticleIdList></Reference><Reference><Citation>45. Tariot PN, Salzman C, Yeung PP, ei al.: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therap. 2000; 22: 1068-1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">11048905</ArticleId></ArticleIdList></Reference><Reference><Citation>46. Ballard C, Margallo-Lana M, Juszczak E, et al.: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ. 2005; 330: 874-874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556156</ArticleId><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference><Reference><Citation>47. De Deyn P, Jeste DV, Swanink R, et al.: Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study. J Clin Psychopharmacol. 2005; 25: 463-467.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160622</ArticleId></ArticleIdList></Reference><Reference><Citation>48. Baskys A: Lewy body dementia: The litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004; 65(Suppl 11): 16-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264967</ArticleId></ArticleIdList></Reference><Reference><Citation>49. Mulsant BH, Gharabawi GM, Bossie CA, et al.: Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004; 65: 1708-1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641877</ArticleId></ArticleIdList></Reference><Reference><Citation>50. Gareri P, Cotroneo A, Lacava R, et al.: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl. 2004; 9: 207-215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207416</ArticleId></ArticleIdList></Reference><Reference><Citation>51. Fontaine CS, Hynan LS, Koch K, et al.: A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003; 64: 726-730.</Citation><ArticleIdList><ArticleId IdType="pubmed">12823090</ArticleId></ArticleIdList></Reference><Reference><Citation>52. Schneider LS, Tariot PN, Lyketsos CG; et al.: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9: 346-360.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739062</ArticleId></ArticleIdList></Reference><Reference><Citation>53. McShane R, Keene J, Gedling K, et al.: Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997; 314: 266-270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2125727</ArticleId><ArticleId IdType="pubmed">9022490</ArticleId></ArticleIdList></Reference><Reference><Citation>54. Saxton J, McGonigle-Gibson K, Swihart A, et al.: Assessment of severely impaired patients: Description and validation of a new neuropsychological test battery. PsycholAssess. 1990; 2: 298-303.</Citation></Reference><Reference><Citation>55. http.//www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 11, 2005.</Citation></Reference><Reference><Citation>56. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA4. 2005; 294: 1934-1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>57. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular adverse events in dementia trials. Can Med Assoc J. 2002; 167: 1269-1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134141</ArticleId><ArticleId IdType="pubmed">12451085</ArticleId></ArticleIdList></Reference><Reference><Citation>58. Wooltorton E. Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J 2004; 170: 1395-1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395813</ArticleId><ArticleId IdType="pubmed">15111472</ArticleId></ArticleIdList></Reference><Reference><Citation>59. Abilify package insert. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.; 2005.</Citation></Reference><Reference><Citation>60. Herrmann N, Lanct6t KL. Do atypical antipsychotics cause stroke? CNSDrugs. 2005; 19: 91-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15697324</ArticleId></ArticleIdList></Reference><Reference><Citation>61. Sleeper RB: Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother. 2005; 39: 1573-1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">16076907</ArticleId></ArticleIdList></Reference><Reference><Citation>62. Zhao Q, Xie C, Pesco-Koplowitz L, et al.: Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol. 2003; 43: 180-186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12616671</ArticleId></ArticleIdList></Reference><Reference><Citation>63. Weiser M, Rotmensch HH, Korczyn AD, et al.: A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int JGeriatr Psychiatry. 2002; 17: 343-346.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994888</ArticleId></ArticleIdList></Reference><Reference><Citation>64. Huang F, Lasseter KC, Janssens L, et al.: Pharmacokinetic and safety assessments of galantamine and risperidone after thetwo drugs are administered alone and together. J Clin Pharmacol. 2002; 42: 1341-1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12463729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16625511</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>8</Issue><PubDate><MedlineDate>2006 Apr 16-30</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Treatment of non cognitive symptoms of Alzheimer's disease].</ArticleTitle><Pagination><StartPage>482</StartPage><EndPage>488</EndPage><MedlinePgn>482-8</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION AND DEVELOPMENT" NlmCategory="BACKGROUND">Owing to their functional repercussions, the secondary or non-cognitive symptoms displayed by patients with Alzheimer's disease (AD) are very important both for the patients themselves and for the work of the caregiver. In this article we review the treatment of some of them, such as psychotic disorders and depressive symptoms. Atypical neuroleptic drugs are the preferred treatment for symptoms such as delusions, hallucinations, agitation and aggressive behaviour. The most widely used are olanzapine and risperidone. Their pharmacological characteristics, therapeutic effectiveness and side effects are reviewed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Broader and better designed clinical studies are required to evaluate their usefulness. Recent reports, from 2004, have described a significant increase in the mortality rate (3.5 vs. 1.5%) and in the risk of suffering a stroke (1.3 vs. 0.4%) in elderly demented patients associated to the use of olanzapine and risperidone. The good tolerance and absence of anticholinergic effects of the serotonin reuptake inhibitors, fluoxetin and paroxetine, make them the first-choice medication for the treatment of the depressive symptoms in AD. Despite their widespread use, the evidence currently available with respect to their therapeutic effectiveness is not very convincing and clinical trials with a wider scope and a better design need to be carried out.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grau-Veciana</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hospital de la Santa Creu i Sant Pau, Departamento de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. jgrau@hsp.santpau.es</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento de los s&#xed;ntomas no cognitivos de la enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>41VRH5220H</RegistryNumber><NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>30</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16625511</ArticleId><ArticleId IdType="pii">rn2005217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16582044</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prediction of psychosis onset in Alzheimer disease: The role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes.</ArticleTitle><Pagination><StartPage>352</StartPage><EndPage>360</EndPage><MedlinePgn>352-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms in Alzheimer disease (AD+P) identify a heritable phenotype associated with more rapid cognitive decline. The authors have proposed that AD+P is itself a composite of a misidentification and a paranoid subtype with increased cognitive impairment restricted to the misidentification type. Most prior studies of the clinical correlates of AD+P have been limited, however, by the inclusion of prevalent cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis at study entry were assessed at the time of initial presentation and then annually. Psychotic symptoms were assessed using the CERAD Behavioral Rating Scale. Survival analyses used Cox proportional hazard models with time-dependent covariates to examine the predictors of psychosis onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 288 subjects completed at least one follow-up examination. Mean duration of follow-up was 22.1 months. The incidence of psychosis was 0.19 per person-year. Cognitive impairment was associated with onset of psychosis, largely as a result of its association with onset of the misidentification, but not the paranoid, subtype. Including psychotropic medication use in the model revealed an association of antidepressant use with the onset of psychosis. This latter association appeared to arise from an underlying association between depression and the risk of psychosis onset rather than from antidepressant treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings are consistent with the hypothesis that the misidentification and the paranoid subtypes each define a more biologically homogeneous group than AD+P as a whole. Further exploration of the relationship between depressive symptoms and psychosis in patients with AD is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilkosz</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000192500.25940.1b</ArticleId><ArticleId IdType="pii">S1064-7481(12)60684-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16582043</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>351</EndPage><MedlinePgn>343-51</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to investigate the cumulative effect of the genes likely involved in Alzheimer disease (AD)-related psychosis and their interaction with disease stage and environmental factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred thirty-four patients with AD underwent clinical and neuropsychologic examination, behavioral and psychiatric disturbances evaluation, and were subsequently divided into two subgroups according to the presence (AD-P) or the absence (AD-nP) of psychotic symptoms. Cathecol-O-methyltransferase (COMT), serotonin gene-linked promoter region (5-HTTLPR), and Apolipoprotein E (ApoE) genotypes were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COMT*H (H/H or H/liter; odds ratio [OR]: 2.4; 95% confidence interval [CI]: 1.13-5.11) and 5-HTTLPR*S (S/S or S/liter, OR: 2.14; 95% CI: 1.13-4.07) were associated with AD-P. A gene dose effect was observed; in fact, carriers of both polymorphisms showed a fivefold risk for psychosis compared with patients bearing no polymorphisms. An interaction between these two genetic variations with disease stage and ischemic cardiomyopathy was found, the latter influencing AD-P risk only if "at-risk" genetic polymorphisms were present. The combined trend effect of COMT*H plus 5-HTTLPR*S and advance disease stage on AD-P risk was approximately 200% greater than that predicted by assuming additive effects, whereas the one obtained by COMT*H plus 5-HTTLPR*S and ischemic cardiomyopathy was 50% greater. ApoE genotype did not influence AD-P risk.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings claim for a synergic effect of COMT*H and 5-HTTLPR*S polymorphisms on the risk of psychosis in AD and for their interaction with disease stage and ischemic cardiomyopathy. This study suggests that considering both the genetic background and the environmental correlates might provide new insight for understanding psychosis mechanisms related to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Ageing Brain and Dementia, Department of Neurology, University of Brescia, Brescia, Italy. bborroni@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Agosti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cornali</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Caimi</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16582043</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000192491.50802.c3</ArticleId><ArticleId IdType="pii">S1064-7481(12)60683-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">16563063</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2006</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0888-5109</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</Title><ISOAbbreviation>Consult Pharm</ISOAbbreviation></Journal><ArticleTitle>Advances in pharmacotherapy of psychotic disorders in the elderly.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>550</EndPage><MedlinePgn>539-50</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the literature on the pharmacotherapy of psychosis in the elderly.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Searches of MEDLINE (1996-April 2002) and the Cochrane Database using the terms psychosis, elderly, geriatric, dementia, Alzheimer's disease, Parkinson's disease, antipsychotics, atypical antipsychotics, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and haloperidol were performed. An updated search of psychosis, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole occurred in April 2003.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Reviews, case reports, and open-labeled and controlled trials were selected.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Psychotic symptoms in the elderly can occur in the context of psychiatric disorders, medical conditions, or as a medication complication. Behavioral problems (e.g., agitation, aggression) can accompany psychosis and may not respond to nonpharmacological strategies. Pharmacological management of psychosis in the elderly with typical antipsychotics (e.g., haloperidol, chlorpromazine) can result in intolerable adverse effects (e.g., sedation, anticholinergic effects, extrapyramidal symptoms, tardive dyskinesia, and orthostatic hypotension). The atypical antipsychotic agents (e.g., risperidone, olanzapine, quetiapine, ziprasidone) and the dopamine-serotonin system stabilizer aripiprazole offer more tolerable adverse effects profiles. Most information supporting the use of the atypical antipsychotics is derived from open-label trials involving patients with dementia or Parkinson's disease; however, data from large randomized, controlled trials is emerging. In general, psychosis in elderly patients responds to low doses of antipsychotics. Patients must be monitored closely for adverse effects, especially in light of the new information associating cerebrovascular adverse events with risperidone in patients with dementia. Further trials are required to determine if this is a disease- or drug-specific phenomenon.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Psychosis in elderly patients can be managed with antipsychotic agents. The atypical antipsychotics are effective and offer advantages over typical antipsychotics with regard to a reduced rate of adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>Cynthia K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Department of Pharmacy, Virginia Commonwealth University, Richmond 23298-0533, USA. ckkirkwo@vcu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Givone</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Consult Pharm</MedlineTA><NlmUniqueID>9013983</NlmUniqueID><ISSNLinking>0888-5109</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16563063</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">16553497</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0888-5109</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</Title><ISOAbbreviation>Consult Pharm</ISOAbbreviation></Journal><ArticleTitle>Do atypical antipsychotics cause weight gain in nursing home dementia residents?</ArticleTitle><Pagination><StartPage>809</StartPage><EndPage>812</EndPage><MedlinePgn>809-12</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the effects of atypical antipsychotics on weight gain in the elderly resident with dementia or Alzheimer's disease, complicated with agitation and/or psychosis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective chart review.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Twenty-seven long-term care facilities in Indiana.</AbstractText><AbstractText Label="PATIENTS/PARTICIPANTS" NlmCategory="METHODS">Residents of long-term care facilities with a diagnosis of dementia or Alzheimer's disease, complicated by agitation and/or psychosis, and receiving atypical antipsychotics for a minimum of four weeks.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Changes in weight after initiation of atypical antipsychotic therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety residents were evaluated. Mean age was 83.4 years; 71% were female. Forty-nine percent of the residents gained weight. The residents who received risperidone, olanzapine, or quetiapine gained an average of 5.6 pounds, 8.2 pounds, and 6.1 pounds, respectively. Seven residents had a significant weight gain, and seven residents had a significant weight loss.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In our population we did not observe any significant weight change in individuals receiving risperidone, olanzapine, or quetiapine. Further prospective studies are needed to determine if there is a difference in potential weight gain among the various atypical antipsychotics in residents with dementia or Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gurevitz</LastName><ForeName>Samuel L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Care Pharmaceutical Services, Inc., Griffith, IN 46319, USA. slgurevitz@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costakis</LastName><ForeName>Terry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Leiter</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Consult Pharm</MedlineTA><NlmUniqueID>9013983</NlmUniqueID><ISSNLinking>0888-5109</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16553497</ArticleId><ArticleId IdType="doi">10.4140/tcp.n.2004.809</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16538225</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1018-4813</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of human genetics : EJHG</Title><ISOAbbreviation>Eur J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Use of phenotypic covariates in association analysis by sequential addition of cases.</ArticleTitle><Pagination><StartPage>529</StartPage><EndPage>534</EndPage><MedlinePgn>529-34</MedlinePgn></Pagination><Abstract><AbstractText>Optimal use of phenotype information is important in complex disease gene mapping. We describe a method, sequential addition, for the analysis of case-control data by taking into account of a quantitative trait that is measured in cases but not in controls. The method also provides an estimate of the best phenotype definition for future studies. We demonstrate proof of principle, using an example of incorporation of age-at-onset data into a study of a small sample for association between APOE and late-onset Alzheimer's disease. The sequential addition method finds evidence of association when conventional case-control methods fail. We also illustrate the use of the method for taking account of a dimensional measure of psychosis in a study of the schizophrenia susceptibility gene, dysbindin, in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macgregor</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biostatistics and Bioinformatics Unit, Department of Psychological Medicine, Cardiff University, Cardiff, UK. stuart.macgregor@qimr.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Hum Genet</MedlineTA><NlmUniqueID>9302235</NlmUniqueID><ISSNLinking>1018-4813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16538225</ArticleId><ArticleId IdType="doi">10.1038/sj.ejhg.5201604</ArticleId><ArticleId IdType="pii">5201604</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16530421</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1043-2760</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Trends in endocrinology and metabolism: TEM</Title><ISOAbbreviation>Trends Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>The use of mifepristone in the treatment of neuropsychiatric disorders.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>121</EndPage><MedlinePgn>117-21</MedlinePgn></Pagination><Abstract><AbstractText>Mifepristone is a potent glucocorticoid and progesterone receptor antagonist. The pathophysiology of a number of neuropsychiatric disorders implicates abnormalities in glucocorticoid function. These include mood disorders such as psychotic major depression and bipolar depression. In addition, cognitive disorders such as Alzheimer's disease might also be partially mediated by abnormalities in the hypothalamic-pituitary-adrenal axis. Preliminary studies suggest that mifepristone might have a role in the treatment of a number of neuropsychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeBattista</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA. debattista@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belanoff</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Trends Endocrinol Metab</MedlineTA><NlmUniqueID>9001516</NlmUniqueID><ISSNLinking>1043-2760</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>320T6RNW1F</RegistryNumber><NameOfSubstance UI="D015735">Mifepristone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Trends Endocrinol Metab. 2006 Dec;17(10):389</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Endocrinol Metab. 2006 Dec;17(10):384-5; author reply 387-9. doi: 10.1016/j.tem.2006.10.009</RefSource><PMID Version="1">17070696</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Endocrinol Metab. 2006 Dec;17(10):380.</RefSource><PMID Version="1">17252626</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000311" MajorTopicYN="N">Adrenal Glands</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015735" MajorTopicYN="N">Mifepristone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011965" MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>44</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16530421</ArticleId><ArticleId IdType="doi">10.1016/j.tem.2006.02.006</ArticleId><ArticleId IdType="pii">S1043-2760(06)00032-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16529524</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1172-7047</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>185</EndPage><MedlinePgn>173-85</MedlinePgn></Pagination><Abstract><AbstractText>Drugs that potentiate the activity of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor cause a complex cascade of consequences in experimental models, ranging from enhancement of long-term potentiation to induction of neurotrophic factors. Animal studies characterising the pharmacological and behavioural effects of these substances have provided the rationale for several initial attempts to use these drugs in neuropsychiatric clinical settings. Applications in schizophrenia, Alzheimer's disease and mild cognitive impairment have been initiated. Other trials with these compounds include the treatment of Fragile X syndrome, and possible future applications may be in the field of Parkinson's disease. The literature published to date is limited mostly to small phase I or II trials, so there is no conclusive evidence for or against the use of these drugs. Substantial questions remain concerning which compounds to use, in what dose, for what condition and for how long.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marenco</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genes, Cognition and Psychosis Program, Clinical Brain Disorders Branch, National Institute of Mental Health, Bethesda, Maryland 20892, USA. marencos@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberger</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>101</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16529524</ArticleId><ArticleId IdType="doi">10.2165/00023210-200620030-00001</ArticleId><ArticleId IdType="pii">2031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11701187</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Jun;40(8):992-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">11406190</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2004;49(1):10-2</Citation><ArticleIdList><ArticleId IdType="pubmed">14730194</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2002 Jul;43(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12213254</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1997 Aug;121(8):1707-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9283707</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2004;123(4):1011-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14751292</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 1993 Dec;15(4):326-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8153879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2002 Sep;62(3):566-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12181433</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):777-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8290599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2003 Jan 24;112(2):257-69</Citation><ArticleIdList><ArticleId IdType="pubmed">12553913</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neurol. 1997;37(3):195-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9137935</ArticleId></ArticleIdList></Reference><Reference><Citation>Receptors Channels. 1993;1(4):267-78</Citation><ArticleIdList><ArticleId IdType="pubmed">7915948</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1990 May;424:533-43</Citation><ArticleIdList><ArticleId IdType="pubmed">1975272</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2002 Apr 5;440(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11959085</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2002 Aug;136(7):1033-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12145103</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15635706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1993 Sep;13(9):3904-15</Citation><ArticleIdList><ArticleId IdType="pubmed">8103555</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Oct 1;57(2-3):221-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12223253</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2003 Apr 25;970(1-2):221-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12706264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2004 Mar;55(3):447-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14991827</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2005;11(12):1511-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15892659</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2004 Feb;4(1):4-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15018832</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1998 Feb 27;243(1-3):152-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9535136</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2003 Jun;44(8):1013-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12763094</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2005 Aug;49(2):254-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15993447</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1997 Aug;146(2):553-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9270067</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1982;78(2):104-11</Citation><ArticleIdList><ArticleId IdType="pubmed">6817363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Jan 1;20(1):8-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10627576</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Nov;61(11):1136-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15520361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(2):136-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11840305</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Aug 1;17(15):5928-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9221789</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2003 Oct;307(1):297-305</Citation><ArticleIdList><ArticleId IdType="pubmed">12893840</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1998 Jul 20;799(2):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9675296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1998 Apr 1;18(7):2748-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9502832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1985;444:489-91</Citation><ArticleIdList><ArticleId IdType="pubmed">3860106</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2003;121(2):509-21</Citation><ArticleIdList><ArticleId IdType="pubmed">14522010</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 1998 Jul 30;41(16):2946-59</Citation><ArticleIdList><ArticleId IdType="pubmed">9685234</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2005 Jan;6(1):25-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15675601</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Sep;33(2-3):199-227</Citation><ArticleIdList><ArticleId IdType="pubmed">11011066</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1996 Nov 4;738(2):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8955535</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2001 May;43(5):411-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11394932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(7):782-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12192623</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7667-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7644474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1995 Dec;15(12 ):8023-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8613739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2000 Nov 16;43(23):4354-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11087558</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2000 Aug 4;401(2):205-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10924928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1998 Apr 1;18(7):2740-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9502831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 2003 Jun;23(3):419-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12825836</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1992 Dec;458:409-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1302270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Jan 7;397(6714):72-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9892356</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Apr;179(1):154-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15672275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 Nov 1;16(21):6634-47</Citation><ArticleIdList><ArticleId IdType="pubmed">8824304</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2002 Dec;303(3):1075-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12438530</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Nov;41(6):650-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11640919</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drug Rev. 2005 Spring;11(1):77-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15867954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2005 Feb;92(3):668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15659236</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Jun;40(8):1019-27</Citation><ArticleIdList><ArticleId IdType="pubmed">11406193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 1985 May;22(5):745-52</Citation><ArticleIdList><ArticleId IdType="pubmed">4011635</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1997 Sep;133(2):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9342782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1994 Jul;46(1):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">8058047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Jul 30;23(17):6690-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12890761</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Jun;40(8):1028-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11406194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem. 2002 May;10(5):1229-48</Citation><ArticleIdList><ArticleId IdType="pubmed">11886787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1995 Jan;272(1):300-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7815345</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Aug;180(4):743-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15864556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2004;18(1):55-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15084795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1996 Aug;278(2):627-38</Citation><ArticleIdList><ArticleId IdType="pubmed">8768713</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11158-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7972026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1999 Apr;289(1):392-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10087029</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1995 Feb 17;186(2-3):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7777185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2003 Aug;306(2):752-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12730350</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1997 May;145(1):89-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9184112</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2000 Aug 4;401(2):145-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10924919</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drug Rev. 2002 Fall;8(3):255-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12353058</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2004 Oct;27(10):589-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15374669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2003 Aug;64(2):269-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12869631</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1995 Jul 7;193(3):181-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7478178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 2003 Jul;64(1):5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12815155</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2005 Apr;313(1):277-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15626725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2004 Oct;24(10):1098-109</Citation><ArticleIdList><ArticleId IdType="pubmed">15529010</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Biol. 2005 Sep;3(9):e299</Citation><ArticleIdList><ArticleId IdType="pubmed">16104830</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Jan;6(1):83-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11244490</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2004 Feb 20;486(2):163-74</Citation><ArticleIdList><ArticleId IdType="pubmed">14975705</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1992 Jan;3(1):81-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1611039</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 1996 Apr;22(4):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8867027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2001 Oct;21(5):484-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11593073</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Jun;40(8):984-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11406189</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2002 Feb;19(2):138-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11860268</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1990 Nov;9(11):3545-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2170117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 1998 Aug;5(2):67-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9746904</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1992 Dec 11;598(1-2):173-84</Citation><ArticleIdList><ArticleId IdType="pubmed">1486479</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Sep 1;44(5):324-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9755354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16505135</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer disease.</ArticleTitle><Pagination><StartPage>293</StartPage><EndPage>294</EndPage><MedlinePgn>293-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16505135</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000192510.47271.44</ArticleId><ArticleId IdType="pii">S1064-7481(12)62047-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16505133</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.</ArticleTitle><Pagination><StartPage>280</StartPage><EndPage>291</EndPage><MedlinePgn>280-91</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F([2,381]) = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE &lt;10) showing significant differences at end point favoring risperidone treatment (chi(2) ([1]) = 5.11, p = 0.024). Mean risperidone dose was 1.03 +/- 0.24 mg per day. All-cause discontinuation rates were 25% for both risperidone and placebo. Treatment-emergent adverse events occurred in 74% risperidone versus 64% placebo patients, with somnolence occurring significantly more frequently with risperidone (16.2% versus 4.6%). Nine (3.8%) risperidone- and six (2.5%) placebo patients died during or within 30 days after treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This trial did not confirm earlier findings in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, VA Medical Center, Medical University of South Carolina, Charleston, 29406, USA. mintzerjm@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Caers</LastName><ForeName>Ivo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Van Hove</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kushner</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gharabawi</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16505133</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000194643.63245.8c</ArticleId><ArticleId IdType="pii">S1064-7481(12)62044-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16505124</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>210</EndPage><MedlinePgn>191-210</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease (AD) and other dementia. Several clinical trials have not shown efficacy, and there have been concerns about adverse events. The objective of this study was to assess the evidence for efficacy and adverse events of atypicals for people with dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE, the Cochrane Register of Controlled Trials, meetings, presentations, and information obtained from sponsors were used in this study. Published and unpublished randomized, placebo-controlled, double-blind, parallel-group trials in patients with AD or dementia of atypical antipsychotics marketed in the United States were studied. Clinical and trials characteristics, outcomes, and adverse events were extracted. Data were checked by a second reviewer. Fifteen trials including 16 contrasts of atypical antipsychotics with placebo met selection criteria: aripiprazole (k = 3), olanzapine (k = 5), quetiapine (k = 3), and risperidone (k = 5). A total of 3,353 patients were randomized to drug and 1,757 to placebo. Standard meta-analysis methods were used to summarize outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Quality of the reporting of trials varied. Efficacy on rating scales was observed by meta-analysis for aripiprazole and risperidone, but not for olanzapine. Response rates were frequently not reported. There were smaller effects for less severe dementia, outpatients, and patients selected for psychosis. Approximately one-third dropped out without overall differences between drug and placebo. Adverse events were mainly somnolence and urinary tract infection or incontinence across drugs, and extrapyramidal symptoms or abnormal gait with risperidone or olanzapine. Cognitive test scores worsened with drugs. There was no evidence for increased injury, falls, or syncope. There was a significant risk for cerebrovascular events, especially with risperidone; increased risk for death overall was reported elsewhere.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone. Incomplete reporting restricts estimates of response rates and clinical significance. Dropouts and adverse events further limit effectiveness. Atypicals should be considered within the context of medical need and the efficacy and safety of alternatives. Individual patient meta-analyses are needed to better assess clinical significance and effectiveness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH900001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId><ArticleId IdType="doi">10.1097/01.JGP.0000200589.01396.6d</ArticleId><ArticleId IdType="pii">S1064-7481(12)62035-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16490049</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1351-5101</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset.</ArticleTitle><Pagination><StartPage>176</StartPage><EndPage>182</EndPage><MedlinePgn>176-82</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder with mixed cognitive and behavioural clinical manifestations. The possession of apolipoprotein-E (ApoE) epsilon4 allelic variant is one of the most important risk factors for developing late-onset AD (LOAD). In this study we analysed the relationship between the entire range of behavioural symptoms, cognitive deficit, and sociodemographic characteristics and ApoE epsilon4 allele possession with multivariate logistic regression models in LOAD patients. Patients included (n = 171) were consecutively admitted in a memory clinic for the first diagnostic visit. Levels of behaviour and cognition within the last month were assessed by the Neuropsychiatric Inventory and Mini Mental State Examination. Presence of clinically significant psychosis, delusions and hallucinations at the early stage of the illness, from the onset to the first visit, was measured with diagnostic criteria. ApoE epsilon4 allele possession was associated with increased levels of delusions within the last month from the first visit (OR 1.23; 95% CI 1.01-1.50; P &lt; 0.05) and with the presence of categorical delusions at the early stage until the first visit (OR 3.11; 95% CI 1.21-8.01; P &lt; 0.02). In this study, which considers the entire range of behavioural expressions in LOAD patients at the early stage of the illness, the relationship between behaviour and ApoE epsilon4 allele is confirmed for delusions only.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Tor Vergata, Rome, Italy. G.spalletta@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardini</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bellincampi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Federici</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Trequattrini</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16490049</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01165.x</ArticleId><ArticleId IdType="pii">ENE1165</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16467951</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0933-7954</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Social psychiatry and psychiatric epidemiology</Title><ISOAbbreviation>Soc Psychiatry Psychiatr Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Psychiatric disorders certified on death certificates in an English population.</ArticleTitle><Pagination><StartPage>409</StartPage><EndPage>414</EndPage><MedlinePgn>409-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychiatric disorders are sometimes certified on death certificates, but seldom selected as the underlying cause of death. The majority of deaths with a certified psychiatric cause are usually omitted from official mortality statistics, which are typically based on the underlying cause alone.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To report on death rates for psychiatric disorders, as certified on death certificates, including all mentioned causes as well as the underlying cause of death.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Analysis of database including all certified causes of death in 1979-1999, in three time periods defined by coding rule changes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Statistics on the underlying cause of death grossly under-estimated certified psychiatric disorders. For example, in the first period of our study they missed 88% of deaths in which schizophrenia was a certified cause, 98% of affective psychosis, and 96% of depression. Over time, considering all certified causes, age-standardised death rates for schizophrenia declined, those for affective psychosis showed no change, and those for depression and dementia increased.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The decline in mortality rates for schizophrenia, and the increase for depression and dementia, may reflect real changes over time in disease prevalence at death, although other explanations are possible and are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldacre</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Unit of Health-Care Epidemiology, Dept. of Public Health, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK. michael.goldacre@dphpc.ox.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Myfanwy</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cook-Mozaffari</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Soc Psychiatry Psychiatr Epidemiol</MedlineTA><NlmUniqueID>8804358</NlmUniqueID><ISSNLinking>0933-7954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="Y">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003644" MajorTopicYN="Y">Death Certificates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16467951</ArticleId><ArticleId IdType="doi">10.1007/s00127-006-0035-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br Med J (Clin Res Ed). 1988 Feb 20;296(6621):583-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3126913</ArticleId></ArticleIdList></Reference><Reference><Citation>Popul Trends. 1998 Summer;(92):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9679268</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1988 Jun;152:793-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3167465</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 1993 Aug;47(4):293-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8228765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Public Health Med. 2003 Sep;25(3):249-53</Citation><ArticleIdList><ArticleId IdType="pubmed">14575203</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1993 Nov;163:620-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8298830</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 1994 Jun;48(3):318-22</Citation><ArticleIdList><ArticleId IdType="pubmed">8051535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 Mar 3;335(8688):513-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1968536</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16466588</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Association between cognitive function, behavioral syndromes and two-year clinical outcome in Chinese subjects with late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>517</StartPage><EndPage>526</EndPage><MedlinePgn>517-26</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine associations between behavioral and psychological symptoms of dementia (BPSD), cognitive function and clinical deterioration over 2 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and four Chinese subjects with late-onset Alzheimer's Disease (AD) who presented to psychogeriatric clinics were followed for an average of 22.5 months. BPSD subgroups were categorized by latent class analysis using the Neuropsychiatric Inventory. Comprehensive cognitive profiles were performed with the Mattis Dementia Scale, the Hong Kong List Learning Test (HKLLT) and the Category Verbal Fluency Test. Interactions between cognitive function and behavioral syndromes were evaluated. Potential predictors for clinical deterioration were computed with logistic regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three latent classes of subjects with similar behavioral syndromes were identified: Low BPSD (44%), Affective (32%) and Psychosis (24%) groups. Association between cognitive functions and BPSD was not significant. At follow-up, a higher proportion of subjects in the Affective (70%) and Low BPSD (49%) groups remained stable at the same Clinical Dementia Rating. Baseline scores in the "recognition" test of the HKLLT and age were significant predictors for "deceased" status at 2-year follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The lack of association between behavioral syndromes and cognitive function suggests that these relatively independent dimensions of dementia should be examined individually for different prognostic significance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Linda C W</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Chinese University of Hong Kong, Shatin, Hong Kong. cwlam@cuhk.edu.hk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>Victor W C</ForeName><Initials>VW</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Vivian P Y</ForeName><Initials>VP</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Helen F K</ForeName><Initials>HF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16466588</ArticleId><ArticleId IdType="doi">10.1017/S1041610205002930</ArticleId><ArticleId IdType="pii">S1041610205002930</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16446631</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Treatment of dementia with Lewy bodies].</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>136</EndPage><MedlinePgn>131-6</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies (DLB) is known for its partial resistance and hypersensitivity to some treatments, but DLB is treatable with cholinesterase inhibitors, sometimes better than in Alzheimer's disease. Cholinesterase inhibitors have a symptomatic effect on cognition and behavior. Nevertheless, new antipsychotics are sometimes also useful to manage psychotic symptoms. Although DLB patients respond less well to levodopa than patients with Parkinson's disease, 75 percent of DLB patients improve with levodopa, which is the best-tolerated dopaminergic agent. Nonpharmacological strategies include speech therapy, physiotherapy, psychotherapy, and educational support groups for care givers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lebert</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre de la M&#xe9;moire, EA 2691, Clinique Neurologique, H&#xf4;pital Roger Salengro, Centre Hospitalier Universitaire, Lille. f-lebert@chru-lille.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Rhun</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Prise en charge th&#xe9;rapeutique de la d&#xe9;mence &#xe0; corps de Lewy.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019090" MajorTopicYN="Y">Case Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026741" MajorTopicYN="N">Physical Therapy Modalities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013070" MajorTopicYN="N">Speech Therapy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>32</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16446631</ArticleId><ArticleId IdType="doi">10.1016/s0035-3787(06)74993-1</ArticleId><ArticleId IdType="pii">MDOI-RN-01-2006-162-1-0035-3787-101019-200508785</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16437455</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2006</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>CD003476</StartPage><MedlinePgn>CD003476</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD003476</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aggression, agitation or psychosis occur in the majority of people with dementia at some point in the illness. There have been a number of trials of atypical antipsychotics to treat these symptoms over the last five years, and a systematic review is needed to evaluate the evidence in a balanced way.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether evidence supports the use of atypical antipsychotics for the treatment of aggression, agitation and psychosis in people with Alzheimer's disease.</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">The trials were identified from a last updated search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 December 2004 using the terms olanzapine, quetiapine, risperidone, clozapine, amisulpride, sertindole, zotepine, aripiprazole, ziprasidone. This Register contains articles from all major healthcare databases and many ongoing trials databases and is updated regularly.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised, placebo-controlled trials, with concealed allocation, where dementia and psychosis and/or aggression were assessed.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">1. Two reviewers extracted data from included trials2. Data were pooled where possible, and analysed using appropriate statistical methods3. Analysis included patients treated with an atypical antipsychotic, compared with placebo</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Sixteen placebo controlled trials have been completed with atypical antipsychotics although only nine had sufficient data to contribute to a meta-analysis and only five have been published in full in peer reviewed journals. No trials of amisulpiride, sertindole or zotepine were identified which met the criteria for inclusion. The included trials led to the following results:1. There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo.2. There was a significant improvement in psychosis amongst risperidone treated patients.3. Risperidone and olanzpaine treated patients had a significantly higher incidence of serious adverse cerebrovascular events (including stroke), extra-pyramidal side effects and other important adverse outcomes.4. There was a significant increase in drop-outs in risperidone (2 mg) and olanzapine (5-10 mg) treated patients.5. The data were insufficient to examine impact upon cognitive function.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">Evidence suggests that risperidone and olanzapine are useful in reducing aggression and risperidone reduces psychosis, but both are associated with serious adverse cerebrovascular events and extra-pyramidal symptoms. Despite the modest efficacy, the significant increase in adverse events confirms that neither risperidone nor olanzapine should be used routinely to treat dementia patients with aggression or psychosis unless there is marked risk or severe distress. Although insufficient data were available from the considered trials, a meta-analysis of seventeen placebo controlled trials of atypical neuroleptics for the treatment of behavioural symptoms in people with dementia conducted by the Food and Drug Administration (using data not in the public domain) suggested a significant increase in mortality (OR 1.7).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Kings College London, Wolfson Centre for Age-Related Diseases, Wolfson Wing, Hodgkin Building, Guy's Campus, London, UK, SE1 1UL. clive.ballard@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waite</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1002/14651858.CD003476</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="Y">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Professor Ballard and Dr Waite have given sponsored talks for Janssen, Astra&#x2010;Zeneca and Eli Lilly; and Clive Ballard has acted as a paid advisor to Janssen and Astra&#x2010;Zeneca.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16437455</ArticleId><ArticleId IdType="pmc">PMC11365591</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD003476.pub2</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Ballard 2005 {published data only}</Title><Reference><Citation>Ballard C, Margallo&#x2010;Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jocoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330(874):DOI: 10.1136/bmj.38369.459988.8F.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556156</ArticleId><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Breder 2004 {published data only}</Title><Reference><Citation>Breder C, Swanink R, Marcus R, Kostic D, Iwamoto T, Carson W, McQuade R, Bristol&#x2010;Myers Squibb Company, Wallingford, CT, USA. Dose&#x2010;Ranging Study of Aripiprazole in Patients With Dementia of Alzheimer's Disease. NeuroBiology of Aging 2004;25(S2):190.</Citation></Reference></ReferenceList><ReferenceList><Title>Brodaty 2001 {published data only}</Title><Reference><Citation>Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo&#x2010;controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. The Journal of Clinical Psychiatry 2003;64(2):134&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Clarnette R, Ames D, Snowdon J, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F. Psychological symptoms are improved with risperidone in patients with dementia&#x2010;related psychosis. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:Abstract No 330.</Citation></Reference><Reference><Citation>Brodaty H, Clarnette R, Ames D, Snowdon, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F. Risperidone in the treatment of agitation, aggression and psychosis of dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:Abstract No 289.</Citation></Reference><Reference><Citation>Brodaty H, Grossman F, Bruynseels J, Lyons B. Risperidone in the treatment of agitation and psychosis of dementia. International Psychogeriatrics 2001;13(Suppl 2):S108.</Citation></Reference><Reference><Citation>Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F. Psychological symptoms are improved with risperidone in patients with dementia&#x2010;related psychosis. Proceedings of the 23rd Congress of the Collegium Internationale Neuro&#x2010;Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23&#x2010;27 2002, Montreal, Canada. 2002; Vol. 5, issue Suppl 1:S91.</Citation></Reference><Reference><Citation>Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F. Risperidone in the treatment of agitation, aggression and psychosis of dementia. Proceedings of the 23rd Congress of the Collegium Internationale Neuro&#x2010;Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23&#x2010;27 2002, Montreal, Canada. 2002; Vol. 5, issue Suppl 1:S91.</Citation></Reference><Reference><Citation>Kirwan J, Brodaty H, Ames D, Snowdon J, Woodward M, Clarnette R, Lee E. Risperidone in the treatment of agitation and psychosis of dementia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18&#x2010;23; Philadelphia, PA, USA. 2002.</Citation></Reference><Reference><Citation>Rabinowitz J, Katz IR, Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Journal of Clinical Psychiatry, The 2004;65(10):1329&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491235</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward M, Brodaty H, Lee E. Risperidone in the treatment of agitation and psychosis of dementia: A multicentre, double&#x2010;blind, placebo controlled study. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3&#x2010;6, Geneva. 2002:255.</Citation></Reference></ReferenceList><ReferenceList><Title>CATIE {published data only}</Title><Reference><Citation>Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome&#x2010;driven re&#x2010;randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29(1):73&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail MS, Schneider LS, Tariot P, Dagerman KS, Davis S. NIMH Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer's disease (CATIE&#x2010;AD): Clinical course. NeuroBiology of Aging 2004;25(S2):P1&#x2010;320, p 188.</Citation></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia bulletin 2003;29(1):57&#x2010;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot P, Lebowitz B. Health outcomes and effectiveness of atypical antipsychotics in outpatients with psychosis or agitation associated with AD. Proceedings of the World Alzheimer Congress; 2000 Jul 9&#x2010;13, Washington, DC. 2000b.</Citation></Reference><Reference><Citation>Schneider LS, Tariot PN, Alexopoulos G, Davis K, Davis S, Jeste D, Katz I, Keefe R, LaVange L, Lebowitz B, Lyketsos C, Pollock B, Rabins P, Rosenheck R, Small G, Stroup S, Davis CE, Ferris S, Hsiao J, Krishnan R, Lieberman J, Mittelman M, Mohs R, Perkins D, Swartz M. Comparative Effectiveness of Antipsychotic Medications in patients with Alzheimer's Disease. Clinicaltrialsgov 2000a.</Citation></Reference><Reference><Citation>Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenbeck RA, Small GW, Lebowitz B, Lieberman JA. National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry 2001;9(4):346&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>DeDeyn 2003 {published data only}</Title><Reference><Citation>Anon. Aripiprazole improves psychotic symptoms in Alzheimer's disease outpatients. http://mblcommunications.com/newsdetail.php3?id=90 2003h.</Citation></Reference><Reference><Citation>Anon. Safety experience in elderly patients with psychosis associated with Alzheimer's disease. http://www.healthscout.com/rxdetail/68/101/3/main.html 2003g.</Citation></Reference><Reference><Citation>Anon. Study of aripiprazole in the treatment of patients with psychosis associated with dementia of the Alzheimer's type. Clinicaltrials.gov 2003b.</Citation></Reference><Reference><Citation>Breder C, Deyn PP, Jeste DV, Auby P, Carson W, Marcus R, Kujawa M, McQuade RD, Schneider LS, Mintzer J. Aripiprazole for psychosis of Alzheimer's disease. NCDEU Poster abstacts 2003, issue Poster session II&#x2010;65.</Citation></Reference><Reference><Citation>Darves B. Aripiprazole Effective in Reducing Psychotic Symptoms Associated with AD&#x2010;related Dementia. Annual Meeting of the American Association for Geriatric Psychiatry, Honolulu, Hawai, March 2003. 2003.</Citation></Reference><Reference><Citation>Deyn P, Jeste DV, Swanink R, Kostic D, Breder C. Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo&#x2010;Controlled Study. Journal of Clinical Psychopharmacology 2005;25(5):463&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160622</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyn PP, Jeste D, Aubey P, Goyvaerts H, Breder C, Schnieder L, Mintzer J. Aripiprazole for psychosis of Alzheimer's disease. IPA, 11th International Congress, Chicago, USA 18 August 2003. 2003:PA&#x2010;010.</Citation></Reference><Reference><Citation>Mintzer J, Deyn PP, Jeste D. Aripripazole in dementia of the Alzheimer's Type. The International Psychogeriatric Association European Regional Meeting, Geneva, Switzerland, 1&#x2010;4 April 2004. 2003.</Citation></Reference></ReferenceList><ReferenceList><Title>F1D&#x2010;MC&#x2010;HGAO/Satterle {published data only}</Title><Reference><Citation>Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacology Bulletin 1995;31:534.</Citation></Reference></ReferenceList><ReferenceList><Title>F1D&#x2010;MC&#x2010;HGEU/Clark/St {published data only}</Title><Reference><Citation>Clark W, Street J, Sanger T, Breier A. Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17&#x2010;21, Nashville. 2000e:176.</Citation></Reference><Reference><Citation>Clark WS, Street J, Gannon KS, Sanger T, Breier A. Reduction of psychotic symptoms in patients with lewy&#x2010;body&#x2010;like&#x2010;symptoms treated with olanzapine. European Journal of Neurology 1999a;6(Suppl 3):27.</Citation></Reference><Reference><Citation>Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. Journal of the European College of Neuropsychopharmacology 1999c;9(suppl 5):S332.</Citation></Reference><Reference><Citation>Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. European Journal of Neurology 1999b;6(Suppl 3):115.</Citation></Reference><Reference><Citation>Clark WS, Street J, Sanger T, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17&#x2010;21, Nashville. 2000a:144.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Journal of Clinical Psychiatry 2001a;62(1):34&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11235926</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark WS, Street JS, Gannon KS, Sanger TM, Breier A. Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15&#x2010;20, Vancouver, Canada. 1999c:172.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. International Journal of Neuropsychopharmacology 2000a;3(Suppl 1):S357.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15&#x2010;20, Vancouver, Canada. 1999b:172.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Sanger TM, Breier A. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. International Journal of Neuropsychopharmacology 2000b;3(Suppl 1):S357.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Sanger TM, Breier A, Cummings JL. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. Schizophrenia Research 2001b;49(1&#x2010;2 Suppl):222.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Sanger TM, Feldman PD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. Biological Psychiatry 2000c;47(Suppl):S162.</Citation></Reference><Reference><Citation>Clark WS, Street JS, Sanger TM, Feldman PD, Breier A. Reduction of psychotic symptoms in patients with Lewy body&#x2010;like symptoms treated with olanzapine. Biological Psychiatry 2000d;47:163S.</Citation></Reference><Reference><Citation>Feldman PD, Clark WS, Breier A, Sanger TM, Street JS. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Schizophrenia Research 2001b;49(1&#x2010;2 Suppl):227.</Citation></Reference><Reference><Citation>Kennedy J, Basson B, Zagar A, Clark W, Sanger T, Street J, Stauffer V, Bymaster F, Tollefson G. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17&#x2010;21, Nashville. 2000g:175.</Citation></Reference><Reference><Citation>Kennedy JS, Basson BB, Zagar AJ, Clark WS, Sanger TM, Street JS, Stauffer VL, Bymaster FP, Tollefson GD. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioural disturbances. Clinical Neuropsychological Assessment 2000f;1(6):42&#x2010;3.</Citation></Reference><Reference><Citation>Kennedy JS, Basson BR, Zagar AJ, Gilmore JA, Wei H, Kinon BJ. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances: continued improvement in quality of life despite weight change during olanzapine or haloperidol treatment. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25&#x2010;29, Philadelphia. 2000c.</Citation></Reference><Reference><Citation>Kennedy JS, Clark WS, Street JS, Sanger TM, Breier A. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. Clinical Neuropsychological Assessment 2000d;1(6):53&#x2010;4.</Citation></Reference><Reference><Citation>Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. International Journal of Geriatric Psychiatry 2001;16 Suppl 1:S71&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748790</ArticleId></ArticleIdList></Reference><Reference><Citation>Slawson DC. Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)? [Commentary on Street JS, Clark WS, Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double&#x2010;blind, randomized, placebo&#x2010;controlled trial Archives of General Psychiatry 2000;57: 968&#x2010;76]. Evidence Based Practice 2001;4(1):5&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J, Clark KS, Gannon KS, Mitan S, Kadam D, Sanger T. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease. Journal of the European College of Neuropsychopharmacology 1999e;9(suppl 5):S331.</Citation></Reference><Reference><Citation>Street J, Clark S, Juliar B, Feldman P, Kadam D, Breier A. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia. Journal of the European College of Neuropsychopharmacology 2000g;10(Suppl 4):S365&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J, Clark SW, Gannon KS, Mitan S, Kadman D, Sanger T, Tamura R, Tollefson GD. Effect of olanzapine on psychosis and behavioural disturbances associated with alzheimer's disease. Journal of the American Geriatrics Society 1999g;47:S89.</Citation></Reference><Reference><Citation>Street J, Clark WS, Gannon K, Mitan S, Kadam D, Sanger T, Tamura R, Tollefson GD. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disaese. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15&#x2010;20, Vancouver, Canada. 1999f:123.</Citation></Reference><Reference><Citation>Street J, Clark WS, Gannon KS, Mitan S, Kadman D, Famura R, Tollefson GD. Olanzapine in the treatment of psychosis and behavioural disturbances assocated with alzheimer's disease. Schizophrenia Research 1999a;1,2 &amp; 3:298.</Citation></Reference><Reference><Citation>Street J, Clark WS, Gannon KS, Mitan S, Sanger T, Tollefson GD. Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease. Schizophrenia Research 2000a;41(1):191.</Citation></Reference><Reference><Citation>Street J, Clark WS, Gannon KS, Sanger T, Breier A. Reduction of psychotic symptoms in patients with Lewy body&#x2010;like symptoms treated with olanzapine. Journal of the European College of Neuropsychopharmacology 1999d;9(Suppl 5):S331&#x2010;2.</Citation></Reference><Reference><Citation>Street J, Gannon K, Mitan S, Clark WS, Tollefson GD, Sanger T. Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6&#x2010;11, Hamburg 1999b;Abstracts Volume II:72.</Citation></Reference><Reference><Citation>Street JS, Clark WS, Cummings JL, Kadam DL, Mitan SJ, Sanger TM, Bymaster FP, Tamura RN, Feldman PD, Gannon KS, Tollefson GD, Breier A. Olanzapine in the treatment of psychosis and behavioural disturbances associated with alzheimer's disease. Journal of Neurosurgery 2001c;187(Suppl 1):S57.</Citation></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A, HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double&#x2010;blind, randomized, placebo&#x2010;controlled trial. Archives of General Psychiatry 2000b;57(10):968&#x2010;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, Mitan S, Sanger TM, Tollefson GD. Olanzapine in the treatment of psychosis and behavioral disturbances associated with alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15&#x2010;20, Washington DC. 1999c.</Citation></Reference><Reference><Citation>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A. Long&#x2010;term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer`s dementia. Biological Psychiatry 2000c;47(8):S162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A. Long&#x2010;term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia. Schizophrenia Research 2001a;49(Suppl 1&#x2010;2):246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A, Mitan SJ. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17&#x2010;21, Nashville. 2000f:144.</Citation></Reference><Reference><Citation>Street JS, Clark WS, Juliar BI, Feldman PD, Kadam DI, Breirer A. Long&#x2010;term efficacy of olanzapine in the control of psychotic and behavioural symptoms in patients with alzheimer's dementia. International Journal of Neuropsychopharmacology 2000d;3(Suppl 1):S356.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A. Long&#x2010;term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. International Journal of Geriatric Psychiatry 2001b;16(Suppl 1):S62&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS/Clark SW, Juliar EJ, Feldman PD, Kadam DL, Breier A. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia. Neurology 2000e;54(Suppl 2):A414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton G, Mintzer JE, Breier A, Clark WS, Feldman D, Street JS. Olanzapine in the treatment of anxiety in patients with alzheimer's disease. Schizophrenia Research 2001;49(Suppl 1&#x2010;2):247.</Citation></Reference></ReferenceList><ReferenceList><Title>F1D&#x2010;MC&#x2010;HGGU/Deberdt {published data only}</Title><Reference><Citation>Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. American Journal of Geriatric Psychiatry 2005;13(8):722&#x2010;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">16085789</ArticleId></ArticleIdList></Reference><Reference><Citation>Eli Lilly Inc. Olanzapine versus Risperidone and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia. http//www.ifpma.org/clinicaltrials.html 2005:1&#x2010;38.</Citation></Reference></ReferenceList><ReferenceList><Title>F1D&#x2010;MC&#x2010;HGIV/DeDeyn {published data only}</Title><Reference><Citation>Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(2):115&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>RIS&#x2010;INT&#x2010;24/DeDeyn {published data only}</Title><Reference><Citation>DeDeyn P. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17&#x2010;22, 1997. 1997a:10.</Citation></Reference><Reference><Citation>DeDeyn P, Lemmens P, Smedt D. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7&#x2010;13, Davos, Switzerland 1998c;29(1,2):145.</Citation></Reference><Reference><Citation>DeDeyn P, Lemmens P, Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12&#x2010;16 Glasgow, Scotland. 1998a:ABSTRACT REF: PW11025.</Citation></Reference><Reference><Citation>DeDeyn P, Lemmens P, Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8&#x2010;12, Waikoloa, Hawai, USA. 1997b.</Citation></Reference><Reference><Citation>DeDeyn P, Middelheim AZ, Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 10th European College of Neuropsychopharmacology Congress (ECNP); 1997 Sep 13&#x2010;17, Vienna, Austria. 1997.</Citation></Reference><Reference><Citation>DeDeyn PP, Smedt G. Long&#x2010;term safety and efficacy of risperidone in the treatment of behavioral disturbances in elderly patients with dementia. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31&#x2010;Nov 4, Paris. 1998b:Abstract: P4007.</Citation></Reference><Reference><Citation>DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999a;53(5):946&#x2010;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens P, DeDyne P, DeSmedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30&#x2010;Jun 4, Toronto , Canada. 1998:160.</Citation></Reference></ReferenceList><ReferenceList><Title>RIS&#x2010;USA&#x2010;232/Colon {published data only}</Title><Reference><Citation>Colon S, Figueroa C, Thein S, Siegal A, Arias B, Ganadara J, Haefner G, Segal S, Steen S, Blanchette P, Mee&#x2010;Lee D, Lindahl L, Rappaport SA, Kelsh D, Rayner A, Litman R, Shua&#x2010;Haim J, Brenner R, Calder C, Sloan B, Gupta S, Lantz M, Levy M, Lebadeva Z, Patel M, Beckett L, Cranmer K, Richter R, Ainslie G, Rosenzweig A, Mintzer J, Fuller W, Gwirtsman H, Petrie W, Barnhart B, Demmler RW, Fedro D, Frank HD, Gazda S, Lewis R, Peters P, Schiffer R, Weiner M, Williams B, Winston J, Swerdlow R, RIS&#x2010;USA&#x2010;232. Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease. Clinical Trials Journal 2002:1&#x2010;6.</Citation></Reference></ReferenceList><ReferenceList><Title>RIS&#x2010;USA&#x2010;63/Katz {published data only}</Title><Reference><Citation>Brecher M. Follow&#x2010;up study of risperidone in the treatment of patients with dementia: Interim results on tardive dyskinesia and dyskinesia severity. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31&#x2010;Nov 4, Paris. 1998a:Abstract: P4005.</Citation></Reference><Reference><Citation>Brecher M. Nursing home research from industry's perspective. International Psychogeriatrics 1996;8(Suppl 3):367&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154590</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecher M, Clyde C, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17&#x2010;22, 1997. 1997:10.</Citation></Reference><Reference><Citation>Brecher M, Katz I, Clyde C, The Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior. Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12&#x2010;16 Glasgow, Scotland. 1998b.</Citation></Reference><Reference><Citation>Brecher M, Okamoto A, Napolitano J, Kane JM, Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. American Journal of Geriatric Psychiatry 1999a;7(4):53&#x2010;4.</Citation></Reference><Reference><Citation>Brecher M, Okamoto A, Napolitano J, Kane JM, The Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperdione for up to one year. Schizophrenia Research 1999b;1,2 &amp; 3:362.</Citation></Reference><Reference><Citation>DeDeyn PP, DeSmedt G. Efficacy and safety of risperidone in elderly patients with dementia pooled results from phase III controlled trials. Proceedings of the 40th Annual meeting of the new clinical drug evalution unit, Boca Raton, Florida, USA, May 30&#x2010;June 2, 2000. 2000b.</Citation></Reference><Reference><Citation>Grossman F, Gharabawi G. Elderly patients with dementia and psychosis treated with risperidone. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3&#x2010;6, Geneva. 2002a:194.</Citation></Reference><Reference><Citation>Grossman F, Gharabawi G. Elderly patients with dementia and psychosis treated with risperidone. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002b:Abstract No 299.</Citation></Reference><Reference><Citation>Janssen Pharmaceutica. Low dose risperidone helps overcome burden of Alzheimer's disease. Pharmacoeconomics 1997;143:10.</Citation></Reference><Reference><Citation>Katz I, Brecher M, Clyde C, Jeste D, Mintzer J, Napolitano J, The Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8&#x2010;11, San Diego, California. 1998.</Citation></Reference><Reference><Citation>Katz I, Brecher M, Clyde C, Napolitano J, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7&#x2010;13, Davos, Switzerland 1998a;29(1,2):145.</Citation></Reference><Reference><Citation>Katz I, Brecher M, Clyde C, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8&#x2010;12, Waikoloa, Hawai, USA. 1997:292.</Citation></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double&#x2010;blind trial. Journal of Clinical Psychiatry 1999;60(2):107&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher MB, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30&#x2010;Jun 4, Toronto, Canada. 1998b:156.</Citation></Reference><Reference><Citation>Mintzer J. Pharmacological treatment of nonagressive agitated symptoms related to dementia: analysis of 617 patients in a multicenter placebo&#x2010;controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:Abstract No 336.</Citation></Reference><Reference><Citation>Schneider L, Katz IR, Napolitano J, Martinez R, Azen SP. Psychosis of Alzheimer's disease: validity of the construct, and response to risperidone. Research and practice in Alzheimer's disease 2004;9(2004):153&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. American Journal of Geriatric Psychiatry 2003a;11(4):414&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837670</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>STAR/046 {published data only}</Title><Reference><Citation>Astrazeneca 1. Additional results presented. http://www.astrazeneca.com/pressrelease/2577.aspx 2004.</Citation></Reference><Reference><Citation>Astrazeneca 2. Study suggests potential benefits in agitation associated with dementia. http://www.astrazeneca.com/ 2004.</Citation></Reference><Reference><Citation>Tariot P. Medication helps quell the agitation of dementia. http://www.urmc.rochester.edu/pr/news/story.cfm?id=593 2004f.</Citation></Reference></ReferenceList><ReferenceList><Title>Streim 2004 {published data only}</Title><Reference><Citation>Kujawa MJ, Marcus R, Breder C, Kostic D, Archibald DG, Iwamoto T, Carson WH, Yamamoto Y, Bristol&#x2010;Myers Squibb Company, Plainsboro, NJ, USA. Safety and Tolerability Profile of Aripiprazole in Elderly Patients With Psychosis of Alzheimer's Disease: A Pooled Analysis. NeuroBiology of Aging 2004;25(S2):183.</Citation></Reference><Reference><Citation>Streim J, Breder C, Swanink R, McQuade R, Iwamoto T, Carson W, Stock E, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Flexible&#x2010;Dose Aripiprazole in Psychosis of Alzheimer's Disease. NeuroBiology of Aging 2004;25(S2):191.</Citation></Reference></ReferenceList><ReferenceList><Title>Tariot 2002/039 {published data only}</Title><Reference><Citation>Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. Journal of clinical psychiatry, The 2004i;65 Suppl 11:11&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264966</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Allain 2003 {published data only}</Title><Reference><Citation>Allain H, Tessier T, Bentue&#x2010;Ferrer D, et al. Effects of Risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology (Berl) 2003;165(4):419&#x2010;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Beuzen 1999 {published data only}</Title><Reference><Citation>Beuzen JN, Taylor N, Wesnes K, Wood A. comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. Journal of Psychopharmacology (Oxf) 1999;13(2):152&#x2010;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">10475721</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cassidy 2001 {published data only}</Title><Reference><Citation>Cassidy EL, Sheikh JI. Specific interventions for agitation in Alzheimer's disease. ClinicalTrials.gov 2001.</Citation></Reference></ReferenceList><ReferenceList><Title>Chan 2001 {published data only}</Title><Reference><Citation>Chan WC, Lam LCW, Choy CNP, Leung VPY, Li SW, Chiu HFK. A double&#x2010;blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.. Int J Geriatr Psychiatry 2001;16(12):1156&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748775</ArticleId></ArticleIdList></Reference><Reference><Citation>Onalaja D, Jainer AK. Re: Chan et al A double&#x2010;blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. author reply. International Journal of Geriatric Psychiatry 2002;17(11):1076&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12404659</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Davidson 2001 {published data only}</Title><Reference><Citation>Davidson M. Long&#x2010;term safety of risperidone. Journal of Clinical Psychiatry 2001;62(Suppl 21):26&#x2010;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584985</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Defilippi 2000 {published data only}</Title><Reference><Citation>Defilippi JL, Crismon ML. Antipsychotic agents in patients with dementia. Pharmacotherapy 2000; Vol. 20, issue 1:23&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10641973</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Devanand 1996 {published data only}</Title><Reference><Citation>Devanand DP. Antipsychotic treatment in outpatients with dementia. International Psychogeriatrics 1996;8(Suppl 3):355&#x2010;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154588</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Devanand 1998 {published data only}</Title><Reference><Citation>Devanand, DP, Michaels K, Sackeim HA, Marder K, Mayeux RP. Antipsychotics in the treatment of dementia complicated by Psychosis. Conference proceedings 151st Annual Meeting of the American Psychiatric Association.; 30th May&#x2010;4th June, 1998; Toronto, Ontario, Canada. 1998:No. 27D.</Citation></Reference></ReferenceList><ReferenceList><Title>Ebell 2000 {published data only}</Title><Reference><Citation>Ebell M. Which is most effective for managing the behavioral symptoms of dementia: risperidone or haloperidol?. Evidence&#x2010;Based&#x2010;Practice 2000;3(1):2&#x2010;3.</Citation></Reference></ReferenceList><ReferenceList><Title>F1D&#x2010;MC&#x2010;HGHX {published data only}</Title><Reference><Citation>Clinical Study Summary: Study F1D&#x2010;MC&#x2010;HGHX.</Citation></Reference></ReferenceList><ReferenceList><Title>Fontaine 2003 {published data only}</Title><Reference><Citation>Fontaine CS, Hynan LS, Koch K, Martin Cook K, Svetlik D, Weiner MF. A double&#x2010;blind comparison of olanzapine versus risperidone in the acute treatment of dementia&#x2010;related behavioral disturbances in extended care facilities. Journal of Clinical Psychiatry 2003;64(6):726&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12823090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Grossberg 1997 {published data only}</Title><Reference><Citation>Buckley P, Cutler N, Silber C, O'Neil J, Mack R. The safety and tolerability of Sertindole in elederly patients with dementia. Schizophrenia Research 1997;24(1&#x2010;2):201.</Citation></Reference><Reference><Citation>Cutler N, Sramek J, Kurtz N, Jhee S, O'Neil I, Mack R. The safety and tolerability of Sertindole in Elderly Patients with Dementia. Proceedings of the 10th Annual Meeting and Symposium of the American Academy of Geriatric Psychiatry; 1997 Mar 2&#x2010;5, Orlando. 1997:3.</Citation></Reference><Reference><Citation>Grossberg GT, Cutler NR, Silber C, O'Neil J, Mack R. Sertindole Treatment in Elderly Patients with Dementia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17&#x2010;22, San Diego. 1997.</Citation></Reference></ReferenceList><ReferenceList><Title>Hoeltmann 2002 {published data only}</Title><Reference><Citation>Hoeltmann BJ, Delius&#x2010;Stute H, Rettig K, Schwalen S. Less daytime sedation, dizziness and abnormal gait under risperidone in comparison with melperone. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:Abstract No 347.</Citation></Reference></ReferenceList><ReferenceList><Title>Howard 2003 {published data only (unpublished sought but not used)}</Title><Reference><Citation>Howard R, Bullock R, Burns A, Lindesay J, O'Brien JT. The CALM&#x2010;AD trial &#x2010; a randomised clinical trial of a cholinesterase inhibitor and atypical antipsychotic in the management of agitation in dementia. National Research Register.</Citation></Reference></ReferenceList><ReferenceList><Title>Jones 2000 {published data only}</Title><Reference><Citation>Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM. A double&#x2010;blind, placebo&#x2010;controlled study of short&#x2010;acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10&#x2010;14, San Juan, Puerto Rico. 2000:190.</Citation></Reference></ReferenceList><ReferenceList><Title>Lavretsky 1998 {published data only}</Title><Reference><Citation>Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. American Journal of Geriatric Psychiatry 1998; Vol. 6, issue 2:127&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581208</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Legangneux 1998 {published data only}</Title><Reference><Citation>Legangneux E, McEwen J, Wesnes K, et al. Effects of low doses of amisulpride on psychomotor and memory performances in healthy elderly subjects. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31&#x2010;Nov 4, Paris. 1998:Abstr P.2.004.</Citation></Reference></ReferenceList><ReferenceList><Title>McKeith 2000 {published data only}</Title><Reference><Citation>McKeith IG, Daniel S, Ballard CG, Swann A, Fairbairn AF, Perry EK. Recent advances in therapy in dementia with lewy bodies. Proceedings of the International Psychogeriatric Association Conference (Non&#x2010;Alzheimer Cognitive Impairment); 2000 Apr 4&#x2010;7, Newcastle upon Tyne. 2000.</Citation></Reference></ReferenceList><ReferenceList><Title>Meehan 2001 {published data only}</Title><Reference><Citation>Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM. A double&#x2010;blind, placebo&#x2010;controlled study of short&#x2010;acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10&#x2010;14, San Juan, Puerto Rico. 2000:190.</Citation></Reference><Reference><Citation>Meehan KM, Wang H, David JR, Nisivoccia, Jones B, Beasley CM, Fieldman A, Breier A. A double&#x2010;blind, placebo&#x2010;controlled study of rapid&#x2010;acting intramuscular olanzapine and lorazepam in acutley agitated patients with dementia. Journal of the American Geriatrics Society 2001b;49(4):S92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927174</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Breier A. A double&#x2010;blind, placebo&#x2010;controlled study of intramuscular (IM) olanzapine and IM lorazepam in acutely agitated patients with dementia. Biological Psychiatry 2001a;49(8 Suppl 1):55S.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927174</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double&#x2010;blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26(4):494&#x2010;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927174</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Breier A. A double&#x2010;blind, placebo&#x2010;controlled study of short&#x2010;acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23&#x2010;26, San Francisco. 2001c.</Citation></Reference><Reference><Citation>Mintzer J, Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C Jr, Feldman P, Breier A. A double&#x2010;blind, placebo&#x2010;controlled study of rapid&#x2010;acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:Abstract No 133.</Citation></Reference></ReferenceList><ReferenceList><Title>Meguro 2004 {published data only}</Title><Reference><Citation>Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. Journal of geriatric psychiatry and neurology 2004;17(2):61&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15157345</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mintzer 2002b {published data only}</Title><Reference><Citation>Mintzer J, Meehan K, Wang H, et al. A double&#x2010;blind, placebo&#x2010;controlled study of rapid&#x2010;acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002, issue Abstr 133.</Citation></Reference></ReferenceList><ReferenceList><Title>Parsa 2000 {published data only}</Title><Reference><Citation>Parsa MA, Poggi E, Barte L. Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil. Journal of the European College of Neuropsychopharmacology. Proceedings of the 13th ECNP Congress; 2000 Jul 9&#x2010;13, Munich 2000; Vol. 10, issue Suppl 3:S302.</Citation></Reference></ReferenceList><ReferenceList><Title>Pesco 2000 {published data only}</Title><Reference><Citation>Pesco&#x2010;Koplowitz L, Parier JL, Zhao Q, Heron J. Pharmacokinetics of risperidone/donepezil combination. Biological Psychiatry 2000;47:167S.</Citation></Reference></ReferenceList><ReferenceList><Title>Ruggiero 1997 {published data only}</Title><Reference><Citation>Ruggiero U, Ovallesco V, Pizza V, Agresta A, Colucci D'amato C. Clozapine and validation therapy in the treatment of dementia. Functional Neurology 1997;12(3&#x2010;4):240&#x2010;1.</Citation></Reference></ReferenceList><ReferenceList><Title>Slawson 2001 {published data only}</Title><Reference><Citation>Slawson DC. Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)?. Evidence Based Practice 2001;4(1):5&#x2010;6.</Citation></Reference></ReferenceList><ReferenceList><Title>Tariot 2000 {published data only}</Title><Reference><Citation>Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long&#x2010;term use of quetiapine in elderly patients with psychotic disorder. Clinical&#x2010;Therapeutics 2000; Vol. 22, issue 9:1068&#x2010;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11048905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Weiser 2002 {published data only}</Title><Reference><Citation>Weiser M, Davidson M, Rotmensch H, et al. A pilot randomized open&#x2010;label trial assessing safety and pharmacokinetic parameters of co&#x2010;adminstration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20&#x2010;25, Stockholm, Sweden. 2002:abstract 633.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994888</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiser M, Rotmensch HH, Korczyn AD, et al. A pilot, randomized, open&#x2010;label trial assessing safety and pharmakokinetic parameters of co&#x2010;administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. International Journal of Geriatric Psychiatry 2002;17(4):343&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994888</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Williams 2000 {published data only}</Title><Reference><Citation>Williams H, Clarke R, Bouras N, Martin J, Holt G. Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. Journal of Intellectual Disability Research 2000; Vol. 44, issue 2:164&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10898380</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wolfgang 1999 {published data only}</Title><Reference><Citation>Wolfgang SA. Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia [letter]. American Journal of Health System Pharmacy 1999;56(21):2245&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10565707</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies awaiting assessment</Title><ReferenceList><Title>DeDeyn 1999b {published data only}</Title><Reference><Citation>Deyn PP, Brecher M, DeSmedt G. Risperidone in 969 patients with dementia. XI World Congress of Psychiatry , Hamburg, August 6&#x2010;11, 1999. 1999b:Abstracts Volume II:70.</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>Ballard 2002 {published data only}</Title><Reference><Citation>No information. Ongoing study Starting date of trial not provided. Contact author for more information.</Citation></Reference></ReferenceList><ReferenceList><Title>Blanchard 2000 {published data only}</Title><Reference><Citation>Blanchard MR. Risperidone in the treatment of behavioural disturbances in dementia. National Research Register 2000.</Citation></Reference></ReferenceList><ReferenceList><Title>No Author 2000 b {published data only}</Title><Reference><Citation>No author. Risperidone vs Olanzapine vs Placebo (ORP): Alzheimer's Disease with Psychosis. John Hospkins University Clinical Trials Database 2000j. [MEDLINE: ]</Citation></Reference></ReferenceList><ReferenceList><Title>No author 2000 g {published data only}</Title><Reference><Citation>Anon. A study to evaluate Olanzapine for Alzheimer's disease. Centerwatch 2000n.</Citation></Reference></ReferenceList><ReferenceList><Title>No Author 2004 f {published data only}</Title><Reference><Citation>Anon. A Safety &amp; Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed with Dementia. Clinicaltrials.gov 2004i.</Citation></Reference></ReferenceList><ReferenceList><Title>Pellegrino 2000 {published data only}</Title><Reference><Citation>Pellegrino M. A 10&#x2010;week, double&#x2010;blind, comparative study evaluation of the effectiveness of Risperidone versus Olanzapine to placebo in patients with Alzheimer's Dementia. Centerwatch 2000. [MEDLINE: ]</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Ballard 1996</Title><Reference><Citation>Ballard CG, Eastwood C, Gahir M, et al. A follow up study of depression in the carers of dementia sufferers. BMJ 1996;312:947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2350802</ArticleId><ArticleId IdType="pubmed">8616308</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ballard 1999a</Title><Reference><Citation>Ballard CG, O'Brien JT. Pharmacological treatment of behavioural and psychological signs in Alzheimer's disease: how good is the evidence for current pharmacological treatment?. BMJ 1999;319:138&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1116255</ArticleId><ArticleId IdType="pubmed">10406732</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ballard 1999b</Title><Reference><Citation>Ballard CG, Ayre G, Gray A. Psychotic symptoms and behavioural disturbances in dementia: a review. Revue Neurologique 1999b;155(suppl 4):s44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10637938</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ballard 2001</Title><Reference><Citation>Ballard CG, O'Brien J, James I, et al. Quality of life for people with dementia living in nursing home and residential care. International Psychogeriatrics 2001;13:93&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352339</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>CAMCOG</Title><Reference><Citation>Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. CAMCOG&#x2010;&#x2010;a concise neuropsychological test to assist dementia diagnosis: socio&#x2010;demographic determinants in an elderly population sample. British journal of clinical psychology 1995;34(Pt 4):529&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8563660</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chalmers 1983</Title><Reference><Citation>Chalmers TC, Celano P, Sacks HS, Smith H, Junior. Bias in Treatment Assignment in Controlled Clinical Trials. N Eng J Med 1983;309:1358&#x2010;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">6633598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chouinard 1980</Title><Reference><Citation>Chouinard G, Ross&#x2010;Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences 1980;7:233.</Citation></Reference></ReferenceList><ReferenceList><Title>CMO 2004</Title><Reference><Citation>Chief Medical Officer. New advice issued on risperidone and olanzapine. http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4075751&amp;chk=f0tw6s 2004.</Citation></Reference></ReferenceList><ReferenceList><Title>Cohen&#x2010;Mansfield 1996</Title><Reference><Citation>Cohen&#x2010;Mansfield J. Conceptualization of agitation: results based on the Cohen&#x2010;Mansfield Agitation Inventory and the Agitation Behaviour Mapping Instrument. International Psychogeriatrics 1996;8(suppl. 3):309&#x2010;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154580</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>CSM 2004</Title><Reference><Citation>Anon. New advice issued on risperidone and olanzapine. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;useSecondary=true&amp;ssDocName=CON002047&amp;ssTargetNodeId=389 2004.</Citation></Reference></ReferenceList><ReferenceList><Title>Cummings 1994</Title><Reference><Citation>Cummings JL, Mega M, Gray K. The Neuropsychiatric Inventory: Comprehensive Assessment of Psychopathology in Dementia. Neurology 1994;44:2308&#x2010;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>DSM IV</Title><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Press, 1994.</Citation></Reference></ReferenceList><ReferenceList><Title>FDA 2005</Title><Reference><Citation>Food, Drug Administration. FDA Alert [4/11/2005]: Increased Mortality in Patients with Dementia&#x2010;Related Psychosis. http://www.fda.gov/cder/drug/InfoSheets/HCP/risperidoneHCP.htm April 2005.</Citation></Reference></ReferenceList><ReferenceList><Title>Furniss 1998</Title><Reference><Citation>Furniss L, lloyd N, Craig SK, et al. Medication use in nursing homes for elderly. International Journal of Geriatric Psychiatry 1998;13:433&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9695030</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gilley 1991</Title><Reference><Citation>Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer's disease. Journal of Neuropsychiatry 1991;3:371&#x2010;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Guy 1976</Title><Reference><Citation>Guy W. Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration. NIMH Psychopharmacology Research Branch, 1976:218&#x2010;22.</Citation></Reference></ReferenceList><ReferenceList><Title>ICD&#x2010;10</Title><Reference><Citation>World Health Organization. The ICD&#x2010;10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organisation, Division of Mental Health, 1992.</Citation></Reference></ReferenceList><ReferenceList><Title>Jadad 1996</Title><Reference><Citation>Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, McQuay H. Assessing the quality of reports of randomised clinical trials: Is blinding necessary?. Controlled Clin Trials 1996;17:1&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lonergan 2002</Title><Reference><Citation>Lonergan E, Luxenberg J, Colford J, Birks J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, Issue 2 Art. No.: CD002852. DOI: 10.1002/14651858.CD002852.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076456</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McKeith 1992</Title><Reference><Citation>McKeith IG, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1882909</ArticleId><ArticleId IdType="pubmed">1356550</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McKhann 1984</Title><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer&#x2019;s Disease: Report of the NINCDS&#x2010;ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 1984;4:939&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McShane 1997</Title><Reference><Citation>McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow&#x2010;up. BMJ 1997;314:211&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2125727</ArticleId><ArticleId IdType="pubmed">9022490</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mintzer 2001</Title><Reference><Citation>Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. The Journal of Clinical Psychiatry 2001;62(suppl 21):23&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584984</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mulrow &amp; Oxman 1997</Title><Reference><Citation>Mulrow CD, Oxman AD. Cochrane Collaboration Handbook [updated 9 December 1996].. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1. Oxford: Update Software, 1997.</Citation></Reference></ReferenceList><ReferenceList><Title>Rabins 1982</Title><Reference><Citation>Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. Journal of the American Medical Society 1982;248:333&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reilly 2000</Title><Reference><Citation>Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc&#x2010;interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reisberg 1987</Title><Reference><Citation>Reisberg B. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry 1987;48(suppl. 5):9&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schneider 1990</Title><Reference><Citation>Schneider LS, Pollock VE, Lyness SA. A meta&#x2010;analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society 1990;38:552&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schneider 1997</Title><Reference><Citation>Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH and the Alzheimer's Disease Cooperative Group Study. Validity and reliability of the Alzheimer's Disease Cooperative Study&#x2010; Clinical Global Impression of Change. Alzheimer Disease and Associated disorders 1997;11(suppl 2):S22&#x2010;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schneider 2005</Title><Reference><Citation>Schneider Ls, Dagerman KS Insel P. Risk of death with atypical antipsychotic drug treatment. Jouranl of the American Medical Association 2005;294(15):1934&#x2010;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schulz 1995</Title><Reference><Citation>Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408&#x2010;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">7823387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Simpson 1970</Title><Reference><Citation>Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212(suppl 44):11&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">4917967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Steele 1990</Title><Reference><Citation>Steele C, Rovner B, Chase BA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 1990;147:1049&#x2010;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tune 1991</Title><Reference><Citation>Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioural symptoms of Alzheimer's disease. Psychiatr Clinics North Am 1991;14:353&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">1676507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Waite 2002</Title><Reference><Citation>Waite J. Keep taking the medicine. Age and Ageing 2002;31(6):423&#x2010;425. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">12446286</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Ballard 2006</Title><Reference><Citation>Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003476.pub2</ArticleId><ArticleId IdType="pmc">PMC11365591</ArticleId><ArticleId IdType="pubmed">16437455</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16416397</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1641-4640</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Folia neuropathologica</Title><ISOAbbreviation>Folia Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Short-term treatment with rivastigmine and plasma levels of Abeta peptides in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>340</StartPage><EndPage>344</EndPage><MedlinePgn>340-4</MedlinePgn></Pagination><Abstract><AbstractText>Deregulation of APP metabolism is considered to be a key pathogenic event in Alzheimer's disease. Data from cell cultures indicate that the secretion of Abeta1-42 might be inhibited by cholinesterase inhibitors, possibly via M1 receptors stimulation. Treatment with tacrine, a dual acetyl- and butyrylcholinesterase inhibitor, had no significant effect on mean plasma Abeta species concentrations. However, a correlation was observed between higher drug concentrations and lower Abeta levels that might indicate an effect on APP metabolism with an increased alpha-cleavage. Abeta1-40 and Abeta1-42 levels were measured in the plasma of 28 AD subjects by means of a commercially available ELISA before rivastigmine treatment and at week 2 after the first dose of the drug (3 mg/day) had been administered. Treatment with rivastigmine exhibited a significant effect on mean plasma concentrations of Abeta1-42 (mean difference 7.8+/-8.4, t=-4.9, pmean difference 7.8+/-8.4, t=-4.9, p&lt;0.001) with a negative correlation with the patients age (Pearson's R=-0.40, p=0.035). No significant effect on plasma Abeta1-40 was observed. The observed increase of mean levels of plasma Abeta1-42 after rivastigmine treatment might indicate an effect of the drug on Abeta metabolism, mobilization of Abeta1-42 from deposits in the affected brain areas and a consecutive Ab1-42 brain-to-plasma efflux. The negative correlation between Abeta1-42 plasma levels changes and age may be a sign of impairment of this process in the older patients. A large individual variation of the observed response, however, excludes drawing definite conclusions. Whether those subjects who respond to rivastigmine in terms of Abeta1-42 plasma levels changes also respond clinically needs to be established.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of &#x141;&#xf3;d&#x17a;, 8/10 Czechos&#x142;owacka St, 92-216 &#x141;&#xf3;d&#x17a;, Poland. tmsobow@csk.am.lodz.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Folia Neuropathol</MedlineTA><NlmUniqueID>9437431</NlmUniqueID><ISSNLinking>1509-572X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16416397</ArticleId><ArticleId IdType="pii">5376</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16416395</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1641-4640</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Folia neuropathologica</Title><ISOAbbreviation>Folia Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Microglial cells in neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>321</EndPage><MedlinePgn>311-21</MedlinePgn></Pagination><Abstract><AbstractText>Microglia are resident immune cells of the CNS. They are involved in the pathogenesis of diverse neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, prion diseases as well as multiple sclerosis, amyotrophic lateral sclerosis and AIDS dementia complex. It is widely accepted that microglia contribute to the neurodegeneration through a release of a variety of proinflammatory substances. In fact, they are not the only cells which contribute to immunological processes inside the nervous system. The CNS is composed of different cell populations that answer to pathological factors and influence each other and modulate their reactions. These complex interactions are responsible for the development of brain pathology. This paper reviews the available information on microglial cells contribution to AD, PD and prion diseases development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wojtera</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of &#x141;&#xf3;d&#x17a;, 8/10 Czechos&#x142;owacka St, 92-216 &#x141;&#xf3;d&#x17a;, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikorska</LastName><ForeName>Beata</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142; P</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Folia Neuropathol</MedlineTA><NlmUniqueID>9437431</NlmUniqueID><ISSNLinking>1509-572X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>110</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16416395</ArticleId><ArticleId IdType="pii">5374</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16401890</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.</ArticleTitle><Pagination><StartPage>182</StartPage><EndPage>191</EndPage><MedlinePgn>182-91</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although QOL is an important indicator to assess multiple facets of life, the QOL of Alzheimer's disease (AD) subjects with impaired cognitive ability due to dementia has not yet been fully investigated. In this study, we developed the Japanese version of the Quality of Life-Alzheimer's disease (QOL-AD) scale by means of back-translation, and ascertained its reliability and validity for evaluating the quality of life in AD subjects. We also hypothesized that the presence of neuropsychiatric symptoms may determine the characteristics and determinants of both the patients' and the caregivers' responses to the patients' QOL questionnaire.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We administered the QOL-AD questionnaire to subjects with mild or moderate AD (n = 140). The test-retest reliability was evaluated by the same interviewer after a month's interval. Data from the following tests were also collected to ascertain the validity of the questionnaire: Short Memory Questionnaire (SMQ), Neuropsychiatry Inventory (NPI), Hyogo Activities of Daily Living Scale (HADL) and Mini-Mental State Examination (MMSE).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Japanese version of the QOL-AD questionnaire demonstrated good internal reliability for both the patients' (Cronbach's alpha = 0.84) and the caregivers' responses (Cronbach's alpha = 0.82) and good test-retest reliability for both the patients' (intraclass correlation coefficient = 0.84) and caregivers' reports (intraclass correlation coefficient = 0.91). The concordance between the patients' self-report and the caregivers' observation was moderate (Pearson correlation coefficient = 0.60). The score for the 'mood factor' (apathy, depression/dysphoria) in NPI predicted the overall QOL score as determined from both the patients' and the caregivers' responses for subjects with mild (MMSE&gt;or=21, n = 88) and moderate (MMSE&lt; 21, n = 52) AD. The score for the 'psychosis factor' (delusions, hallucinations, anxiety, agitation, disinhibition, irritability, aberrant motor activity) in NPI predicted the total QOL score as determined by the patients and the caregivers among subjects with moderate AD only.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As hypothesized, the presence of neuropsychiatric symptoms may be an important predictor of both the patients' and caregivers' responses to the patients' QOL questionnaire. QOL-AD appears to be a promising measure of the QOL of subjects with mild to moderate AD in Japan.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Teruo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaaki</LastName><ForeName>Shutaro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Junko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shinagawa</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tatsumi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Toshiaki A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012803" MajorTopicYN="Y">Sick Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16401890</ArticleId><ArticleId IdType="doi">10.1159/000090744</ArticleId><ArticleId IdType="pii">90744</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16395846</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1-2</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole: an overview of a novel antipsychotic.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>75</EndPage><MedlinePgn>67-75</MedlinePgn></Pagination><Abstract><AbstractText>Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydroaripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties. At least 1 to 2 weeks, and sometimes up to 4 weeks, may pass before aripiprazole reaches its full effect. The efficacy of aripiprazole was investigated in the treatment of schizophrenia, in the treatment of acute manic episode associated with Bipolar I Disorder, and in the treatment of psychosis associated with Alzheimer's dementia. Aripiprazole has demonstrated superiority to placebo in clinical studies of the treatment of both schizophrenia and acute bipolar mania. Aripiprazole has been evaluated for safety in 5592 patients who participated in multiple dose, premarketing trials in schizophrenia, bipolar mania, and dementia of the Alzheimer's type. The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day. Dosage increases should not be made before 2 weeks of continuous therapy, the time needed to achieve steady state. At least 1 to 2 weeks, and sometimes up to 4 weeks, may pass before aripiprazole reaches its full effect. In this presentation was given an overview of novel antipsychotic aripiprazole.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uzun</LastName><ForeName>Suzana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, School of Medicine, University of Zagreb, Psychiatric Hospital Vrapce, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozumplik</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Mimica</LastName><ForeName>Ninoslav</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Folnegovi&#x107;-Smalc</LastName><ForeName>Vera</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S514OZH3B</RegistryNumber><NameOfSubstance UI="C517414">dehydroaripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>32</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16395846</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16388704</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Awareness and behavioral problems in dementia patients: a prospective study.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>17</EndPage><MedlinePgn>3-17</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The results of studies of the association between awareness and clinical correlates in patients with dementia are inconclusive. The aims of this study were to investigate whether awareness changed during the course of dementia and to determine whether awareness was associated with certain behavioral symptoms. Specifically, it was hypothesized that relatively intact awareness was related to affective disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and ninety-nine patients with dementia were included in a prospective 18-month follow-up study. Behavioral problems were assessed with the Neuropsychiatric Inventory and the Cornell Scale for Depression in Dementia. Awareness was assessed by means of the Guidelines for the Rating of Awareness Deficits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cross-sectional analyses showed awareness to be positively associated with age, gender, education and socioeconomic status, and negatively associated with psychosis, apathy, and overall behavioral disorders at baseline. After 1 year, a higher level of awareness was related to depression and anxiety. The level of awareness at baseline also predicted depression and anxiety after 1 year. Awareness decreased during the study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A higher level of awareness is associated with subsyndromal depression and anxiety, whereas lack of awareness is associated with psychosis and apathy. The level of awareness decreases as dementia progresses. Clinicians should be more alert to changes in awareness in patients with dementia because psychosocial support might help to prevent the development of affective symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aalten</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, University of Maastricht, Maastricht, the Netherlands. paalten@np.unimaas.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Valen</LastName><ForeName>Evelien</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>de Vugt</LastName><ForeName>Marjolein E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lousberg</LastName><ForeName>Richel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jolles</LastName><ForeName>Jelle</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16388704</ArticleId><ArticleId IdType="doi">10.1017/S1041610205002772</ArticleId><ArticleId IdType="pii">S1041610205002772</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16375658</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1567-2050</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.</ArticleTitle><Pagination><StartPage>553</StartPage><EndPage>558</EndPage><MedlinePgn>553-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The Alzheimer's Disease Cooperative Study (ADCS) is conducting a clinical trial to address whether chronic valproate treatment can delay emergence of behavioral symptoms in outpatients with AD. Since there were no data on the safety and tolerability of divalproex sodium in outpatients with dementia, we undertook a pilot study to inform the design of the ADCS study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 20 outpatients with probable AD, MMSE 10-20, without history of agitation or psychosis. This was a 10-week randomized, double-blind, placebo-controlled study assessing the safety and tolerability of 1,000 mg/day and 1,500 mg/day of divalproex sodium delayed-release for 8 weeks followed by extended-release for 2 weeks. Other outcome measures addressed cognition, function, global status, side effects, and laboratory data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants assigned to active treatment ingested approximately 30% less of their prescribed study medication compared to those receiving placebo (p &lt; .05 Wilcoxon Rank Sum test). The average tolerated dose for all participants at week 8 was 810 mg/day or 11.5 mg/kg/day, similar to the dose tolerated by nursing home patients. The most common side effects were sleepiness and tiredness, with worse cognitive performance in those assigned to 1500 mg/day.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results were used to design the multi-center ADCS trial. Doses of less than 1000 mg/day of divalproex sodium were the maximum tolerated by these outpatients with AD. A larger study of divalproex sodium dose tolerability is needed to define treatment in outpatients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Profenno</LastName><ForeName>Louis A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakimovich</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Connie J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AGO 10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Curr Alzheimer Res. 2005 Dec;2(5):495-6. doi: 10.2174/156720505774932250</RefSource><PMID Version="1">16375652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16375658</ArticleId><ArticleId IdType="doi">10.2174/156720505774932205</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16352909</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0251-5350</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Neuroepidemiology</Title><ISOAbbreviation>Neuroepidemiology</ISOAbbreviation></Journal><ArticleTitle>Hallucinations, cognitive decline, and death in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>75</EndPage><MedlinePgn>68-75</MedlinePgn></Pagination><Abstract><AbstractText>The relation of psychotic symptoms to cognitive decline and mortality in Alzheimer's disease (AD) was examined during a mean of 2.2 years in 478 persons selected from clinical settings. Psychotic symptoms were ascertained at baseline and cognition was assessed semiannually with nine tests from which a global measure was formed. In analyses that controlled for age, sex, race, and education, hallucinations (29.6%), especially visual ones, were associated with more rapid global cognitive decline and increased mortality, even after controlling for baseline level of cognition and use of antipsychotic medication, and the association with mortality increased with higher level of education. Delusions and misperceptions were not strongly related to cognitive decline or mortality. The results suggest that hallucinations in Alzheimer's disease, particularly visual ones, are associated with more rapid progression.</AbstractText><CopyrightInformation>Copyright (c) 2006 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush Institute for Healthy Aging, and Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA. rwilson@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>N T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Gilley</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Bienias</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG09966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG10315</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuroepidemiology</MedlineTA><NlmUniqueID>8218700</NlmUniqueID><ISSNLinking>0251-5350</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="Y">Hallucinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16352909</ArticleId><ArticleId IdType="doi">10.1159/000090251</ArticleId><ArticleId IdType="pii">90251</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16341377</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0034-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>133</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Revista medica de Chile</Title><ISOAbbreviation>Rev Med Chil</ISOAbbreviation></Journal><ArticleTitle>[An update on the treatment of psychological and behavioral symptoms associated to dementia].</ArticleTitle><Pagination><StartPage>1242</StartPage><EndPage>1251</EndPage><MedlinePgn>1242-51</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral disturbances in dementias are relevant because they are very common, they worsen patients' medical and cognitive condition, increase the caregiver burden and accelerate the admission to nursing homes. The different behavioral disturbances in dementias can appear isolated, but in most cases, patients present a combination of disturbances producing one of two main syndromes: the psychotic or the affective syndrome. Proper handling of these behavioral disturbances requires a correct characterization of the syndrome, discarding medical or environmental causes and selecting the drug with the better effectiveness and safety profile for each patient. In spite of the important number of psychotropics available, there is not enough scientific evidence about their real effectiveness and security in patients with Alzheimer's disease. This article reviews recent advances in the treatment of most common and disruptive behavioral disturbances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Slachevsky</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Neurolog&#xed;a Cognitiva y Demencias, Servicio de Neurolog&#xed;a, Hospital del Salvador, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ntomas psicol&#xf3;gicos y conductuales asociados a demencias: actualizaci&#xf3;n terap&#xe9;utica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Rev Med Chil</MedlineTA><NlmUniqueID>0404312</NlmUniqueID><ISSNLinking>0034-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16341377</ArticleId><ArticleId IdType="doi">10.4067/s0034-98872005001000015</ArticleId><ArticleId IdType="pii">S0034-98872005001000015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16315159</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>1153</StartPage><EndPage>1157</EndPage><MedlinePgn>1153-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of Alzheimer's disease (AD) and mixed dementia (MD) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidone for aggression.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This post-hoc analysis included only patients diagnosed with AD or MD with psychosis, defined by a score of &gt;or= 2 on any item of the Behavioral Pathology of Alzheimer's Disease (BEHAVE-AD) psychosis subscale at both screening and baseline. Co-primary efficacy endpoints were changes in scores on BEHAVE-AD psychosis subscale and Clinical Global Impression of Change (CGI-C).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 93 patients (46 risperidone and 47 placebo) fulfilled the psychosis of AD criteria. Mean change at endpoint in BEHAVE-AD psychosis subscale with risperidone was superior to placebo (-5.2 vs -3.3; p = 0.039). Distribution of CGI-C at endpoint also favoured risperidone (p &lt; 0.001). The superior improvement with risperidone compared with placebo occurred as early as the first two weeks and persisted to the end of the treatment period. At endpoint, 59% of risperidone-treated patients were responders (i.e. were 'very much' or 'much' improved) compared with 26% of patients receiving placebo. The mean risperidone dose was 1.03 +/- 0.61 mg/day. Twelve weeks of treatment were completed by 37 patients treated with risperidone (80%) and 35 with placebo (74%). A total of 46 (98%) placebo- and 44 (96%) risperidone-treated patients experienced at least one adverse event, with only somnolence occurring more frequently in the risperidone group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Risperidone effectively reduces psychosis and improves global functioning in elderly patients with moderate-to-severe psychosis of AD and MD.</AbstractText><CopyrightInformation>Copyright (c) 2005 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Academic Department of Psychogeriatrics, School of Psychiatry, University of New South Wales, Sydney, Australia. h.brodaty@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Clarnette</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16315159</ArticleId><ArticleId IdType="doi">10.1002/gps.1409</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16310680</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0924-9338</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.</ArticleTitle><Pagination><StartPage>490</StartPage><EndPage>496</EndPage><MedlinePgn>490-6</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD), constitute a major clinical component of Alzheimer's disease (AD). There is a growing interest in BPSD as they are responsible for a large share of the suffering of patients and caregivers, and they strongly determine the patient's lifestyle and management. Better detection and understanding of these symptoms is essential to provide appropriate management. This article is a consensus produced by the behavioral group of the European Alzheimer's Disease Consortium (EADC). The aim of this article is to present clinical description and biological correlates of the major behavioral and psychological symptomatology in AD. BPSD is not a unitary concept. Instead, it should be divided into several symptoms or more likely: groups of symptoms, each possibly reflecting a different prevalence, course over time, biological correlate and psychosocial determinants. There is some clinical evidence for clusters within groups of BPSD. Biological studies indicate that patients with AD and BPSD are associated with variations in the pathological features (atrophy, brain perfusion/metabolism, histopathology) when compared to people with AD without BPSD. An individually tailored approach taking all these aspects into account is warranted as it may offer more, and better, pharmacological and non-pharmacological treatment opportunities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Centre M&#xe9;moire de Ressources &amp; de Recherche, CHU, Hopital Pasteur, Universit&#xe9; de Nice-Sophia Antipolis, 30, Avenue de la Voie Romaine, 06002 Nice cedex 1, France. philippe.robert15@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>E Jane</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Riello</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kyriazopoulou</LastName><ForeName>Nora</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="Y">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="Y">Societies, Medical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16310680</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2004.09.031</ArticleId><ArticleId IdType="pii">S0924-9338(04)00257-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16300905</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2008</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0306-9877</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Neuropharmacology of cognition and memory: a unifying theory of neuromodulator imbalance in psychiatry and amnesia.</ArticleTitle><Pagination><StartPage>394</StartPage><EndPage>431</EndPage><MedlinePgn>394-431</MedlinePgn></Pagination><Abstract><AbstractText>The case of HM, a man with intractable epilepsy who became amnesic following bilateral medial temporal lobe surgery nearly half a century ago has instigated ongoing research and theoretical speculation on the nature of memory and the role of the hippocampus. Neuropsychological testing showed that although HM had extensive anterograde memory loss he could still acquire motor and cognitive skills implicitly, but could not remember the context of this learning. This has lead to declarative and procedural descriptions of the memory process. Cholinergic and monoaminergic neurotransmitter systems have also been implicated in the memory process and anticholinergic drugs traditionally have been associated with impairment of declarative memory. The cholinergic hypothesis of Alzheimer's disease is a classic example of an application of these neuropharmacological findings. In schizophrenia, preattentive deficits have been amply demonstrated by unconscious priming studies. Memory processes are also impaired in these patients. Dopamine, glutamate and even cholinergic dysfunction has been implicated in the clinical picture of schizophrenia. The present paper will attempt to bring together both the anatomical and pharmacological data from these disparate fields of research under a cohesive theory of cognition and memory. A hypothesis is presented for an inverse relationship between monoaminergic and cholinergic systems in the modulation of implicit (unconscious) and explicit (conscious) cognitive processes. It is postulated that muscarinic cholinergic receptors and monoaminergic systems facilitate unconscious and conscious processes, respectively, and they disfacilitate conscious and unconscious processes, respectively (the purported inverse relationship). In fact, the muscarinic and monoaminergic modulations of a neural network are proposed to be finely balanced such that, if, the activity of one receptor system is modified then this by necessity has effects on the other system. It takes into account receptor subtypes and their effects mediated through excitatory and inhibitory G-protein complexes. For example, m1/D2 and D1/m4 paired receptor subtypes, colocalized on separate neurons would have opposing functional effects. A theory is then presented that the critical underlying pathophysiology of schizophrenia involves a hypofunctional muscarinic cholinergic system, which induces abnormal facilitation of monoaminergic subsystems such as dopamine (e.g., a decrease in m1R function would potentiate D2R function). This extends the idea of an inverted U function for optimal monoaminergic concentrations. Not only would this impair unconscious preattentive processes, but according to the hypothesis, explicit cognition as well including memory deficits and would underlie the mechanism of psychosis. Contrary to current thinking a different view is also presented for the role of the hippocampus in the memory process. It is postulated that long-term explicit memory traces in the neocortex are laid down by phasic coactivation of forebrain projecting monoaminergic systems above some basal firing rate, such as the rostral serotonergic raphe, which projects diffusely to the cortex and according to a modified Hebbian principle. This is the proposed principal function of the hippocampal theta rhythm. The phasic activation of the cholinergic basal forebrain is mediated by projections from a separate cortical structure, possibly the lateral prefrontal cortex. Phasic muscarinic receptor activation is proposed to strengthen implicit memory traces (at a synaptic level) in the neocortex. Thus, the latter are spared by medial temporal surgery explaining the dissociation of explicit from implicit memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vakalopoulos</LastName><ForeName>Costa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>hinemoa@bigpond.net.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009480" MajorTopicYN="Y">Neuropharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="Y">Psychiatry</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16300905</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2005.09.037</ArticleId><ArticleId IdType="pii">S0306-9877(05)00521-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16286441</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study.</ArticleTitle><Pagination><StartPage>976</StartPage><EndPage>983</EndPage><MedlinePgn>976-83</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Neuropsychiatric symptoms (NPS) are common in Alzheimer disease (AD). It is important in terms of management to know their natural history and their effects on service use. The authors aimed to determine the persistence and change in severity of NPS over 6 months in participants with AD, and the relationship to initial severity, drug management, use of services, and cost of care.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">NPS scores and data on cognition, psychotropic medication, service use, and costs of care were collected on 224 participants at baseline and on 198 at 6-month follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 224 patients, 210 (93.8%) had NPS at baseline; 168 (75.0%) had at least one clinically significant symptom, 118 (80.4%) of whom had persistent significant symptoms at 6-month follow-up. There was no significant change in mean NPS score for any symptom over 6 months, but many individuals became better or worse; 61.2% of those with at least one significant baseline symptom in any domain improved. Those with persistent symptoms had more severe baseline symptoms. Deterioration in NPS was predicted by deterioration in MMSE. Those with at least one clinically significant symptom had higher care costs than those without.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NPS were highly persistent overall, but many individuals became better or worse. Persistence was predicted by having more severe symptoms at baseline. Clinically significant levels of NPS were associated with greater costs of care. The relatively few associations found between specific psychiatric treatments and changes in NPS reflect both undertreatment and the complexity of symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seung-Ho</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Dept. of Mental Helath Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rive</LastName><ForeName>Beno&#xee;t</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006701" MajorTopicYN="N">Home Nursing</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16286441</ArticleId><ArticleId IdType="doi">10.1176/appi.ajgp.13.11.976</ArticleId><ArticleId IdType="pii">S1064-7481(12)61767-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16272189</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-8811</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>The efficacy and safety of quetiapine for treatment of geriatric psychosis.</ArticleTitle><Pagination><StartPage>661</StartPage><EndPage>666</EndPage><MedlinePgn>661-6</MedlinePgn></Pagination><Abstract><AbstractText>Quetiapine, an atypical antipsychotic, is effective for psychosis in younger patients, with limited adverse effects reported. This open-label naturalistic study was conducted to assess the 4-week efficacy and safety of quetiapine for treatment of geriatric psychosis. Clinical efficacy was evaluated using the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression Improvement (CGI-I) instruments before and after 4 weeks of quetiapine treatment. The sample population consisted of 100 geropsychiatric inpatients with psychosis, with the therapeutic evaluation completed by 91. Eighty-one of these 91 patients (89.0%) experienced mild-to-substantial improvement, as determined from the CGI-I. Further, a mean reduction in BPRS score of 39.5% (from baseline) was also determined. The mean daily dose of quetiapine for the fourth week was 276.1 177.2mg/day (range 50-800). Higher quetiapine dosages were administered for patients with functional psychoses compared to an analogous group with organic mental disorders. The most common adverse effects were somnolence (30.0%), lower-limb weakness (28.0%) and dizziness (27.0%). Body weight and fasting triglyceride were significantly elevated after quetiapine treatment (2.2% and 8.9% from baseline, respectively). Based on the results of this study, it appears that quetiapine is an efficacious and safe treatment for geriatric inpatients with psychosis, however, there is a wide dosing range and optimal dosage is diagnosis-dependent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cheng-Hung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Taipei Veterans General Hospital and Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jen-Ping</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16272189</ArticleId><ArticleId IdType="doi">10.1177/0269881105056669</ArticleId><ArticleId IdType="pii">19/6/661</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16263838</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003.</ArticleTitle><Pagination><StartPage>2022</StartPage><EndPage>2030</EndPage><MedlinePgn>2022-30</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors reviewed studies published between 1990 and 2003 that reported the prevalence, incidence, and persistence of, as well as the risk factors associated with, psychosis of Alzheimer's disease.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">PubMed and PsycINFO databases were searched by using the terms "psychosis and Alzheimer disease" and "psychosis and dementia." Empirical investigations presenting quantitative data on the epidemiology of and/or risk factors for psychotic symptoms in Alzheimer's disease were included in the review. A total of 55 studies, including a total of 9,749 subjects, met the inclusion criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Psychosis was reported in 41% of patients with Alzheimer's disease, including delusions in 36% and hallucinations in 18%. The incidence of psychosis increased progressively over the first 3 years of observation, after which the incidence seemed to plateau. Psychotic symptoms tended to last for several months but became less prominent after 1 year. African American or black ethnicity and more severe cognitive impairment were associated with a higher rate of psychosis. Psychosis was also associated with more rapid cognitive decline. Some studies found a significant association between psychosis and age, age at onset of Alzheimer's disease, and illness duration. Gender, education, and family history of dementia or psychiatric illness showed weak or inconsistent relationships with psychosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Psychotic symptoms are common and persistent in patients with Alzheimer's disease. Improved methods have advanced the understanding of psychosis in Alzheimer's disease, although continued research, particularly longitudinal studies, may unveil biological and clinical associations that will inform treatments for these problematic psychological disturbances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ropacki</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, 9500 Gilman Dr., Mail Code 0603V, La Jolla, CA 92093-0603, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-66248</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2022</ArticleId><ArticleId IdType="pii">162/11/2022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16257094</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms.</ArticleTitle><Pagination><StartPage>1595</StartPage><EndPage>1603</EndPage><MedlinePgn>1595-603</MedlinePgn></Pagination><Abstract><AbstractText>Several studies have been conducted to understand the genetic correlates of Alzheimer disease (AD)-related behavioral and psychological symptoms in dementia (BPSD). However, given that BPSD rarely occur in isolation, it has been suggested that targeting BPSD individually is too narrow of an approach if one wants to accurately define all the associated risk factors. To date, we know of no work on genetic polymorphisms related to behavioral endophenotypes in AD. The present study sought to evaluate the relationship between such behavioral endophenotypes in AD and genetic variations in dopamine- or serotonin-related genes, such as catechol-O-methyltransferase (COMT) or 5-HTT gene-linked promoter region (5-HTTLPR), and apolipoprotein E (APOE). Among 232 AD patients who underwent clinical and neuropsychological examination, a behavioral and psychiatric evaluation, and genotyping at COMT, 5-HTTPLR, and APOE; 66.4% showed more than one behavioral symptom. By Principal Component Analysis of Neuropsychiatric Inventory (NPI) symptoms four endophenotypes were identified, these were termed "psychosis", "moods", "apathy", and "frontal". Modeling NPI symptom-endophenotype-genotype relationships, and taking into account possible confounds (i.e. demographic characteristics, comorbidities, concomitant pharmacological treatments, and disease severity) by latent variable models, COMT and 5-HTTLPR genetic variations correlated with "frontal" and "psychosis" endophenotypes. APOE genotype did not correlate with any endophenotype. These findings suggest that the possibility of identifying distinct phenotypes on a genetic basis among AD patients exists, and suggest that clustering of BPSD into endophenotypes might provide a new strategy for guiding future research on this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Italy. bborroni@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Agosti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Archetti</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Franzoni</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Caimi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.029</ArticleId><ArticleId IdType="pii">S0197-4580(05)00301-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16255839</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Use of aripiprazole for psychosis and agitation in dementia.</ArticleTitle><Pagination><StartPage>335</StartPage><EndPage>340</EndPage><MedlinePgn>335-40</MedlinePgn></Pagination><Abstract><AbstractText>We report the case of an elderly woman with Alzheimer's disease, risk factors for vascular dementia, and atrium-ventricular blockade, who presented with severe agitation and psychosis. She was treated with aripiprazole and assessed with the Neuropsychiatric Inventory (NPI) over the course of 14 weeks. NPI scores showed a marked decrease in psychosis and agitation at week 4, and complete recovery at week 14, except for depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laks</LastName><ForeName>Jerson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Disorders, Institute of Psychiatry, Federal University of Rio de Janeiro, RJ, Brazil. jlaks@centroin.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miotto</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marinho</LastName><ForeName>Valeska</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Eliasz</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16255839</ArticleId><ArticleId IdType="doi">10.1017/S1041610205002541</ArticleId><ArticleId IdType="pii">S1041610205002541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16254428</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>39</EndPage><MedlinePgn>33-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of the apolipoprotein E (ApoE) epsilon4 allele on the efficacy and tolerability of galantamine treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 202 patients with mild to moderate Alzheimer's disease participated in a 16-week, prospective, multi-center, randomized, double-blind galantamine trial in a Korean population. Patients were assessed at baseline and after 4, 8 and 16 weeks of randomized treatment using the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog/11), the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the Disability Assessment for Dementia Scale (DAD), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) and adverse events. ApoE genotypes were determined for all subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 202 subjects, 115 carried at least one ApoE epsilon4 allele and 87 did not. In both ApoE epsilon4 carriers and ApoE epsilon4 noncarriers, significant improvements were detected relative to baseline on ADAS-cog/11, CIBIC-plus, DAD and BEHAVE-AD. ApoE epsilon4 noncarriers showed better improvement in mean total BEHAVE-AD score and mean psychosis (delusions and hallucinations) subscale score than ApoE epsilon4 carriers. The incidence of weight loss was significantly higher in ApoE epsilon4 carriers (n = 11; 9.6%) than in ApoE epsilon4 noncarriers (n = 1; 1.2%) during this 16-week study, even though 92% of patients who complained of weight loss completed this 16-week trial successfully.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ApoE epsilon4 genotype does not affect galantamine-related improvements in cognition, global rating, function and behavior. Longer prospective studies with larger patient populations are required to confirm these new findings.</AbstractText><CopyrightInformation>Copyright 2006 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Guk-Hee</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Division of Neuroscience and Psychological Medicine, Imperial College, School of Medicine, and West London Mental Health NHS, London, UK. suhgh@chol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hee Yeon</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chang Uk</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Byoung Hoon</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Kyu</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>NamJin</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>JaeHyun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kee</LastName><ForeName>Baik Seok</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Daekwan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young-Hoon</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Young-Su</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>InJa</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sungku</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><CollectiveName>Korean Galantamine Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16254428</ArticleId><ArticleId IdType="doi">10.1159/000089217</ArticleId><ArticleId IdType="pii">89217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16250069</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>1020</StartPage><EndPage>1027</EndPage><MedlinePgn>1020-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This was an exploratory study of olanzapine as potential treatment for improvement in cognition in patients with Alzheimer's disease without prominent psychobehavioral symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Non-psychotic/non-agitated patients (n = 268) with Alzheimer's disease, who had baseline Mini-Mental State Examination (MMSE) scores of 14-26 were randomized to treatment with olanzapine (2.5 to 7.5 mg/d) or placebo for 26 weeks. The primary objectives were to determine if treatment with olanzapine improved cognition as indexed by the Alzheimer's disease Assessment Scale for Cognition (ADAS-Cog) and the Clinician's Interview-Based Impression of Change (CIBIC) after 26 weeks of therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients treated with olanzapine vs placebo experienced significant worsening ADAS-Cog scores at weeks 12 (p = 0.03) and 26 (p = 0.004). Changes in CIBIC scores were not significantly different between treatment groups at either assessment. A post hoc analysis revealed that olanzapine-treated patients with more cognitive impairment at baseline (MMSE scores of 14-18) (n = 35) experienced significantly greater deterioration in ADAS-Cog performance than patients in the placebo group (n = 24; p &lt; 0.001); whereas in patients with less cognitive impairment (n = 78, baseline MMSE scores of 23-26) between-group ADAS-Cog changes were not significant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this 26-week study non-psychotic/non-agitated patients with Alzheimer's disease treated with olanzapine experienced significant worsening of cognition as compared to placebo.</AbstractText><CopyrightInformation>Copyright (c) 2005 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Alberta and Chinook Regional Health System, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deberdt</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Siegal</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Micca</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Degenhardt</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ahl</LastName><ForeName>Jonna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Meyers</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16250069</ArticleId><ArticleId IdType="doi">10.1002/gps.1397</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16223962</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric complications in Parkinson disease.</ArticleTitle><Pagination><StartPage>844</StartPage><EndPage>851</EndPage><MedlinePgn>844-51</MedlinePgn></Pagination><Abstract><AbstractText>Although Parkinson disease (PD) is primarily considered a movement disorder, the high prevalence of psychiatric complications suggests that it is more accurately conceptualized as a neuropsychiatric disease. Affective disorders, cognitive impairment, and psychosis are particularly common in PD and are associated with excess disability, worse quality of life, poorer outcomes, and caregiver distress. Yet, in spite of this and their frequent occurrence, there is incomplete understanding of the epidemiology, phenomenology, risk factors, neuropathophysiology, and optimal treatment strategies for these disorders. Psychiatric complications are typically comorbid, and there is great intra- and inter-individual variability in presentation. The hallmark neuropathophysiological changes that occur in PD plus the association between exposure to dopaminergic medications and certain psychiatric disorders suggest a neurobiological basis for most psychiatric symptoms, although psychological factors are probably involved in the development of affective disorders. Although antidepressants, antipsychotics, and cognition-enhancing agents are commonly prescribed in PD, controlled studies demonstrating efficacy and tolerability of these drugs are virtually nonexistent. Because of the high prevalence and complexity of psychiatric complications in PD, geriatric psychiatrists are in a position to offer valuable consultation and clinical care to this population. This article provides an overview of the epidemiology, pathophysiology, clinical presentation, and management of the most common psychiatric complications in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. weintrau@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23MH067894</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16223962</ArticleId><ArticleId IdType="doi">10.1176/appi.ajgp.13.10.844</ArticleId><ArticleId IdType="pii">S1064-7481(12)61733-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16191230</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>15 Suppl 1</Volume><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Behavioral symptoms in vascular cognitive impairment and vascular dementia.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>138</EndPage><MedlinePgn>133-8</MedlinePgn></Pagination><Abstract><AbstractText>Noncognitive or behavioral and psychological symptoms (BPSD) are common in vascular dementia. Many occur with the same frequency as in Alzheimer's disease, though depression, emotional lability, and apathy may be more common and psychosis less so. There is a particularly strong relationship between cerebrovascular disease and depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, UK. j.t.o'brien@ncl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16191230</ArticleId><ArticleId IdType="doi">10.1017/S1041610203009098</ArticleId><ArticleId IdType="pii">S1041610203009098</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16160622</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>467</EndPage><MedlinePgn>463-7</MedlinePgn></Pagination><Abstract><AbstractText>This study compared the efficacy, safety, and tolerability of aripiprazole, a novel antipsychotic, with placebo in patients with psychosis associated with Alzheimer's Disease (AD). This 10-week, double-blind, multicenter study randomized 208 outpatients (mean age, 81.5 years) with AD-associated psychosis to aripiprazole (n = 106) or placebo (n = 102). The initial aripiprazole dose of 2 mg/d was titrated upwards (5, 10, or 15 mg/d) according to efficacy and tolerability. Evaluations included Neuropsychiatric Inventory (NPI) Psychosis subscale and Brief Psychiatric Rating Scale (BPRS), adverse event (AE) reports, extrapyramidal symptoms (EPS) rating scales, and body weight. Overall, 172 patients (83%) completed the study. Mean aripiprazole dose at end point was 10.0 mg/d. The NPI Psychosis subscale score showed improvements in both groups (aripiprazole, -6.55; placebo, -5.52; P = 0.17 at end point). Aripiprazole-treated patients showed significantly greater improvements from baseline in BPRS Psychosis and BPRS Core subscale scores at end point compared with placebo. AEs were generally mild to moderate in severity and included (aripiprazole vs. placebo): urinary tract infection (8% vs. 12%), accidental injury (8% vs. 5%), somnolence (8% vs. 1%), and bronchitis (6% vs. 3%). Somnolence was mild and not associated with falls or accidental injury. There were no significant differences from placebo in EPS scores, or clinically significant ECG abnormalities, vital signs, or weight. In conclusion, aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis. Aripiprazole was safe and well tolerated in this patient population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Middelheim General Hospital, ZNA, Memory Clinic, and Laboratory of Neurochemistry and Behavior, University of Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Swanink</LastName><ForeName>Rene</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kostic</LastName><ForeName>Dusan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Breder</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Taro</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Clin Psychopharmacol. 2005 Dec;25(6):560</RefSource><Note>Carson, William H [added]; Iwamoto, Taro [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16160622</ArticleId><ArticleId IdType="doi">10.1097/01.jcp.0000178415.22309.8f</ArticleId><ArticleId IdType="pii">00004714-200510000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16116579</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>872</StartPage><EndPage>875</EndPage><MedlinePgn>872-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuroleptics are only modestly effective in dementia and associated with a range of adverse effects including cognitive decline. Effects of the drugs on molecular pathology in brain tissue from people with dementia have not been investigated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare the severity of Alzheimer type pathology in matched groups of people with dementia with Lewy bodies (DLB), treated and not treated with neuroleptics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The relationship between neuroleptics and Alzheimer-type pathology was determined in 40 (17 neuroleptic treated, 23 neuroleptic free, matched for age, disease duration and psychosis) clinically prospectively studied, autopsy diagnosed DLB patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In regression analyses, taking neuroleptics was significantly associated with increased neurofibrillary tangles but not amyloid plaques in cortical areas examined. The patient characteristics and the frequencies of key psychiatric symptoms were similar in the patients taking and not taking neuroleptics.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although patients were not randomized and the results which are observed need to be interpreted cautiously, if substantiated, this is an important finding with major implications for the pharmacological management of DLB patients and highlights the need to determine the impact of neuroleptics upon tangle pathology in AD.</AbstractText><CopyrightInformation>Copyright (c) 2005 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age Related Diseases, King's College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16116579</ArticleId><ArticleId IdType="doi">10.1002/gps.1378</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16092095</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20 Suppl 12</Volume><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov Disord</ISOAbbreviation></Journal><ArticleTitle>Treatment of dementia with Lewy bodies and Parkinson's disease dementia.</ArticleTitle><Pagination><StartPage>S77</StartPage><EndPage>S82</EndPage><MedlinePgn>S77-82</MedlinePgn></Pagination><Abstract><AbstractText>Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Austria. werner.poewe@uibk.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16092095</ArticleId><ArticleId IdType="doi">10.1002/mds.20544</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16085789</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.</ArticleTitle><Pagination><StartPage>722</StartPage><EndPage>730</EndPage><MedlinePgn>722-30</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors compared efficacy of olanzapine versus placebo and risperidone as measured by the Neuropsychiatric Inventory and Clinical Global Impression-Severity of Psychosis scale in patients with dementia-related psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with moderate-to-severe psychotic symptoms associated with dementia were recruited from outpatient or residential settings and randomly assigned to 10-week, double-blind, flexible-dose treatment with olanzapine (N=204; 2.5 mg-10 mg/day; mean: 5.2 mg/day), risperidone (N=196; 0.5 mg-2 mg/day; mean: 1.0 mg/day) or placebo (N=94).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most measures of neuropsychiatric functioning improved in all treatment groups, including the placebo group, and no significant treatment differences occurred. Overall discontinuation was lowest in the placebo group, and the olanzapine group had a significantly higher incidence of discontinuation due to adverse events (16.2%) relative to placebo (3.2%) and risperidone (8.7%) groups. Treatment-emergent extrapyramidal symptoms were more numerous for risperidone- than placebo- or olanzapine-treated patients. Abnormally high prolactin levels occurred in 78.0% of risperidone patients, compared with 16.7% for olanzapine and 5.0% for placebo. The incidence of weight gain greater than 7% from baseline was higher in the olanzapine group relative to risperidone, but neither active-treatment group showed a statistical difference from placebo (1.1%). No other statistically significant and clinically relevant differences were seen for any other vital sign, electrocardiographic measure, or laboratory hematology and chemistry, including glucose, except for cholesterol, which decreased from baseline to endpoint in both active-treatment groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients' neuropsychiatric functioning improved with olanzapine, risperidone, and placebo treatment. There was a substantial response in the placebo group, and no significant differences emerged among treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deberdt</LastName><ForeName>Walter G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Indianapolis, IN, USA. deberdt_walter@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dysken</LastName><ForeName>Maurice W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Rappaport</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Carrie A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Hay</LastName><ForeName>Donald P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Dossenbach</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Degenhardt</LastName><ForeName>Elisabeth K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Geriatr Psychiatry. 2006 Apr;14(4):384; author reply 384-5. doi: 10.1097/01.JGP.0000196634.50128.23</RefSource><PMID Version="1">16582052</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019955" MajorTopicYN="N">Conduct Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16085789</ArticleId><ArticleId IdType="doi">10.1176/appi.ajgp.13.8.722</ArticleId><ArticleId IdType="pii">S1064-7481(12)60941-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16082692</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>139B</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>32</EndPage><MedlinePgn>28-32</MedlinePgn></Pagination><Abstract><AbstractText>Probands with late onset Alzheimer's disease (LOAD) exhibit positive symptoms of psychosis, 30-60% of the time. Positive symptoms of psychosis have been shown to appear prior to the onset of dementia to be accompanied by greater cognitive deficits, and to predict a more rapid decline. A study of the distribution of AD with psychosis (ADP) in families from the NIMH Alzheimer's Disease Genetic Initiative sample indicates that the trait is heritable, and linkage studies of multiplex ADP families have found suggestive peaks on 2p, 6q, 8p, and 21q. A genome scan of idiopathic psychosis, schizophrenia, in the Icelandic population identified a risk haplotype within the 5' region of neuregulin-1 (NRG1) on 8p12. Associations with NRG1 SNPs have also been found in other schizophrenia populations from Scotland, Ireland, and China. Here, we report results demonstrating a significant linkage peak for ADP on 8p12 in the NIMH AD dataset, encompassing the NRG1 region. We also demonstrate that there is a significant association with a NRG1 SNP (single nucleotide polymorphism), rs392499, with ADP, chi2 = 7.0, P = 0.008. This same SNP is part of a 3-SNP haplotype preferentially transmitted to individuals with this phenotype. Our results suggest that NRG1 plays a role in increasing the genetic risk to positive symptoms of psychosis in a proportion of LOAD families.</AbstractText><CopyrightInformation>(c) 2005 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Go</LastName><ForeName>Rodney C P</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL 35294, USA. rgo@uab.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Rodney T</ForeName><Initials>RT</Initials></Author><Author ValidYN="Y"><LastName>Wiener</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002898" MajorTopicYN="N">Chromosomes, Human, Pair 8</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16033289</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-6667</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>11</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.</ArticleTitle><Pagination><StartPage>1493</StartPage><EndPage>1520</EndPage><MedlinePgn>1493-520</MedlinePgn></Pagination><Abstract><AbstractText>Historically, immunological research in psychiatry was based on empirical findings and early epidemiological studies indicating a possible relationship between psychiatric symptoms and acute infectious diseases. However, aetiopathological explanations for psychiatric disorders are no longer closely related to acute infection. Nevertheless, immune hypotheses have been discussed in schizophrenia, affective disorders and infantile autism in the last decades. Although the variability between the results of the epidemiological studies conducted to date is strikingly high, there is still some evidence that the immune system might play a role in the aetiopathogenesis of these three psychiatric diseases, at least in subgroups of patients. In anxiety disorders immunological research is still very much in its infancy, and the few and inconsistent data of immune changes in these patients are believed to reflect the influence of short- or long-term stress exposure. Nevertheless, there are also some hints raising the possibility that autoimmune mechanisms could interrupt neurotransmission, which would be of significance in certain patients with anxiety and panic disorders. Drug and alcohol (ethanol) dependence are not believed to be primarily influenced by an immunological aetiology. On the other hand, immune reactions due to different drugs of abuse and alcohol may directly or indirectly influence the course of concomitant somatic diseases. In different organic brain disorders the underlying somatic disease is defined as a primary immune or autoimmune disorder, for instance HIV infection or systemic lupus erythematosus (SLE). For other neurodegenerative disorders, such as Alzheimer's disease, immunoaetiopathological mechanisms are supported by experimental and clinical studies. Treatment strategies based on immune mechanisms have been investigated in patients with schizophrenia and affective disorders. Furthermore, some antipsychotics and most antidepressants are known to have direct or indirect effects on the immune system. Different immunotherapies have been used in autism, including transfer factor, pentoxifylline, intravenous immunoglobulins and corticosteroids. Immunosuppressive and/or immunomodulating agents are well established methods for treating the neuropsychiatric sequelae of immune or autoimmune disorders, for example AIDS and SLE. Therapeutic approaches in Alzheimer's disease also apply immunological methods such as strategies of active/passive immunisation and NSAIDs. Considering the comprehensive interactive network between mind and body, future research should focus on approaches linking targets of the different involved systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperner-Unterweger</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria. barbara.sperner-unterweger@uibk.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>408</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16033289</ArticleId><ArticleId IdType="doi">10.2165/00003495-200565110-00004</ArticleId><ArticleId IdType="pii">65114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Community Psychol. 1983 Aug;11(4):423-39</Citation><ArticleIdList><ArticleId IdType="pubmed">6637903</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1996 Aug;20(5):900-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8865966</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1984 Oct;58(1):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">6236915</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1999 Jun 1;162(11):6303-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10352239</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1991 May;5(8):2194-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2022315</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 May 1;45(9):1212-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10331114</ArticleId></ArticleIdList></Reference><Reference><Citation>Birth Defects Orig Artic Ser. 1978;14(5):339-64</Citation><ArticleIdList><ArticleId IdType="pubmed">80239</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1994 Nov;98(2):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7955530</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 Jan-Feb;61(1):6-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10024062</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunogenetics. 1992;36(4):203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1639438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Oct 1;57(2-3):247-58</Citation><ArticleIdList><ArticleId IdType="pubmed">12223256</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Jun 15;43(12):887-96</Citation><ArticleIdList><ArticleId IdType="pubmed">9627743</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Feb 1;35(3):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7909694</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2000 Jan 17;387(3):343-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10650181</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1994 Jul-Aug;2(2):70-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9384885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1979 Aug;91(2):194-9</Citation><ArticleIdList><ArticleId IdType="pubmed">313732</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Genomics Hum Genet. 2004;5:379-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15485354</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 1997 Aug;9(4):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9287190</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Oct 1;56(7):476-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15450782</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 4:62-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10654111</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 1991 Aug;35(4):298-306</Citation><ArticleIdList><ArticleId IdType="pubmed">1943879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Mar;48(2-3):149-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9543204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Jul;65(7):940-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15291683</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2003;20(2):101-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12534311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2002 May;1(1):3</Citation><ArticleIdList><ArticleId IdType="pubmed">12849527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 May;150(1-2):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15081255</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2000 Apr;149(3):319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10823414</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Jul 1;50(3):169-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11439237</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Dec 15;40(12):1294-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8959295</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1991 Mar;83(3):438-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2004485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Neurol. 1996 Nov;11(6):501-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9120235</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1999;40(2):57-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10474057</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 31;302(5646):834-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14593170</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Nov 9;333(19):1242-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7566000</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Apr;132:342-8</Citation><ArticleIdList><ArticleId IdType="pubmed">638387</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Nov 22;345(21):1567-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11794225</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Sep 1;38(5):297-302</Citation><ArticleIdList><ArticleId IdType="pubmed">7495923</ArticleId></ArticleIdList></Reference><Reference><Citation>Folia Haematol Int Mag Klin Morphol Blutforsch. 1980;107(2):221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6159262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2002 Nov;110(5):957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12415036</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1986 Jun;73(6):651-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2428210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Jan 15;47(1):27-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11163542</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Biol Med (Maywood). 2003 Sep;228(8):882-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12968059</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Aug;47(8):713-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2378542</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):285-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15023509</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 1993 Mar;7(1):97-103</Citation><ArticleIdList><ArticleId IdType="pubmed">7682457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1995 Mar-Apr;29(2):141-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7666381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1995 Aug 26;346(8974):552-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7544856</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1986 Nov;16(4):757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">3029788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Mar;5(2):150-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10822342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zh Nevropatol Psikhiatr Im S S Korsakova. 1961;61:869-74</Citation><ArticleIdList><ArticleId IdType="pubmed">13755515</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 May;56(5):407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10232294</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2000 Sep 29;405(1-3):375-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11033342</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12102-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10518583</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Apr 15;53(8):707-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12706957</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med Monogr Suppl. 1992;20:1-97</Citation><ArticleIdList><ArticleId IdType="pubmed">1565705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2000 Apr 12;9(6):861-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10767308</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 May 21;216(4548):892-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6281883</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 Jan;41(1):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6691787</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2001 Jul 6;423(2-3):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11448490</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 1996 May;50(3):179-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8803617</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Mar 1;43(5):315-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9513745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1980 Oct 11;2(8198):769-72</Citation><ArticleIdList><ArticleId IdType="pubmed">6107453</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Aug;52(8):668-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7632120</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 1997 Oct;15(6):711-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9402221</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Sep;160(9):1691-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12944347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2002 Aug;129(1-2):168-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12161033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1995 Feb;14(3):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7766533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Child Schizophr. 1971 Apr-Jun;1(2):146-60</Citation><ArticleIdList><ArticleId IdType="pubmed">5172389</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1995 Jul-Aug;16(4):523-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8544901</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1980 Apr;61(4):313-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6969531</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 2002 May;27(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12062637</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1993 Apr;17(2):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8488968</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 Nov-Dec;61(6):850-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10593638</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Mar;63(1-3):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">11246085</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Chem Neuropathol. 1996 May-Aug;28(1-3):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8871944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1996 Feb;26(1):87-97</Citation><ArticleIdList><ArticleId IdType="pubmed">8819772</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Mar 15;55(6):588-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15013827</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Sep 13;215(3):201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8899748</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Aug 1;56(3):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12072172</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1999 Jul 27;38(1):61-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10427611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervenarzt. 1994 Mar;65(3):169-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8177357</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 May;157(5):683-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10784457</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Rev. 1995;17(1):10-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8521927</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1987 May;150:598-608</Citation><ArticleIdList><ArticleId IdType="pubmed">3307980</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Protein Chem. 1998;52:223-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9917922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2003 Apr;2(4):215-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12849209</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8382-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1681536</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2004;146:151-65</Citation><ArticleIdList><ArticleId IdType="pubmed">14699963</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1998 Sep-Oct;60(5):570-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9773760</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunology. 1993 Nov;80(3):395-400</Citation><ArticleIdList><ArticleId IdType="pubmed">8288316</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1994 Jul;15(7):301-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8086097</ArticleId></ArticleIdList></Reference><Reference><Citation>Redox Rep. 2000;5(2-3):112-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10939286</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2000 Aug 3;11(11):2433-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10943699</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1997;74(1):27-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9336014</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2001 Nov;25(5 Suppl):S45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11682273</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 Dec;22(9):1927-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9884135</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2002 Apr;16(4):663-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11929383</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Sep;83(18):7114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3018757</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 May;147(5):661-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2327498</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1985 Jan;20(1):110-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3155486</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 Mar-Apr;61(2):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10204970</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Allergy. 2003 Feb;33(2):199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">12580912</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Sep 7;33(1-2):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9783348</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):709-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15276697</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4634-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11296294</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Jun 22;32(1):69-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9690337</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2000 Nov-Dec;62(6):790-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11138998</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Nov;58(11):1032-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11695949</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 2001 Aug;130(2):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11490364</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2001 Sep;15(3):199-226</Citation><ArticleIdList><ArticleId IdType="pubmed">11566046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Res. 1978 Oct;10(5):291-3</Citation><ArticleIdList><ArticleId IdType="pubmed">216300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 2002 Aug;32(4):337-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12199139</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Mar;156:357-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2346834</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1992;26(1-2):23-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1282223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1999 May;134(5):607-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10228297</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jan;82(2):612-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2578670</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1989 Jul;16(7):904-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2549241</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1999;461:179-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10442174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Jan;6(1):79-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11244489</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Apr 1;54(3):281-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11950553</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 May-Jun;61(3):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10367603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1996 Jan;37(1):89-126</Citation><ArticleIdList><ArticleId IdType="pubmed">8655659</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Pharmacother. 2002 Mar;56(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12000135</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2002 Feb 16;324(7334):393-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11850369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1992 Mar;6(3):181-92</Citation><ArticleIdList><ArticleId IdType="pubmed">1571312</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Neurol. 1999 Jun;14(6):388-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10385847</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Oct 15;50(8):609-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11690596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(8):47-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1661515</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2000 Aug;55(2):137-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10904430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1997 Sep 15;159(6):2994-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9300724</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2002 Jul;46(7):1851-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12124869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med. 1993 Oct;25(5):489-96</Citation><ArticleIdList><ArticleId IdType="pubmed">8251150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2001 Nov 1;120(1-2):170-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11694332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Aug;6(8):916-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 Feb;22(1):150-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9514300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1995 May 15;154(10):5511-27</Citation><ArticleIdList><ArticleId IdType="pubmed">7730652</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1994;20(2):263-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8085130</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1998 Aug;22(6):947-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9789879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Biochem. 1996 Nov;33 ( Pt 6):536-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8937585</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res. 1992 Dec;5(4):196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">1489765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;90(7):87-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1979461</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2002 Jan;105(1):60-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12086227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 2003 Apr;9(2):222-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12707852</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Jul;44(7):660-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3606332</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jun 13;54(11):2066-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10851364</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacology. 1996 Aug;34(1):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">8880223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Jul 2;344(8914):59-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7912324</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1992 Apr;160:533-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1996 Oct 18;22(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8908685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2002 Feb;16(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11846437</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1987 Aug;22(8):1025-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3496920</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 1998 May-Jun;33(3):202-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9632045</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1986 Sep 19;256(11):1474-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3747066</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1986 Jun;16(2):189-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2941410</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Psychol. 1985 Nov;40(11):1245-50</Citation><ArticleIdList><ArticleId IdType="pubmed">4083613</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1998 May 1;85(1):106-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9627004</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Pediatr Neurol. 2004 Sep;11(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15575416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 1991 Sep;11(5):246-53</Citation><ArticleIdList><ArticleId IdType="pubmed">1839029</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacol Immunotoxicol. 1992;14(4):783-96</Citation><ArticleIdList><ArticleId IdType="pubmed">1294623</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 May;22(3):621-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9622442</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2003 Apr;16(2):209-19</Citation><ArticleIdList><ArticleId IdType="pubmed">12692094</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1994 Apr 18;643(1-2):40-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7518332</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1992;26(1-2):12-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1335559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Neurol. 1998 Feb;13(2):79-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9512308</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1985 Aug;147:137-44</Citation><ArticleIdList><ArticleId IdType="pubmed">2994791</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1990 Jul-Aug;3(4):269-75</Citation><ArticleIdList><ArticleId IdType="pubmed">1980614</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Rheumatol. 1987 Aug;26(4):307-10</Citation><ArticleIdList><ArticleId IdType="pubmed">3496935</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1997 Aug 29;26(2-3):227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9323355</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2001 Dec;15(4):319-39</Citation><ArticleIdList><ArticleId IdType="pubmed">11782102</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2001 Dec;15(4):282-318</Citation><ArticleIdList><ArticleId IdType="pubmed">11782101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1997 Mar;38(3):337-49</Citation><ArticleIdList><ArticleId IdType="pubmed">9232480</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 Mar;48(3):626-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 2002 Apr;63(4):311-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1996 Jul 5;224(1):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8694821</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2002 Nov;8(11):1270-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12379846</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1993 May;113(3):472-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8316610</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2000 Sep 25;96(1):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10980328</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Feb;48(2):171-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1671201</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Psychol. 1994 Jan;13(1):14-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8168466</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1997 Dec;96(6):412-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1985;14(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">4069344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 May;107(5):E84</Citation><ArticleIdList><ArticleId IdType="pubmed">11331734</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2001 Apr;56(4):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11339860</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 1987 Sep;31(5):443-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2891284</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 1995;20(2):111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7899532</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Dev Immunol. 2004 Jun;11(2):165-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15330453</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2002 Jul;3(3):162-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12478882</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1989 Oct;46(10):890-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2478093</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1996;402:225-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8787664</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Mar;31(2-3):113-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10719139</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2002 Aug;59(2):154-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12208201</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 1994 Dec;8(4):293-312</Citation><ArticleIdList><ArticleId IdType="pubmed">7696716</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1967 Jan;16(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4163019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1988;540:602-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3144935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 Jul;152(1-2):176-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15223250</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Rheumatol Rep. 2002 Aug;4(4):337-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12126586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 2000 Oct;30(5):475-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11098887</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1999 Jul;23(7):1199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">10443986</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2000 May 8;160(9):1354-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10809041</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2004 Oct;21(10):1457-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15672635</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2000 Feb;10(1):138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10679428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1998 Jan 23;241(1):17-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9502205</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1997;247(4):228-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9332905</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 1995 Sep;32(2):233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7500834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1994 Feb;11(3):245-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8193063</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 1999 Aug;49(6):441-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10483922</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1998;248(6):282-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9928906</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Feb 9;29(3):263-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9516667</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2004 Jan-Mar;18(1):38-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15195462</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1997 Oct;21(7):1226-31</Citation><ArticleIdList><ArticleId IdType="pubmed">9347083</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Nov 15;50(10):743-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11720692</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2002 Oct;16(5):590-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12401473</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1962 Apr;6:320-3</Citation><ArticleIdList><ArticleId IdType="pubmed">13892633</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 May 1;43(9):701-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9583005</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Med. 1990;8(1):95-110</Citation><ArticleIdList><ArticleId IdType="pubmed">2198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1995;18:101-28</Citation><ArticleIdList><ArticleId IdType="pubmed">7605057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Nov;5(6):604-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11126391</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Mar 15;43(6):458-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9532351</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 1998 Apr;44(4):858-62</Citation><ArticleIdList><ArticleId IdType="pubmed">9554499</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12142963</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2000 Sep 1;44(3):165-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10962218</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1991 May-Jun;53(3):332-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1882014</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 May;161(5):889-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15121655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 Jul;4(4):317-27</Citation><ArticleIdList><ArticleId IdType="pubmed">10483047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Jun;49(3):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9629951</ArticleId></ArticleIdList></Reference><Reference><Citation>Anxiety. 1994;1(1):22-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9160542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1997 Sep;75(3):199-216</Citation><ArticleIdList><ArticleId IdType="pubmed">9504140</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 1995 Nov;23(4):603S</Citation><ArticleIdList><ArticleId IdType="pubmed">8654788</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Sep;150(9):1408-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8102512</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2000;26(2):287-95</Citation><ArticleIdList><ArticleId IdType="pubmed">10885631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1992 Mar;22(1):33-45</Citation><ArticleIdList><ArticleId IdType="pubmed">1375597</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jul;55(7):580-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9672048</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1992 May;111(3):475-89</Citation><ArticleIdList><ArticleId IdType="pubmed">1594722</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 Nov;156(1-2):1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15526402</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Jan;155(1):4-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9433332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 Mar;4(2):179-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10208450</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Sep-Oct;33(5):407-18</Citation><ArticleIdList><ArticleId IdType="pubmed">10504009</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1992 Jan;160:71-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1544015</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Sep;34(9):1065-70</Citation><ArticleIdList><ArticleId IdType="pubmed">901136</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 2003;43:545-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1999 Jan;13(1):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1991;17(4):669-78</Citation><ArticleIdList><ArticleId IdType="pubmed">1805356</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2000 Apr;24(4):560-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10798594</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Jul 1;46(1):110-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10394480</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1999 May 4;37(1):97-106</Citation><ArticleIdList><ArticleId IdType="pubmed">10227112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):634-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11673791</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Oct 11;87(2-3):129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10579546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 Feb;147(1-2):43-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14741426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Mar 6;363(9411):750</Citation><ArticleIdList><ArticleId IdType="pubmed">15016483</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Mar 15;51(6):480-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11922883</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Aug 30;120(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14500112</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1996 Aug;26(4):439-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8863094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med Today. 2000 Jun;6(6):238-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10840382</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Nov 7;347(19):1477-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12421889</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Feb 15;43(4):270-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9513736</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 2004 Apr;32(3):243-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15282117</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2000 Mar;10(2):119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10706993</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Mar 15;45(6):704-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10188000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Jun 12;353(9169):2026-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10376617</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Jan 15;66(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9061799</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 May 15;47(10):910-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10807964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1997 Oct;42(4):666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9382481</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1999 Apr;23(4):673-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10235303</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1993 Mar;23(1):67-78</Citation><ArticleIdList><ArticleId IdType="pubmed">8463203</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jan 18;85(1):33-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10195314</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1979 Nov;9(4):611-8</Citation><ArticleIdList><ArticleId IdType="pubmed">390590</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Clin Top Infect Dis. 1997;17:291-315</Citation><ArticleIdList><ArticleId IdType="pubmed">9189671</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2000 Oct;28(1):19-24</Citation><ArticleIdList><ArticleId IdType="pubmed">11086979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Neurol. 2003 Apr;28(4):292-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12849883</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2001 Dec;15(4):401-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11782106</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Dec 15;46(12):1649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10624546</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 May;89(5):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8067274</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1994 Nov;17(11):486-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7531891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 1995 Sep;58(3):342-50</Citation><ArticleIdList><ArticleId IdType="pubmed">7665990</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1995 Jul;16(7):318-22</Citation><ArticleIdList><ArticleId IdType="pubmed">7576063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 1998 Aug;45(2):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9753383</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1997 Sep;21(6):974-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9309304</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jun;159(6):1029-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12042193</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Jan 15;47(1):13-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11163541</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Sep;81(3):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15337324</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2000 Dec;7(6 Pt B):682-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11114266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1999 Apr;29(2):157-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10382136</ArticleId></ArticleIdList></Reference><Reference><Citation>Altern Med Rev. 2003 Nov;8(4):410-25</Citation><ArticleIdList><ArticleId IdType="pubmed">14653768</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jan 15;53(2):157-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12547472</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Read. 1999 Jan-Feb;9(1):57-60, 62</Citation><ArticleIdList><ArticleId IdType="pubmed">12728886</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2003 Nov;27(11):1819-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Neurosci. 1992;14(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">1350976</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Jul 8;400(6740):173-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Sep;152(9):1291-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7653683</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1985 Oct;20(10):1039-46</Citation><ArticleIdList><ArticleId IdType="pubmed">4041510</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2003 Jan-Feb;65(1):75-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12554818</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Mar;31(2-3):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10719147</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr J Psychiatry Relat Sci. 1992;29(1):33-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1314787</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1997 Jun 20;25(3):177-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9264173</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2004 Sep;19(6):326-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15363470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2003 Jul;250(7):788-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12883918</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Apr;156(4):634-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10200747</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Aug;150(8):1189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">8328562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1995 Aug 18;34(4):301-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8550956</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1997 Feb 28;23(3):253-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9075304</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249(5):238-46</Citation><ArticleIdList><ArticleId IdType="pubmed">10591989</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Jul;156(7):1103-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10401462</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Jun 22;32(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9690329</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):221-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14561187</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2002 Oct;16(5):503-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12401464</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1982 Sep;17(9):1003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6982729</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Neurol Sci. 1990;239(5):283-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1971787</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2005;7(1-2):103-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15639803</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1985 Aug;147:145-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2994792</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jan 18;85(1):7-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10195312</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1983 Jan;18(1):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6131701</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2002 Mar;9(2):107-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11895365</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1997 Aug;20(8):357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">9246730</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2002 Oct;3(10):824-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 Aug;22(5 Suppl):212S-215S</Citation><ArticleIdList><ArticleId IdType="pubmed">9727638</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 2004 Jan;32(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15066704</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1994;29(1):12-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8127418</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 May;41(5):484-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6609689</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1999 Apr;20(4):386-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10088140</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2001 Apr;81(2):629-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11274341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1998 Feb 28;351(9103):637-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9500320</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1981 Dec;16(12):1123-36</Citation><ArticleIdList><ArticleId IdType="pubmed">6186298</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Oct 1;290(13):1763-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14519711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2003 Oct;17(5):365-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12946658</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2001 Dec;15(4):340-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11782103</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Klin (Munich). 2002 Dec 15;97(12):730-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12491066</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1992 Sep;262(3):923-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1527733</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 Aug;22(5 Suppl):184S-187S</Citation><ArticleIdList><ArticleId IdType="pubmed">9727631</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2002 Dec;5(4):345-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12466034</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1998 Jul-Aug;60(4):479-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9710294</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1993;19(2):355-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8322038</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Jan 1;35(1):27-31</Citation><ArticleIdList><ArticleId IdType="pubmed">8167199</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Nov 22;345(21):1515-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2004 Jun;29(3):289-302</Citation><ArticleIdList><ArticleId IdType="pubmed">15181240</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2002 Feb;12(1):115-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11861174</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2002;45(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11803234</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Apr 15;55(8):797-803</Citation><ArticleIdList><ArticleId IdType="pubmed">15050860</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1995 Dec;18(6):482-99</Citation><ArticleIdList><ArticleId IdType="pubmed">8681310</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 2000 May 22;74(1-2):109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">10799783</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3043-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8610165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 1997 Apr;3(2):174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9111180</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Mar;164(3):365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7832833</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Mar 22;85(3):275-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10333380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Apr;9(4):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 1999 Jan;24(1):99-113</Citation><ArticleIdList><ArticleId IdType="pubmed">10098222</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci. 2002 Mar 01;7:d593-607</Citation><ArticleIdList><ArticleId IdType="pubmed">11861216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1999 Mar;24(2):103-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10212552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2003 Nov;112(5):e420</Citation><ArticleIdList><ArticleId IdType="pubmed">14595086</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 1995 Nov;42(5):505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7481553</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunopharmacol. 2001 Apr;1(4):665-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11357879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Mar 16;337(8742):645-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1671995</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Feb 15;53(4):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12586452</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 2002 May;27(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12062638</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1985 May;146:503-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2990626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2000 Jun;123 ( Pt 6):1102-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10825350</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 May;22(3):567-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9622433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 2000 Oct;30(5):481-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11098888</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1987 May;26(3):333-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3597287</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1963 Jun;8:614-21</Citation><ArticleIdList><ArticleId IdType="pubmed">13944963</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8788-92</Citation><ArticleIdList><ArticleId IdType="pubmed">7568018</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Pharmacother. 2003 Oct;57(8):372-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14568232</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2001 Aug;25(8):1198-205</Citation><ArticleIdList><ArticleId IdType="pubmed">11505051</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1991 Jan;109(1):5-24</Citation><ArticleIdList><ArticleId IdType="pubmed">2006229</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1992 May 1;31(9):896-908</Citation><ArticleIdList><ArticleId IdType="pubmed">1637930</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 1994 Mar;29(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8080593</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 2004 Sep-Oct;39(5):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15289211</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2004 May;11(3):515-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15138176</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1996;246(5):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8863007</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1991 Aug 29;325(9):606-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1713648</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):767-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11383977</ArticleId></ArticleIdList></Reference><Reference><Citation>Best Pract Res Clin Rheumatol. 2002 Apr;16(2):229-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12041951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):774-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15289276</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 May;37(2):147-60</Citation><ArticleIdList><ArticleId IdType="pubmed">1678892</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 1999 Sep;6(5):696-700</Citation><ArticleIdList><ArticleId IdType="pubmed">10473520</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 1996 May;49(1):53-71</Citation><ArticleIdList><ArticleId IdType="pubmed">8817698</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Prev Med. 2003 Aug;25(2):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12880876</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16027741</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-4184</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1026</StartPage><EndPage>1036</EndPage><MedlinePgn>1026-36</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms in subjects with Alzheimer disease (AD with psychosis, AD+P) define a phenotype characterized by greater cognitive burden than in AD without psychosis. We have proposed that genes of small effect may contribute to the risk for expression of psychosis in multiple disorders, including AD. Recently, sex-differential association of a three-locus haplotype, including a G--&gt;A transition at codon 108/158 of catechol-O-methyltransferase (COMT) resulting in a Val--&gt;Met substitution, has been reported to confer an increased risk for schizophrenia. The main objective of the study was to determine if COMT genetic variation is associated with risk of psychosis in AD, and included a case-control study of 373 individuals diagnosed with AD with, or without, psychosis. All subjects were characterized for alleles at the three loci associated with schizophrenia, RS737865, COMT G--&gt;A 108/158 (RS4680), and RS165599, and for a C/T transition adjacent to an estrogen response element (ERE6) in the COMT P2 promoter region. Both single locus and haplotype tests of association were conducted. Logit models were used to examine independent and interacting effects of alleles at the associated loci. All analyses were stratified by sex. In female subjects, RS4680 demonstrated a modest association with AD+P; RS737865 demonstrated a trend towards an association. There was a highly significant association of AD+P with the four-locus haplotype, which resulted from additive effects of alleles at RS4680 and ERE6 (or RS737865, as this locus was in almost absolute linkage disequilibrium (LD) with ERE6). In male subjects, no single locus test was significant, but there remained a strong association between AD+P and the four-locus haplotype. This association appeared to result from interaction of the ERE6/RS737865, RS4680, and RS165599 loci. Genetic variation in COMT is associated with AD+P, and thus appears to contribute to psychosis risk across disorders. Sex-differential associations of COMT with psychosis may result from variation at, or in LD with, ERE6. Examination of variation at ERE6 in subjects with schizophrenia, and further examination of the independent and additive effects of variations in COMT on gene expression, is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Neuropsychiatry, Department of Psychiatry, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA. sweetra@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>B G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Sukonick</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Kastango</LastName><ForeName>K B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>Bacanu</LastName><ForeName>S-A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Chowdari</LastName><ForeName>K V</ForeName><Initials>KV</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Ferrell</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52247</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH57881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59666</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH64173</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH65416</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH66231</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH71533</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00056</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId><ArticleId IdType="doi">10.1038/sj.mp.4001709</ArticleId><ArticleId IdType="pii">4001709</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16023301</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0306-9877</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>TrkB partial agonists: potential treatment strategy for epilepsy, mania, and autism.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>175</EndPage><MedlinePgn>173-5</MedlinePgn></Pagination><Abstract><AbstractText>Brain-derived neurotrophic factor (BDNF) is a member of a family of neurotrophins that, by activating a tyrosine kinase B receptor (TrkB), regulates a wide variety of processes in the nervous system, including neural development, function and survival. Evidence suggests that excess BDNF is involved in the pathogenesis of epilepsy, mania and autism. Thus, agents that can decrease BDNF-TrkB pathway signaling may be therapeutic for these diseases. However, blocking BDNF-TrkB pathways with TrkB antagonists may be harmful, as BDNF-TrkB deficiency has been related to major depression and Alzheimer's disease. A partial agonist is an agent that elicits a maximum response that is less than that of an agonist (e.g., the physiological ligand), so, in the presence of excess full agonist, a partial agonist would act as an antagonist. Interestingly, a dopaminergic partial agonist, aripiprazole, has been successfully developed for the treatment of psychotic disorders. Recently specific TrkB partial agonists have been synthesized by O'Leary and Hughes; it is proposed that these partial TrkB agonists may provide a novel strategy for the treatment of epilepsy, mania or autism, which may be associated with BDNF-TrkB hyperfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2, 11217 Taipei, Taiwan. sjtsai@vghtpe.gov.tw</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020813" MajorTopicYN="N">Receptor, trkB</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16023301</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2005.05.033</ArticleId><ArticleId IdType="pii">S0306-9877(05)00280-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16009739</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Heritability of psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>624</StartPage><EndPage>627</EndPage><MedlinePgn>624-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors have previously demonstrated familial clustering of psychotic symptoms in late-onset Alzheimer disease (LOAD+P) and sought to estimate and explore the nature of the heritability of LOAD+P.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The heritability of LOAD+P, defined by single and multiple psychotic symptoms, was estimated with data from the National Institute of Mental Health AD Genetics Initiative.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The estimated heritability for LOAD+P defined by multiple psychotic symptoms was 61%; for LOAD+P defined by any occurrence of psychotic symptoms, it was 30%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Multiplicity of symptoms may represent a useful means for defining a genetically determined LOAD+P phenotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bacanu</LastName><ForeName>Silviu-Alin</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Univ. of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chowdari</LastName><ForeName>Kodavali V</ForeName><Initials>KV</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>Vishwajit L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH57881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH53459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01489</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId><ArticleId IdType="doi">10.1176/appi.ajgp.13.7.624</ArticleId><ArticleId IdType="pii">S1064-7481(12)61730-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15998824</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1469-0756</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>957</Issue><PubDate><Year>2005</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Postgraduate medical journal</Title><ISOAbbreviation>Postgrad Med J</ISOAbbreviation></Journal><ArticleTitle>Sexually inappropriate behaviour in demented elderly people.</ArticleTitle><Pagination><StartPage>463</StartPage><EndPage>466</EndPage><MedlinePgn>463-6</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine the prevalence, aetiology, and treatment profile of abnormal sexual behaviour in subjects with dementia in psychogeriatric practices.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cross sectional study was conducted in a long term care psychiatry consultation service, community based geriatric psychiatry service, and an inpatient dementia behavioural unit in Edmonton, Canada.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty one subjects (1.8%) had sexually inappropriate behaviour. Of those cognitively impaired subjects with sexually inappropriate behaviour, 20 (48.8%) were living in nursing homes and the rest, 21 (51.2%) in the community. Of these subjects, 53.7% had vascular dementia, 22% had Alzheimer's, and 9.8% had mild cognitive impairment. History of alcohol misuse and psychosis were reported in 14.6% and 9.8% of subjects respectively. Twenty seven (65.7%) had verbally inappropriate behaviour and 36 (87.8%) had physically inappropriate behaviour. In this study, verbally inappropriate behaviour was more commonly seen in the community sample (81%) than in the nursing home sample (50%) (p = 0.04). Behavioural treatment was also more commonly seen in the community sample (81%) than in the nursing home sample (45%) (p = 0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this study sexually inappropriate behaviour was seen in all stages of dementia, more commonly associated with subjects of vascular aetiology, and is as commonly seen in community dwelling subjects with dementia as in nursing home subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alagiakrishnan</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Department of Medicine, University of Alberta, Edmonton, Canada. kalagiak@cha.ab.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Brahim</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Senthilselvan</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chimich</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Kagan</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Postgrad Med J</MedlineTA><NlmUniqueID>0234135</NlmUniqueID><ISSNLinking>0032-5473</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000416" MajorTopicYN="N" Type="Geographic">Alberta</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15998824</ArticleId><ArticleId IdType="pmc">PMC1743300</ArticleId><ArticleId IdType="doi">10.1136/pgmj.2004.028043</ArticleId><ArticleId IdType="pii">81/957/463</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 2000 May 23;54(10):2024</Citation><ArticleIdList><ArticleId IdType="pubmed">10822454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2003 Sep;51(9):1326</Citation><ArticleIdList><ArticleId IdType="pubmed">12919253</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1997 Fall;9(4):591-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9447502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 Sep;48(9):368-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2957362</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1999 Jan;13(1):60-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10192644</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1992;4 Suppl 2:161-84</Citation><ArticleIdList><ArticleId IdType="pubmed">1288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Jul;157:86-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2397368</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1987 Oct;37(10):1649-53</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol A Biol Sci Med Sci. 1996 Nov;51(6):M325-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8914506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1999 Feb;47(2):231-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9988296</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 2002 Nov-Dec;35(3):195-203</Citation><ArticleIdList><ArticleId IdType="pubmed">14764358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1998 Apr;38(2):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">9573663</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1995 Oct;8 Suppl 1:S18-27</Citation><ArticleIdList><ArticleId IdType="pubmed">8561840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1996 Jul;9(3):142-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8873879</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1992 Mar;49(3):297-300</Citation><ArticleIdList><ArticleId IdType="pubmed">1536633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15988345</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>9</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Diagnosis of psychological and behavioural disorders in Alzheimer's disease].</ArticleTitle><Pagination><StartPage>661</StartPage><EndPage>660</EndPage><MedlinePgn>661-6, 660</MedlinePgn></Pagination><Abstract><AbstractText>Although Alzheimer's disease has long been considered mainly a cognitive disorder, behavioral and psychological symptoms are present from its onset and at all the stages of the disease in most patients. They must be identified from the beginning because they orient the diagnosis. They include affective and emotional disorders, delusions and hallucinations, disorders of instinctual behavior and behavioral problems. The best tool for assessing them is the Neuropsychiatric Inventory (NPI). They are generally related to neurobiological aspects of the disease but may, especially when acute, have multiple etiologies: somatic, iatrogenic, psychological and environmental. They condition the course of the disease. As a source of suffering and reduced quality of the life and as the primary cause of distress for the caregivers and hence of hospitalization and institutionalization, they increase the costs of care. The challenge today is to learn more about them and thus improve their treatment and especially their prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pancrazi</LastName><ForeName>M-P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>H&#xf4;pital Notre Dame de Bon Secours, Paris. mp.pancrazi@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metais</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Maladie d'Alzheimer, diagnostic des troubles psychologiques et comportementaux.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010808" MajorTopicYN="N">Physical Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020919" MajorTopicYN="N">Sleep Disorders, Intrinsic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>38</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15988345</ArticleId><ArticleId IdType="doi">10.1016/s0755-4982(05)84010-2</ArticleId><ArticleId IdType="pii">S0755-4982(05)84010-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15978552</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease subjects with psychosis have increased schizotypal symptoms before dementia onset.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>330</EndPage><MedlinePgn>325-30</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent findings have demonstrated the familiality of psychotic symptoms occurring during Alzheimer disease (AD with psychosis, AD+P), particularly for subjects with multiple psychotic symptoms. We have proposed a model in which genes that confer a small risk for psychosis interact with neurodegenerative illness to yield manifest psychotic symptoms during AD. One prediction of this model would be that AD+P subjects would have evidence of increased degrees of subsyndromal psychosis before AD onset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used the psychosis (positive symptoms) and psychotic personality disorder sections (paranoid, schizoid, and schizotypal) of the Family Interview for Genetic Studies (FIGS) to interview the primary caregivers of AD subjects. Caregivers were specifically instructed to answer questions with regard to the subject's behavior before AD onset. Interviewers were blind to presence of psychosis during AD. Subjects were grouped by whether they had at least one or had multiple psychotic symptoms during AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Scores on the FIGS subscales were generally low, reflecting a low frequency of endorsement of psychotic symptoms before AD. There was a trend for the schizotypal scores to be elevated in the AD+P group, which was highly significant in the AD+P group with multiple psychotic symptoms. There was no significant association of paranoid or schizoid scores with either group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although limited by small sample size and retrospective design, these data are novel in that they indicate an association of subsyndromal psychotic symptoms before AD onset with psychosis in AD. Subsyndromal psychosis might be useful for classifying AD+P families for genetic mapping studies. Prospective confirmation is required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eror</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15978552</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2005.04.017</ArticleId><ArticleId IdType="pii">S0006-3223(05)00472-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15977989</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1567-2050</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>Biochemical markers and risk factors of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>64</EndPage><MedlinePgn>47-64</MedlinePgn></Pagination><Abstract><AbstractText>As the spectrum of therapeutic options broadens, the possibility of an early and accurate diagnosis of Alzheimer's disease (AD), or even isolation of a group at high risk of subsequent cognitive decline, is focusing widespread attention. Therefore, biological markers or risk factors of AD are highly desirable. In this work, we give an overview of the most extensively studied AD biomarkers, namely beta-amyloid, tau protein, and phosphorylated tau-protein, alone or in combination. Moreover, we describe the role of inflammatory markers (cytokines, acute phase proteins), oxidative stress markers (isoprostanes, 8-hydroxyguanine, 3-nitrotyrosine, plasma antioxidants, redox transition metals), homocysteine and related vitamins, cholesterol and 24S-hydroxycholesterol in the diagnostic process or prediction of AD. We briefly review less popular, though promising markers of AD - markers of apoptosis, neuronal thread protein, acetyl- and butyrylcholinesterase, sulfatide, kallikreins, matrix-degrading metalloproteinases, and novel isoforms of beta-amyloid and tau. Finally, we discuss the clinical applicability of AD-related biological markers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry &amp; Psychotic Disorders, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005609">Free Radicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005609" MajorTopicYN="N">Free Radicals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>206</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15977989</ArticleId><ArticleId IdType="doi">10.2174/1567205052772704</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15960295</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1400</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Acta neurobiologiae experimentalis</Title><ISOAbbreviation>Acta Neurobiol Exp (Wars)</ISOAbbreviation></Journal><ArticleTitle>Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>124</EndPage><MedlinePgn>117-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55782/ane-2005-1544</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1544</ELocationID><Abstract><AbstractText>Plasma alpha beta levels have been examined in sporadic Alzheimer's disease yielding conflicting results; both no difference and an increase in plasma concentrations of alpha beta42 and alpha beta40 in sporadic cases of AD as compared to controls have been reported. Elevated plasma alpha beta42 levels may be detected several years before the onset of symptoms (in mild cognitive impairment stadium). Levels of alpha beta40 and alpha beta42 were measured in plasma from 54 patients with AD, 39 subjects with MCI and 35 controls using a commercially available ELISA. Mean plasma alpha beta42 levels were significantly higher in MCI as compared to both AD (P &lt; 0.001) and control subjects (P &lt; 0.001), while alpha beta40 did not differ between the groups. No correlations were observed between alpha beta levels and age, MMSE scores or gender. According to ROC curve analysis the maximum accuracy in discriminating MCI versus both controls and AD subjects has been achieved using a cut-off value of 3.8.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland. tmsobow@csk.umed.lodz.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142; P</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Acta Neurobiol Exp (Wars)</MedlineTA><NlmUniqueID>1246675</NlmUniqueID><ISSNLinking>0065-1400</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15960295</ArticleId><ArticleId IdType="doi">10.55782/ane-2005-1544</ArticleId><ArticleId IdType="pii">1544</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15948179</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0360-4012</ISSN><JournalIssue CitedMedium="Print"><Volume>81</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis.</ArticleTitle><Pagination><StartPage>572</StartPage><EndPage>580</EndPage><MedlinePgn>572-80</MedlinePgn></Pagination><Abstract><AbstractText>We previously found that the atypical antipsychotic drugs (APDs) clozapine, olanzapine, quetiapine, and risperidone reduce PC12 cell death induced by hydrogen peroxide, N-methyl-4-phenylpyridinium ion, or beta-amyloid peptide (Abeta(25-35)). Such neurotoxic substances have in common the capability of causing oxidative stress. Atypical APDs have been used in treating schizophrenia and in treating psychotic symptoms of patients with Alzheimer's disease (AD), in which Abeta is involved by causing oxidative stress. Therefore, we hypothesized that atypical APDs might alleviate oxidative stress in PC12 cells, thus protecting them from apoptosis. PC12 cells were seeded in plates or chambers for 24 hr and cultured for another 24 hr with olanzapine or quetiapine in the medium, and then the cells were cultured in the new medium containing Abeta(25-35) and/or olanzapine, quetiapine, but not serum, for various periods. It was shown that cultures treated with olanzapine + Abeta(25-35), or quetiapine + Abeta(25-35), had significantly higher cell viabilities and lower rates of apoptosis compared with the cultures exposed only to Abeta(25-35). In addition, the drugs blocked the activation of caspase-3 caused by Abeta(25-35). Furthermore, olanzapine and quetiapine prevented Abeta(25-35)-induced overproduction of intracellular reactive oxygen species, Abeta(25-35)-induced decrease in mitochondrial membrane potential, and Abeta(25-35)-induced changes in activities of the key antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase. In consideration of the wealth of evidence linking oxidative stress to the pathophysiology of schizophrenia and AD, these findings give us a new insight into the therapeutic actions of atypical antipsychotics in patients with the disorders.</AbstractText><CopyrightInformation>2005 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Haiyun</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dyck</LastName><ForeName>Lillian E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin-Min</ForeName><Initials>XM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.11.1.6</RegistryNumber><NameOfSubstance UI="D002374">Catalase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.11.1.9</RegistryNumber><NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505410">Casp3 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002374" MajorTopicYN="N">Catalase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15948179</ArticleId><ArticleId IdType="doi">10.1002/jnr.20570</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15936921</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0887-6177</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists</Title><ISOAbbreviation>Arch Clin Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological functioning of dementia patients with psychosis.</ArticleTitle><Pagination><StartPage>771</StartPage><EndPage>783</EndPage><MedlinePgn>771-83</MedlinePgn></Pagination><Abstract><AbstractText>The current research sought to test the hypothesis that psychotic symptoms in patients with dementia might be due to relatively greater executive control and visuoperceptual deficits. Twenty-four dementia patients with psychosis and 24 outpatients without psychosis diagnosed with either probable Alzheimer's disease (AD) or possible/probable Ischemic Vascular Dementia (IVD) were studied. Groups did not differ with respect to age, education, severity of dementia, or depression. Presence and severity of psychosis was measured with a modification of the Neuropsychiatric Inventory (NPI; Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., &amp; Gorbein, J. (1994). The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308-2314). Between-group and regression analyses found a consistent relationship such that patients with psychosis obtained low scores on the Boston Revision Wechsler Memory Scale-Mental Control subtest (WMS-MC subtest), a test of executive control. On some analyses patients with psychosis also made more perceptual errors on tests of naming and obtained higher scores on tests of delayed recognition memory. However, the relationship between severity of psychosis and performance on visuoperceptual and memory measures was considerably less robust. These data suggest a strong relationship between severity of psychosis and poor performance on executive control. Less evidence was obtained to support our contention that psychotic symptoms in dementia may arise from an interaction of neuropsychological deficits involving greater impairment in executive and visuoperceptual functioning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Mary W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Psychology, Manhattanville College, Purchase, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libon</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Clin Neuropsychol</MedlineTA><NlmUniqueID>9004255</NlmUniqueID><ISSNLinking>0887-6177</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15936921</ArticleId><ArticleId IdType="doi">10.1016/j.acn.2005.04.011</ArticleId><ArticleId IdType="pii">S0887-6177(05)00071-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15922506</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-8467</ISSN><JournalIssue CitedMedium="Print"><Volume>107</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical neurology and neurosurgery</Title><ISOAbbreviation>Clin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.</ArticleTitle><Pagination><StartPage>497</StartPage><EndPage>508</EndPage><MedlinePgn>497-508</MedlinePgn></Pagination><Abstract><AbstractText>This analysis used pooled data from three randomized, placebo-controlled trials that examined the efficacy and safety of risperidone for the treatment of agitation, aggression, and psychosis associated with dementia in elderly nursing home residents to assess the risk-benefit of the use of risperidone in this population. The efficacy data (risperidone n=722, placebo n=428) were obtained from the Cohen-Mansfield agitation inventory (CMAI) and behavioral pathology in Alzheimer's disease (BEHAVE-AD) total and subscales. Additionally, clinical global impression (CGI) assessments were performed. Subgroup analyses were performed by type of dementia, severity of dementia, presence or absence of somnolence as an adverse event, and presence or absence of psychosis at baseline. Safety assessments included evaluation of treatment emergent adverse events, Extrapyramidal Symptom Rating Scale, ECG and vital signs, and Mini-Mental State Examination (MMSE). The mean dose of risperidone at end point was 1.0 mg/day (0.02 S.E.). The observed mean change at end point was significantly higher for risperidone than for placebo on CMAI total score (-11.8 versus -6.4, respectively; p&lt;0.001), total aggression score (-5.0 versus -1.8, respectively; p&lt;0.001), BEHAVE-AD total score (-6.1 and -3.6, respectively; p&lt;0.001), and psychotic symptoms score (-2.1 and -1.3, respectively; p=0.003). The main treatment effects of risperidone were similar in all subgroup analyses. Additionally, risperidone-treated patients scored significantly better than placebo-treated patients on the CGI scales at end point. The incidence of treatment-emergent adverse events was comparable between risperidone (84.3%) and placebo (83.9%). More patients discontinued due to adverse events in the risperidone-treated group (17.2%) than in the placebo group (11.2%). Differences in adverse event incidences between placebo and risperidone were observed for extrapyramidal symptoms (EPS), mild somnolence and the less common cerebrovascular adverse events (CAE). Risperidone induced neither orthostatic, nor anticholinergic side effects nor falls nor cognitive decline. Of all atypical antipsychotics, risperidone has the largest database of double-blind controlled trials to support its efficacy and safety in the treatment of agitation, aggression, and psychosis associated with dementia. At the recommended doses, risperidone displayed a favorable risk-benefit profile. Risperidone was well tolerated with respect to EPS, somnolence, and anticholinergic side effects in this elderly population. In view of the risk for CAEs, risperidone, should be targeted towards the treatment of those patients in whom psychotic and behavioral symptoms of dementia are prominent and associated with significant distress, functional impairment or danger to the patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory Clinic, Middelheim Hospital, ZNA, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk-Antwerp, Belgium. dedeyn@skynet.be</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurol Neurosurg</MedlineTA><NlmUniqueID>7502039</NlmUniqueID><ISSNLinking>0303-8467</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15922506</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2005.03.013</ArticleId><ArticleId IdType="pii">S0303-8467(05)00076-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15922057</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-4328</ISSN><JournalIssue CitedMedium="Print"><Volume>161</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav Brain Res</ISOAbbreviation></Journal><ArticleTitle>Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>299</StartPage><EndPage>305</EndPage><MedlinePgn>299-305</MedlinePgn></Pagination><Abstract><AbstractText>Alterations in cholinergic functions have been reported to be associated with neuropsychiatric symptoms in dementia. Increased M1 muscarinic receptor binding in temporal cortex is associated with delusions in dementia with Lewy bodies (DLB) patients and increased M2/M4 receptor binding with psychosis in Alzheimer's disease. However, the relation between M2 and M4 muscarinic receptor and psychotic symptoms in DLB is unknown. The aim of this study was to measure M2 and M4 receptors in the anterior cingulate cortex in DLB and to correlate the neurochemical findings with neuropsychiatric symptoms. Muscarinic M2 and M4 receptor levels in the anterior cingulate cortex and adjacent cortex (Brodmann's area [BA] 32) were measured separately by using a radioligand binding protocol based on binding of [(3)H]AF-DX 384 in the presence and absence of dicyclomine, a potent M4 receptor antagonist. M2 receptor binding was significantly increased, while M4 receptor binding was unchanged in the cingulate cortex and BA32 of DLB patients compared with age-matched controls. Impaired consciousness was significantly associated with increased M4 binding and delusions were significantly associated with increased M2 binding. Increased M2 and M4 receptor binding in DLB was also associated with visual hallucinations. Upregulation of M2 and M4 muscarinic receptors in cingulate and adjacent cortex may thus contribute to the development of psychosis in DLB, with potential implications for treatments with drugs acting on these receptors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teaktong</LastName><ForeName>Thanasak</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, MRC Building, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE46BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piggott</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Mckeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Elaine K</ForeName><Initials>EK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043585">Receptor, Muscarinic M2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043588">Receptor, Muscarinic M4</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>118290-27-0</RegistryNumber><NameOfSubstance UI="C065959">AFDX 384</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4KV4X8IF6V</RegistryNumber><NameOfSubstance UI="D004025">Dicyclomine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001345" MajorTopicYN="N">Autoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004025" MajorTopicYN="N">Dicyclomine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043585" MajorTopicYN="N">Receptor, Muscarinic M2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043588" MajorTopicYN="N">Receptor, Muscarinic M4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15922057</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2005.02.019</ArticleId><ArticleId IdType="pii">S0166-4328(05)00065-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15896220</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>279</EndPage><MedlinePgn>274-9</MedlinePgn></Pagination><Abstract><AbstractText>In order to clarify the characteristics of Behavioral and Psychological Symptoms of Dementia (BPSD) in patients with mild Alzheimer's disease (AD), BPSD among the severities of Clinical Dementia Rating (CDR) in 74 patients with AD were compared using the Neuropsychiatric inventory (NPI). The result, when compared between mild (CDR = 0.5, 1) and moderate or severe (CDR = 2, 3) AD, was a significant difference in frequency of euphoria, disinhibition and aberrant motor behavior, but no significant difference was found in frequency of delusions, hallucinations, agitation, dysphoria, anxiety, apathy and irritability. In addition, a significant difference was found in the mean scores of the composite score for euphoria, apathy, disinhibition and aberrant motor behavior, but no significant difference was found in the mean scores of the composite score for delusions, hallucinations, agitation, dysphoria, anxiety and irritability. That is, the mild AD groups (CDR 0.5 or 1) had delusions, hallucinations, agitation, dysphoria, anxiety, apathy and irritability as frequently as the moderate or severe AD groups (CDR 2 or 3), and had the equivalent level of composite scores to the moderate or severe AD groups (CDR 2 or 3) in delusion, hallucination, agitation, dysphoria, anxiety and irritability. Therefore, it was supposed that psychotic symptoms (delusion, hallucination) and emotional symptoms (agitation, dysphoria, anxiety, irritability) are important BPSD in patients with mild AD as well as those with moderate or severe AD, and there are needs for health, welfare and medical services for these symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shimabukuro</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tohoku University Hospital, Sendai, Japan. cocoa-thk@umin.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awata</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="Y">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15896220</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2005.01371.x</ArticleId><ArticleId IdType="pii">PCN1371</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15889961</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Development of subtle psychotic symptoms with memantine: a case report.</ArticleTitle><Pagination><StartPage>658</StartPage><EndPage>659</EndPage><MedlinePgn>658-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Dustin</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Overman</LastName><ForeName>Gerald P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>Nadeem</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sunderland</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003221" MajorTopicYN="N">Confusion</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004325" MajorTopicYN="N">Dreams</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15889961</ArticleId><ArticleId IdType="doi">10.4088/jcp.v66n0519f</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15884745</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2720</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Psychiatric quarterly</Title><ISOAbbreviation>Psychiatr Q</ISOAbbreviation></Journal><ArticleTitle>Determinants of geropsychiatric inpatient length of stay.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>212</EndPage><MedlinePgn>195-212</MedlinePgn></Pagination><Abstract><AbstractText>Despite efforts to decrease lengths of acute psychiatric hospital stays, some geriatric inpatients continue to have extended stays. This research examined factors related to length of stay (LOS), including legal and administrative factors not traditionally included in prior studies. The charts of 384 patients, representing all 464 discharges from an inpatient geropsychiatric unit over a one-year period, were evaluated retrospectively and analyzed using logistic regression and logarithmic transformation. The LOS of over 12% of the inpatients was 26 days or more (average LOS 14.1). Factors significantly associated with longer LOS were: receiving electroconvulsive therapy (ECT), higher Brief Psychiatric Rating Scale (BPRS) positive symptoms scores, falling, pharmacology complications, multiple prior psychiatric hospitalizations, requiring court proceedings to continue hospitalization or medicate against will, consultation delays and not performing ECT on weekends. Neither demographics nor diagnoses alone had influence on length of stay. Incorporation of LOS predictors into Medicare Inpatient Prospective Payment System (IPPS) would more accurately account for the complexity in the cost of caring for geropsychiatry patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Braceland Center for Mental Health and Aging, Institute of Living, Hartford Hospital, CT 06106, USA. kblank@harthosp.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hixon</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gruman</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Robison</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hickey</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Harold I</ForeName><Initials>HI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Q</MedlineTA><NlmUniqueID>0376465</NlmUniqueID><ISSNLinking>0033-2720</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017630">Connexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471697">GJB7 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017630" MajorTopicYN="N">Connexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005852" MajorTopicYN="N">Geriatric Psychiatry</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008329" MajorTopicYN="N">Managed Care Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="N">Psychiatric Department, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15884745</ArticleId><ArticleId IdType="doi">10.1007/s11089-005-2339-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1990 Feb;147(2):179-82</Citation><ArticleIdList><ArticleId IdType="pubmed">2301655</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1990 Mar;31(3):243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2333356</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 1994 Jun;28(2):288-97</Citation><ArticleIdList><ArticleId IdType="pubmed">7993284</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1997 Nov;48(11):1427-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9355170</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2001 Fall;72(3):215-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11467156</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1999 Sep;100(3):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10493089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Summer;8(3):232-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10910422</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 Sep;171:242-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9337977</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Work Health Care. 2001;33(2):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11760111</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1991 Jul-Aug;32(4):345-54</Citation><ArticleIdList><ArticleId IdType="pubmed">1935025</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1994 Nov;24(4):1025-30</Citation><ArticleIdList><ArticleId IdType="pubmed">7892347</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1993 Apr;28(2):84-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8511668</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 Aug;16(8):762-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11536342</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Jul;27(4):961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9234473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1985 Dec;36(12):1262-4, 1270</Citation><ArticleIdList><ArticleId IdType="pubmed">4086000</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 1997 Summer;68(2):91-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9114467</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1987 Aug;144(8):1025-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3605424</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1998 Jan;13(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9489573</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 Jan-Feb;61(1):21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10024064</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2001 Oct;52(10):1367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11585954</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1997 Nov;48(11):1461-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9355176</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 Oct;16(10):965-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11607940</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2003 Mar;19(1):17-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12621272</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 2002 Jan-Feb;43(1):24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11927754</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1997 Aug;32(6):312-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9299923</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2000 Oct;51(10):1278-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11013327</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1995 Fall;7(3):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">8821348</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Dec;90(6):466-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7892782</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2001 Sep;13(3):384-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11556275</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 1997 Mar;44(5):623-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9032830</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Feb;143(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3080906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1995 Sep;17(5):326-34</Citation><ArticleIdList><ArticleId IdType="pubmed">8522147</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1988;24(1):112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3387514</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2003 Sep;54(9):1271-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12954945</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Nov;142(11):1272-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4061685</ArticleId></ArticleIdList></Reference><Reference><Citation>MD Comput. 1993 Mar-Apr;10(2):87-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8469101</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1998 Sep;98(3):250-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9761415</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1998 Aug;49(8):1049-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9712211</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1982 Dec;20(12):1197-208</Citation><ArticleIdList><ArticleId IdType="pubmed">7176731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1993 Nov;15(6):392-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8112563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1989 Jul;40(7):741-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2777231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15884743</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2720</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Psychiatric quarterly</Title><ISOAbbreviation>Psychiatr Q</ISOAbbreviation></Journal><ArticleTitle>Precipitants of elderly psychiatric patient assaults on staff: preliminary empirical inquiry.</ArticleTitle><Pagination><StartPage>167</StartPage><EndPage>175</EndPage><MedlinePgn>167-75</MedlinePgn></Pagination><Abstract><AbstractText>Although there have been several studies of the characteristics of psychiatric patient assailants, there have been only six comprehensive, empirical assessments of precipitants to these assaults and no precipitant study has focused solely on elderly psychiatric patient assailants. This one and one-half year, retrospective study continued the inquiry into the nature of patient assault precipitants and focused only on elderly assailants. Older, male patients with a diagnosis of schizophrenia and histories of violence toward others and substance use disorder physically assaulted primarily male, mental health workers. These staff victims experienced disruptions in the domains of mastery, attachment, and meaning as well as the symptomatology associated with psychological trauma. The most common precipitants to these assaults were denial of services and acute psychosis. The findings and implications for health care providers in long-term care settings where elderly psychiatric patients reside are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>Raymond B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Psychology/6B, Worcester State Hospital, Massachusetts Department of Mental Health, 305 Belmont Street, Worcester, MA 01604, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Q</MedlineTA><NlmUniqueID>0376465</NlmUniqueID><ISSNLinking>0033-2720</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003419" MajorTopicYN="N">Crisis Intervention</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008404" MajorTopicYN="N" Type="Geographic">Massachusetts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009784" MajorTopicYN="N">Occupational Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="N">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="N">Risk Management</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15884743</ArticleId><ArticleId IdType="doi">10.1007/s11089-005-2337-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harv Rev Psychiatry. 2000 Nov;8(5):261-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11118235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ment Health Adm. 1994 Winter;21(1):24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10131885</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Dec;22(4):923-40, x</Citation><ArticleIdList><ArticleId IdType="pubmed">10623979</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1999 Mar;50(3):384-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10096644</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2002 Fall;73(3):229-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12143084</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2005 Winter;76(4):317-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16217626</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1992 Summer;6(2):77-88</Citation><ArticleIdList><ArticleId IdType="pubmed">1389083</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2003 Mar-Apr;18(2):93-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12708224</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Emerg Ment Health. 2000 Fall;2(4):241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11217155</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1991 Aug;84(2):163-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1950611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1994 Jul;45(7):700-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7927295</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2001 May-Jun;16(3):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11398563</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Sep;150(9):1368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8352348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1991 Jun;42(6):585-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1864567</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosoc Nurs Ment Health Serv. 1991 May;29(5):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2066912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1981 Jul;32(7):497-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7239475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15876335</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2006</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6314</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Acta neurologica Scandinavica</Title><ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation></Journal><ArticleTitle>Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>359</EndPage><MedlinePgn>353-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Patients with clinical and pathological diagnosis of Parkinson's disease (PD) may, at death, also be found to have the pathological changes of Alzheimer's disease (AD). With this study we aim to determine the influence of AD pathology on the clinical phenotype of PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 64 patients who donated their brains to the University of Miami Brain Endowment Bank(TM) and fulfilled the clinical and pathological criteria for PD. For the evaluation of AD pathology we used the CERAD criteria. Dementia was diagnosed, in life, also using standard criteria. Case histories were abstracted and reviewed by one investigator (SP) who then made comparisons between patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with AD pathology (PD-AD) were older both at the time of diagnosis and death. The presence of AD pathology did not seem to influence disease duration in our cohort of PD patients. As expected there was a clear relation between AD pathology and dementia but not all PD-AD patients were demented. Psychosis and depression were also found to be more prevalent in the PD-AD patients. In the comparison between demented and non-demented PD-AD patients dementia was more likely to appear in patients with PD and definite criteria for AD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Apart from dementia AD pathology seems to be associated with a number of other clinical characteristics of PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papapetropoulos</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Miami, Miami, FL, USA. spapapetropoulos@med.miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Neurol Scand</MedlineTA><NlmUniqueID>0370336</NlmUniqueID><ISSNLinking>0001-6314</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15876335</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0404.2005.00411.x</ArticleId><ArticleId IdType="pii">ANE411</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15852364</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov Disord</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>994</EndPage><MedlinePgn>989-94</MedlinePgn></Pagination><Abstract><AbstractText>We determined whether apolipoprotein E epsilon4 (ApoE4) or catechol-O-methyltransferase (COMT) genotypes were associated with dementia, hallucinations, Alzheimer's disease pathological findings (AP), or cortical Lewy bodies (CLBs) in autopsy-confirmed cases of Parkinson's disease (PD). Outcomes were obtained from medical records. Pathology reports identified AP and CLBs. Brain tissue was genotyped. A total of 47 subjects (33 men, 14 women) had PD onset at 62.4 +/- 8.7 years of age and died at 77.8 +/- 5.6 years of age. Demented and hallucinating patients did not differ in age at onset (AO) of PD or age at death, or the proportion ApoE4+, AP+, or CLB+ compared to nondemented patients or non-hallucinating patients. ApoE4 and COMT (low metabolizer [LH], intermediate metabolizer [HL], or high metabolizer [HH]) did not influence AO, death, or dementia- or hallucination-free survival, based on age or duration of treatment. All seven subjects with AP were demented and had hallucinations. CLBs were associated with dementia but not hallucinations. In Cox regression models adjusting for AO and duration of treatment, increased risk of dementia was associated with male sex but not significantly with ApoE4; inclusion of AP in the model did not affect the results; COMT was not a risk factor for dementia. Psychosis risk was not associated with ApoE4, COMT, or sex. The observation that males have increased dementia risk and the trend for ApoE4 requires confirmation in larger prospective autopsy studies.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Camicioli</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Alberta, Edmonton, Alberta, Canada. rcamicio@ualberta.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reece</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Chunhai</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15852364</ArticleId><ArticleId IdType="doi">10.1002/mds.20481</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15814818</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2005</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1539-6150</ISSN><JournalIssue CitedMedium="Internet"><Volume>2005</Volume><Issue>14</Issue><PubDate><Year>2005</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Science of aging knowledge environment : SAGE KE</Title><ISOAbbreviation>Sci Aging Knowledge Environ</ISOAbbreviation></Journal><ArticleTitle>Dementia of the Alzheimer's type and accelerated aging in Down syndrome.</ArticleTitle><Pagination><StartPage>dn1</StartPage><MedlinePgn>dn1</MedlinePgn></Pagination><Abstract><AbstractText>This case study, of a woman with Down syndrome and dementia of the Alzheimer's type (DAT), follows the course of her decline over an 11-year period until death at age 57. Detailed neuropathological findings are also presented. This case illustrates features of premature aging that are typically associated with Down syndrome, and the progressive changes in memory and cognition that are usually associated with DAT. Although the subject's cardiovascular condition and thyroid disorder were treated, they may have contributed to the decline of her memory. This case shows the difficulty in diagnosing dementia in an individual with mental retardation who suffered comorbid episodes of depression and psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devenny</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Psychology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA. dadevenny@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegiel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zigman</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Krinsky-McHale</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>W P</ForeName><Initials>WP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Aging Knowledge Environ</MedlineTA><NlmUniqueID>101146039</NlmUniqueID><ISSNLinking>1539-6150</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15814818</ArticleId><ArticleId IdType="doi">10.1126/sageke.2005.14.dn1</ArticleId><ArticleId IdType="pii">2005/14/dn1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15804926</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2011</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1355-4794</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurocase</Title><ISOAbbreviation>Neurocase</ISOAbbreviation></Journal><ArticleTitle>Non-cognitive symptoms in mild cognitive impairment subjects.</ArticleTitle><Pagination><StartPage>65</StartPage><EndPage>71</EndPage><MedlinePgn>65-71</MedlinePgn></Pagination><Abstract><AbstractText>The term mild cognitive impairment (MCI) is used to identify individuals with worse cognitive performance than those with normal aging, and who are at risk of dementia, especially Alzheimer's disease (AD). Although the MCI concept is based on the presence of specific cognitive deficits, several studies have shown that these subjects can develop depression, disruptive behaviors (e.g., agitation, aggression), and psychosis. In this study, we examined the baseline psychiatric characteristics of 228 MCI (Mean age: 71.2, Mini-mental State Examination [MMSE] score: 25.9) and 427 mildly demented Probable AD (Mean age: 73.2; Mean MMSE score: 23.5) subjects from a referral dementia clinic. The psychiatric assessment was conducted by geriatric psychiatrists using semi-structured interviews. The proportion of subjects with major depression (MCI: 7.5% vs. Probable AD: 8%) and aggression (MCI: 10% vs. Probable AD: 12.5%) was similar in the two groups. There were more Probable AD patients with psychomotor agitation (52% vs. 38%), delusions (29% vs. 14%), and hallucinations (9% vs. 4%) than MCI subjects. Within MCI groups, we did not observe any differences between MCI subjects with amnesic syndrome versus MCI subjects with a much broader cognitive deficit. These results showed that the MCI syndrome is not circumscribed to a neuropsychological definition, but occurs with a wide range of psychiatric syndromes. Furthermore, it is possible that the development of disruptive behaviors and psychosis, in MCI subjects with no previous history of psychiatric illness, constitutes a strong indication that there is an underlying neurodegenerative disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA 15213, USA. lopezol@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KO2-MH01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurocase</MedlineTA><NlmUniqueID>9511374</NlmUniqueID><ISSNLinking>1355-4794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15804926</ArticleId><ArticleId IdType="doi">10.1080/13554790490896893</ArticleId><ArticleId IdType="pii">P565W45M84V5Q107</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15775717</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5-6</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease.</ArticleTitle><Pagination><StartPage>276</StartPage><EndPage>281</EndPage><MedlinePgn>276-81</MedlinePgn></Pagination><Abstract><AbstractText>The occurrence of behavioral and psychological symptoms of dementia (BPSD) is currently recognized as an important aspect of Alzheimer's disease (AD). We evaluated the frequency and severity of BPSD with the Neuropsychiatric Inventory across the various degrees and phases of the disease in 50 consecutive AD outpatients. Apathy, aberrant motor activity, dysphoria and anxiety were the symptoms most frequently reported by the caregivers, ranging in the whole study sample from 46 to 74%. A clear trend towards increasing frequency with the severity of disease was found for delusions, hallucinations and aberrant motor activity. A major effect of the duration of the disease was found in the probability of developing hallucinations and aberrant motor activity. Apart from hallucinations, all BPSD were present starting from a mild degree of dementia. A better understanding of the global spectrum of BPSD in AD is warranted in order to improve the allocation of health resources toward the treatment of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piccininni</LastName><ForeName>Maristella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Unit, Ospedale S.M. Nuova, Florence, Italy. dr.maristella@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Carlo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Baldereschi</LastName><ForeName>Marzia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zaccara</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Inzitari</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15775717</ArticleId><ArticleId IdType="doi">10.1159/000084552</ArticleId><ArticleId IdType="pii">84552</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15764864</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0893-0341</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>The effect of a memory screening program on the early diagnosis of Alzheimer disease.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Alzheimer Disease (AD) is often diagnosed at a moderately advanced stage, even though its early detection has become increasingly important, because of the continuing development of treatments that may improve its outcome.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if a free memory screening program is associated with an earlier diagnosis of AD, compared with traditional referral methods, such as by physicians and family members.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A retrospective study of 1489 consecutive patients with AD who presented to an outpatient memory disorders clinic between 1993 and 2002. Subjects were classified according to referral source (memory screening, physician, family/friend, other), and self-reported ethnicity (white non-Hispanic, white Hispanic). The associations between referral source and the presenting cognitive and behavioral status of subjects were evaluated using analysis of variance and logistic regression analyses, after controlling for potentially confounding factors.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Score on the Folstein Mini-Mental State Examination (MMSE), duration of cognitive symptoms, and presence of psychosis, defined as delusions and/or hallucinations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After controlling for ethnicity, gender, and the year of diagnosis, subjects with AD, who were referred by the memory screening program, scored significantly higher at presentation on the MMSE (20.8 +/- 5.7), than those referred by physicians (18.8 +/- 6.6), family/friends (16.8 +/- 6.6), or other referral sources (15.3 +/- 7.1). Subjects with AD, referred by the memory screening program, also had a lower reported duration of illness at presentation, and a decreased frequency of psychosis compared with those referred by family/friend and other methods. Other factors related to a diagnosis of AD at a later stage included female gender, Hispanic ethnicity, and a diagnosis early in the 1993 to 2002 time period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The memory screening program referred patients with AD to a memory clinic at an earlier phase of illness compared with traditional methods such as physician referral.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Warren W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida 33140, USA. billy@msmc.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luis</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Loewenstein</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bravo</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>Ray</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005431" MajorTopicYN="N" Type="Geographic">Florida</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15764864</ArticleId><ArticleId IdType="doi">10.1097/01.wad.0000155380.63231.68</ArticleId><ArticleId IdType="pii">00002093-200501000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15755190</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-867X</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Geriatrics</Title><ISOAbbreviation>Geriatrics</ISOAbbreviation></Journal><ArticleTitle>Psychoses in late life: evaluation and management of disorders seen in primary care.</ArticleTitle><Pagination><StartPage>26</StartPage><EndPage>33</EndPage><MedlinePgn>26-33</MedlinePgn></Pagination><Abstract><AbstractText>As the ranks of Baby Boomers move into later life and develop age-related cognitive conditions, an increased incidence in the number of psychotic conditions is expected. When psychotic conditions occur after age 60, the causes and management pose challenges for clinicians caring for the older adult. This article will review the differential diagnosis and management of psychoses in late life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khouzam</LastName><ForeName>Hani R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Chemical Dependency Treatment Program, VA Central California Health Care System, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battista</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Emes</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ahles</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatrics</MedlineTA><NlmUniqueID>2985102R</NlmUniqueID><ISSNLinking>0016-867X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>26</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15755190</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15728296</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Steroid dementia: an overlooked diagnosis?</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>709</EndPage><MedlinePgn>707-9</MedlinePgn></Pagination><Abstract><AbstractText>The authors studied a 72-year-old man with polymyalgia rheumatica who, after taking 100 mg of prednisone for 3 months, developed a psychosis followed by dementia. It was initially considered that the dementia was a separate neurodegenerative condition, probably of Alzheimer type, but when steroids were discontinued, he rapidly returned to his previous level of functioning. Reviewing the literature regarding the effects of steroids on cerebral function, the authors found that such cases of "reversible dementia" are not uncommon, although rarely given the emphasis they deserve. The authors believe, given the extensive use of steroids in medical practice, that physicians should be more aware of this important cause of reversible dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sacks</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="SummaryForPatientsIn"><RefSource>Neurology. 2005 Feb 22;64(4):E18-9. doi: 10.1212/wnl.64.4.e18</RefSource><PMID Version="1">15728273</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2006 Jan 10;66(1):155; author reply 155. doi: 10.1212/01.wnl.0000203713.04232.82</RefSource><PMID Version="1">16401879</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2007 Feb 20;68(8):622. doi: 10.1212/01.wnl.0000254625.14676.48</RefSource><PMID Version="1">17310040</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="Y">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062787" MajorTopicYN="N">Drug Overdose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="N">Euphoria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011111" MajorTopicYN="N">Polymyalgia Rheumatica</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15728296</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000151977.18440.C3</ArticleId><ArticleId IdType="pii">64/4/707</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15707619</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3932</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>3</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Neuropsychologia</Title><ISOAbbreviation>Neuropsychologia</ISOAbbreviation></Journal><ArticleTitle>Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>442</StartPage><EndPage>449</EndPage><MedlinePgn>442-9</MedlinePgn></Pagination><Abstract><AbstractText>Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk of than others. Therefore, the hypothesis of this study is that an imbalance between the cholinergic and serotonergic systems is related to cognitive symptoms and psychological syndromes of dementia (BPSD) in patients with AD. Cholinergic and serotonergic functions were assessed in post-mortem frontal and temporal cortex from 22 AD patients who had been prospectively assessed with the Mini-Mental State examination (MMSE) for cognitive impairment and with the Present Behavioral Examination (PBE) for BPSD including aggressive behavior, overactivity, depression and psychosis. Not only cholinergic deficits, but also the cholinacetyltransferase/serotonin ratio significantly correlated with final MMSE score both in frontal and temporal cortex. In addition, decreases in cholinergic function correlated with the aggressive behavior factor, supporting a dual role for the cholinergic system in cognitive and non-cognitive disturbances associated to AD. The serotonergic system showed a significant correlation with overactivity and psychosis. The ratio of serotonin to acetylcholinesterase levels was also correlated with the psychotic factor at least in women. It is concluded that an imbalance between cholinergic-serotonergic systems may be responsible for the cognitive impairment associated to AD. Moreover, the major findings of this study are the relationships between neurochemical markers of both cholinergic and serotonergic systems and non-cognitive behavioral disturbances in patients with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Alloza</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Bea</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Diez-Ariza</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>C P L-H</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Lasheras</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychologia</MedlineTA><NlmUniqueID>0020713</NlmUniqueID><ISSNLinking>0028-3932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15707619</ArticleId><ArticleId IdType="doi">10.1016/j.neuropsychologia.2004.06.007</ArticleId><ArticleId IdType="pii">S0028-3932(04)00163-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15706675</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1760-1703</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychologie &amp; neuropsychiatrie du vieillissement</Title><ISOAbbreviation>Psychol Neuropsychiatr Vieil</ISOAbbreviation></Journal><ArticleTitle>[Cerebral infarct and atypical antipsychotic agents].</ArticleTitle><Pagination><StartPage>299</StartPage><MedlinePgn>299</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Accidents vasculaires c&#xe9;r&#xe9;braux et antipsychotiques atypiques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Psychol Neuropsychiatr Vieil</MedlineTA><NlmUniqueID>101203421</NlmUniqueID><ISSNLinking>1760-1703</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15706675</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15704016</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0213-4853</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Neurologia (Barcelona, Spain)</Title><ISOAbbreviation>Neurologia</ISOAbbreviation></Journal><ArticleTitle>[Main components of Neuropsychiatric Inventory in Alzheimer's disease. Definition of behavioral syndromes].</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>16</EndPage><MedlinePgn>9-16</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Behavioral disturbances are an important part of the clinical picture of Alzheimer's disease (AD). Behavior is usually assessed considering each symptom one by one. Few studies have tried a more comprehensive approach. We assessed behavior in AD patients in order to define patterns of behavioral disturbances, thereby improving its classification.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Ninety consecutive AD patients were evaluated from November 1997 to November 2000. All patients meet the NINCDS-ADRDA criteria for probable or possible AD. Patients with atypical clinical features were not included. Clinical evaluation included of the Neuropsychiatric Inventory ("chronic" scores), Mini-Mental State Examination, RDRS-2 and CDR. Statistical analysis was performed with factor analysis (SPSS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Factor analysis rendered a three-factor solution. Each factor can be considered a behavioral syndrome: the psychotic syndrome (hallucinations and delusions), the affective syndrome (depression, euphoria and anxiety) and the discontrol syndrome (agitation, irritability and disinhibition). A relevant number of patients had mild behavioral disturbances, not meeting statistical criteria for the syndromes defined above.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Behavioral disturbances in AD can be classified into four groups or syndromes. Our results are in accordance with and expand the results of previous reports, using different behavior scales and statistical analysis. Future studies must be aimed at better characterizing the extensive group with mild behavioral disturbances, not sufficiently defined by the methods applied in the present and previous studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amer-Ferrer</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Son Dureta, Palma de Mallorca. gamerferrer@telefonica.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Pe&#xf1;a</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Soriano</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Mart&#xed;n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Componentes principales del Inventario Neuropsiqui&#xe1;trico en la enfermedad de Alzheimer. Definici&#xf3;n de s&#xed;ndromes de conducta.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurologia</MedlineTA><NlmUniqueID>9005460</NlmUniqueID><ISSNLinking>0213-4853</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15704016</ArticleId><ArticleId IdType="pii">51090113</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15681626</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>38</EndPage><MedlinePgn>33-8</MedlinePgn></Pagination><Abstract><AbstractText>Cobalamin deficiency may cause cognitive deficits and even dementia. In Alzheimer's disease, the most frequent cause of dementia in elderly persons, low serum levels of vitamin B12, may be misleading. The aim of this work was to characterize the cognitive pattern of B12 deficiency and to compare it with that of Alzheimer's disease. Nineteen patients with low levels of vitamin B12 were neuropsychologically evaluated before treatment and a year later. Results were compared with those of 10 healthy control subjects. Final results suggest that there is a different pattern in both diseases. Twelve elderly patients with dementia improved with treatment. Seven elderly demented patients did not improve; they deteriorated after 1 year although their levels of cobalamin were normal. Analysis of the initial evaluation showed that the 2 groups of patients had a different neuropsychological profile. The group that improved had initially more psychotic problems and more deficits in concentration, visuospatial performance, and executive functions. They did not show language problems and ideomotor apraxia, which were present in the second group. Their memory pattern was also different. These findings suggest that cobalamin deficiency may cause a reversible dementia in elderly patients. This dementia may be differentiated from that of Alzheimer's disease by a thorough neuropsychological evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osimani</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kaplan Hospital, Rehovot, Israel and the Department of Behavioral Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Porat-Katz</LastName><ForeName>Bat-Sheba</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Abarbanel</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014806" MajorTopicYN="N">Vitamin B 12 Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15681626</ArticleId><ArticleId IdType="doi">10.1177/0891988704272308</ArticleId><ArticleId IdType="pii">18/1/33</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15667381</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>87</EndPage><MedlinePgn>83-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe the effect of cholinesterase inhibitors (CEIs) on the natural course of Alzheimer's disease (AD) using clinically meaningful outcomes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional and longitudinal study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Referral dementia clinic.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">One hundred thirty-five matched pairs of patients with probable AD.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">The risk of AD patients being classified as slow progressors (Mini-Mental State Examination (MMSE) score change &lt;or=2 at 1-year follow-up) was examined as a function of treatment with CEIs. A logistic regression analysis, controlling for age, sex, education level, MMSE score, Blessed Dementia Rating Scale (BDRS) for activities of daily living (ADLs), extrapyramidal signs, psychosis, major depression, and use of antidepressants, antipsychotics, and sedative/hypnotics determined the factors that best predict slow progression and nursing home admission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-one (60%) of the patients on CEIs and 53 (39%) of the patients who never used CEIs were considered slow progressors (P=.001) at 1-year follow-up. Slow progression was associated only with CEI use (relative risk (RR)=2.45, 95% confidence interval (CI)=1.45-4.16), and sedative/hypnotics use was associated with a MMSE change of 3 points or more (RR=0.35, 95% CI=0.13-0.93). CEI use had a protective effect on nursing home admission (RR=0.095, 95% CI=0.03-0.30), whereas higher scores on the BDRS for ADLs increased risk of admission at 24- and 36-month follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CEI use had a clinically meaningful effect on the natural history of AD. Patients taking CEIs were 2.5 times more likely to progress slowly and had a lower risk of nursing home admission after 2 years, even after controlling for multiple factors that can alter the course of the disease, and a slower rate of decline during the first year of follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. lopezol@upmc.edu &lt;lopezol@upmc.edu&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-MH01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Geriatr Soc. 2005 Oct;53(10):1831; author reply 1831-3. doi: 10.1111/j.1532-5415.2005.53528_1_1.x</RefSource><PMID Version="1">16181190</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15667381</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53015.x</ArticleId><ArticleId IdType="pii">JGS53015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15660411</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Components of behavioral pathology in dementia.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>145</EndPage><MedlinePgn>137-45</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to examine the occurence of the noncognitive behavioral and psychological symptoms and signs of dementia in a geriatric chronic-care hospital and to separate agitated and affective components of behavioral pathology using factor analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The frequency and severity of Alzheimer's disease, vascular dementia, mixed dementia and Lewy Body dementia was assessed in 145 consecutive residents of a chronic-care hospital. The presence of noncognitive behavioral symptoms was evaluated with the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) and the Cohen-Mansfield Agitation Inventory (CMAI). A Factor analysis on the BEHAVE-AD subscores was performed to create symptom clusters. Analysis of covariance and post hoc tests were used to compare means of factor variables between different types of dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Statistical analysis showed a significant correlation between severity of dementia and BEHAVE-AD total score and between severity of dementia and CMAI total score. Factor analysis with Varimax rotation revealed the presence of three behavioral subsyndromes: agitation, affectivity and day/night disturbances.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The finding of three factors of behavioral pathology in demented patients reflects the possibility that different etiological mechanisms could explain the expression of the symptoms and signs of psychosis in demented patients.</AbstractText><CopyrightInformation>2005 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schreinzer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Psychiatry, Medical University Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballaban</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Brannath</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hilger</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fasching</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="Y">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15660411</ArticleId><ArticleId IdType="doi">10.1002/gps.1263</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15641877</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>12</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.</ArticleTitle><Pagination><StartPage>1708</StartPage><EndPage>1714</EndPage><MedlinePgn>1708-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Older individuals with dementia are highly sensitive to the effects of muscarinic receptor blockade.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">This was a 6-week multisite, randomized clinical trial.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone.</AbstractText><AbstractText Label="ASSESSMENTS" NlmCategory="METHODS">Anticholinergic activity was measured with a radioreceptor assay, and plasma levels of antipsychotic medications were determined. Primary outcomes were assessed with the Udvalg for Kliniske Undersogelser (UKU) scale and somnolence adverse events; secondary outcome measures included scores on the Neuropsychiatric Inventory (NPI) and other scales.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no between-treatment differences in the UKU scale or in somnolence adverse events. Statistically significant improvements (p &lt; .001) from baseline were found for the NPI measures, with no between-treatment group differences. Olanzapine was associated with significant increases from baseline in anticholinergic activity, while risperidone was not; the between-treatment group differences were not statistically significant. Increase in anticholinergic activity was associated with an increase in anticholinergic side effects and slower performance on the Trail Making Test Part A. Higher endpoint anticholinergic activity was associated with higher endpoint scores on several items from the NPI, including delusions, anxiety, and aberrant motor behavior.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Efficacious doses of olanzapine increased anticholinergic activity in older patients with dementia, while similarly efficacious doses of risperidone did not. Patients whose anticholinergic activity increased were more likely to experience anticholinergic side effects and to have worsening in certain cognitive domains. These data suggest that certain patients may be vulnerable to the anticholinergic activity associated with antipsychotic treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, Department of Psychiatry, Division of Geriatric Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. mulsantbh@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharabawi</LastName><ForeName>Georges M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Bossie</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Lian</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rick A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Tune</LastName><ForeName>Larry E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Bastean</LastName><ForeName>Jeni N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014145" MajorTopicYN="N">Trail Making Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15641877</ArticleId><ArticleId IdType="doi">10.4088/jcp.v65n1217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15633073</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4259</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[State of the art management of BPSD in dementia].</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>38</EndPage><MedlinePgn>31-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To obtain a cross-sectional overview of therapeutic practice concerning non-cognitive, behavioral signs and symptoms of dementia (BPSD) in Germany, Austria, and Switzerland.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We selected 24 psychiatrists (8 from each country) for a questionnaire-based survey with 28 detailed practical questions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Attitudes and preferences were in line with the state of the art as documented in the literature, with the exception of the fact that 30 % of the physicians favored a too brief therapeutic trial with selective serotonin re-uptake inhibitors (SSRIs) for agitation. According to the international literature the preferred treatment of psychotic symptoms in Parkinsons's disease is also a little bit different. Modern atypical antipsychotics, and particularly risperidone, were highly favored for agitation, delirium, psychotic symptoms, and rage outbursts; benzodiazepines (oxazepam and lorazepam), and to an extent also low-potency conventional antipsychotics, were favored only for brief ad hoc medication courses. Anxiety and depressive symptoms were preferentially treated with SSRI, with the exception of short-term therapy of generalized anxiety where benzodiazepines were favored. Benzodiazepines and zolpidem were favored for insomnia without pronounced nocturnal agitation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Psychiatrists at memory clinics in German-speaking Europe have therapeutic attitudes and practices that are consistent with the current state of the art.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rainer</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Memory-Klinik und Psychiatrische Abteilung, Donauspital, Sozialmedizinisches Zentrum Ost, Wien, Osterreich. Michael.Rainer@wienkav.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Hermann A M</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Masching</LastName><ForeName>Andreas J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Haushofer</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Zeitgem&#xe4;sses Management von nicht kognitiven Symptomen bei Demenz.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N" Type="Geographic">Switzerland</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15633073</ArticleId><ArticleId IdType="doi">10.1055/s-2003-814885</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24945337</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1365-1501</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>International journal of psychiatry in clinical practice</Title><ISOAbbreviation>Int J Psychiatry Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Risperidone in the treatment of behavioural and psychological symptoms of dementia in patients diagnosed with vascular or mixed-type dementia.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>51</EndPage><MedlinePgn>45-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13651500510014729</ELocationID><Abstract><AbstractText>Objective Studies have found that the atypical antipsychotic drug, risperidone, reduces non-cognitive symptoms, such as aggression, agitation, and psychosis, in patients with Alzheimer's disease. This study assessed whether these effects extend to patients with vascular or mixed-type dementia. Methods In this multicentre, open-label, prospective study, 75 elderly patients with vascular or mixed-type dementia and concomitant behavioural and psychological symptoms were treated with risperidone for up to 6 months. Results Risperidone decreased the frequency and severity of overall behavioural and psychological symptoms, as determined by the Neuropsychiatric Inventory, to a mean total score of 7.2&#xb1;0.7 at end-point compared with 21.0&#xb1;1.5 at baseline (P&lt;0.001). Risperidone improved functional capacity (Blessed Dementia Rating Scale, Reisberg's Global Deterioration Scale) and depression (Cornell Scale for Depression in Dementia). A total of four adverse events (5.3%) were spontaneously reported: two cases of hypotension, one of somnolence, and one of paresthesia. Scores on the Udvalg for Kliniske Undersogeler extrapyramidal symptom subscale remained stable from baseline to end-point. Conclusion Overall, these findings indicate that risperidone was effective in reducing behavioural and psychological symptoms and was well tolerated, particularly with respect to extrapyramidal symptoms, in this elderly population diagnosed with vascular or mixed-type dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz-Jentoft</LastName><ForeName>Alfonso J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Hospital Ram&#xf3;n y Cajal, Servicio de Geriatria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bur&#xf3;n</LastName><ForeName>Jos&#xe9;-Antonio</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Diago</LastName><ForeName>Jes&#xfa;s I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Gallego</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Psychiatry Clin Pract</MedlineTA><NlmUniqueID>9709509</NlmUniqueID><ISSNLinking>1365-1501</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BPSD</Keyword><Keyword MajorTopicYN="N">mixed-type dementia</Keyword><Keyword MajorTopicYN="N">open-label</Keyword><Keyword MajorTopicYN="N">risperidone</Keyword><Keyword MajorTopicYN="N">vascular dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24945337</ArticleId><ArticleId IdType="doi">10.1080/13651500510014729</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15588758</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1313</StartPage><EndPage>1322</EndPage><MedlinePgn>1313-22</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Prior proton magnetic resonance spectroscopy (MRS) studies have consistently reported decreased brain n-acetyl aspartate (NAA) levels and increased myo-inositol (mI) levels in subjects with Alzheimer's disease (AD) relative to healthy comparison subjects. These studies have usually been conducted in small and homogeneous populations of patients with established Alzheimer's disease. Few studies have tested the usefulness of this finding in a general population seeking evaluation for memory loss and other cognitive declines. We designed a study to evaluate the significance of single-voxel proton MRS findings in these patients with memory loss and other cognitive declines. GENERAL METHOD: Thirty-five subjects with a primary complaint of memory loss and other cognitive declines were consecutively referred over a period of 13 months to a specialty clinic. Patients with a diagnosis of mild to moderate probable Alzheimer's disease (N = 22), non-Alzheimer's dementia (depression, multiinfarct dementia, Parkinson's Disease, Korsakoff's Psychosis, and bipolar disorder; N = 13), and healthy comparison subjects (N = 18) were examined with respect to possible differences in metabolites using proton MRS in a 3.4-ml anterior temporal lobe voxel.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The Alzheimer's disease group had 10.7% lower NAA/creatine (Cr) ratios relative to the healthy comparison group and 9.4% lower NAA/creatine relative to the non-Alzheimer's dementia group (15.0% lower NAA/creatine relative to the depression subgroup of the non-Alzheimer's dementia group). There were no significant differences in choline (Cho) or myo-inositol ratios among the groups. There were significant correlations between NAA/creatine ratios and mini-mental status exam (MMSE) scores in subjects with Alzheimer's disease (t = 2.41, p = 0.032) but not in subjects with non-Alzheimer's dementia or in its depression subgroup.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study found a reduction in the neuronal marker NAA in the anterior temporal lobe of patients diagnosed with probable Alzheimer's disease, using a short add-on proton MRS exam. This change was not observed in patients whose memory loss and other cognitive declines were not attributed to Alzheimer's disease, suggesting that it may aid in the diagnosis or detection of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frederick</LastName><ForeName>Blaise D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>McLean Hospital Brain Imaging Center, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>In Kyoon</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Satlin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Kyung Heup</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minue J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Yurgelun-Todd</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Renshaw</LastName><ForeName>Perry F</ForeName><Initials>PF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>MU72812GK0</RegistryNumber><NameOfSubstance UI="D003401">Creatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003401" MajorTopicYN="N">Creatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011522" MajorTopicYN="Y">Protons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15588758</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2004.08.013</ArticleId><ArticleId IdType="pii">S0278-5846(04)00180-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15585443</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0277-0008</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>12</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.</ArticleTitle><Pagination><StartPage>1759</StartPage><EndPage>1783</EndPage><MedlinePgn>1759-83</MedlinePgn></Pagination><Abstract><AbstractText>Cognitive impairment in schizophrenia occurs in the early phases of the disease and remains throughout its course. The basis for cognition lies in two main brain regions: the prefrontal cortex and hippocampus. Positron emission tomography, functional magnetic resonance imaging, and proton magnetic spectroscopy studies have shown that prefrontal cortex and hippocampus activity and cell density are lower in patients with schizophrenia than in healthy controls. Dopamine remains the fundamental neurotransmitter involved with schizophrenia. Catechol- O -methyltransferase accounts for about 60% of dopamine metabolism in the prefrontal cortex. Functional polymorphism for the catechol- O -methyltransferase genotypes has been identified in patients with schizophrenia. Those with the valine-valine genotype demonstrate rapid inactivation of dopamine, and performance in cognitive testing in patients is poorer with this allele than with other genotypes. N -methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate acid receptors are also strongly associated with cognitive impairment. Changes occur in apolipoproteins D and E, cholinesterase enzyme activity, neurotensin, and neural growth factors, leading to a possible neurodegenerative process and cognitive impairment in patients with schizophrenia. A fundamental link between psychosis and neurocognition probably arises from complex interactions between these systems at the intracellular secondary messenger system and with protein phosphorylation. Atypical antipsychotics evaluated in receptor models, cell cultures, and animal behavior paradigms indicate that these agents may provide neuroprotective effects. Clinical studies with atypical antipsychotics have consistently demonstrated improvement in cognitive symptoms, and such improvement appears to be correlated with improvement of negative symptoms. A neurodevelopmental model of cognitive impairment in schizophrenia aids in understanding why atypical antipsychotics improve cognitive symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jann</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA. jann_mw@mercer.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>87</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15585443</ArticleId><ArticleId IdType="doi">10.1592/phco.24.17.1759.52346</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15582912</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-8811</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Alcohol, wine and mental health: focus on dementia and stroke.</ArticleTitle><Pagination><StartPage>449</StartPage><EndPage>456</EndPage><MedlinePgn>449-56</MedlinePgn></Pagination><Abstract><AbstractText>The relative risks of coronary heart disease (CHD) and overall mortality are reduced by moderate consumption of alcoholic beverages, particularly wine, which has major implications for public health. It appears likely that this beneficial effect of alcohol will soon be extended to some mental disorders. Although data on psychosis and mood and anxiety disorders are currently lacking, it appears that the relative risks of developing ischaemic stroke and Alzheimer's or vascular dementia are also lowered by moderate alcohol consumption. Such findings are still tentative because of the inherent methodological problems involved in population-based epidemiological studies, and it is unclear whether the benefit can be ascribed to alcohol itself or to other constituents specific to wine such as polyphenols. Plausible biological mechanisms have been advanced for the protective effect of alcohol and wine against CHD, many of which will also play roles in their protective actions against cerebrovascular disease and dementia. The specific antioxidant properties of wine polyphenols may be particularly important in preventing Alzheimer's disease. Because of the substantially unpredictable risk of progression to problem drinking and alcohol abuse, the most sensible advice to the general public is that heavy drinkers should drink less or not at all, that abstainers should not be indiscriminately encouraged to begin drinking for health reasons, and that light to moderate drinkers need not change their drinking habits for health reasons, except in exceptional circumstances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinder</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Medical Affairs, Organon International Inc., Roseland, NJ, USA. pinde003@planet.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="Y">Alcohol Drinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014920" MajorTopicYN="Y">Wine</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15582912</ArticleId><ArticleId IdType="doi">10.1177/0269881104047272</ArticleId><ArticleId IdType="pii">18/4/449</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15580868</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>106</Volume><Issue>9</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[What is impaired consciousness? Revisiting impaired consciousness as psychiatric concept].</ArticleTitle><Pagination><StartPage>1083</StartPage><EndPage>1109</EndPage><MedlinePgn>1083-109</MedlinePgn></Pagination><Abstract><AbstractText>For decades, psychiatrists have considered that concepts of impaired consciousness in the study of psychiatry were inconsistent with those applied in the field of neurology, in which the usefulness of the concept of consciousness has long been seriously doubted. Gloor concluded that the concept of consciousness does not further the understanding of seizure mechanisms or brain function, which is the current representative opinion of most epileptologists. Loss of consciousness tends to be reduced to aggregates of individual impairments of higher cognitive functions, and the concept of consciousness is preferably avoided by neurologists by assigning various behavioral disturbances during disturbed consciousness to particular neuropsychological centers. In contrast, psychiatrists, especially those in Europe, are more likely to include phenomena involving problems related to phenomenological intentionality in impaired consciousness. For the present study, we first divided consciousness into vigilance and recursive consciousness, and then attempted to determine what kind of impaired consciousness would be an ideal candidate to represent pure disturbance of recursive consciousness. Then, 4 patients, 1 each with pure amnestic states followed immediately by complex partial seizures, an akinetic mutistic state caused by absence status, and mental diplopia as a manifestation of postictal psychosis, as well as a patient with Alzheimer's disease who gracefully performed Japanese tea ceremony, were studied. Based on our findings, we concluded that impaired consciousness as a generic term in general medicine does not indicate any unitary entity corresponding to some well-demarcated physiological function or constitute a base from which recursive consciousness emerges as a superstructure. From that, we stressed that a pure form of impairment of recursive consciousness could occur without the impaired consciousness named generically in general medicine. Second, following observation of an additional 3 cases, descriptions of naissance of the first word (taken from the autobiography of Helen Keller), visual object agnosia, and chronic schizophrenia with schizophasia were discussed to examine the relationship between impairments of recursive consciousness and semantic generation dysfunction. Attempts to bridge semantic generation and recursive consciousness, performed by psychopathologists such as Bin Kimura and Hiroyuki Koide, were also briefly discussed. In light of these case presentations and related discussions, we re-examined traditional theories of impaired consciousness, including Mayer-Gross's Gestalt theory, later replaced by Conrad and Henri Ey's theory related to intentionality. Furthermore, we attempted to link Denett's theory of consciousness to those traditional theories as well as to our own postulations, and neuropsychological data such as those of implicit memory and blindsight. Finally, the significance of Freud's unconsciousness in the framework of neuroscience was discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanemoto</LastName><ForeName>Kousuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Aichi Medical University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003243" MajorTopicYN="N">Consciousness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003244" MajorTopicYN="N">Consciousness Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15580868</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15548484</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>12</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease.</ArticleTitle><Pagination><StartPage>1692</StartPage><EndPage>1696</EndPage><MedlinePgn>1692-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The epsilon4 allele of the apolipoprotein E (ApoE) gene has been defined as a critical factor for early onset neurodegeneration in Pick's, Parkinson's, and Alzheimer's disease. Unexpectedly, the epsilon4 allele appeared to delay the age of onset in Huntington's disease (HD) patients. Furthermore, sex specific effects were reported on earlier age of onset due to the ApoE epsilon2epsilon3 genotype in males with HD. The age of onset of HD is known to be negatively correlated with increasing lengths of pathogenetic CAG expansions in the huntingtin gene.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In order to examine the effects of CAG block lengths, we have correlated ApoE genotypes with the age of onset in 145 patients symptomatic for HD with psychiatric and somatic symptoms (depression, psychosis, dementia, choreic, and other movement disorders) harbouring only modestly expanded huntingtin alleles (41-45 CAGs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The negative correlation between age of onset and CAG block length was established in our HD cohort. Statistically significant effects of the epsilon4 allele were not obvious regarding clinical characteristics including age of onset, nor were any sex differences for the epsilon2epsilon3 genotype observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ApoE genotype does not affect the course of HD significantly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saft</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Huntington Center NRW, Department of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrich</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Brune</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gencik</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>P H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Przuntek</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Epplen</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018911" MajorTopicYN="N">Trinucleotide Repeats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15548484</ArticleId><ArticleId IdType="pmc">PMC1738834</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2003.022756</ArticleId><ArticleId IdType="pii">75/12/1692</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Hum Genet. 1996 Jul;59(1):16-22</Citation><ArticleIdList><ArticleId IdType="pubmed">8659522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1993 Aug;4(4):398-403</Citation><ArticleIdList><ArticleId IdType="pubmed">8401589</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1998 Nov;43(9):933-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9825166</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 1999 Feb;36(2):108-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10051007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1999 May;45(5):611-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10319883</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Lipidol. 1999 Jun;10(3):207-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10431657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 1999 Jul;246(7):574-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10463359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hum Genet. 1999 Jul;63(Pt 4):301-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10738542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Jul 13;406(6792):195-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10910361</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2000 Jul-Aug;21(4):555-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10924769</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 Jul 12;412(6843):143-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11449262</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Aug 28;57(4):658-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11524475</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Genomics Hum Genet. 2000;1:507-37</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2002 Aug;15(4):483-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12151847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2003 Dec;250(12):1469-74</Citation><ArticleIdList><ArticleId IdType="pubmed">14673581</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1993 Aug 13;261(5123):921-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1993 Jun;2(6):637</Citation><ArticleIdList><ArticleId IdType="pubmed">8353483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Probes. 1993 Jun;7(3):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8366869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1993 Aug;4(4):393-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8401588</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3872-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9108071</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15491235</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>10</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.</ArticleTitle><Pagination><StartPage>1329</StartPage><EndPage>1334</EndPage><MedlinePgn>1329-34</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a post hoc exploratory analysis of an integrated database from 3 randomized, controlled trials of risperidone versus placebo in treating 1150 nursing home residents with BPSD. Changes in scores were measured for items on the Cohen-Mansfield Agitation Inventory (CMAI) and Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On the CMAI, risperidone was significantly more effective in treating hitting (p = .000), hurt self or other (p = .005), cursing or verbal aggression (p = .000), repetitive sentences or questions (p = .001), scratching (p = .041), general restlessness (p = .001), grabbing onto people (p = .028), constant request for attention (p = .041), pacing and aimless wandering (p = .013), and performing repetitious mannerisms (p = .045). On the BEHAVE-AD, risperidone was significantly more effective in treating physical threats and/or violence (p = .000), verbal outbursts (p = .000), other anxieties (p = .01), agitation (p = .000), tearfulness (p = .03), and nonparanoid delusions (p = .02).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The items from the BEHAVE-AD and CMAI that were improved with risperidone included psychotic, agitated, and aggressive symptoms. These data suggest that risperidone is more effective than placebo in treating a variety of symptoms associated with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabinowitz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bar Ilan University, Ramat Gan, Israel. jrabin@netvision.net.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Greenspan</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15491235</ArticleId><ArticleId IdType="doi">10.4088/jcp.v65n1006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15488308</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>370</Volume><Issue>2-3</Issue><PubDate><Year>2004</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>129</EndPage><MedlinePgn>127-9</MedlinePgn></Pagination><Abstract><AbstractText>There is emerging evidence that psychosis in Alzheimer Disease (AD) represents a clinically relevant phenotype with a distinct biological process. It has been reported that a functional polymorphism of the catechol-O-methyltransferase (COMT) gene predisposes to an increased risk for schizophrenia and likely to psychosis susceptibility. Aim of this study was to evaluate functional COMT genetic variation as a risk factor for psychosis in Alzheimer Disease. One hundred eighty-one AD patients and 208 age-matched controls underwent clinical and neuropsychological examination, behavioural and psychiatric disturbances evaluation, and ApoE and COMT genotyping. The distribution of COMT genotypes did not significantly differ in AD compared to controls. Among patients with psychosis (32.6%), 88.1% were COMT*H carriers (COMT H/H or COMT H/L, p &lt; .01). The Odds Ratio (OR) for risk of psychosis in COMT*H carriers was 2.66 (confidence interval, CI 95%: 1.6-6.62), taking into account possible confounding factors. A comparable influence of COMT polymorphism on psychosis over the course of the disease was reported. These findings suggest that COMT polymorphism influences on the risk of psychosis since the early stages, and claims for the possibility to identify distinct phenotypes on genetic basis among AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Brescia, Brescia, Italy. bborroni@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agosti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bonomi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ghianda</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>Gian Luigi</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Caimi</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15488308</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2004.08.006</ArticleId><ArticleId IdType="pii">S0304-3940(04)00988-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15481076</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2004</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1040</StartPage><EndPage>1046</EndPage><MedlinePgn>1040-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cognitive impairment is an important determinant for functional impairment in Alzheimer's disease. The role of non-cognitive symptom is uncertain. The objective of this study was to investigate the role of non-cognitive symptoms as predictive factors for functional outcome in A.D.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective study. Subjects were recruited from the Memory Clinic in Queen Mary Hospital over a two years period. Patients with diagnosis of probable A.D. by NINCDS-ADRDA were identified. Demographic data, Folstein Mini-Mental Status Examination (MMSE), Clinical Dementia Rating (CDR), Neuropsychiatric inventory (NPI), Barthel activities of daily living (ADL) as well as Lawton's Instrumental activities of daily living (IADL) were retrieved.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">100 patients were identified. Univariate analysis identified statistically significant correlation between hallucination and disinhibition score with Barthel Index (r=-0.43, p &lt;0.001; r=-0.30, p=0.002 respectively); hallucination and aberrant motor act score with Lawton's IADL (r=-0.21, p=0.038; r=-0.21, p=0.038). MMSE was statistical significantly correlated with the above two functional scores. NPI was not statistical significantly correlated with any one of the functional measures. Multivariate regression analyses showed that hallucination score was an independent predictive factors for the Barthel index but not for the Lawton's IADL. MMSE score was identified to be independent predictive factor for all functional measures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Global cognitive impairment and hallucination was an important independent predictive factor for functional outcomes. Screening hallucination during the course of A.D. would be helpful. Further studies are needed to show the benefit of treatment of hallucination on the improvement of functional outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>W Y W</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Medicine, Queen Mary Hospital, Hong Kong, SAR, China. wmok00@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>L W</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>N Y</ForeName><Initials>NY</Initials></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="N">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15481076</ArticleId><ArticleId IdType="doi">10.1002/gps.1207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15481075</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2004</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Behavioural and psychological syndromes in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1035</StartPage><EndPage>1039</EndPage><MedlinePgn>1035-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The origins of behavioural and psychological symptoms of dementia are still poorly understood. By focusing on piecemeal behaviours as opposed to more robust syndrome change valid biological correlates may be overlooked. Our understanding of BPSD via the identification of neuropsychiatric syndromes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 435 subjects from old age psychiatry and elderly care memory outpatient clinics fulfilling the criteria for diagnosis of probable Alzheimer's disease. Behavioural and psychological symptoms were assessed using the Neuropsychiatric Inventory. Principal components factor analysis was carried out on the composite scores of the 12 symptom domains to identify behavioural syndromes (factors). Results were confirmed by performing three different rotations: Varimax, Equamax and Quartimax.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four factors were identified (which accounted for 57% of the variance): 'affect' factor-depression/dysphoria, anxiety, irritability/lability and agitation/aggression; 'physical behaviour' factor-apathy, aberrant motor behaviour, sleep disturbance and appetite/eating disturbance; 'psychosis' factor-delusions and hallucinations; 'hypomania' factor-disinhibition and elation/euphoria. These groups were unchanged when different methods of rotation were used.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report novel observations that agitation/aggression/irritability cluster within a depressive symptom factor and apathy is found within a physical behaviour factor.</AbstractText><CopyrightInformation>Copyright 2004 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirakhur</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Queen's University of Belfast, Belfast, Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>McLlroy</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15481075</ArticleId><ArticleId IdType="doi">10.1002/gps.1203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15480840</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0300-9564</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>10-11</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neural transmission (Vienna, Austria : 1996)</Title><ISOAbbreviation>J Neural Transm (Vienna)</ISOAbbreviation></Journal><ArticleTitle>Cognitive dysfunction and dementia in Parkinson's disease.</ArticleTitle><Pagination><StartPage>1303</StartPage><EndPage>1315</EndPage><MedlinePgn>1303-15</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and the ventral tegmental area, in combination with a varying loss of central noradrenergic (locus coeruleus), cholinergic (nucleus basalis of Meynert) and serotonergic (dorsal raphe nuclei) integrity, leading to a multitude of motor and non-motor behavioral disturbances. Apart from the clinical motor hallmarks, in the early stages of disease, subtle cognitive dysfunction might be seen comprising mainly executive dysfunction, with secondary visuospatial and mnemonic disturbances. In about 20-40% of patients, these problems may eventually proceed to dementia, which constitutes an important risk factor for caregiver distress, decreased quality of life and nursing home placement. Dementia in PD is typically characterized by a progressive dysexecutive syndrome with attentional deficits and fluctuating cognition, often accompanied by psychotic symptoms. It is thought to be the result of a combination of both subcortical and cortical changes. PD-related dopaminergic deficiency in the nucleus caudatus and mesocortical areas (due to degeneration of projections from the substantia nigra and ventral tegmental area) and cholinergic deficiency in the cortex (due to degeneration of ascending projections from the nucleus basalis of Meynert), combined with additional Alzheimer-pathology and cortical Lewy bodies, may greatly contribute to dementia. Current treatment of dementia in PD is based on compensation of the profound cholinergic deficiency. Recent studies with the cholinesterase inhibitors galantamine, donepezil and rivastigmine show promising results in improving cognition and ameliorating psychotic symptoms, which must further be confirmed in randomized controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosboom</LastName><ForeName>J L W</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoffers</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>E Ch</ForeName><Initials>ECh</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm (Vienna)</MedlineTA><NlmUniqueID>9702341</NlmUniqueID><ISSNLinking>0300-9564</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>145</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15480840</ArticleId><ArticleId IdType="doi">10.1007/s00702-004-0168-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15472417</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3886</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurology India</Title><ISOAbbreviation>Neurol India</ISOAbbreviation></Journal><ArticleTitle>Memantine: pharmacological properties and clinical uses.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>309</EndPage><MedlinePgn>307-9</MedlinePgn></Pagination><Abstract><AbstractText>Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is an uncompetitive N-methyl-D-aspartate receptor antagonist and reduces glutamatergic excitotoxicity. Though Alzheimer's disease (AD) is the commonest cause of dementia in the world, there is no "cure" available for the same. Cholinesterase inhibitors such as donepezil and rivastigmine have been shown to provide symptomatic relief in patients with AD but have no effect on disease progression or survival. Moreover, they are not helpful in more severe stages of dementia. Memantine has been shown to cause modest improvement in clinical symptoms in severe stages of AD and may retard the disease progression. Moreover, it has been shown to be useful in various forms of dementia including AD, vascular dementia and Wernicke-Korsakoff psychosis. It is also the first drug to cause complete disappearance of pendular nystagmus due to multiple sclerosis. The current review focuses on the pharmacological properties of memantine and examines the recent evidence in favor of memantine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neurological Sciences, Christian Medical College Hospital, Vellore 632004, India. drsudhirkumar@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Neurol India</MedlineTA><NlmUniqueID>0042005</NlmUniqueID><ISSNLinking>0028-3886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020915" MajorTopicYN="N">Korsakoff Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009759" MajorTopicYN="N">Nystagmus, Pathologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>121</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15472417</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15389761</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>132B</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>13</EndPage><MedlinePgn>9-13</MedlinePgn></Pagination><Abstract><AbstractText>Cases of early onset AD have been attributed to three genes, PSEN1, PSEN2, and APP, while the only gene consistently associated with late onset AD (LOAD) is APOE. Several genome scans have now been performed for LOAD with inconsistent findings in several genomic regions, possibly reflecting the underlying genetic heterogeneity. Many lines of evidence suggest that the absence or presence of psychotic symptoms, common in AD, might delineate distinct etiologic disease subtypes. We have performed a genome scan of 148 AD pedigrees (ages of onset more than 50 years) including the presence or absence of delusions and hallucinations as covariates. This approach identified linkage to a locus on chromosome 14q24.3, close to the PSEN1 locus (LOD score 3.91; genome-wide empirical P = 0.052), derived from individuals that do not have co-morbid hallucinations. The finding appears stronger (LOD score 5.74; genome-wide empirical P = 0.048) in families that include younger affected members (AAO between 50 and 65 years), however it is not present without the inclusion of the covariate and we observe no correlation between the presence of hallucinations and the age of onset. A mutation screen of PSEN1 did not detect any coding region or splice site mutations. This linkage finding suggests the presence of a gene causing AD without co-morbid hallucinations and with an earlier (yet not early) age at onset (AAO) in the 14q24 region. This region requires further study to replicate the finding and identify the genetic variant responsible for the linkage.</AbstractText><CopyrightInformation>Copyright 2004 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avramopoulos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Johns Hopkins University, Department of Psychiatry, School of Medicine, Meyer 4 Room 139, 600 N. Wolfe St, Baltimore, MD 21287, USA. adimitr1@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG021804</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH46290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002883" MajorTopicYN="N">Chromosomes, Human, Pair 14</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15389761</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30074</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15377733</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The role of norepinephrine in the behavioral and psychological symptoms of dementia.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>276</EndPage><MedlinePgn>261-76</MedlinePgn></Pagination><Abstract><AbstractText>The behavioral and psychological symptoms of dementia (BPSD) are common serious problems that are a major contributor to caregiver burden. Despite their significance, the underlying neurobiology of these disturbances is still unclear. This review examines the role of norepinephrine (NE) on BPSD, including depression, aggression, agitation and psychosis. A number of lines of evidence suggest that NE dysfunction leading to BPSD may result from increased NE activity and/or hypersensitive adrenoreceptors compensating for loss of NE neurons with progression of Alzheimer's disease (AD). With greater appreciation of the underlying neurobiology of behavioral and psychological symptoms of dementia (BPSD) more effective, rational, targeted pharmacotherapy will hopefully emerge.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto, ON M4N 3M5, Canada. Nathan.Herrmann@sw.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanct&#xf4;t</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Lyla R</ForeName><Initials>LR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.17.1</RegistryNumber><NameOfSubstance UI="D004299">Dopamine beta-Hydroxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004299" MajorTopicYN="N">Dopamine beta-Hydroxylase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>149</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15377733</ArticleId><ArticleId IdType="doi">10.1176/jnp.16.3.261</ArticleId><ArticleId IdType="pii">16/3/261</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15359558</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>215</StartPage><EndPage>218</EndPage><MedlinePgn>215-8</MedlinePgn></Pagination><Abstract><AbstractText>Two patients diagnosed with dementia with Lewy bodies (DLB) presented with prominent behavioral disturbances. The first patient experienced well-formed visual hallucinations, movement disorders, and cognitive decline and was increasingly resistant to care. He was treated with galantamine 4 mg bid, which was increased to 8 mg bid after four weeks. Improvements in behavior, attention, and cognition made it possible for this patient to be transferred back to long-term care after 32 days. The second patient had increasing confusion, fluctuating cognition, agitation, and psychosis. He was given donepezil initially, then switched to galantamine 4 mg bid. He was assessed as stable for discharge with improved behavior control after three weeks. Both patients also were receiving an atypical antipsychotic (quetiapine) and an antidepressant (venlafaxine and sertraline, respectively).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Alvin C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Geriatric Behavioral Services, Bethesda Rehabilitation Hospital, St. Paul, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15359558</ArticleId><ArticleId IdType="pmc">PMC10833944</ArticleId><ArticleId IdType="doi">10.1177/153331750401900411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barber R, Panikkar A, McKeith IG: Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry. 2001; 16 Suppl 1: S12-S18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748785</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG: Dementia with Lewy bodies. Br J Psychiatry. 2002; 180: 144-147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823325</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996; 47(5): 1113-1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher DS, Whitehouse PJ: Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(5 Suppl 6): S2-S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Catt KE, Lopez OL, et al.: Dementia with Lewy bodies: Response of delirium-like features to donepezil. Neurology.1998; 51(5): 1512-1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">9818904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Grace J, McKeith I, et al.: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998; 351(9108): 1032-1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546516</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JH, Fernandez HH: Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol. 2002; 15(3): 156-170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230086</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel W, Caligiuri M, Galasko D, et al.: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study. Int J Geriatr Psychiatry.2000; 15(9): 794-802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984725</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebocontrolled international study. Lancet. 2000; 356(9247): 2031-2036.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145488</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000; 54(12): 2261-2268.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000; 54(12): 2269-2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000; 321(7274): 1445-1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27547</ArticleId><ArticleId IdType="pubmed">11110737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Mintzer J, Truyen L, et al.: Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry.2001; 71(5): 589-595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737604</ArticleId><ArticleId IdType="pubmed">11606667</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards K, Hershey L, Lichter D, et al.: Galantamine in the management of dementia with Lewy bodies: A 24-week, open-label study. Poster presented at: 11th Congress of the International Psychogeriatric Association; August 17-22, 2003; Chicago, IL.</Citation></Reference><Reference><Citation>Edwards KR, Hershey L, Wray L, et al.: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis. Dement Geriatr Cogn Disord. 2004; 17(Suppl 1): 40-48.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676468</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm A, Michel M, Stern GA, et al.: The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999; 39(6): 668-676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650676</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen CK: Occupational therapy: Functional assessment of the severity of mental disorders. Hosp Community Psychiatry. 1988; 39(2): 140-142.</Citation><ArticleIdList><ArticleId IdType="pubmed">3345978</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR: &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975; 12(3): 189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews W, Parker G, Barrett E: The SSRI antidepressants: Exploring their &#x201c;other&#x201d; possible properties. J Affect Disord.1998; 49(2): 141-144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9609678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Court JA, Piggott M, et al.: Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002; 11(3): 461-474.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435378</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Ballard C, McKeith I, et al.: Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci.2001; 13(3): 374-379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11514644</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Kalaria RN: Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications. Alzheimer Dis Assoc Disord.1995; 9(Suppl 2): 3-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8534421</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Ruiz C, Court J, Lee M, et al.: Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand Suppl. 2000; 176: 34-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15353383</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype.</ArticleTitle><Pagination><StartPage>449</StartPage><EndPage>456</EndPage><MedlinePgn>449-56</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Psychotic symptoms occur in 30%-60% of individuals with Alzheimer disease (AD) with psychosis (AD+P). AD+P identifies a distinct AD phenotype, with increased severity of cognitive impairment and a more rapid cognitive decline. Using factor and cluster analysis, we previously proposed two subtypes of patients with AD+P, one characterized by misidentifications and hallucinations (Misidentification), the other by persecutory delusions (Paranoid). We hypothesized that these two groups differed in their patterns of cognitive impairment, compared with AD subjects without psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects (N=119) with possible or probable AD were assessed with a comprehensive neuropsychological test battery at the time of initial presentation. Psychotic symptoms were ascertained with the CERAD Behavioral Rating Scale. Cognitive test scores were compared among groups by use of general linear-regression models, with age, education, and duration of illness entered as covariates. All results were corrected for multiple comparisons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Misidentification group was significantly more impaired than the Non-Psychotic group on tests of verbal fluency and visuospatial function. The Paranoid group did not differ from the Non-Psychotic group on any test.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results support the identification of the Misidentification and Paranoid groups as distinct subgroups of AD+P. The ability to detect meaningful biologic associations of AD+P in future studies would be enhanced by separate analysis of the Misidentification and Paranoid phenotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-Madri&#xf1;an</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Univ. of Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>37</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15353383</ArticleId><ArticleId IdType="doi">10.1176/appi.ajgp.12.5.449</ArticleId><ArticleId IdType="pii">S1064-7481(12)61217-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>